

1

2

3

4

5

6

7

8 **Non-Radioactive Murine Local Lymph Node Assay: Modified by Daicel**
9 **Chemical Industries, Ltd. Based on ATP Content Test Method Protocol**
10 **(LLNA: DA)**

11 **Revised Draft Background Review Document**

12

13

March 2009

14

15

16

17

18

19

20

21

22

23

24

25

26

[This Page Intentionally Left Blank]

27

28

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Table of Contents

Page Number

List of Abbreviations and Acronyms..... vii

Interagency Coordinating Committee on the Validation of Alternative Methods:

Agency Representatives ix

Acknowledgements..... x

Prefacexiii

Executive Summary xv

1.0 Introduction 1

 1.1 Public Health Perspective..... 1

 1.2 Historical Background for the Murine Local Lymph Node Assay..... 1

 1.3 The LLNA: DA..... 3

2.0 LLNA: DA Test Method Protocol..... 4

 2.1 Decision Criteria 6

3.0 LLNA: DA Validation Database 7

4.0 Reference Data..... 11

5.0 LLNA: DA Test Method Data and Results..... 12

6.0 LLNA: DA Test Method Accuracy 13

 6.1 LLNA: DA Database Used for the Accuracy Analysis 13

 6.2 Accuracy Analysis Using the $SI \geq 3.0$ Decision Criterion..... 14

 6.3 Accuracy Analysis ($SI \geq 3.0$) Based on ICCVAM-Recommended LLNA
Performance Standards Reference Substances 17

 6.4 Discordant Results for Accuracy Analysis Using the $SI \geq 3.0$ Decision
Criterion..... 22

 6.5 Accuracy Analysis Using a Single Alternative Decision Criteria 29

54 6.6 Discordant Results for Accuracy Analysis Using a Single Alternative
 55 Decision Criteria 36

56 6.7 Accuracy Analysis Using Multiple Alternative Decision Criteria 44

57 6.8 Discordant Results for Accuracy Analysis Using Multiple Alternative
 58 Decision Criteria 45

59 **7.0 LLNA: DA Test Method Reliability 49**

60 7.1 Intralaboratory Reproducibility 49

61 7.2 Interlaboratory Reproducibility 50

62 7.3 Reproducibility for the LLNA: DA Accuracy Analysis Using Multiple
 63 Alternative Decision Criteria 59

64 **8.0 LLNA: DA Data Quality 62**

65 **9.0 Other Scientific Reports and Reviews 63**

66 **10.0 Animal Welfare Considerations 65**

67 10.1 Rationale for the Need to Use Animals 65

68 10.2 Basis for Determining the Number of Animals Used 65

69 10.3 Reduction Considerations 65

70 **11.0 Practical Considerations 66**

71 11.1 Transferability of the LLNA: DA 66

72 11.2 Laboratories and Major Fixed Equipment Required to Conduct the
 73 LLNA: DA 66

74 11.3 LLNA: DA Training Considerations 67

75 **12.0 References 68**

76 **Appendix A Standard Operating Procedures for the LLNA: DA Test Method A-1**

77 **Appendix B Physico-Chemical Properties and Chemical Classes of Substances
 78 Tested in the LLNA: DA B-1**

79 **Appendix C Comparative LLNA: DA, Traditional LLNA, Guinea Pig, and**
80 **Human Skin Sensitization Data.....C-1**

81 **Appendix D Data for the LLNA: DA Interlaboratory and Interlaboratory**
82 **Validation StudiesD-1**

83 **Appendix E LLNA: DA Accuracy Analyses Using Additional Approaches for**
84 **Combining Multiple Test Results E-1**

85 **Appendix F Reproducibility Analyses for the LLNA: DA Using a Decision Criterion**
86 **of $SI \geq 3.0$ or $SI \geq 2.5$ F-1**

87

87	List of Tables		
88			Page Number
89	Table 2-1	Comparison of the LLNA: DA and Traditional LLNA Experimental	
90		Procedure.....	6
91	Table 3-1	Traditional LLNA EC3 Values and Chemical Classifications of	
92		Substances Tested in the LLNA: DA.....	9
93	Table 6-1	Performance of the LLNA: DA in Predicting Skin Sensitization	
94		Potential Using Decision Criteria of $SI \geq 3.0$ to Identify Sensitizers.....	16
95	Table 6-2	Performance of the LLNA: DA ($SI \geq 3.0$) Compared to the ICCVAM-	
96		Recommended LLNA Performance Standards Reference Substances	
97		(Sorted by Traditional LLNA EC3 Value).....	20
98	Table 6-3	Characteristics of the Substances Tested in the LLNA: DA Compared to	
99		the ICCVAM-Recommended LLNA Performance Standards Reference	
100		Substances	21
101	Table 6-4	Discordant Results for the LLNA: DA (Using $SI \geq 3.0$ for Sensitizers)	
102		Compared to Traditional LLNA and Guinea Pig Reference Data.....	25
103	Table 6-5	Discordant Results for the LLNA: DA (Using $SI \geq 3.0$ for Sensitizers)	
104		Compared to Traditional LLNA and Human Reference Data	28
105	Table 6-6	Performance of the LLNA: DA Compared to the Traditional LLNA	
106		in Predicting Skin Sensitization Potential Using Alternative Decision	
107		Criteria Based on the Most Prevalent Outcome for Substances with	
108		Multiple Tests.....	33
109	Table 6-7	Performance of the LLNA: DA in Predicting Skin Sensitization	
110		Potential Comparing Decision Criteria of $SI \geq 3.0$ versus $SI \geq 2.0$	
111		Based on the Most Prevalent Outcome for Substances with Multiple	
112		Tests	35
113	Table 6-8	Discordant Results for the LLNA: DA Using Alternative Decision	
114		Criteria Compared to the Traditional LLNA Based on the Most	
115		Prevalent Outcome for Substances with Multiple Tests.....	41
116	Table 6-9	Discordant Results for the LLNA: DA (Using $SI \geq 2.0$ for Sensitizers)	
117		Compared to Traditional LLNA and GP Reference Data.....	43

118	Table 6-10	Discordant Results for the LLNA: DA (Using $SI \geq 2.0$ for Sensitizers)	
119		Compared to Traditional LLNA and Human Reference Data.....	44
120	Table 6-11	Discordant Results for the LLNA: DA When Multiple Decision Criteria are	
121		Used.....	48
122	Table 7-1	Intralaboratory Reproducibility of EC3 and EC2.5 Values Using	
123		the LLNA: DA.....	50
124	Table 7-2	Substances and Allocation for the First Phase of the Interlaboratory	
125		Validation Study for the LLNA: DA	52
126	Table 7-3	Substances and Allocation for the Second Phase of the Interlaboratory	
127		Validation Study for the LLNA: DA	53
128	Table 7-4	Qualitative Results for the First Phase of the Interlaboratory Validation	
129		Study for the LLNA: DA ($SI \geq 2.5$).....	54
130	Table 7-5	Qualitative Results for the Second Phase of the Interlaboratory Validation	
131		Study for the LLNA: DA ($SI \geq 2.5$).....	55
132	Table 7-6	EC2.5 Values from the First Phase of the Interlaboratory Validation Study	
133		for the LLNA: DA.....	57
134	Table 7-7	EC2.5 Values from the Second Phase of the Interlaboratory Validation Study	
135		for the LLNA: DA.....	58
136	Table 7-8	Interlaboratory Reproducibility of the EC3 for Substances Tested in the	
137		Traditional LLNA	59
138	Table 7-9	Frequency of Maximum SI for LLNA: DA Tests by Category and Traditional	
139		LLNA Outcome	60
140	Table 7-10	Concordance of LLNA: DA Tests for Substances with Multiple Tests by	
141		Maximum SI Category.....	61
142			

142
143
144
145
146
147

List of Figures

Page Number

Figure 6-1 Performance of the LLNA: DA Compared to the Traditional LLNA in
Predicting Skin Sensitization Potential Using Alternative SI Based on the
Most Prevalent Outcome for Substances with Multiple Tests 32

147

List of Abbreviations and Acronyms

148	ACD	Allergic contact dermatitis
149	ANOVA	Analysis of variance
150	AOO	Acetone: olive oil (4:1)
151	aq.	Aqueous
152	ATP	Adenosine triphosphate
153	BRD	Background review document
154	CASRN	Chemical Abstracts Service Registry Number
155	CPSC	U.S. Consumer Product Safety Commission
156	CI	Confidence interval
157	Conc.	Concentration
158	CV	Coefficient of variation
159	DMF	<i>N,N</i> -dimethylformamide
160	DMSO	Dimethyl sulfoxide
161	EC2	Estimated concentration needed to produce a stimulation index of two
162		
163	EC2.5	Estimated concentration needed to produce a stimulation index of 2.5
164		
165	EC3	Estimated concentration needed to produce a stimulation index of three
166		
167	ECt	Estimated concentration needed to produce a stimulation index of a specified threshold
168		
169	ECETOC	European Centre for Ecotoxicology and Toxicology of Chemicals
170		
171	EPA	U.S. Environmental Protection Agency
172	FN	False negative
173	FP	False positive
174	GP	Guinea pig
175	HMT	Human maximization test
176	ICCVAM	Interagency Coordinating Committee on the Validation of Alternative Methods
177		
178	ILS	Integrated Laboratory Systems
179	ISO	International Organization for Standardization
180	IWG	Immunotoxicity Working Group
181	JaCVAM	Japanese Center for the Validation of Alternative Methods
182	K _{ow}	Octanol-water partition coefficient
183	LLNA	Murine local lymph node assay
184	LLNA: DA	Murine LLNA modified by Daicel Chemical Industries, Ltd. based on ATP content
185		
186	MEK	Methyl ethyl ketone
187	Min	Minimal
188	Mod	Moderate
189	Mol.	Molecular
190	NA	Not applicable
191	NICEATM	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods
192		

193	NT	Not tested
194	NTP	National Toxicology Program
195	OECD	Organisation for Economic Co-operation and Development
196	PBS	Phosphate buffered saline
197	Ref.	Reference
198	RLU	Relative luminescence units
199	SD	Standard deviation
200	SI	Stimulation index
201	SLS	Sodium lauryl sulfate
202	Stats.	Statistics
203	TG	Test guideline
204	Trad.	Traditional
205	U.S.	United States
206	Unk	Unknown
207	vs.	Versus

Interagency Coordinating Committee on the Validation of Alternative Methods: Agency Representatives

Agency for Toxic Substances and Disease Registry

- Moiz Mumtaz, Ph.D.

Consumer Product Safety Commission

- Marilyn L. Wind, Ph.D. (Chair)
- ◇ Kristina Hatlelid, Ph.D.
- Joanna Matheson, Ph.D.

Department of Agriculture

- Jodie Kulpa-Eddy, D.V.M. (Vice-Chair)
- ◇ Elizabeth Goldentyer, D.V.M.

Department of Defense

- Robert E. Foster, Ph.D.
- ◇ Patty Decot
- Peter J. Schultheiss, D.V.M., D.A.C.L.A.M.
- Harry Salem, Ph.D.

Department of Energy

- Michael Kuperberg, Ph.D.
- ◇ Marvin Stodolsky, Ph.D.

Department of the Interior

- Barnett A. Rattner, Ph.D.
- ◇ Sarah Gerould, Ph.D.

Department of Transportation

- George Cushmac, Ph.D.
- ◇ Steve Hwang, Ph.D.

Environmental Protection Agency

Office of Science Coordination and Policy

- Karen Hamernik, Ph.D.

Office of Research and Development

- ◇ Julian Preston, Ph.D.
- Suzanne McMaster, Ph.D.

Office of Pesticide Programs

- Amy Rispin, Ph.D.
- Deborah McCall

OECD Test Guidelines Program

- Jerry Smrcek, Ph.D.

- Principal agency representative
- ◇ Alternate principal agency representative

Food and Drug Administration

Office of the Commissioner

- Suzanne Fitzpatrick, Ph.D., D.A.B.T.

Center for Drug Evaluation and Research

- ◇ Abigail C. Jacobs, Ph.D.
- Paul C. Brown, Ph.D.

Center for Devices and Radiological Health

- Melvin E. Stratmeyer, Ph.D.
- Vasant G. Malshet, Ph.D., D.A.B.T.

Center for Biologics Evaluation and Research

- Richard McFarland, Ph.D., M.D.
- Ying Huang, Ph.D.

Center for Food Safety and Nutrition

- David G. Hattan, Ph.D.
- Robert L. Bronaugh, Ph.D.

Center for Veterinary Medicine

- Devaraya Jagannath, Ph.D.
- M. Cecilia Aguila, D.V.M.

National Center for Toxicological Research

- William T. Allaben, Ph.D.
- Paul Howard, Ph.D.

Office of Regulatory Affairs

- Lawrence D'Hoostelaere, Ph.D.

National Cancer Institute

- Alan Poland, M.D.
- ◇ T. Kevin Howcroft

National Institute of Environmental Health Sciences

- William S. Stokes, D.V.M., D.A.C.L.A.M.
- ◇ Raymond R. Tice, Ph.D.
- Rajendra S. Chhabra, Ph.D., D.A.B.T.
- Jerrold J. Heindel, Ph.D.

National Institute for Occupational Safety and Health

- Paul Nicolaysen, V.M.D.
- ◇ K. Murali Rao, M.D., Ph.D.

National Institutes of Health

- Margaret D. Snyder, Ph.D.

National Library of Medicine

- Pertti (Bert) Hakkinen, Ph.D.
- ◇ Jeanne Goshorn, M.S.

Occupational Safety and Health Administration

- Surender Ahir, Ph.D.

Acknowledgements

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Immunotoxicity Working Group (IWG)

U.S. Consumer Product Safety Commission

Joanna Matheson, Ph.D. (IWG Co-Chair)
Marilyn Wind, Ph.D.

U.S. Environmental Protection Agency

Office of Pesticide Programs

Masih Hashim, D.V.M., Ph.D.
Marianne Lewis
Deborah McCall
Timothy McMahon, Ph.D.
Amy Rispin, Ph.D.

Office of Prevention, Pesticides, and Toxic Substances

Ronald Ward, Ph.D.

Office of Research and Development

Marsha Ward, Ph.D.

Office of Science Coordination and Policy

Karen Hamernik, Ph.D.

U.S. Food and Drug Administration

Center for Devices and Radiological Health

Daniel Lyle, Ph.D.
Vasant G. Malshet, Ph.D., D.A.B.T.
Jeffrey Toy, Ph.D.

Center for Drug Evaluation and Research

Paul Brown, Ph.D.
Abigail Jacobs, Ph.D. (IWG Co-Chair)
Jiaqin Yao, Ph.D.

Center for Veterinary Medicine

Ruth Barratt, Ph.D., D.V.M.

National Institute of Environmental Health Sciences

Dori Germolec, Ph.D.
William S. Stokes, D.V.M., D.A.C.L.A.M.
Raymond R. Tice, Ph.D.

National Institute for Occupational Safety and Health

B. Jean Meade, D.V.M., Ph.D.

National Library of Medicine

Pertti (Bert) Hakkinen, Ph.D.

European Centre for the Validation of Alternative Methods – Liaison

Silvia Casati, Ph.D.

Japanese Center for the Validation of Alternative Methods – Liaison

Hajime Kojima, Ph.D.

**National Toxicology Program Interagency Center for the Evaluation of
Alternative Toxicological Methods (NICEATM)**

National Institute of Environmental Health Sciences

William Stokes, D.V.M., D.A.C.L.A.M.
Director; Project Officer

Raymond Tice, Ph.D.

Deborah McCarley
Special Assistant; Assistant Project Officer

NICEATM Support Contract Staff (Integrated Laboratory Systems [ILS], Inc.)

David Allen, Ph.D.

Eleni Salicru, Ph.D.

Thomas Burns, M.S.

Catherine Sprankle

Linda Litchfield

Frank Stack

Gregory Moyer, M.B.A.

Judy Strickland, Ph.D., D.A.B.T.

Michael Paris

173

174 **Statistical Consultant for ILS, Inc.**

175 Joseph Haseman, Ph.D.

176

Other Acknowledgements

177 ICCVAM and NICEATM gratefully acknowledge Kenji Idehara, Ph.D. of Daicel Chemical
178 Industries, Ltd. (Tokyo, Japan) and Takashi Omori, Ph.D. of Kyoto University School of
179 Public Health (Kyoto, Japan) for submitting data to NICEATM used for the evaluation of the
180 LLNA: DA test method.

181

Preface

182 In 1999, the U.S. Interagency Coordinating Committee on the Validation of Alternative
183 Methods (ICCVAM) recommended the murine (mouse) local lymph node assay (LLNA) as a
184 valid test method to assess the skin sensitization potential of most types of substances
185 (ICCVAM 1999). ICCVAM concluded that the LLNA (referred to herein as the “traditional
186 LLNA”) provided several advantages compared to the guinea pig method, including
187 elimination of potential pain and distress, use of fewer animals, less time required to perform,
188 and availability of dose-response information. United States and international regulatory
189 authorities subsequently accepted the traditional LLNA as an alternative test method for
190 allergic contact dermatitis testing. It is now commonly used around the world.

191 One disadvantage of the traditional LLNA is that it requires injection of a radioactive marker
192 to measure cell proliferation in lymph nodes. To avoid the use of radioactive markers,
193 scientists have recently developed several non-radioactive versions of the LLNA. In 2007,
194 the U.S. Consumer Product Safety Commission (CPSC) asked ICCVAM and the National
195 Toxicology Program Interagency Center for the Evaluation of Alternative Methods
196 (NICEATM) to evaluate the scientific validity of these non-radioactive versions. ICCVAM
197 assigned the nomination a high priority, and established the ICCVAM Immunotoxicity
198 Working Group (IWG) to work with NICEATM to review the current literature and evaluate
199 available data to assess the validity of three such test methods. A comprehensive draft
200 background review document (BRD) provided the information, data, and analyses supporting
201 the validation status of each of the non-radioactive test methods. ICCVAM also developed
202 draft test method recommendations for each test method regarding its usefulness and
203 limitations, test method protocol, performance standards, and future studies.

204 NICEATM and ICCVAM provided the draft BRDs and draft test method recommendations
205 to an international independent scientific peer review panel (referred to hereafter as “Panel”)
206 for their consideration at a public meeting on March 4-6, 2008. A report of the Panel meeting
207 was subsequently published on the NICEATM-ICCVAM website.¹ Both the Panel and
208 ICCVAM concluded that more information was needed before a recommendation on the
209 usefulness and limitations of each of the three test methods could be made. The Panel

¹ http://iccvam.niehs.nih.gov/methods/immunotox/llna_PeerPanel.htm.

210 recommended that NICEATM obtain additional existing data that was not available to the
211 Panel and reanalyze the performance of each non-radioactive LLNA test method. NICEATM
212 subsequently obtained additional data and prepared revised draft BRDs. ICCVAM also
213 prepared revised draft test method recommendations based on the revised draft BRDs. This
214 revised draft BRD addresses the validation database for the LLNA developed by Daicel
215 Chemical Industries, Ltd., based on adenosine triphosphate content (LLNA: DA).

216 The Panel will meet to consider the revised draft BRDs and to evaluate the extent to which
217 the available information supports the revised ICCVAM draft test method recommendations.
218 ICCVAM will consider the conclusions and recommendations of the Panel, along with
219 comments received from the public and the Scientific Advisory Committee on Alternative
220 Toxicological Methods (i.e., the ICCVAM-NICEATM advisory committee), and then
221 finalize the BRDs and test method recommendations. These will then be forwarded to
222 Federal agencies for their consideration and acceptance decisions, where appropriate.

223 We gratefully acknowledge the organizations and scientists who provided data and
224 information for this document. We also acknowledge the efforts of those individuals
225 contributing to the preparation of this revised draft BRD, including the following staff from
226 the NICEATM Support Contractor, Integrated Laboratory Systems, Inc.: David Allen, Ph.D.,
227 Thomas Burns, M.S., Gregory Moyer, M.B.A., Michael Paris, Eleni Salicru, Ph.D., Catherine
228 Sprankle, Frank Stack, and Judy Strickland, Ph.D. We also thank the members of the
229 ICCVAM IWG, chaired by Abigail Jacobs, Ph.D. (U.S. Food and Drug Administration) and
230 Joanna Matheson, Ph.D. (CPSC), and ICCVAM representatives who subsequently reviewed
231 and provided comments throughout the process leading to this final revised draft version.

232 Marilyn Wind, Ph.D.
233 Deputy Associate Executive Director
234 Directorate for Health Sciences
235 CPSC
236 Chair, ICCVAM

237 RADM William S. Stokes, D.V.M., D.A.C.L.A.M.
238 Assistant Surgeon General, U.S. Public Health Service
239 Director, NICEATM
240 Executive Director, ICCVAM

241
242 March 2009

243

Executive Summary

244 **Background**

245 In 1999, the Interagency Coordinating Committee on the Validation of Alternative Methods
246 (ICCVAM) recommended to U.S. Federal agencies that the murine local lymph node assay
247 (LLNA) is a valid substitute for currently accepted guinea pig (GP) test methods to assess the
248 allergic contact dermatitis (ACD) potential of many, but not all, types of substances. ACD is
249 an allergic skin reaction characterized by redness, swelling, and itching that can result from
250 contact with a sensitizing chemical or product. The recommendation was based on a
251 comprehensive evaluation that included an independent scientific peer review panel (Panel)
252 assessment of the validation status of the LLNA. The Panel report and the ICCVAM
253 recommendations (ICCVAM 1999) are available at the National Toxicology Program
254 Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)-
255 ICCVAM website.² The LLNA was subsequently incorporated into national and international
256 test guidelines for the assessment of skin sensitization (Organisation for Economic Co-
257 operation and Development [OECD] Test Guideline 429 [OECD 2002]; International
258 Organization for Standardization [ISO] 10993-10: Tests for Irritation and Sensitization [ISO
259 2002]; U.S. Environmental Protection Agency [EPA] Health Effect Testing Guidelines on
260 Skin Sensitization [EPA 2003]).

261 In 2007, the U.S. Consumer Product Safety Commission (CPSC) formally nominated several
262 activities related to the LLNA for evaluation by ICCVAM and NICEATM.³ One of the
263 nominated activities was assessment of the validation status of non-radioactive modifications
264 to the current version of the LLNA ([ICCVAM 1999; Dean et al. 2001] referred to hereafter
265 as the “traditional LLNA”), which uses radioactivity to detect sensitizers. The information
266 described in the original (i.e., January 2008) and this background review document (BRD)
267 was compiled by ICCVAM and NICEATM in response to this nomination. The BRD
268 provides a comprehensive review of available data and information regarding the usefulness
269 and limitations of one of these test methods, the LLNA based on adenosine triphosphate

² http://iccvam.niehs.nih.gov/docs/immunotox_docs/llna/llnarep.pdf.

³ http://iccvam.niehs.nih.gov/methods/immunotox/llnadocs/CPSC_LLNA_nom.pdf.

270 (ATP) content in the draining auricular lymph nodes (referred to hereafter as the “LLNA:
271 DA”).

272 ***Revisions to the LLNA: DA Evaluation***

273 NICEATM and ICCVAM convened an independent scientific peer review panel meeting on
274 March 4-6, 2008. The Panel peer reviewed the draft BRD and commented on the extent that
275 it supported the draft ICCVAM test method recommendations on the usefulness and
276 limitations of the LLNA: DA. Both ICCVAM and the Panel concluded that more information
277 was needed before a recommendation on the usefulness and limitations of the LLNA: DA
278 could be made.⁴ The Panel indicated that the following information was needed: a detailed
279 protocol, individual animal data, and an evaluation of interlaboratory reproducibility. The
280 Panel recommended that NICEATM obtain additional data in order to reanalyze the
281 performance of the LLNA: DA. In response to this recommendation, NICEATM obtained
282 additional LLNA: DA data from the test sponsor, which were used to update the evaluation.
283 These data include:

- 284 • Individual animal data for the LLNA: DA intralaboratory validation study of
285 31 substances (Idehara et al. 2008). These data were used in the updated
286 accuracy analyses represented in **Section 6.0**
- 287 • Individual animal data for 14 additional LLNA: DA substances tested in the
288 intralaboratory validation study (Idehara unpublished). These data were used
289 in the updated accuracy analyses represented in **Section 6.0**
- 290 • Individual animal data for the LLNA: DA two-phased interlaboratory
291 validation study of 14 substances (Omori et al. 2008). These data were used in
292 the updated accuracy analyses represented in **Section 6.0** and the additional
293 quantitative analyses of test method reproducibility, which are detailed in
294 **Section 7.0** of this BRD.

295 ***Test Method Protocol***

296 The test method protocol in this revised draft BRD is the same as the test method protocol
297 discussed in the January 2008 draft BRD. Daicel Chemical Industries, Ltd. developed the

⁴ http://iccvam.niehs.nih.gov/methods/immunotox/llna_PeerPanel.htm.

298 LLNA: DA test method based on modifications to the traditional LLNA (Yamashita et al.
299 2005). While the traditional LLNA assesses cellular proliferation by measuring the
300 incorporation of radioactivity into the DNA of dividing lymph node cells, the LLNA: DA
301 assesses cellular proliferation by measuring increases in ATP content in the lymph node as an
302 indicator of the cell number. In addition, the LLNA: DA also differs from the traditional
303 LLNA in the timing and administration of the test substance. In the traditional LLNA, the
304 test substance is applied on days 1, 2, and 3 and the auricular lymph nodes are excised on day
305 6. In the LLNA: DA, the test substance is applied on days 1, 2, 3, and 7 and the auricular
306 lymph nodes are excised on day 8. Furthermore, one hour prior to each application of the test
307 substance, 1% sodium lauryl sulfate is applied to increase absorption of the test substance
308 through the skin. A stimulation index (SI) is used to identify a substance as a sensitizer (i.e.,
309 the ratio of the mean ATP content of the substance treatment group to the mean ATP content
310 of the vehicle treatment group).

311 ***Validation Database***

312 The validation database in this revised draft BRD has been updated from the January 2008
313 draft BRD to include 15 additional substances. The accuracy and reliability of the LLNA:
314 DA was assessed using data submitted to NICEATM for 45 substances tested in one
315 laboratory (Idehara et al. 2008; Idehara unpublished) and 14 substances, one not previously
316 examined, tested in a two-phased interlaboratory validation study (17 laboratories). The
317 reference test data for these substances were obtained from the traditional LLNA, GP skin
318 sensitization tests, and/or human skin sensitization tests. One substance, benzocaine, yielded
319 both positive and negative results in the traditional LLNA and therefore was not considered
320 in the performance evaluation of the LLNA: DA. LLNA studies for another substance,
321 toluene 2,4-diisocyanate, were not conducted according to the traditional LLNA test method
322 protocol described (ICCVAM 1999; Dean et al. 2001). Of the remaining 44 substances with
323 sufficient traditional LLNA data, 32 were classified by the traditional LLNA as skin
324 sensitizers and 12 were classified as nonsensitizers.

325 ***Test Method Accuracy***

326 The accuracy evaluation in this revised draft BRD has been updated from the January 2008
327 draft BRD to include the results for 15 additional substances. Other revisions include the

328 evaluation of multiple decision criteria compared to traditional LLNA results ($SI \geq 2.0$ was
329 further compared with GP and human outcomes) and the additional evaluation of two
330 different criteria used simultaneously to classify sensitizers and nonsensitizers compared to
331 traditional LLNA results. Based on the evaluation of multiple decision criteria, the optimal
332 performance was achieved using $SI \geq 2.5$ to classify sensitizers and $SI \leq 1.7$ to classify
333 nonsensitizers. When these two criteria are used, false positive results (0/12) and false
334 negative results (0/32) are eliminated compared with the traditional LLNA. However, using
335 these criteria, 10 substances have an $SI > 1.7$ and an $SI < 2.5$, which includes five substances
336 that were sensitizers and five substances that were nonsensitizers in the traditional LLNA.
337 Other available information could be used to interpret LLNA: DA results when the SI falls
338 between 1.7 and 2.5, such as peptide reactivity. Forty percent (2/5) of the traditional LLNA
339 sensitizers in this range had peptide reactivity data (i.e., one substance had minimal peptide
340 reactivity and one substance had high peptide reactivity). Eighty percent (4/5) of the
341 traditional LLNA nonsensitizers in this range had peptide reactivity data (i.e., all four
342 substances had minimal peptide reactivity).

343 When using the decision criterion of $SI \geq 2.5$ to classify sensitizers versus nonsensitizers,
344 compared to the traditional LLNA, accuracy was 91% (40/44), with a false positive rate of
345 0% (0/12), and a false negative rate of 13% (4/32). Among the discordant substances, no
346 unique characteristics were identified that could be used as rationale for excluding any
347 particular types of substances from testing in the LLNA: DA.

348 ***Test Method Reliability – Intralaboratory Reproducibility***

349 The intralaboratory evaluation in this revised draft BRD has been updated from the January
350 2008 draft BRD to include, in addition to $SI \geq 3.0$, an evaluation of $SI \geq 2.5$ for the same
351 substances. Intralaboratory reproducibility for the LLNA: DA was assessed using data for
352 two substances (isoeugenol and eugenol) that were tested at varying concentrations in three
353 different experiments. The EC3 (estimated concentration needed to produce an SI of three)
354 coefficient of variation (CV) for the reproducibility of isoeugenol and eugenol was 21% and
355 11%, respectively. The EC2.5 (estimated concentration needed to produce an SI of 2.5) CV
356 for the reproducibility of isoeugenol and eugenol was 33% and 13%, respectively.

357 ***Test Method Reliability – Interlaboratory Reproducibility***

358 The interlaboratory reproducibility evaluation in this revised draft BRD is a new addition
359 because interlaboratory data were not available for evaluation in the January 2008 draft BRD.
360 This revised draft BRD also includes a reproducibility analysis using separate SI criteria to
361 identify sensitizers and nonsensitizers. The two-phased multilaboratory validation study
362 included 17 different laboratories in which 14 different substances were examined. In the
363 first phase of the study, 10 laboratories each tested up to 12 substances, while in the second
364 phase of the study seven laboratories (different from the 10 laboratories in the first phase of
365 the interlaboratory validation study) each tested up to five substances. In both studies, each
366 substance was tested once at three different doses, which were provided to the participating
367 laboratories by the validation study management team.

368 When using $SI \geq 2.5$ as the decision criterion, the qualitative (positive/negative)
369 interlaboratory concordance analysis for the 12 substances that were tested in up to 10
370 laboratories during the first phase of the LLNA: DA interlaboratory validation study resulted
371 in 100% (3/3 or 10/10) concordance for 10 substances (i.e., seven sensitizers and three
372 nonsensitizers in the traditional LLNA) and 67% (2/3) concordance for two substances (i.e.,
373 two sensitizers in the traditional LLNA). The CV values for the EC2.5 ranged from 26% (i.e.,
374 hexyl cinnamic aldehyde) to 133% (i.e., cobalt chloride) and the mean CV was 79%. The
375 qualitative interlaboratory concordance analysis for the five substances tested in up to seven
376 laboratories during the second phase of the validation study resulted in 100% (4/4 or 7/7)
377 concordance for four substances (i.e., three sensitizers and one nonsensitizer in the traditional
378 LLNA) and 75% (3/4) concordance for one substance (i.e., a sensitizer in the traditional
379 LLNA). The CV values for the EC2.5 ranged from 20% (i.e., hexyl cinnamic aldehyde) to
380 92% (i.e., cobalt chloride) and the mean CV was 62%.

381 When using $SI \geq 2.5$ to classify sensitizers and $SI \leq 1.7$ to classify nonsensitizers, the
382 concordance analysis for the 14 substances with multiple tests indicated that the SI results for
383 87% (27/31) of the tests that yielded $SI \leq 1.7$ were for substances that were classified as
384 nonsensitizers by the traditional LLNA; 13% (4/31) of the tests that yielded $SI \leq 1.7$ were for
385 substances that were classified as sensitizers by the traditional LLNA. Fifty-eight percent
386 (7/12) of the tests that yielded $1.7 < SI < 2.5$ were for substances that were classified as
387 sensitizers by the traditional LLNA.

388 *Animal Welfare Considerations*

389 The animal welfare considerations in this revised draft BRD have not changed from the
390 January 2008 draft BRD. The LLNA: DA will use the same number of animals when
391 compared to the updated ICCVAM-recommended LLNA protocol (ICCVAM 2009).
392 However, since use of the traditional LLNA is restricted in some institutions because it
393 involves radioactivity, availability and use of the non-radioactive LLNA: DA may lead to
394 further reduction in use of the GP tests, which would provide for reduced animal use and
395 increased refinement due to the avoidance of pain and distress in the LLNA procedure.

396 *Test Method Transferability*

397 The test method transferability considerations in this revised draft BRD have not changed
398 from the January 2008 draft BRD. The transferability of the LLNA: DA is expected to be
399 similar to the traditional LLNA. Notably, the test method developer indicates that when the
400 LLNA: DA test method is conducted, all the procedural steps from lymph node excision to
401 the determination of ATP content should be performed without delay since ATP content
402 decreases over time (Idehara et al. 2008; Omori et al. 2008). Compared to the traditional
403 LLNA, the LLNA: DA will not require laboratories, equipment, and licensing permits for
404 handling radioactive materials. The level of training and expertise needed to conduct the
405 LLNA: DA should be similar to the traditional LLNA except that the understanding and
406 practice of luciferase methodology is required.

407 *ICCVAM Revised Draft Test Method Recommendations*

408 ICCVAM developed revised draft test method recommendations for the LLNA: DA based on
409 the new data and analyses. Test method recommendations are provided for test method
410 usefulness and limitations, test method protocol, and future studies, in order to further
411 characterize its usefulness and limitations. These are provided in a separate document, *Draft*
412 *ICCVAM Test Method Recommendations, Non-Radioactive Murine Local Lymph Node*
413 *Assay: Modified by Daicel Chemical Industries, Ltd. Based on ATP Content Test Method*
414 *Protocol*.

415 **1.0 Introduction**

416 **1.1 Public Health Perspective**

417 Allergic contact dermatitis (ACD) is a frequent occupational health problem. According to
418 the U.S. Department of Labor Bureau of Labor Statistics, in 2005, 980 cases of ACD
419 involved days away from work.⁵ ACD develops in two phases, induction and elicitation. The
420 induction phase occurs when a susceptible individual is exposed topically to a skin-
421 sensitizing substance. Induction depends on the substance passing through the epidermis,
422 where it forms a hapten complex with dermal proteins. The Langerhans cells, the resident
423 antigen-presenting cells in the skin, process the hapten complex. The processed hapten
424 complex then migrates to the draining lymph nodes. Antigen presentation to T-lymphocytes
425 follows, which leads to the clonal expansion of these cells. At this point, the individual is
426 sensitized to the substance (Basketter et al. 2003; Jowsey et al. 2006). Studies have shown
427 that the magnitude of lymphocyte proliferation correlates with the extent to which
428 sensitization develops (Kimber and Dearman 1991, 1996).

429 The elicitation phase occurs when the individual is again topically exposed to the same
430 substance. As in the induction phase, the substance penetrates the epidermis, is processed by
431 the Langerhans cells, and presented to circulating T-lymphocytes. The antigen-specific T-
432 lymphocytes are then activated, which causes release of cytokines and other inflammatory
433 mediators. This release produces a rapid dermal immune response that can lead to ACD
434 (ICCVAM 1999; Basketter et al. 2003; Jowsey et al. 2006).

435 **1.2 Historical Background for the Murine Local Lymph Node Assay**

436 In 1999, the Interagency Coordinating Committee on the Validation of Alternative Methods
437 (ICCVAM) recommended that the murine local lymph node assay (LLNA) is a valid
438 substitute for currently accepted guinea pig (GP) test methods to assess the ACD potential of
439 many, but not all, types of substances. The recommendation was based on a comprehensive
440 evaluation that included an independent scientific peer review panel (Panel) assessment of
441 the validation status of the LLNA. The Panel report and the ICCVAM recommendations
442 (ICCVAM 1999) are available at the National Toxicology Program (NTP) Interagency

⁵ <http://www.bls.gov/>.

443 Center for the Evaluation of Alternative Toxicological Methods (NICEATM)-ICCVAM
444 website.⁶ ICCVAM forwarded recommendations to U.S. Federal agencies that the LLNA
445 should be considered for regulatory acceptance or other non-regulatory applications for
446 assessing the ACD potential of substances, while recognizing that some testing situations
447 would still require the use of traditional GP test methods (ICCVAM 1999; Sailstad et al.
448 2001). The LLNA was subsequently incorporated into national and international test
449 guidelines for the assessment of skin sensitization (Organisation for Economic Co-operation
450 and Development [OECD] Test Guideline [TG] 429 [OECD 2002]; International Standards
451 Organization [ISO] 10993-10: Tests for Irritation and Sensitization [ISO 2002]; U.S.
452 Environmental Protection Agency [EPA] Health Effect Testing Guidelines on Skin
453 Sensitization [EPA 2003]).

454 On January 10, 2007, the U.S. Consumer Product Safety Commission (CPSC) formally
455 nominated several activities related to the LLNA for evaluation by ICCVAM and
456 NICEATM.⁷ One of the nominated activities was an assessment of the validation status of
457 non-radioactive modifications to the current version of the LLNA ([ICCVAM 1999; Dean et
458 al. 2001] referred to hereafter as the “traditional LLNA”), which uses radioactivity to detect
459 sensitizers. The information described in this draft background review document (BRD) was
460 compiled by ICCVAM and NICEATM in response to this nomination. The draft BRD
461 provides a comprehensive review of available data and information regarding the usefulness
462 and limitations of one of these test methods, the LLNA based on adenosine triphosphate
463 (ATP) content in the draining auricular lymph nodes (referred to hereafter as the “LLNA:
464 DA”). Further, ICCVAM and its IWG developed draft test method recommendations based
465 on this evaluation.

466 A Panel reviewed the original draft BRD in March 2008 to evaluate the extent to which the
467 information contained in the draft BRD supported the draft test method recommendations.
468 The Panel concluded that additional information was needed to evaluate the test method,
469 including a detailed test method protocol, quantitative data for the test method, and an
470 evaluation of interlaboratory reproducibility. In response to this recommendation, NICEATM

⁶ http://iccvam.niehs.nih.gov/docs/immunotox_docs/llna/llnarep.pdf.

⁷ http://iccvam.niehs.nih.gov/methods/immunotox/llnadocs/CPSC_LLNA_nom.pdf.

471 obtained additional LLNA: DA data and information, which were used in this revised draft
472 BRD for review by the Panel. These data and information include:

- 473 • A detailed description of the standard operating procedure of the LLNA: DA
474 test method used for the two-phased interlaboratory validation study (see
475 **Appendix A**)
- 476 • Individual animal data for the LLNA: DA intralaboratory validation study of
477 31 substances (Idehara et al. 2008). These data were used in the updated
478 accuracy analyses represented in **Section 6.0**
- 479 • Data for 14 additional LLNA: DA intralaboratory substances (Idehara
480 unpublished). These data were used in the updated accuracy analyses
481 represented in **Section 6.0**
- 482 • Individual animal data for the LLNA: DA two-phased interlaboratory
483 validation study of 14 substances (Omori et al. 2008). These data were used in
484 the updated accuracy analyses represented in **Section 6.0** and the additional
485 quantitative analyses of test method reproducibility, which are detailed in
486 **Section 7.0** of this BRD.

487 ICCVAM will consider the conclusions and recommendations of the Panel, along with
488 comments received from the public and its advisory committee (i.e., the Scientific Advisory
489 Committee on Alternative Toxicological Methods), when developing the final BRD and final
490 test method recommendations on the usefulness and limitations of each non-radioactive
491 alternative LLNA test method that is being considered.

492 **1.3 The LLNA: DA**

493 The LLNA: DA was developed by Daicel Chemical Industries, Ltd. as a non-radioactive
494 modification (Yamashita et al. 2005) to the current version of the LLNA. The traditional
495 LLNA assesses cellular proliferation by measuring the incorporation of radioactive
496 thymidine or iodine into the DNA of dividing lymph node cells. In contrast, the LLNA: DA
497 assesses ATP content in the lymph node by employing a luciferin-luciferase assay to measure
498 bioluminescence. Since ATP content is linearly related to living cell number, this
499 measurement serves as a surrogate for cell number at the time of sampling.

500 This document provides:

- 501 • A comprehensive summary of the LLNA: DA test method protocol
- 502 • The substances used in the validation of the test method and the test results
- 503 • The performance characteristics (accuracy and reliability) of the test method
- 504 • Animal welfare considerations
- 505 • Other considerations relevant to the usefulness and limitations of this test
- 506 method (e.g., transferability, cost of the test method).

507 **2.0 LLNA: DA Test Method Protocol**

508 The test method protocol in this revised draft BRD is the same as the test method protocol
509 discussed in the January 2008 draft BRD. Notably, this revised draft BRD now includes a
510 detailed standard operating procedure for the LLNA: DA test method and supplemental data
511 evaluating the effect of 1% sodium lauryl sulfate (SLS) pre-treatment on lymph node
512 proliferation that was not available for inclusion in the January 2008 draft BRD (**Appendix**
513 **A**). The LLNA: DA test method protocol (**Appendix A**) differs from the ICCVAM-
514 recommended test method protocol for the traditional LLNA (ICCVAM 2009) in the method
515 used to assess lymphocyte proliferation in the auricular lymph nodes (**Table 2-1**). In
516 addition, there are substantive differences between the two test method protocols regarding
517 test substance application and timing for the collection of the lymph nodes. In the traditional
518 LLNA, the test substance is administered on three consecutive days (days 1, 2, and 3). On
519 day 6, radiolabeled thymidine or iodine is administered via the tail vein and the lymph nodes
520 are excised five hours later. A lymph node cell suspension is then prepared and radioactive
521 thymidine or iodine incorporation is determined by β -scintillation or γ -scintillation counting,
522 respectively. In the LLNA: DA, the test substance is applied on days 1, 2, 3, and additionally
523 on day 7. During the initial development of the LLNA: DA, the study group (Yamashita et al.
524 2005) determined the optimal dosing schedule by evaluating whether the addition of a fourth
525 application (day 7) was useful for increasing lymph node proliferation. Based on a
526 statistically significant increase in lymph node weight-based stimulation indexes (SIs) for
527 mice that received a fourth application (day 7) of the test substance, this test method protocol
528 was chosen. Furthermore, one hour prior to each application of the test substance, a solution
529 of 1% SLS is applied to the dorsum of the treated ears to increase absorption of the test

530 substance across the skin (van Och et al. 2000). Various researchers have shown that a
531 solution of 1% SLS does not elicit a positive response in the traditional LLNA but when
532 applied prior to test substance administration there is generally an increased response
533 compared to the test substance alone (van Och et al. 2000; De Jong et al. 2002). Similar
534 results were observed by Idehara et al. (2008) (see also **Appendix A**). Lastly, twenty-four to
535 30 hours after the last test substance application (day 7), the auricular lymph nodes are
536 excised and a lymph node cell suspension is prepared, and the ATP content is measured by
537 luciferin-luciferase assay.

538

538 **Table 2-1 Comparison of the LLNA: DA and Traditional LLNA Experimental**
 539 **Procedure**

	Days 1, 2, & 3	Days 4 & 5	Day 6	Day 7	Day 8
LLNA: DA	<ul style="list-style-type: none"> • Pretreat with 1% SLS solution • After one hour, apply 25 µL of test substance or vehicle to dorsum of each ear 	No Treatment	No Treatment	<ul style="list-style-type: none"> • Pretreat with 1% SLS solution • After one hour, apply 25 µL of test substance or vehicle to dorsum of each ear 	<ul style="list-style-type: none"> • Excision of auricular lymph nodes • Measurement of ATP content in lymph node cells
Traditional LLNA	<ul style="list-style-type: none"> • Apply 25 µL of test substance or vehicle to dorsum of each ear 	No Treatment	<ul style="list-style-type: none"> • Administer ³H-thymidine or ¹²⁵I via tail vein • Excision of auricular lymph nodes • Measurement of radioactivity incorporated into lymph node cells 	No Treatment	No Treatment

540 Abbreviations: ATP = adenosine triphosphate; ³H = tritiated; ¹²⁵I = iodine-125; LLNA = murine local lymph node assay;
 541 LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content; SLS =
 542 sodium lauryl sulfate.
 543

544 2.1. Decision Criteria

545 Similar to the traditional LLNA, an SI is used in the LLNA: DA to distinguish skin
 546 sensitizers from nonsensitizers. The formula for calculating the SI in the LLNA: DA is the
 547 ratio of the mean ATP content of the auricular lymph nodes collected from the test substance
 548 treatment group to the mean ATP content of the auricular lymph nodes collected from the
 549 vehicle treatment group (measured in relative luminescence units; RLU)

$$550 \quad SI = \frac{\text{mean ATP content of auricular lymph nodes in test treatment group (RLU)}}{\text{mean ATP content of auricular lymph nodes in vehicle treatment group (RLU)}}$$

551 In the intra- and interlaboratory validation studies for the LLNA: DA, an SI ≥ 3.0 was used
 552 as the threshold for labeling a substance as a sensitizer, which is the same threshold used in
 553 the traditional LLNA. As noted in **Section 6.0**, alternative decision criteria are evaluated in
 554 this revised draft BRD to determine the threshold that provides optimum performance.

555

555 **3.0 LLNA: DA Validation Database**

556 The validation database in this revised draft BRD has been updated from the January 2008
557 draft BRD to include 15 additional substances. To evaluate the usefulness and limitations of
558 the LLNA: DA, Daicel Chemical Industries, Ltd., tested a total of 45 substances in one
559 laboratory (Idehara et al. 2008; Idehara unpublished data). They further evaluated two of the
560 45 substances (i.e., isoeugenol and eugenol) in the LLNA: DA at varying concentrations in
561 three different experiments in order to assess intralaboratory reproducibility. In addition, a
562 two-phased interlaboratory validation study evaluated the reproducibility of the LLNA: DA
563 (**Section 7.0**). In the first phase, 10 laboratories tested 12 coded substances (**Table 7-2**) and
564 in the second phase, seven different laboratories tested five coded substances (**Table 7-3**).
565 Between the 17 laboratories, 14 different substances were examined and one of those
566 substances, 3-aminophenol, was not previously tested among the 45 substances in the
567 intralaboratory validation study.

568 Taken together, all 46 substances tested in the LLNA: DA were previously tested in the
569 traditional LLNA and data for 39 of the substances were considered in the original ICCVAM
570 evaluation (ICCVAM 1999). Cinnamic alcohol, diethyl maleate, diethyl phthalate, ethyl
571 acrylate, glutaraldehyde, methyl methacrylate, and toluene 2,4-diisocyanate were the seven
572 substances tested in the LLNA: DA not evaluated in the ICCVAM 1999 report. Of the 46
573 substances tested in the LLNA: DA, 33 were classified by the traditional LLNA as skin
574 sensitizers,⁸ 12 were classified as nonsensitizers, and one (i.e., benzocaine) was classified as
575 equivocal due to highly variable results and therefore was not included in the performance
576 analyses (ICCVAM 1999)⁹ (**Table 3-1**). For the sensitizers in the traditional LLNA, the
577 range of traditional LLNA EC3 values (estimated concentrations needed to produce a
578 stimulation index of three) was from 0.009% to 90% (**Table 3-1**). Similar to benzocaine,
579 traditional LLNA data for toluene 2,4-diisocyanate, not evaluated in the original ICCVAM
580 1999 report, were not suitable for comparison. The LLNA test method protocol followed for
581 the study that tested toluene 2,4-diisocyanate (van Och et al. 2000) was a modified version of

⁸ Resorcinol was classified as a nonsensitizer based on original LLNA data (ICCVAM 1999) but recent LLNA data have instead suggested that it is actually a sensitizer (Basketter et al. 2007) and is therefore classified as a sensitizer for this evaluation.

⁹ A series of 12 tests conducted in two laboratories resulted in some positive results that were not reproducible (Basketter et al. 1995).

582 the traditional LLNA which was not performed in accordance with OECD TG 429 (OECD
583 2002) or ICCVAM 1999 and Dean et al. 2001. One variation was that the BALB/c strain of
584 mouse was used for the experiments, and not the CBA/Ca or CBA/J strains as specified by
585 ICCVAM (1999), Dean et al. (2001) or OECD TG 429 (2002). In addition, the ears of the
586 mice were pretreated with a solution of 1% SLS before treatment with the test substance. The
587 authors also stated that the auricular lymph nodes were excised and pooled for each animal.
588 Thus, of the 46 substances with LLNA: DA data and traditional LLNA data, 44 were
589 included in the accuracy analyses described in **Section 6.0**.

590 **Appendix B** provides information on the physico-chemical properties (e.g., physical form),
591 Chemical Abstracts Service Registry Number (CASRN), and chemical class for each
592 substance tested. When available, chemical classes for each substance were retrieved from
593 the National Library of Medicine's ChemID Plus database. If chemical classes were not
594 located, they were assigned for each test substance using a standard classification scheme,
595 based on the National Library of Medicine Medical Subject Headings classification system.¹⁰
596 A substance could be assigned to more than one chemical class; however, no substance was
597 assigned to more than three classes. Classification of substances into chemical classes is not
598 intended to indicate the impact of structure on biological activity with respect to sensitization
599 potential. Instead, chemical class information is being presented to provide an indication of
600 the variety of structural elements that are present in the substances that were evaluated in this
601 analysis.

602

¹⁰ <http://www.nlm.nih.gov/mesh/meshhome.html>.

602 **Table 3-1 Traditional LLNA EC3 Values and Chemical Classifications of**
 603 **Substances Tested in the LLNA: DA**

Substance Name	Chemical Class ¹	Traditional LLNA EC3 (%) ²	No. ³
5-Chloro-2-methyl-4-isothiazolin-3-one ^b	Sulfur Compounds; Heterocyclic Compounds	0.009	1
p-Benzoquinone ^b	Quinones	0.010	1
2,4-Dinitrochlorobenzene ^{a, c}	Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Nitro Compounds	0.049	15
Benzalkonium chloride ^a	Amines; Onium Compounds	0.070 ⁴	1
Glutaraldehyde ^{a, c}	Aldehydes	0.080	3
p-Phenylenediamine ^a	Amines	0.110	6
Toluene 2,4-diisocyanate ^{5, a}	Hydrocarbons, Cyclic; Isocyanates	0.110	1
Potassium dichromate ^{a, d}	Inorganic Chemical, Chromium Compounds; Inorganic Chemical, Potassium Compounds	0.170	12
Propyl gallate ^b	Carboxylic Acids	0.320	1
Phthalic anhydride ^a	Anhydrides; Carboxylic Acids	0.360	1
Formaldehyde ^{a, c}	Aldehydes	0.500	4
Cobalt chloride ^{a, c, d}	Inorganic Chemical, Elements; Inorganic Chemical, Metals	0.600	2
Isoeugenol ^{a, c}	Carboxylic Acids	1.540	47
2-Mercaptobenzothiazole ^a	Heterocyclic Compounds	1.700	1
Cinnamic aldehyde ^a	Aldehydes	1.910	6
3-Aminophenol ^c	Amines; Phenols	3.200	1
Benzocaine ^a	Carboxylic Acids	3.400 ⁶	1
Diethyl maleate ^b	Carboxylic Acids	3.600	4
Trimellitic anhydride ^a	Anhydride; Carboxylic Acids	4.710	2
Nickel (II) sulfate hexahydrate ^{a, c, d}	Inorganic Chemical, Elements; Inorganic Chemical, Metals	4.800	1
Resorcinol ^a	Phenols	6.330	1
Sodium lauryl sulfate ^a	Alcohols; Sulfur Compounds; Lipids	8.080	5
Citral ^a	Hydrocarbons, Other	9.170	6
Hexyl cinnamic aldehyde ^{a, c, d}	Aldehydes	9.740	21
Eugenol ^a	Carboxylic Acids	10.090	11
Abietic acid ^{a, c}	Hydrocarbons, Cyclic; Polycyclic Compounds	11.920	5
Phenyl benzoate ^b	Carboxylic Acids	13.600	3
Cinnamic alcohol ^b	Alcohols	21.000	1
Hydroxycitronellal ^a	Hydrocarbons, Other	23.750	6
Imidazolidinyl urea ^a	Urea	24.000	1
Ethylene glycol dimethacrylate ^b	Carboxylic Acids	28.000	1
Butyl glycidyl ether ^b	Ethers	30.900	1
Ethyl acrylate ^b	Carboxylic Acids	32.800	2
Methyl methacrylate ^b	Carboxylic Acids	90.000	1
1-Bromobutane ^a	Hydrocarbons, Halogenated	NA	1
Chlorobenzene ^a	Hydrocarbons, Cyclic; Hydrocarbons, Halogenated	NA	1
Diethyl phthalate ^a	Carboxylic Acids	NA	1
Dimethyl isophthalate ^{b, c}	Carboxylic Acids	NA	1
Hexane ^a	Hydrocarbons, Acyclic	NA	1
Isopropanol ^{a, c}	Alcohols	NA	1
Lactic acid ^{a, d}	Carboxylic Acids	NA	1

Substance Name	Chemical Class ¹	Traditional LLNA EC3 (%) ²	No. ³
Methyl salicylate ^{a, c}	Carboxylic Acids; Phenols	NA	9
Propylparaben ^a	Carboxylic Acids; Phenols	NA	1
Nickel (II) chloride ^b	Inorganic Chemical, Elements; Inorganic Chemical, Metals	NA	2
Salicylic acid ^b	Phenols; Carboxylic Acids	NA	1
Sulfanilamide ^b	Hydrocarbons, Cyclic; Sulfur Compounds	NA	1

604 Abbreviations: EC3 = estimated concentration needed to produce a stimulation index of three; LLNA = murine local lymph
605 node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP
606 content; NA = not applicable; No. = number.

607 ¹Chemical classifications based on the Medical Subject Headings classification for chemicals and drugs, as developed by the
608 National Library of Medicine: <http://www.nlm.nih.gov/mesh/meshhome.html>.

609 ²The traditional LLNA EC3 (stimulation index needed to produce a threshold of three) listed for each substance is from
610 traditional LLNA studies that used the same vehicle as the LLNA: DA (**Appendix D**), except where noted.

611 ³Number of traditional LLNA studies from which the data were obtained.

612 ⁴Benzalkonium chloride was tested in the LLNA: DA using acetone: olive oil (4:1) as the vehicle (**Appendix D**) but is
613 classified as a sensitizer in the traditional LLNA based on results using acetone as the vehicle.

614 ⁵Not included in accuracy analyses. Comparable LLNA reference data from modified LLNA test (van Och et al. 2000).

615 ⁶Not included in accuracy analyses. EC3 value reported in **Table 3-1** for benzocaine is based on data from the NICEATM
616 database but variable and equivocal responses were reported by Basketter et al. (1995) and in the 1999 ICCVAM report.

617 ^aSubstance tested in intralaboratory validation study (Idehara et al. 2008).

618 ^bSubstance tested in intralaboratory validation study (Idehara unpublished data).

619 ^cSubstance tested in phase one of two-phased interlaboratory validation study (Omori et al. 2008).

620 ^dSubstance tested in phase two of two-phased interlaboratory validation study (Omori et al. 2008).

621

622

622 **4.0 Reference Data**

623 As mentioned in **Section 3.0**, 44 of the 46 substances tested in the LLNA: DA are included in
624 the accuracy analyses described in **Section 6.0**. The traditional LLNA reference data used for
625 the accuracy analyses comparisons are from ICCVAM (1999) (**Appendix C**) for 11 of those
626 44 substances. The traditional LLNA reference data for the remaining substances (i.e.,
627 benzalkonium chloride, cinnamic alcohol, diethyl maleate, diethyl phthalate, ethyl acrylate,
628 formaldehyde, glutaraldehyde, imidazolidinyl urea, methyl methacrylate, and nickel [II]
629 sulfate hexahydrate) were obtained from other sources (**Appendix C**) (Gerberick et al. 1992;
630 Hilton et al. 1998; Ryan et al. 2002; Basketter et al. 2005; Gerberick et al. 2005; Betts et al.
631 2006). In addition, Basketter et al. (2007) reassessed the skin sensitization potential of
632 resorcinol in the LLNA, in accordance with OECD TG 429 (2002), which updates
633 information in the ICCVAM 1999 report and from Gerberick et al. (2005) that had
634 previously stated that this substance tested negative in the LLNA.

635 The reference data for the GP tests (guinea pig maximization test or Buehler test) and human
636 tests (human maximization test, human patch test allergen, or other human data) were
637 obtained from Vandenberg and Epstein (1963), Kligman (1966), Marzulli and Maibach
638 (1974), Jordan and King (1977), Klecak et al. (1977), Marzulli and Maibach (1980), Van der
639 Walle et al. (1982), Gad et al. (1986), Robinson et al. (1990), Gerberick et al. (1992),
640 ICCVAM (1999), Basketter et al. (1999, 2001, 2005, 2007), Kwon et al. (2003), Schneider
641 and Akkan (2004), or Betts et al. (2006).

642 An independent quality assurance contractor for the NTP audited the traditional LLNA data
643 provided in the ICCVAM 1999 report. Audit procedures and findings are presented in the
644 quality assurance report on file at the National Institute of Environmental Health Sciences.
645 The audit supports the conclusion that the transcribed test data in the submission were
646 accurate, consistent, and complete as compared to the original study records.

647

647 **5.0 LLNA: DA Test Method Data and Results**

648 The test method data in this revised draft BRD has been updated from the January 2008 draft
649 BRD to include the individual animal data for all the LLNA: DA results evaluated in this
650 BRD that are from published studies (Idehara et al. 2008; Omori et al. 2008). **Appendix C**
651 represents a summary of substances for which there are LLNA: DA data. Forty-five of the
652 substances are from an intralaboratory validation study (Idehara et al. 2008; Idehara
653 unpublished data). In addition, 14 substances evaluated in an independent two-phased
654 interlaboratory validation study are included (Omori et al. 2008). One of the 14 substances
655 (3-aminophenol) was not assessed among the 45 substances evaluated in the intralaboratory
656 validation study. Taking these studies together, **Appendix C** contains information for 46
657 different substances, all with available LLNA: DA and traditional LLNA data, although
658 sufficient comparative LLNA data is only available for 44 of the 46 substances (**Section 3.0**).
659 In addition, 42 of the 46 substances examined in the LLNA: DA have GP data and 43 of the
660 46 substances tested have human skin sensitization data. Based on Idehara et al. (2008,
661 unpublished data), the 45 substances tested in the intralaboratory study were not coded prior
662 to testing. However, the two-phased interlaboratory validation study used coded substances
663 (Omori et al. 2008). Original data for these studies have been received.

664

664 **6.0 LLNA: DA Test Method Accuracy**

665 The accuracy evaluation in this revised draft BRD has been updated from the January 2008
666 draft BRD to include the results for 15 additional substances. Other revisions include the
667 evaluation of multiple decision criteria of which $SI \geq 2.0$ was chosen, based on performance
668 in the LLNA: DA, to be further analyzed and the additional evaluation of two different
669 criteria used simultaneously to classify sensitizers and nonsensitizers.

670 A critical component of a formal evaluation of the validation status of a test method is an
671 assessment of the accuracy of the proposed test method when compared to the current
672 reference test method (ICCVAM 2003). Additional comparisons should also be made against
673 any available human data or experience from testing or accidental exposures. This aspect of
674 assay performance is typically evaluated by calculating:

- 675 • Accuracy (concordance): the proportion of correct outcomes (positive and
676 negative) of a test method
- 677 • Sensitivity: the proportion of all positive substances that are classified as
678 positive
- 679 • Specificity: the proportion of all negative substances that are classified as
680 negative
- 681 • False positive rate: the proportion of all negative substances that are
682 incorrectly identified as positive
- 683 • False negative rate: the proportion of all positive substances that are
684 incorrectly identified as negative.

685 **6.1 LLNA: DA Database Used for the Accuracy Analysis**

686 An accuracy analysis for the LLNA: DA test method was conducted using data from the
687 intralaboratory validation study and the two-phased interlaboratory validation study. Taken
688 together, LLNA: DA test data were available for 46 different substances, 44 of which had
689 sufficient comparative LLNA: DA and traditional LLNA data to conduct an accuracy
690 analysis (**Section 3.0**). Thus, of the 44 substances included in the accuracy analysis, 40 had
691 available LLNA: DA, traditional LLNA, and GP data and 41 had available LLNA: DA,

692 traditional LLNA, and human data. Classification of substances and data available for each
693 substance are provided in **Appendix C**.

694 Multiple LLNA: DA tests were available for 14 substances tested in the intralaboratory
695 (Idehara et al. 2008; Idehara unpublished data) and the two-phased interlaboratory LLNA:
696 DA studies (Omori et al. 2008). For the accuracy analysis, the test results were combined so
697 that each substance was represented by one overall result for the SI analyzed and represented
698 the outcome that was most prevalent. For example, when using $SI \geq 3.0$ as the decision
699 criterion, cobalt chloride was positive because five of the eight LLNA: DA results were
700 positive (**Appendix D**).

701 **6.2 Accuracy Analysis Using the $SI \geq 3.0$ Decision Criterion**

702 The performance characteristics of the LLNA: DA test method were first evaluated using the
703 decision criterion of $SI \geq 3.0$ to identify sensitizers, which was the threshold for a positive
704 response used in both the intralaboratory and two-phased interlaboratory validation studies
705 (**Appendix A**).

706 *6.2.1 Accuracy vs. the Traditional LLNA*

707 Based on the available data (i.e., 44 substances), when compared to the traditional LLNA, the
708 LLNA: DA had an accuracy of 91% (40/44), a sensitivity of 88% (28/32), a specificity of
709 100% (12/12), a false positive rate of 0% (0/12), and a false negative rate of 13% (4/32)
710 (**Table 6-1**).

711 *6.2.2 Accuracy vs. Guinea Pig Data*

712 When the accuracy statistics for the LLNA: DA and the traditional LLNA were compared for
713 substances with available LLNA: DA, traditional LLNA, and GP data, and GP results served
714 as the reference data, the LLNA: DA had a lower accuracy (78% [31/40] vs. 85% [34/40]),
715 sensitivity (85% [22/26] vs. 96% [25/26]), the same specificity (64% [9/14]) and false
716 positive rate (36% [5/14]), and higher false negative rate (15% [4/26] vs. 4% [1/26]) relative
717 to the traditional LLNA (**Table 6-1**).

718 *6.2.3 Accuracy vs. Human Data*

719 When substances with only comparative LLNA: DA, traditional LLNA, and human data
720 were evaluated, and human outcomes served as the reference point, the LLNA: DA had

721 lower accuracy (78% [32/41] vs. 88% [36/41]) and sensitivity (76% [26/34] vs. 88%
722 [30/34]), the same specificity (86% [6/7]) and false positive rate (14% [1/7]), and higher false
723 negative rate (24% [8/34] vs. 12% [4/34]) relative to the traditional LLNA (**Table 6-1**).

724 **Table 6-1 Performance of the LLNA: DA in Predicting Skin Sensitization Potential Using Decision Criterion of SI \geq 3.0 to**
 725 **Identify Sensitizers**

Comparison	n ¹	Accuracy		Sensitivity		Specificity		False Positive Rate		False Negative Rate		Positive Predictivity		Negative Predictivity	
		%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²
LLNA: DA vs. Traditional LLNA	44	91	40/44	88	28/32	100	12/12	0	0/12	13	4/32	100	28/28	75	12/16
Substances with LLNA: DA, Traditional LLNA, and GP Data															
LLNA: DA vs. Traditional LLNA	40	93	37/40	90	27/30	100	10/10	0	0/10	10	3/30	100	27/27	77	10/13
LLNA: DA vs. GP³	40	78	31/40	85	22/26	64	9/14	36	5/14	15	4/26	81	22/27	69	9/13
Traditional LLNA vs. GP³	40	85	34/40	96	25/26	64	9/14	36	5/14	4	1/26	83	25/30	90	9/10
Substances with LLNA: DA, Traditional LLNA, and Human Data															
LLNA: DA vs. Traditional LLNA	41	90	37/41	87	27/31	100	10/10	0	0/10	13	4/31	100	27/27	71	10/14
LLNA: DA vs. Human⁴	41	78	32/41	76	26/34	86	6/7	14	1/7	24	8/34	96	26/27	43	6/14
Traditional LLNA vs. Human⁴	41	88	36/41	88	30/34	86	6/7	14	1/7	12	4/34	97	30/31	60	6/10

726 Abbreviations: GP = guinea pig; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on
 727 ATP content; No. = number; vs. = versus.

728 ¹n = Number of substances included in this analysis.

729 ²The proportion on which the percentage calculation is based.

730 ³GP refers to outcomes obtained by studies conducted using either the guinea pig maximization test or the Buehler test.

731 ⁴Human refers to outcomes obtained by studies conducted using the human maximization test, inclusion of the test substance in a human patch test allergen kit, and/or published
 732 clinical case studies/reports.

733 **6.3 Accuracy Analysis (SI \geq 3.0) Based on ICCVAM-recommended LLNA**
734 **Performance Standards Reference Substances**

735 ICCVAM has developed recommended test method performance standards for the traditional
736 LLNA (ICCVAM 2009),¹¹ which are proposed to evaluate the performance of modified
737 LLNA test methods that are mechanistically and functionally similar to the traditional
738 LLNA. Since the validation studies for the LLNA: DA test method were completed prior to
739 the development of LLNA performance standards, the LLNA: DA is not being evaluated
740 using the ICCVAM-recommended LLNA performance standards. Thus, evaluations of the
741 LLNA: DA test substances to the ICCVAM-recommended LLNA performance standards test
742 substances are shown to provide a general comparison to a set list of reference substances (18
743 required reference substances and four optional reference substances) that represent a diverse
744 substance group. In addition, the ICCVAM-recommended LLNA performance standards are
745 not applicable to the LLNA: DA test method due to two main differences between the
746 LLNA: DA and traditional LLNA test method protocols (i.e., 1% SLS pre-treatment prior to
747 test substance application and an additional test substance application on day 7) (**Section**
748 **2.0**).

749 As shown in **Table 6-2**, all of the 18 required reference substances and three of the four
750 optional reference substances included in the ICCVAM-recommended LLNA performance
751 standards have been tested in the LLNA: DA. When compared to the traditional LLNA, the
752 LLNA: DA at SI \geq 3.0 predicted the same sensitization classification for 16 of the 18
753 required ICCVAM-recommended reference substances tested. One discordant substance, 2-
754 mercaptobenzothiazole, was classified as a sensitizer based on traditional LLNA results (i.e.,
755 EC3 of 1.7%) but as a nonsensitizer based on LLNA: DA data. As indicated in **Table 6-2**,
756 *N,N*-dimethylformamide (DMF) was the vehicle used in both the traditional LLNA and the
757 LLNA: DA tests for 2-mercaptobenzothiazole. The positive result for 2-
758 mercaptobenzothiazole reported in the ICCVAM LLNA performance standards was based on
759 one LLNA experiment that tested the substance at 1%, 3%, and 10% (Gerberick et al. 2005).
760 By comparison, the negative result for 2-mercaptobenzothiazole obtained with the LLNA:
761 DA test method was based on one LLNA: DA experiment that tested the substance at 10%,

¹¹ http://iccvam.niehs.nih.gov/methods/immunotox/llna_PerfStds.htm.

762 25%, and 50% (Idehara et al. 2008). The highest dose tested for 2-mercaptobenzothiazole in
763 the traditional LLNA was the lowest dose tested in the LLNA: DA (i.e., 10%) and resulted in
764 an SI of 8.6 versus 2.0, respectively.

765 Notably, a review of the original LLNA: DA laboratory records for 2-mercaptobenzothiazole
766 indicated that the concurrent positive control (i.e., 10% eugenol in DMF) failed to yield an
767 $SI \geq 3.0$. Consequently the test method developers should have repeated the test for 2-
768 mercaptobenzothiazole to ensure that the result obtained was correctly classified as negative
769 and not the result of a failed experiment. This could explain the discordant result obtained
770 between the traditional LLNA and the LLNA: DA test method for this test substance.

771 The second discordant substance, methyl methacrylate, was classified as a sensitizer based on
772 traditional LLNA results (i.e., EC₃ of 90%) but as a nonsensitizer based on LLNA: DA data.
773 As indicated in **Table 6-2**, acetone: olive oil (4:1; AOO) was the vehicle used in both the
774 traditional LLNA and the LLNA: DA tests for methyl methacrylate. The positive result for
775 methyl methacrylate reported in the ICCVAM LLNA performance standards was based on
776 one LLNA experiment that tested the substance at 10%, 30%, 50%, and 100% (Betts et al.
777 2006). By comparison, the negative result for 2-mercaptobenzothiazole obtained with the
778 LLNA: DA test method was based on one LLNA: DA experiment that tested the substance at
779 25%, 50%, 75%, and 100% (Idehara, unpublished data). The highest dose tested for 2-
780 mercaptobenzothiazole in the traditional LLNA was the same in the LLNA: DA (i.e., 100%)
781 and resulted in an SI of 3.6 versus 1.8, respectively.

782 As shown in **Table 6-2**, when compared to the traditional LLNA, the LLNA: DA at $SI \geq 3.0$
783 predicted the same sensitization for all three of the optional reference substances tested. The
784 optional reference substances, SLS and ethylene glycol dimethacrylate, were categorized as
785 nonsensitizers based on GP and human data but as sensitizers by the LLNA: DA. Thus,
786 similar to the traditional LLNA, these substances were false positive in the LLNA: DA. SLS
787 was tested in the same vehicle (i.e., DMF) in both the traditional LLNA and the LLNA: DA.
788 In addition, the positive results for SLS reported in the ICCVAM LLNA performance
789 standards were based on five LLNA studies that tested SLS at 1%, 2.5%, 5%, 10%, and 20%
790 (Loveless et al. 1996). In comparison, the positive result for SLS obtained with the LLNA:
791 DA test method was based on one LLNA: DA experiment that tested the substance at 1%,

792 2.5%, 5%, and 10% (Idehara et al. 2008). The EC3 values for SLS in the traditional LLNA
793 (i.e., 8.1%) and the LLNA: DA (6.9%) were comparable. In addition, ethylene glycol
794 dimethacrylate was tested in the same vehicle (i.e., methyl ethyl ketone) in both the
795 traditional LLNA and the LLNA: DA. The positive result for ethylene glycol dimethacrylate
796 reported in the ICCVAM LLNA performance standards was based on one LLNA study that
797 tested ethylene glycol dimethacrylate at 10%, 25%, and 50% (Gerberick et al. 2005). In
798 comparison, the positive result for ethylene glycol dimethacrylate obtained with the LLNA:
799 DA test method was based on one LLNA: DA experiment that also tested the substance at
800 10%, 25%, and 50% (Idehara, unpublished data). The EC3 values for ethylene glycol
801 dimethacrylate in the traditional LLNA (i.e., 28%) and the LLNA: DA (34%) were
802 comparable.

803 Lastly, the optional reference substance, nickel (II) chloride, was categorized as a sensitizer
804 based on GP and human data but as a nonsensitizer by the LLNA: DA. Thus, similar to the
805 traditional LLNA, this substance was false negative in the LLNA: DA. Nickel (II) chloride
806 was tested in the same vehicle (i.e., dimethyl sulfoxide [DMSO]) in both the traditional
807 LLNA and the LLNA: DA. In addition, the negative results for nickel (II) chloride reported
808 in the ICCVAM LLNA performance standards were based on two independent LLNA
809 studies that tested the substance at 0.5%, 1%, and 2.5% (Basketter et al. 1999) and at 1%,
810 2.5%, and 5% (Basketter and Scholes 1992). In comparison, the negative result for nickel (II)
811 chloride obtained with the LLNA: DA test method was based on one LLNA: DA experiment
812 that tested the substance at 2.5%, 5%, and 10% (Idehara, unpublished data). The highest dose
813 tested for nickel (II) chloride in the traditional LLNA was the same in the LLNA: DA (i.e.,
814 5%) and resulted in an SI of 2.4 versus 1.3, respectively.

815

815 **Table 6-2 Performance of the LLNA: DA (SI ≥ 3.0) Compared to the ICCVAM-**
 816 **recommended LLNA Performance Standards Reference Substances¹**
 817 **(Sorted by Traditional LLNA EC3 Value)**

Substance	ICCVAM-Recommended LLNA Performance Standards				LLNA: DA ²			
	Vehicle	Result	EC3 (%) ³	N ⁴	Vehicle	Result	EC3 (%) ³	N ⁴
5-Chloro-2-methyl-4-isothiazolin-3-one	DMF	+	0.009	1	DMF	+	0.03	1
2,4-Dinitrochlorobenzene	AOO	+	0.049	15	AOO	+	0.08	11
4-Phenylenediamine	AOO	+	0.11	6	AOO	+	0.07	1
Cobalt chloride	DMSO	+	0.60	2	DMSO	+	1.27	5
Isoeugenol	AOO	+	1.5	47	AOO	+	2.94	4
<i>2-Mercaptobenzothiazole</i>	<i>DMF</i>	<i>+</i>	<i>1.7</i>	<i>1</i>	<i>DMF</i>	<i>-</i>	<i>NA</i>	<i>1</i>
Citral	AOO	+	9.2	6	AOO	+	15.63	1
Hexyl cinnamic aldehyde	AOO	+	9.7	21	AOO	+	11.10	18
Eugenol	AOO	+	10.1	11	AOO	+	4.50	1
Phenyl benzoate	AOO	+	13.6	3	AOO	+	2.26	1
Cinnamic alcohol	AOO	+	21.0	1	AOO	+	21.34	1
Imidazolidinyl urea	DMF	+	24.0	1	DMF	+	18.77	1
<i>Methyl methacrylate</i>	<i>AOO</i>	<i>+</i>	<i>90.0</i>	<i>1</i>	<i>AOO</i>	<i>-</i>	<i>NA</i>	<i>1</i>
Chlorobenzene	AOO	-	NA	1	AOO	-	NA	1
Isopropanol	AOO	-	NA	1	AOO	-	NA	11
Lactic acid	DMSO	-	NA	1	DMSO	-	NA	5
Methyl salicylate	AOO	-	NA	9	AOO	-	NA	4
Salicylic acid	AOO	-	NA	1	AOO	-	NA	1
Sodium lauryl sulfate	DMF	FP	8.1	5	DMF	+	6.88	1
Ethylene glycol dimethylacrylate	MEK	FP	28	1	MEK	+	34.03	1
Xylene	AOO	FP	95.8	1	NT	NT	NT	NT
Nickel chloride	DMSO	FN	NA	2	DMSO	-	NA	1

818 Bolded and italicized text highlights discordant LLNA: DA vs. traditional LLNA test results.

819 Abbreviations: AOO = acetone: olive oil (4:1); DMF = *N,N*-dimethylformamide; DMSO = dimethyl sulfoxide; EC3 =
 820 estimated concentration needed to produce a stimulation index of three; FN = false negative in traditional LLNA when
 821 compared to guinea pig and/or human results; FP = false positive in traditional LLNA when compared to guinea pig and/or
 822 human results; ICCVAM = Interagency Coordinating Committee on the Validation of Alternative Methods; LLNA = murine
 823 local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based
 824 on ATP content; MEK = methyl ethyl ketone; NA = not applicable (stimulation index < 3.0); NT = not tested; SI =
 825 stimulation index.

826 “+” = Sensitizer.

827 “-” = Nonsensitizer.

828 ¹From *Recommended Performance Standards: Murine Local Lymph Node Assay* (ICCVAM 2009; available at:

829 http://iccvam.niehs.nih.gov/methods/immunotox/llna_PerfStds.htm. The table lists the 18 required reference substances
 830 first (sorted from lowest to highest EC3), followed by the four optional reference substances (sorted from lowest to highest
 831 EC3).

832 ²Substances tested in LLNA: DA intralaboratory validation study (Idehara et al. 2008; Idehara unpublished data) and/or two-
 833 phased interlaboratory validation study (Omori et al. 2008).

834 ³Based on mean EC3 when more than one value was available.

835 ⁴Number of LLNA studies from which data were obtained.

836

836 **Table 6-3** provides the range and characteristics for 44 substances tested in the LLNA: DA
 837 based on traditional LLNA data. These substances are compared to the range of 18 required
 838 reference substances included on the ICCVAM-recommended LLNA performance standards
 839 reference substances list (ICCVAM 2009). The table indicates that the range of the
 840 substances tested in the LLNA: DA is similar to that included in the performance standards
 841 list. In general, there are a proportionally increased number of substances tested in the
 842 LLNA: DA in each of the categories included in the table.

843 **Table 6-3 Characteristics of the Substances Tested in the LLNA: DA Compared to**
 844 **the ICCVAM-recommended LLNA Performance Standards Reference**
 845 **Substances¹**

EC3 (%) Range in the Traditional LLNA	No. Substances	Solid/ Liquid	Actual EC3 Range (%) ²	Human Data	Peptide Reactivity (High/Mod/Min/Low/Unk) ³
<0.1	5	4/2⁴	0.009-0.080	5	4/0/0/0/1
	2	1/1	0.009-0.049	2	2/0/0/0/0
≥0.1 to <1	7	5/2	0.11-0.60	7	1/2/0/0/4
	2	2/0	0.11-0.60	2	0/0/0/0/2
≥1 to <10	12	7/5	1.54-9.74	11	4/0/3/1/4
	4	1/3	1.54-9.74	4	2/0/1/0/1
≥10 to <100	10	4/6	10.09-90.00	10	2/1/0/1/6
	5	3/2	10.09-90.00	5	0/1/0/0/4
Negative	12	6/6	NA	10	0/0/8/1/3
	5	1/4	NA	3	0/0/2/0/3
Overall	46	26/21⁴	0.009-90.00	28	11/3/11/3/18
	18	10/8	0.009-90.00	16	4/1/3/0/10

846 Bolded text represents characteristics of the LLNA: DA database, which includes the 44 substances tested in the
 847 intralaboratory validation study (Idehara et al. 2008; Idehara unpublished) and/or the two-phased interlaboratory
 848 validation study (Omori et al. 2008).

849 Abbreviations: EC3 = estimated concentration needed to produce a stimulation index of three; ICCVAM =
 850 Interagency Coordinating Committee on the Validation of Alternative Methods; LLNA = murine local lymph
 851 node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based
 852 on ATP Content; NA = not applicable because maximum SI < 3.0; No. = number; Min = minimal; Mod =
 853 moderate; SI = stimulation index; Unk = unknown.

854 ¹From the ICCVAM-recommended performance standards for the LLNA (ICCVAM 2009), based on the 18
 855 required reference substances.

856 ²Based on traditional LLNA studies for substances tested in the LLNA: DA (bold values) and for the 18
 857 required reference substances in the ICCVAM-recommended LLNA performance standards (ICCVAM 2009).

858 ³Data obtained from Gerberick et al. 2007.

859 ⁴One substance tested in the LLNA: DA, benzalkonium chloride, is categorized as both a solid and a liquid.

860

860 **6.4 Discordant Results for Accuracy Analysis Using the $SI \geq 3.0$ Decision Criterion**

861 *6.4.1 Discordance between the LLNA: DA and the Traditional LLNA*

862 When the outcomes for the 44 substances tested in the LLNA: DA (using $SI \geq 3.0$) and the
863 traditional LLNA were compared, the classifications for four substances were different. The
864 LLNA: DA classified 3-aminophenol, 2-mercaptobenzothiazole, methyl methacrylate, and
865 nickel (II) sulfate hexahydrate as nonsensitizers while the traditional LLNA classified them
866 as sensitizers (**Tables 6-4** and **6-5**). These substances were tested in the same vehicle in both
867 the LLNA: DA and the traditional LLNA tests. One commonality noted between three of the
868 four discordant substances is that they are solids. Furthermore, the molecular weights for 3-
869 aminophenol and methyl methacrylate are both about 100 g/mol and those for 2-
870 mercaptobenzothiazole and nickel (II) sulfate hexahydrate are comparable at 160 g/mol
871 (**Appendix B**). In addition, all four discordant substances are considered nonirritants based
872 on GP data.

873 *6.4.2 Discordance among the LLNA: DA, the Traditional LLNA, and/or the Guinea Pig* 874 *Test*

875 When analyses were restricted to the 40 substances with unequivocal LLNA: DA, traditional
876 LLNA, and GP data, the LLNA: DA at $SI \geq 3.0$ classified three substances differently
877 compared with the traditional LLNA (**Table 6-4**). 2-Mercaptobenzothiazole, methyl
878 methacrylate, and nickel (II) sulfate hexahydrate were identified as nonsensitizers by the
879 LLNA: DA while the traditional LLNA and GP tests classified these substances as
880 sensitizers. The discordant substances were tested at the same or higher concentrations in the
881 LLNA: DA and in the traditional LLNA yet the substances were still classified as
882 nonsensitizers (**Table 6-4**). There are few commonalities among these substances with regard
883 to chemical class, physical form, molecular weight, peptide reactivity (see **Appendix B** for
884 physico-chemical information), EC3 range (based on traditional LLNA, see **Table 3-1**) and
885 potential for skin irritation (**Appendix C**) as follows:

- 886 • 2-Mercaptobenzothiazole is a heterocyclic compound, methyl methacrylate is
887 carboxylic acid, and nickel (II) sulfate hexahydrate is a metal
- 888 • 2-Mercaptobenzothiazole and nickel (II) sulfate hexahydrate exist as solids and
889 methyl methacrylate exists as a liquid

- 890 • Nickel (II) sulfate hexahydrate and methyl methacrylate are soluble in water whereas
891 2-mercaptobenzothiazole is not
- 892 • All three discordant substances have similar molecular weights (approximately 100 to
893 160 g/mol)
- 894 • 2-Mercaptobenzothiazole has a high peptide reactivity, whereas the peptide reactivity
895 for methyl methacrylate and nickel (II) sulfate hexahydrate is not known
- 896 • All three discordant substances are classified as sensitizers by the traditional LLNA
897 (EC3 values were 90.00 for methyl methacrylate, 1.70 for 2-mercaptobenzothiazole,
898 and 4.80 for nickel [II] sulfate hexahydrate)
- 899 • All three discordant substances are nonirritants based on data from guinea pig studies
900 (**Table 6-4**).

901 In addition, benzalkonium chloride, ethyl acrylate, ethylene glycol dimethacrylate,
902 resorcinol, and SLS were positive in both the LLNA: DA and the traditional LLNA, but were
903 negative in the GP test (**Table 6-4**). In contrast, nickel (II) chloride was negative in both the
904 LLNA: DA and the traditional LLNA but was positive in the GP test. There are few
905 commonalities among these substances with regard to chemical class, physical form,
906 molecular weight, peptide reactivity (see **Appendix B** for physico-chemical information),
907 and potential for skin irritation (**Appendix C**) as follows:

- 908 • Benzalkonium chloride is an amine, ethyl acrylate and ethylene glycol dimethacrylate
909 are carboxylic acids, resorcinol is a phenol, and SLS is an alcohol, sulfur, and lipid
910 compound; nickel (II) chloride is a metal.
- 911 • Resorcinol and SLS exist as solids in their physical state and ethyl acrylate and
912 ethylene glycol dimethacrylate exist as liquids in their physical state, whereas
913 benzalkonium chloride can exist in both a solid and liquid physical state; nickel (II)
914 chloride exists as a solid in its physical state.
- 915 • These five substances have varying molecular weights (100 g/mol for ethyl acrylate,
916 110 g/mol for resorcinol, 171 g/mol for benzalkonium chloride, 198 g/mol for
917 ethylene glycol dimethacrylate, and 288 g/mol for SLS); the molecular weight for
918 nickel (II) chloride is about 130 g/mol.

- 919 • These five discordant substances are soluble in water; nickel (II) chloride is slightly
920 soluble in water.
- 921 • Peptide reactivity is identified as minimal for resorcinol, and high for ethyl acrylate
922 and ethylene glycol dimethacrylate, but is not identified for benzalkonium chloride
923 and SLS; peptide reactivity for nickel (II) chloride is also not identified.
- 924 • Benzalkonium chloride and SLS have been found to be skin irritants based on results
925 in mice, rabbits, or humans, while resorcinol is considered a nonirritant based on
926 studies in humans, and ethyl acrylate and ethylene glycol dimethacrylate are
927 considered nonirritants based on studies in guinea pigs; nickel (II) chloride is
928 identified as negative at $\leq 0.15\%$ based on GP studies (**Table 6-4**).
- 929

929 **Table 6-4 Discordant Results for the LLNA: DA (Using SI \geq 3.0 for Sensitizers)**
 930 **Compared to Traditional LLNA and Guinea Pig Reference Data¹**

Substance Name	Vehicle ²	LLNA: DA ³	Traditional LLNA ³	Guinea Pig Studies ⁴	Skin Irritant?
Benzalkonium chloride	AOO ACE ⁵	+ (6.7, 2.5%)	+ (11.1, 2%) ⁶	-	Irritant at 2% and 1% ACE (mice)
Ethyl acrylate	AOO	+ (4.2, 50%) ⁷	+ (4.0, 50%)	-	Nonirritant at 0.3 Molar (GP)
Ethylene glycol dimethacrylate	MEK	+ (4.5, 50%)	+ (7.0, 50%)	-	Nonirritant at 1% (GP)
Resorcinol	AOO	+ (4.3, 25%) ⁸	+ (10.4, 50%)	-	Nonirritant at 15% (humans)
Sodium lauryl sulfate	DMF	+ (3.4, 10%)	+ (8.9, 20%)	-	Irritant at 20% aq. (rabbits); Irritant at 20% (humans)
Nickel (II) chloride	DMSO	- (1.3, 10%)	- (2.4, 5%)	+	Negative at \leq 0.15% (GP)
2-Mercaptobenzothiazole	DMF	- (2.0, 50%) ⁸	+ (8.6, 10%)	+	Nonirritant at 10% (GP); Nonirritant at 25% (humans)
Methyl methacrylate	AOO	- (1.8, 100%)	+ (3.6, 100%)	+	Nonirritant at 3 Molar (GP)
Nickel (II) sulfate hexahydrate	DMSO	- (11.8, 10%)	+ (3.1, 5%)	+	Irritant at 10% (humans); Nonirritant at 0.15% (GP)

931 Abbreviations: ACE = acetone; AOO = acetone: olive oil (4:1); aq. = aqueous; DMF = *N,N*-
 932 dimethylformamide; DMSO = dimethyl sulfoxide; GP = guinea pig; LLNA = murine local lymph node assay;
 933 LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP
 934 content; MEK = methyl ethyl ketone; SI = stimulation index.

935 “+” = Sensitizer.

936 “-” = Nonsensitizer.

937 ¹Data source indicated in **Appendix C**.

938 ²Vehicle listed is that used in both the LLNA: DA and the traditional LLNA, unless otherwise noted.

939 ³Numbers in parentheses are highest SI and maximum concentration tested; highest SI is at maximum
 940 concentration test, unless otherwise noted.

941 ⁴Based on studies using either the guinea pig maximization test or the Buehler test.

942 ⁵Tested in AOO in LLNA: DA and ACE in traditional LLNA.

943 ⁶Highest SI occurred at concentration 1%.

944 ⁷Highest SI occurred at concentration 25%.

945 ⁸Highest SI occurred at concentration 10%.

946

947 6.4.3 Discordance among the LLNA: DA, Traditional LLNA, and/or the Human Outcome

948 When analyses were restricted to the 41 substances with unequivocal LLNA: DA, traditional
 949 LLNA, and human outcomes, the LLNA: DA classified four substances differently compared
 950 with the classification of the traditional LLNA (**Table 6-5**). 3-Aminophenol, 2-

951 mercaptobenzothiazole, methyl methacrylate, and nickel (II) sulfate hexahydrate were
952 identified as nonsensitizers by the LLNA: DA while the traditional LLNA and human
953 outcomes classified these substances as sensitizers. All four discordant substances were
954 tested at similar or higher concentrations in the LLNA: DA and in the traditional LLNA yet
955 the substances were still classified as nonsensitizers (**Table 6-5**). There are few
956 commonalities among these substances with regard to chemical class, physical form,
957 molecular weight, peptide reactivity (see **Appendix B** for physico-chemical information),
958 EC3 range (based on traditional LLNA, see **Table 3-1**) and potential for skin irritation
959 (**Appendix C**):

- 960 • 3-Aminophenol is an amine and phenol compound, 2-mercaptobenzothiazole is a
961 heterocyclic compound, methyl methacrylate is a carboxylic acid, and nickel (II)
962 sulfate hexahydrate is a metal.
- 963 • All four discordant substances exist as solids in their physical state except methyl
964 methacrylate which is a liquid.
- 965 • All four discordant substances are soluble in water except 2-mercaptobenzothiazole.
- 966 • Molecular weights range from 100 to 167 g/mol.
- 967 • 2-Mercaptobenzothiazole has high peptide reactivity and 3-aminophenol has minimal
968 peptide reactivity; peptide reactivity information for methyl methacrylate and nickel
969 (II) sulfate hexahydrate is not available.
- 970 • All four discordant substances are classified as sensitizers by the traditional LLNA
971 (EC3 values are 1.70 for 2-mercaptobenzothiazole, 3.20 for 3-aminophenol, 4.80 for
972 nickel [II] sulfate hexahydrate, and 90.0 for methyl methacrylate).
- 973 • All four discordant substances are classified as nonirritants based on data from guinea
974 pig studies, although human data indicates that nickel (II) sulfate hexahydrate is an
975 irritant at 10% (**Table 6-5**).

976 In addition, the LLNA: DA predicted the same outcome for SLS as the traditional LLNA
977 (i.e., sensitizer), but was discordant when compared to the negative human test result (**Table**
978 **6-5**). Isopropanol, nickel (II) chloride, propylparaben and sulfanilamide were also predicted
979 similarly by the LLNA: DA and the traditional LLNA (i.e., nonsensitizers), but were

980 discordant when compared to the positive human test result (**Table 6-5**). There are few
981 commonalities among these substances with regard to chemical class, physical form,
982 molecular weight, peptide reactivity (see **Appendix B** for physico-chemical information),
983 EC3 range (based on traditional LLNA, see **Table 3-1**) and potential for skin irritation
984 (**Appendix C**):

- 985 • SLS is an alcohol, sulfur, and lipid compound; isopropanol is an alcohol, nickel (II)
986 chloride is a metal, propylparaben is a phenol compound, and sulfanilamide is a
987 cyclic hydrocarbon and sulfur compound.
- 988 • SLS exists as a solid in its physical state; isopropanol is a liquid in its physical state,
989 whereas nickel (II) chloride, propylparaben, and sulfanilamide exist as solids in their
990 physical state.
- 991 • These substances have varying molecular weights that range from 60 to 172 g/mol for
992 isopropanol, nickel (II) chloride, propylparaben, and sulfanilamide to 288 g/mol for
993 SLS.
- 994 • SLS, isopropanol, nickel (II) chloride, and sulfanilamide are soluble in water and
995 propylparaben is not.
- 996 • Isopropanol, propylparaben, and sulfanilamide have minimal peptide reactivity;
997 peptide reactivity data for nickel (II) chloride and SLS is not available.
- 998 • SLS has been found to be a skin irritant based on results in mice, rabbits, or humans;
999 isopropanol, nickel (II) chloride, propylparaben, and sulfanilamide are considered
1000 negative or nonirritants based on studies in rabbits or GP (**Table 6-5**).

1001

1001 **Table 6-5 Discordant Results for the LLNA: DA (Using SI \geq 3.0 for Sensitizers)**
 1002 **Compared to Traditional LLNA and Human Reference Data¹**

Substance	Vehicle ²	LLNA: DA ³	Traditional LLNA ³	Human Outcomes ⁴	Skin Irritant?
Sodium lauryl sulfate	DMF	+ (3.4, 10%)	+ (8.9, 20%)	- (0/22 at 10%)	Irritant at 20% aq. (rabbits); Irritant at 20% (humans)
Isopropanol	AOO	- (1.97, 50%)	- (1.7, 50%) ⁵	+ (case study at 0.001%)	Negative at 100% (rabbits)
Nickel (II) chloride	DMSO	- (1.3, 10%)	- (2.4, 5%)	+ (HMT, data expressed as nickel)	Negative at \leq 0.15% (GP)
Propylparaben	AOO	- (1.3, 25%)	- (1.4, 25%) ⁶	+ (HMT)	Nonirritant at 10% (GP)
Sulfanilamide	DMF	- (0.9, 50%) ⁵	- (1.0, 50%) ⁷	+ (20/25 at 25%)	Nonirritant at 25% (humans)
3-Aminophenol	AOO	- (2.8, 10%)	+ (5.7, 10%)	+	Nonirritant at 5% (GP)
2-Mercaptobenzothiazole	DMF	- (2.0, 50%) ⁸	+ (8.6, 10%)	+ (24/63 at 25%)	Nonirritant at 10% (GP); Nonirritant at 25% (humans)
Methyl methacrylate	AOO	- (1.8, 100%)	+ (3.6, 100%)	+	Nonirritant at 3 M (GP)
Nickel (II) sulfate hexahydrate	DMSO	- (11.8, 10%)	+ (3.1, 5%)	+ (23/88 at 1%)	Irritant at 10% (humans); Nonirritant at 0.15% (GP)

1003 Abbreviations: AOO = acetone: olive oil (4:1); aq. = aqueous; DMF = *N,N*-dimethylformamide; DMSO =
 1004 dimethyl sulfoxide; GP = guinea pig; LLNA = murine local lymph node assay; LLNA: DA = murine local
 1005 lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content; SI = stimulation index.

1006 “+” = Sensitizer.

1007 “-” = Nonsensitizer.

1008 ¹Data source indicated in **Appendix C**.

1009 ²Vehicle listed is that used in both the LLNA: DA and the traditional LLNA, unless otherwise noted.

1010 ³Numbers in parentheses are highest SI and maximum concentration tested; highest SI is at maximum
 1011 concentration tested, unless otherwise noted.

1012 ⁴Based on studies using either the human maximization test, inclusion of the test substance in a human patch
 1013 test allergen kit, and/or published clinical case studies/reports.

1014 ⁵Highest SI occurred at concentration 25%.

1015 ⁶Highest SI occurred at concentration 5%.

1016 ⁷Highest SI occurred at concentration 10% and 25%.

1017 ⁸Highest SI occurred at concentration 10%.

1018

1018 **6.5 Accuracy Analysis Using a Single Alternative Decision Criteria**

1019 In addition to the accuracy analysis using $SI \geq 3.0$ to classify substances as sensitizers, other
1020 decision criteria were evaluated on the LLNA: DA test method performance, using the
1021 traditional LLNA ($SI \geq 3.0$) as the comparative test (**Appendix C**). The performance
1022 characteristics presented in this section are for 13 decision criteria that were used to
1023 determine whether the skin sensitization potential for the substances were positive (i.e.,
1024 sensitizing) or negative (i.e., nonsensitizing). The substances evaluated were the 44
1025 substances discussed in **Section 6.1** with both LLNA: DA and sufficient comparative
1026 traditional LLNA data. The decision criteria analyzed included the following:

- 1027 1. SI values ≥ 1.3 , ≥ 1.5 , ≥ 2.0 , ≥ 2.5 , ≥ 3.0 , ≥ 3.5 , ≥ 4.0 , ≥ 4.5 , or ≥ 5.0
- 1028 2. ATP values of treated groups statistically different from control group based
1029 on analysis of variance (ANOVA) with a post-hoc Dunnett's test, when
1030 multiple treatment groups were tested, or Student's *t*-test when there was only
1031 one dosed group
- 1032 3. Mean ATP values of treated groups $\geq 95\%$ confidence interval (CI) of the
1033 control group mean
- 1034 4. Mean ATP values of treated groups ≥ 2 standard deviations (SD) or ≥ 3 SD
1035 from the control group mean

1036 Multiple tests were available for 14 substances tested with the LLNA: DA. The results for
1037 each of these substances were combined so that each substance was represented by one
1038 positive or negative result for each criterion evaluated for the accuracy analysis. The results
1039 were combined in three ways and a separate accuracy analysis was performed for each
1040 approach.

- 1041 1. The positive/negative outcome for each substance was the most prevalent
1042 outcome for each criterion. If the number of positive and negative outcomes
1043 were equal, the most conservative (i.e., positive) result was used for the
1044 accuracy analyses.

1045 2. The positive/negative outcome for each substance for each criterion was
1046 determined by the outcome of the test with the highest maximum SI of the
1047 multiple tests.

1048 3. The positive/negative outcome for each substance was determined by the
1049 outcome of the test with the lowest maximum SI of the multiple tests.

1050 The analysis using the most prevalent outcome for substances with multiple tests is presented
1051 in this section; the analyses using the highest maximum SI and the lowest maximum SI are
1052 included in **Appendix E**.

1053 When combining multiple test results for a single substance based on the most prevalent
1054 outcome, using the decision criterion of $SI \geq 3.0$ to identify sensitizers, the 44 substances
1055 analyzed yielded an accuracy of 91% (40/44), a sensitivity of 88% (28/32), a specificity of
1056 100% (12/12), a false positive rate of 0% (0/12), and a false negative rate of 13% (4/32)
1057 (**Table 6-6**). The decision criterion of $SI \geq 2.5$ was similar to $SI \geq 3.0$ in its performance
1058 characteristics. In comparison, the decision criteria using higher SI values,
1059 $SI \geq 3.5$ to $SI \geq 5.0$, decreased performance except for specificity, which remained at 100%
1060 (12/12), and the false positive rate, which remained at 0% (0/12) (**Figure 6-1 and Table 6-6**).
1061 Specifically, at $SI \geq 5.0$, accuracy decreased to 57% (25/44) and the false negative rate
1062 increased to 59% (19/32).

1063 The decision criteria using lower SI values, $SI \geq 1.5$ and $SI \geq 1.3$, also decreased
1064 performance compared to $SI \geq 3.0$ except for sensitivity, which increased to 100% (32/32),
1065 and the false negative rate, which decreased to 0% (0/32) (**Figure 6-1 and Table 6-6**).
1066 Notably, the SI decision criterion that exhibited the best overall performance characteristics
1067 compared to $SI \geq 3.0$ was the $SI \geq 2.0$ (**Figure 6-1 and Table 6-6**). Compared to $SI \geq 3.0$, the
1068 lower SI cutoff of 2.0 had the same accuracy (i.e., 91% [40/44]) but had an increased
1069 sensitivity of 97% (31/32), although specificity decreased to 75% (9/12) and the false
1070 positive rate increased to 25% (3/12) while the false negative rate decreased to 3% (1/32).
1071 Use of ANOVA and summary statistics (i.e., mean ATP values of treated groups $\geq 95\%$
1072 confidence interval of the control group mean, or ≥ 2 or 3 SD from the control group mean),
1073 yielded accuracy values of 75 to 84%, with sensitivity values of 88 to 100%, and false


1074 negative rates of 0 to 13%. The specificity for these criteria ranged from 8 to 58% and the
1075 false positive rates were 42 to 92%. None of the statistical criterion evaluated exhibited
1076 increased performance characteristics when compared to $SI \geq 3.0$ (**Table 6-6**).

1077 Since the decision criterion of $SI \geq 2.0$ showed the best overall performance (i.e., similar
1078 accuracy, increased sensitivity, and decreased false negative rate compared to $SI \geq 3.0$), it
1079 was further compared to $SI \geq 3.0$ for accuracy against GP and human data (**Table 6-7**). When
1080 the LLNA: DA was compared to GP outcomes for substances with available LLNA: DA,
1081 traditional LLNA, and GP data (i.e., 40 substances), $SI \geq 2.0$ had the same accuracy (78%
1082 [31/40]), increased sensitivity (92% [24/26] vs. 85% [22/26]) and decreased specificity (50%
1083 [7/14] vs. 64% [9/14]) when compared with $SI \geq 3.0$. Accordingly, the false positive rate was
1084 increased (50% [7/14] vs. 36% [5/14]) and the false negative rate was decreased (8% [2/26]
1085 vs. 15% [4/26]) for $SI \geq 2.0$ compared to $SI \geq 3.0$. The overall performance of the LLNA:
1086 DA ($SI \geq 2.0$) compared to the traditional LLNA ($SI \geq 3.0$) to predict GP outcomes was less
1087 (see **Table 6-7**).

1088 When the LLNA: DA was compared to human outcomes for substances with available
1089 LLNA: DA, traditional LLNA, and human data (i.e., 41 substances), $SI \geq 2.0$ increased the
1090 accuracy (80% [31/41] vs. 78% [32/41]) and sensitivity (85% [29/34] vs. 76% [26/34]) and
1091 decreased the specificity (57% [4/7] vs. 86% [6/7]) when compared with $SI \geq 3.0$.
1092 Accordingly, the false positive rate was increased (43% [3/7] vs. 14% [1/7]) and the false
1093 negative rate was decreased (15% [5/34] vs. 24% [8/34]). The overall performance of the
1094 LLNA: DA ($SI \geq 2.0$) compared to the traditional LLNA ($SI \geq 3.0$) to predict human
1095 outcomes was less (see **Table 6-7**).

1096

1096 **Figure 6-1 Performance of the LLNA: DA Compared to the Traditional LLNA in**
 1097 **Predicting Skin Sensitization Potential Using Alternative SI Based on the**
 1098 **Most Prevalent Outcome for Substances with Multiple Tests**



1099
 1100 As compared to traditional LLNA results, the lines show the change in performance characteristics
 1101 for the LLNA: DA with the SI cutoff used to identify sensitizers. This analysis used LLNA: DA and
 1102 traditional LLNA results for 44 substances (32 traditional LLNA sensitizers and 12 traditional LLNA
 1103 nonsensitizers). For the 14 substances with multiple test results, the results for each substance were
 1104 combined by using the most prevalent outcome. The solid line shows accuracy, the dashed line shows
 1105 the false positive rate, and the dotted line shows the false negative rate.

1106 **Table 6-6 Performance of the LLNA: DA Compared to the Traditional LLNA in Predicting Skin Sensitization Potential**
 1107 **Using Alternative Decision Criteria Based on the Most Prevalent Outcome for Substances with Multiple Tests**

Alternate Criterion	N ¹	Accuracy		Sensitivity		Specificity		False Positive Rate		False Negative Rate		Positive Predictivity		Negative Predictivity	
		%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²
Statistics ³	44	84	37/44	94	30/32	58	7/12	42	5/12	6	2/32	86	30/35	78	7/9
≥95% CI ⁴	44	75	33/44	100	32/32	8	1/12	92	11/12	0	0/32	74	32/43	100	1/1
≥2 SD ⁵	44	77	34/44	91	29/32	42	5/12	58	7/12	9	3/32	81	29/36	63	5/8
≥3 SD ⁶	44	80	35/44	88	28/32	58	7/12	42	5/12	13	4/32	85	28/33	64	7/11
SI ≥ 5.0	44	57	25/44	41	13/32	100	12/12	0	0/12	59	19/32	100	13/13	39	12/31
SI ≥ 4.5	44	70	31/44	59	19/32	100	12/12	0	0/12	41	13/32	100	19/19	48	12/25
SI ≥ 4.0	44	84	37/44	78	25/32	100	12/12	0	0/12	22	7/32	100	25/25	63	12/19
SI ≥ 3.5	44	89	39/44	84	27/32	100	12/12	0	0/12	16	5/32	100	27/27	71	12/17
SI ≥ 3.0	44	91	40/44	88	28/32	100	12/12	0	0/12	13	4/32	100	28/28	75	12/16
SI ≥ 2.5	45	91	40/44	88	28/32	100	12/12	0	0/12	13	4/32	100	28/28	75	12/16
<i>SI ≥ 2.0</i>	<i>44</i>	<i>91</i>	<i>40/44</i>	<i>97</i>	<i>31/32</i>	<i>75</i>	<i>9/12</i>	<i>25</i>	<i>3/12</i>	<i>3</i>	<i>1/32</i>	<i>91</i>	<i>31/34</i>	<i>90</i>	<i>9/10</i>
SI ≥ 1.5	44	89	39/44	100	32/32	58	7/12	42	5/12	0	0/32	86	32/37	100	7/7
SI ≥ 1.3	44	86	38/44	100	32/32	50	6/12	50	6/12	0	0/32	84	32/38	100	6/6

1108 Bolded text indicates the decision criterion chosen by the LLNA: DA validation study team; Italicized text indicates the single decision criterion that had an overall increased performance in predicting
 1109 skin sensitization potential when compared to the traditional LLNA.

1110 Abbreviations: CI = confidence interval; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP Content;
 1111 No. = number; SD = standard deviation; SI = stimulation index.

1112 ¹N = Number of substances included in this analysis.

1113 ²The proportion on which the percentage calculation is based.

1114 ³Analysis of variance for difference of group means when substances were tested at multiple doses or *t*-test when substances were tested at one dose. The ATP data were log-transformed prior to
 1115 statistical analysis. For analysis of variance, significance at $p < 0.05$ was further tested by Dunnett's test.

1116 ⁴The mean ATP of at least one treatment group was outside the 95% confidence interval for the mean ATP of the vehicle control group.

1117
1118
1119

⁵The mean ATP of at least one treatment group was greater than 2 SD from the mean ATP of the vehicle control group.

⁶The mean ATP of at least one treatment group was greater than 3 SD from the mean ATP of the vehicle control group.

1119 **Table 6-7 Performance of the LLNA: DA in Predicting Skin Sensitization Potential Comparing Decision Criteria of**
 1120 **SI \geq 3.0 versus SI \geq 2.0 Based on the Most Prevalent Outcome for Substances with Multiple Tests**

Comparison	n ¹	Accuracy		Sensitivity		Specificity		False Positive Rate		False Negative Rate		Positive Predictivity		Negative Predictivity	
		%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²
LLNA: DA vs. Traditional LLNA	44	91	40/44	88	28/32	100	12/12	0	0/12	13	4/32	100	28/28	75	12/16
		<i>91</i>	<i>40/44</i>	<i>97</i>	<i>31/32</i>	<i>75</i>	<i>9/12</i>	<i>25</i>	<i>3/12</i>	<i>3</i>	<i>1/32</i>	<i>91</i>	<i>31/34</i>	<i>90</i>	<i>9/10</i>
Substances with LLNA: DA, Traditional LLNA, and GP Data															
LLNA: DA vs. Traditional LLNA	40	93	37/40	90	27/30	100	10/10	0	0/10	10	3/30	100	27/27	77	10/13
		<i>93</i>	<i>37/40</i>	<i>97</i>	<i>29/30</i>	<i>80</i>	<i>8/10</i>	<i>20</i>	<i>2/10</i>	<i>3</i>	<i>1/30</i>	<i>94</i>	<i>29/31</i>	<i>89</i>	<i>8/9</i>
LLNA: DA vs. GP³	40	78	31/40	85	22/26	64	9/14	36	5/14	15	4/26	81	22/27	69	9/13
		<i>78</i>	<i>31/40</i>	<i>92</i>	<i>24/26</i>	<i>50</i>	<i>7/14</i>	<i>50</i>	<i>7/14</i>	<i>8</i>	<i>2/26</i>	<i>77</i>	<i>24/31</i>	<i>78</i>	<i>7/9</i>
Traditional LLNA vs. GP³	40	85	34/40	96	25/26	64	9/14	36	5/14	4	1/26	83	25/30	90	9/10
		<i>85</i>	<i>34/40</i>	<i>96</i>	<i>25/26</i>	<i>64</i>	<i>9/14</i>	<i>36</i>	<i>5/14</i>	<i>4</i>	<i>1/26</i>	<i>83</i>	<i>25/30</i>	<i>90</i>	<i>9/10</i>
Substances with LLNA: DA, Traditional LLNA, and Human Data															
LLNA: DA vs. Traditional LLNA	41	90	37/41	87	27/31	100	10/10	0	0/10	13	4/31	100	27/27	71	10/14
		<i>93</i>	<i>38/41</i>	<i>97</i>	<i>30/31</i>	<i>80</i>	<i>8/10</i>	<i>20</i>	<i>2/10</i>	<i>3</i>	<i>1/31</i>	<i>94</i>	<i>30/32</i>	<i>89</i>	<i>8/9</i>
LLNA: DA vs. Human⁴	41	78	32/41	76	26/34	86	6/7	14	1/7	24	8/34	96	26/27	43	6/14
		<i>80</i>	<i>31/41</i>	<i>85</i>	<i>29/34</i>	<i>57</i>	<i>4/7</i>	<i>43</i>	<i>3/7</i>	<i>15</i>	<i>5/34</i>	<i>91</i>	<i>29/32</i>	<i>44</i>	<i>4/9</i>
Traditional LLNA vs. Human⁴	41	88	36/41	88	30/34	86	6/7	14	1/7	12	4/34	97	30/31	60	6/10
		<i>88</i>	<i>36/41</i>	<i>88</i>	<i>30/34</i>	<i>86</i>	<i>6/7</i>	<i>14</i>	<i>1/7</i>	<i>12</i>	<i>4/34</i>	<i>97</i>	<i>30/31</i>	<i>60</i>	<i>6/10</i>

1121 Text is bolded for SI \geq 3.0 and italicized for SI \geq 2.0; performance for SI \geq 3.0 is the same as SI \geq 2.0 for traditional LLNA vs. GP and for traditional LLNA vs. human.
 1122 Abbreviations: GP = guinea pig skin sensitization outcomes; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical
 1123 Industries, Ltd. based on ATP content; No. = number; SI = stimulation index; vs. = versus.

1124 ¹n = Number of substances included in this analysis.

1125 ²The proportion on which the percentage calculation is based.

1126 ³GP refers to outcomes obtained by studies conducted using either the guinea pig maximization test or the Buehler test.

1127 ⁴Human refers to outcomes obtained by studies conducted using the human maximization test, inclusion of the test substance in a human patch test allergen kit, and/or published
 1128 clinical case studies/reports.

1129 **6.6 Discordant Results for Accuracy Analysis Using a Single Alternative Decision** 1130 **Criteria**

1131 This section discusses the discordant results obtained for the analyses using the alternative
1132 decision criteria shown in **Tables 6-6** and **6-7**, in order to provide a comparison to the
1133 discordant substances identified when using the decision criterion of $SI \geq 3.0$ to identify
1134 sensitizers. Discordant results are first discussed using the traditional LLNA as the reference
1135 test (**Section 6.6.1**) and then discordant results for $SI \geq 2.0$, the single optimized alternative
1136 decision criterion, are discussed using the traditional LLNA, GP, and human outcomes as
1137 references (**Section 6.6.2**).

1138 *6.6.1 Discordant Results Using Alternative Decision Criteria Compared with the* 1139 *Traditional LLNA*

1140 **Table 6-8** shows how the number and identity of discordant substances changes with the
1141 alternate decision criteria when using the most prevalent outcome for the substances with
1142 multiple tests. Using $SI \geq 2.0$ as the decision criterion resulted in three nonsensitizers in the
1143 traditional LLNA (i.e., chlorobenzene, hexane, and salicylic acid) being misclassified as
1144 sensitizers in the LLNA: DA. Also, methyl methacrylate, a sensitizer in the traditional
1145 LLNA, was misclassified as a nonsensitizer in the LLNA: DA. As the SI decision criterion
1146 was further reduced to $SI \geq 1.5$ and $SI \geq 1.3$, two additional substances, 1-bromobutane and
1147 methyl salicylate were also misclassified as sensitizers but methyl methacrylate was no
1148 longer incorrectly classified as a nonsensitizer by the LLNA: DA when compared to
1149 traditional LLNA results. In addition, using $SI \geq 1.3$ also misclassified nickel (II) chloride as
1150 a sensitizer in the LLNA: DA compared to the traditional LLNA. Increasing the SI cutoff to
1151 values greater than three increased the number of sensitizers that were misclassified as
1152 nonsensitizers. At $SI \geq 5.0$, 19 substances were discordant. As **Table 6-8** shows, all 19
1153 substances were sensitizers in the LLNA but misclassified as nonsensitizers in the LLNA:
1154 DA.

1155 Use of a statistical test (i.e., ANOVA or *t*-test) to identify sensitizers misclassified two
1156 sensitizers in the traditional LLNA (i.e., 2-mercaptobenzothiazole and methyl methacrylate)
1157 as nonsensitizers in the LLNA: DA and five nonsensitizers (i.e., 1-bromobutane,
1158 chlorobenzene, hexane, salicylic acid, and sulfanilamide) as sensitizers. Use of summary

1159 statistics (i.e., $\geq 95\%$ CI, ≥ 2 SD or ≥ 3 SD) generally misclassified nonsensitizers in the
1160 traditional LLNA as sensitizers in the LLNA: DA. Specifically, using ≥ 3 SD of vehicle
1161 control mean misclassified five nonsensitizers as sensitizers: 1-bromobutane, chlorobenzene,
1162 hexane, nickel (II) chloride, and propylparaben. Using treatment group absorbance ≥ 2 SD of
1163 vehicle control mean misclassified the same five substances as sensitizers, as well as methyl
1164 salicylate and salicylic acid. Using the treatment group absorbance $\geq 95\%$ CI of vehicle
1165 control mean misclassified all the nonsensitizers misclassified as sensitizers in the LLNA:
1166 DA when using either ≥ 3 SD or ≥ 2 SD of vehicle control mean, as well as four additional
1167 substances: diethyl phthalate, dimethyl isophthalate, isopropanol, and lactic acid. In some
1168 instances, use of summary statistics (i.e., $\geq 95\%$ CI, ≥ 2 SD or ≥ 3 SD) misclassified sensitizers
1169 in the traditional LLNA as nonsensitizers in the LLNA: DA. Using ≥ 3 SD of vehicle control
1170 mean misclassified four traditional LLNA sensitizers as LLNA: DA nonsensitizers: butyl
1171 glycidyl ether, ethyl acrylate, methyl methacrylate, and propyl gallate. Using treatment group
1172 absorbance ≥ 2 SD of vehicle control mean only misclassified ethyl acrylate and propyl
1173 gallate as nonsensitizers in the LLNA; DA compared to the traditional LLNA and using the
1174 treatment group absorbance $\geq 95\%$ CI did not misclassify any traditional LLNA sensitizers as
1175 LLNA: DA nonsensitizers.

1176 *6.6.2 Discordant Results for Accuracy Analysis Using a Single Optimized Alternative*
1177 *Decision Criteria (SI ≥ 2.0)*

1178 When analyses were restricted to the 40 substances with unequivocal LLNA: DA, traditional
1179 LLNA, and GP data based on an SI ≥ 2.0 , the LLNA: DA classified three substances (i.e.,
1180 chlorobenzene, salicylic acid, and methyl methacrylate) differently compared with the
1181 classification of the traditional LLNA (**Table 6-9**). Chlorobenzene and salicylic acid were
1182 classified as sensitizers in the LLNA: DA and as nonsensitizers by both the traditional LLNA
1183 and GP outcomes. Methyl methacrylate was classified as a nonsensitizer in the LLNA: DA
1184 and as a sensitizer by both the traditional LLNA and GP outcomes. In contrast, benzalkonium
1185 chloride, ethyl acrylate, ethylene glycol dimethacrylate, resorcinol, and sodium lauryl sulfate
1186 were identified as sensitizers by the LLNA: DA similar to the traditional LLNA but as
1187 nonsensitizers based on GP outcomes. Nickel (II) chloride was identified as a nonsensitizer
1188 by the LLNA: DA similar to the traditional LLNA but as a sensitizer based on GP outcomes.
1189 There are few commonalities among these substances with regard to chemical class, physical

1190 form, molecular weight, peptide reactivity (see **Appendix B** for physico-chemical
1191 information), EC3 range (based on traditional LLNA, see **Table 3-1**) and potential for skin
1192 irritation (**Appendix C**) as follows:

- 1193 • Chlorobenzene is a halogenated hydrocarbon compound and salicylic acid is a phenol
1194 and carboxylic acid; methyl methacrylate is a carboxylic acid; benzalkonium chloride
1195 is an amine (onium compound), ethyl acrylate and ethylene glycol dimethacrylate are
1196 carboxylic acids, resorcinol is a phenol, and SLS is an alcohol, sulfur, and lipid
1197 compound.
- 1198 • Chlorobenzene exists as a liquid and salicylic acid exists as a solid in its physical
1199 state; methyl methacrylate is a liquid; resorcinol and SLS are solids and ethyl acrylate
1200 and ethylene glycol dimethacrylate are liquids, whereas benzalkonium chloride can
1201 exist in both a solid and liquid physical state.
- 1202 • Chlorobenzene has a molecular weight of 113 g/mol and salicylic acid has a
1203 molecular weight of 138 g/mol; methyl methacrylate has a molecular weight of 100
1204 g/mol; the other five discordant substances have varying molecular weights that range
1205 from 100 g/mol for ethyl acrylate, 110 g/mol for resorcinol, 171 g/mol for
1206 benzalkonium chloride, and 198 g/mol for ethylene glycol dimethacrylate to 288
1207 g/mol for SLS.
- 1208 • All the discordant substances are soluble in water.
- 1209 • Chlorobenzene has minimal peptide reactivity; the peptide reactivity for resorcinol is
1210 identified as minimal, and that for ethyl acrylate and ethylene glycol dimethacrylate is
1211 high; peptide reactivity data for salicylic acid, methyl methacrylate, benzalkonium
1212 chloride and SLS is not available.
- 1213 • Methyl methacrylate is identified as a sensitizer by the traditional LLNA (EC3 =
1214 90%); benzalkonium chloride (EC3 = 0.1%), ethyl acrylate (EC3 = 32.8%), ethylene
1215 glycol dimethacrylate (EC3 = 28%), resorcinol (6.3%) and SLS (EC3 = 8.1%) are
1216 identified as sensitizers by the traditional LLNA.
- 1217 • Chlorobenzene has low irritancy potential assumed based on clinical literature while
1218 salicylic acid is an irritant at 20% in mice; methyl methacrylate is a nonirritant in GP;

1219 benzalkonium chloride and SLS have been found to be skin irritants based on results
1220 in mice, rabbits, or humans and ethyl acrylate, ethylene glycol dimethacrylate, and
1221 resorcinol are considered nonirritants based on studies in humans or GP (**Table 6-9**).

1222 When analyses were restricted to the 40 substances with unequivocal LLNA: DA, traditional
1223 LLNA, and human outcomes based on an $SI \geq 2.0$, the LLNA: DA classified three substances
1224 (i.e., hexane, salicylic acid, and methyl methacrylate) differently compared with the
1225 classification of the traditional LLNA (**Table 6-10**). Hexane and salicylic acid were
1226 classified as sensitizers in the LLNA: DA and as nonsensitizer by both the traditional LLNA
1227 and human outcomes. In contrast, methyl methacrylate was identified as a nonsensitizer by
1228 the LLNA: DA but as a sensitizer based on traditional LLNA and human outcomes.
1229 Isopropanol, nickel (II) chloride, propylparaben, and sulfanilamide were all classified as
1230 nonsensitizers by the LLNA: DA and the traditional LLNA but as sensitizers based on human
1231 outcomes (**Table 6-10**). In contrast, SLS was classified as a sensitizer by the LLNA: DA and
1232 traditional LLNA but as a sensitizer based on human outcomes. In instances where the
1233 substances were discordant in the LLNA: DA compared to the traditional LLNA, the
1234 discordant substances were tested at the same maximum concentration. There are few
1235 commonalities among these substances with regard to chemical class, physical form,
1236 molecular weight, peptide reactivity (see **Appendix B** for physico-chemical information),
1237 EC3 range (based on traditional LLNA, see **Table 3-1**) and potential for skin irritation
1238 (**Appendix C**):

- 1239 • Hexane is an acyclic hydrocarbon compound and salicylic acid is a phenol and
1240 carboxylic acid; methyl methacrylate is a carboxylic acid; isopropanol is an alcohol,
1241 nickel (II) chloride is a metal, propylparaben is a phenol compound, and
1242 sulfanilamide is sulfur compound; SLS is an alcohol, sulfur, and lipid compound.
- 1243 • Hexane is a liquid and salicylic acid is a solid; methyl methacrylate is a liquid;
1244 isopropanol is a liquid while nickel (II) chloride, propylparaben, and sulfanilamide
1245 are solids; SLS is a solid.
- 1246 • Hexane has a molecular weight of 86 g/mol; methyl methacrylate has a molecular
1247 weight of 100 g/mol; the other discordant substances have varying molecular weights

- 1248 that range from 60 g/mol for isopropanol, 130 g/mol for nickel (II) chloride, 172
1249 g/mol for sulfanilamide, and 180 g/mol for propylparaben to 288 g/mol for SLS.
- 1250 • Hexane, salicylic acid, isopropanol, methyl methacrylate, nickel (II) chloride,
1251 sulfanilamide, and SLS are soluble in water; propylparaben is not.
 - 1252 • Hexane, isopropanol, propylparaben, and sulfanilamide have minimal peptide
1253 reactivity; peptide reactivity information for salicylic acid methyl methacrylate nickel
1254 (II) chloride SLS is not available.
 - 1255 • Methyl methacrylate is identified as a sensitizer by the traditional LLNA (EC3 =
1256 90%) as is SLS (EC3 = 8.1%).
 - 1257 • Hexane has been found to be an irritant at 100% in humans as has salicylic acid in
1258 mice; isopropanol, nickel (II) chloride, propylparaben, and sulfanilamide are
1259 considered to be nonirritants based on studies in rabbits, GP, or humans; SLS has
1260 been found to be a skin irritants based on results in mice, rabbits, or humans (**Table**
1261 **6-10**).
- 1262

1263
1264**Table 6-8 Discordant Results for the LLNA: DA Using Alternative Decision Criteria Compared to the Traditional LLNA Based on the Most Prevalent Outcome for Substances with Multiple Tests**

Discordant Substance ¹	Alternate Decision Criterion ²												
	Statistics ³	≥95% CI ⁴	≥2 SD ⁵	≥3 SD ⁶	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3
3-Aminophenol (3.2%)					-	-	-	-	-	-			
p-Benzoquinone (0.01%)					-	-	-						
1-Bromobutane (-)	+	+	+	+								+	+
Butyl glycidyl ether (30.9%)				-	-								
Chlorobenzene (-)	+	+	+	+							+	+	+
Cinnamic aldehyde (1.9%)					-								
Citral (9.2%)					-	-							
Cobalt chloride (0.6%)					-	-							
Diethyl maleate (3.6%)					-	-	-						
Diethyl phthalate (-)		+											
Dimethyl isophthalate (-)		+											
Ethyl acrylate (32.8%)			-	-	-	-							
Ethylene glycol dimethacrylate (28%)					-	-							
Formaldehyde (0.5)					-								
Hexane (-)	+	+	+	+							+	+	+
Imidazolidinyl urea (24%)					-								
Isopropanol (-)		+											
Lactic acid (-)		+											

Discordant Substance ¹	Alternate Decision Criterion ²												
	Statistics ³	≥95% CI ⁴	≥2 SD ⁵	≥3 SD ⁶	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3
2-Mercaptobenzothiazole (1.7%)	-				-	-	-	-	-	-			
Methyl methacrylate (90%)	-		-	-	-	-	-	-	-	-	-		
Methyl salicylate (-)		+	+									+	+
Nickel (II) chloride (-)		+	+	+									+
Nickel (II) sulfate hexahydrate (4.8%)					-	-	-	-	-	-			
Phenyl benzoate (13.6%)					-	-							
Propyl gallate (0.320%)			-	-	-								
Propylparaben (-)		+	+	+									
Resorcinol (6.3%)					-	-							
Salicylic acid (-)	+	+	+								+	+	+
Sulfanilamide (-)	+												
Sodium lauryl sulfate (8.1%)					-	-	-	-					
Trimellitic anhydride (4.7%)					-								

1265 Abbreviations: CI = confidence interval; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by
 1266 Daicel Chemical Industries, Ltd. based on ATP Content; SD = standard deviation; SI = stimulation index.

1267 ¹Compared to the traditional LLNA; traditional LLNA result in parentheses are “-” for nonsensitizers and EC3 (%) for sensitizers.

1268 ²LLNA: DA outcomes are indicated by “+” for sensitizer results and “-” for nonsensitizer results.

1269 ³Analysis of variance assessed differences of group means when substances were tested at multiple doses or *t*-test when substances were tested at
 1270 one dose. The ATP data were log-transformed prior to statistical analysis. Significance by analysis of variance at $p < 0.05$ was further tested by
 1271 Dunnett's test.

1272 ⁴The mean ATP of at least one treatment group was outside the 95% CI for the mean ATP of the vehicle control group.

1273 ⁵The mean ATP of at least one treatment group was greater than 2 SD from the mean ATP of the vehicle control group.

1274 ⁶The mean ATP of at least one treatment group was greater than 3 SD from the mean ATP of the vehicle control group.

1275 **Table 6-9 Discordant Results for the LLNA: DA (Using SI \geq 2.0 for Sensitizers)**
 1276 **Compared to Traditional LLNA and GP Reference Data¹**

Substance Name	Vehicle ²	LLNA: DA ³	Traditional LLNA ³	Guinea Pig Studies ⁴	Skin Irritant?
Benzalkonium chloride	AOO ACE ⁵	+ (6.7, 2.5%)	+ (11.1, 2%) ⁶	-	Irritant at 2% and 1% ACE (mice)
Ethyl acrylate	AOO	+ (4.3, 50%) ⁷	+ (4.0, 50%)	-	Nonirritant at 0.3 M (GP)
Ethylene glycol dimethacrylate	MEK	+ (4.5, 50%)	+ (7.0, 50%)	-	Nonirritant at 1% (GP)
Resorcinol	AOO	+ (4.3, 25%) ⁵	+ (10.4, 50%)	-	Nonirritant at 15% (humans)
Sodium lauryl sulfate	DMF	+ (3.4, 10%)	+ (8.9, 20%)	-	Irritant at 20% aq. (rabbits); Irritant at 20% (humans)
Chlorobenzene	AOO	+ (2.4, 25%)	- (1.7, 10%) ⁵	-	No data. Low irritancy potential assumed based on clinical literature.
Salicylic acid	AOO	+ (2.0, 25%)	- (2.4, 25%)	-	Irritant at 20% aq. (mice)
Methyl methacrylate	AOO	- (1.8, 100%)	+ (3.6, 100%)	+	Nonirritant at 3 M (GP)
Nickel (II) chloride	DMSO	- (1.3, 10%)	- (2.4, 5%)	+	Negative at \leq 0.15% (GP)

1277 Abbreviations: ACE = acetone; AOO = acetone: olive oil (4:1); aq. = aqueous ; DMF = *N,N*-
 1278 dimethylformamide; GP = guinea pig; LLNA = murine local lymph node assay; LLNA: DA = murine local
 1279 lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content; SI = stimulation index.

1280 “+” = Sensitizer.

1281 “-” = Nonsensitizer.

1282 ¹Data source indicated in **Appendix C**.

1283 ²Vehicle listed is that used in both the LLNA: DA and the traditional LLNA, unless otherwise noted.

1284 ³Numbers in parentheses are highest SI and maximum concentration tested; highest SI is at maximum
 1285 concentration tested, unless otherwise noted.

1286 ⁴Based on studies using either the human maximization test, inclusion of the test substance in a human patch
 1287 test allergen kit and/or published clinical case studies/reports.

1288 ⁵Benzalkonium chloride tested in AOO vehicle in LLNA: DA and ACE vehicle in traditional LLNA.

1289 ⁶Highest SI occurred at concentration 1%.

1290 ⁷Highest SI occurred at concentration 25%.

1291

1291 **Table 6-10 Discordant Results for the LLNA: DA (Using SI \geq 2.0 for Sensitizers)**
 1292 **Compared to Traditional LLNA and Human Reference Data¹**

Substance	Vehicle ²	LLNA: DA ³	Traditional LLNA ³	Human Outcomes ⁴	Skin Irritant?
Hexane	AOO	+ (2.3, 100%)	- (2.2, 100%)	- (0/25 at 100%)	Irritant at 100% (humans)
Salicylic acid	AOO	+ (2.0, 25%)	- (2.4, 25%)	-	Irritant at 20% aq. (mice)
Sodium lauryl sulfate	DMF	+ (3.4, 10%)	+ (8.9, 20%)	- (0/22 at 10%)	Irritant at 20% aq. (rabbits); Irritant at 20% (humans)
Isopropanol	AOO	- (1.97, 50%)	- (1.7, 50%) ⁵	+ (case study at 0.001%)	Negative at 100% (rabbits)
Nickel (II) chloride	DMSO	- (1.3, 10%)	- (2.4, 5%)	+	Negative at \leq 0.15% (GP)
Propylparaben	AOO	- (1.3, 25%)	- (1.4, 25%) ⁶	+ (HMT)	Nonirritant at 10% (GP)
Sulfanilamide	DMF	- (0.9, 50%) ⁷	- (1.0, 50%) ⁸	+	Nonirritant at 25% (humans)
Methyl methacrylate	AOO	- (1.8, 100%)	+ (3.6, 100%)	+	Nonirritant at 3 M (GP)

1293 Abbreviations: aq. = aqueous; AOO = acetone: olive oil (4:1); DMF = *N,N*-dimethylformamide; GP = guinea
 1294 pig; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel
 1295 Chemical Industries, Ltd. based on ATP content; SI = stimulation index.

1296 “+” = Sensitizer.

1297 “-” = Nonsensitizer.

1298 ¹Data source indicated in **Appendix C**.

1299 ²Vehicle listed is that used in both the LLNA: DA and the traditional LLNA, unless otherwise noted.

1300 ³Numbers in parentheses are highest SI and maximum concentration tested; highest SI is at maximum
 1301 concentration tested, unless otherwise noted.

1302 ⁴Based on studies using either the human maximization test, inclusion of the test substance in a human patch
 1303 test allergen kit and/or published clinical case studies/reports.

1304 ⁵Highest SI occurred at concentration 10%.

1305 ⁶Highest SI occurred at concentration 5%.

1306 ⁶Highest SI occurred at concentration 25%.

1307 ⁶Highest SI occurred at concentration 10 and 25%.

1309 6.7 Accuracy Analysis Using Multiple Alternative Decision Criteria

1310 As detailed in **Section 6.5**, the accuracy of the LLNA: DA when using a number of
 1311 alternative decision criteria was evaluated using the traditional LLNA as the reference test.
 1312 Compared to the traditional LLNA (SI \geq 3.0), the best overall performance (i.e., accuracy of
 1313 91% [40/44] and sensitivity of 97% [31/32]) was achieved using the decision criterion of
 1314 SI \geq 2.0 (**Table 6-6**). The SI \geq 2.0 also produced a false positive rate of 25% (3/12) and a
 1315 false negative rate of 3% (1/32) (**Table 6-6**). Increasing the SI decision criterion to SI \geq 2.5

1316 decreased the false positive rate to 0% (0/12) but increased the false negative rate to 13%
1317 (4/32). The $SI \geq 2.0$ produced one false negative result for the substance methyl methacrylate
1318 (EC3 = 90%). Upon evaluating the LLNA: DA test data for methyl methacrylate, the
1319 maximum SI achieved was 1.81 at 100%. Thus, decreasing the SI decision criterion to
1320 $SI \geq 1.7$ decreased the false negative rate to 0% (0/32). The 0% false positive rate using
1321 $SI \geq 2.5$ and the 0% false negative rate using $SI \geq 1.7$ prompted an evaluation using two
1322 decision criteria for LLNA: DA results: one criterion to classify substances as sensitizers
1323 (i.e., $SI \geq 2.5$) and one criterion to classify substances as nonsensitizers ($SI \leq 1.7$).

1324 It should be noted that this analysis was based on the same strategy for combining results as
1325 that described in **Section 6.5** for the substances tested multiple times (i.e., the
1326 sensitizer/nonsensitizer outcome for each substance using the most prevalent outcome).
1327 **Section 7.3** details the reproducibility of substances tested multiple times and indicates that,
1328 there were no instances of false positive results for nonsensitizers (i.e., $SI \geq 2.5$). Among the
1329 80 tests that produced a maximum $SI \geq 2.5$, 0% (0/80) were nonsensitizers (i.e., produced a
1330 false positive result). See **Section 7.3** for more details regarding these results.

1331 **6.8 Discordant Results for Accuracy Analysis Using Multiple Alternative** 1332 **Decision Criteria**

1333 While optimum false positive and false negative rates can be achieved using these two
1334 different decision criteria, a range of SI values (i.e., $1.7 < SI < 2.5$) now exists for which the
1335 correct classification is not definitive (i.e., there is a chance for false positives or false
1336 negatives for substances in this range). Chemical class, physical form, molecular weight,
1337 peptide reactivity (see **Appendix B** for physico-chemical properties), traditional LLNA EC3
1338 range (**Table 3-1**), or potential for skin irritation (**Appendix C**) were examined to identify
1339 commonalities among the substances that produced SI values between 1.7 and 2.5 in an
1340 attempt to identify similar characteristics among these substances that could be used to
1341 correctly classify such substances.

1342 Ten substances produced SI values between 1.7 and 2.5 (**Table 6-11**). Five of the 10
1343 substances are nonsensitizers (i.e., chlorobenzene, hexane, isopropanol, methyl salicylate,
1344 salicylic acid) and five are sensitizers (i.e., 3-aminophenol, cobalt chloride, 2-
1345 mercaptobenzothiazole, methyl methacrylate, nickel [II] sulfate hexahydrate) based on

1346 traditional LLNA results. Among the five nonsensitizers, six chemical classes are
1347 represented; two substances are classified as carboxylic acids (i.e., salicylic acid and methyl
1348 salicylate [also a phenol]), one substance is a halogenated and cyclic hydrocarbon (i.e.,
1349 chlorobenzene), one substance is an acyclic hydrocarbon (i.e., hexane), and one substance is
1350 an alcohol (i.e., isopropanol). Other characteristics of the nonsensitizers (based on traditional
1351 LLNA data) include:

- 1352 • Four substances are liquids (i.e., chlorobenzene, hexane, isopropanol, and
1353 methyl salicylate) and one substance is a solid (i.e., salicylic acid).
- 1354 • Molecular weights range from 60 g/mol for isopropanol, 86 g/mol for hexane,
1355 113 g/mol for chlorobenzene, 138 g/mol for salicylic acid to 152 g/mol for
1356 methyl salicylate.
- 1357 • All five substances are soluble in water.
- 1358 • The peptide reactivity for chlorobenzene, hexane, isopropanol, and methyl
1359 salicylate is minimal; peptide reactivity information for salicylic acid is not
1360 available.
- 1361 • Hexane, methyl salicylate, and salicylic acid are considered irritants based on
1362 data in either mice or humans and isopropanol is considered negative based on
1363 data in rabbits; irritancy data for chlorobenzene is not available but irritancy
1364 potential is assumed to be low based on clinical literature (**Table 6-11**).

1365 Among the five sensitizers, five chemical classes are represented; one substance is a
1366 carboxylic acid (i.e., methyl methacrylate), two substances are metals (i.e., nickel [II] sulfate
1367 hexahydrate and cobalt chloride), one substance is a phenol (i.e., 2-aminophenol [also an
1368 amine]), and one substance is a heterocyclic compound (i.e., 2-mercaptobenzothiazole).
1369 Other characteristics of the substances that are classified as sensitizers by the traditional
1370 LLNA include:

- 1371 • Four substances are solids (i.e., 3-aminophenol, cobalt chloride, 2-
1372 mercaptobenzothiazole, and nickel [II] sulfate hexahydrate) and one substance
1373 is a liquid (i.e., methyl methacrylate).

- 1374
- 1375
- 1376
- 1377
- 1378
- 1379
- 1380
- 1381
- 1382
- 1383
- 1384
- 1385
- 1386
- 1387
- 1388
- Molecular weights range from 100 g/mol for methyl methacrylate, 109 g/mol for 3-aminophenol, 130 g/mol for cobalt chloride, 155 g/mol for nickel (II) sulfate hexahydrate to 167 g/mol for 2-mercaptobenzothiazole.
 - 2-Mercaptobenzothiazole is insoluble in water; the other four substances are soluble in water.
 - The peptide reactivity for 2-mercaptobenzothiazole is high and that for 3-aminophenol is minimal; peptide reactivity data for the three other substances is not available.
 - The EC3 values for the five substances identified as sensitizers by the traditional LLNA are: 0.6% for cobalt chloride, 1.7% for 2-mercaptobenzothiazole, 3.2% for 3-aminophenol, 4.8% for nickel [II] sulfate hexahydrate, and 90% for methyl methacrylate.
 - All five substances are considered nonirritants based on available GP data (**Table 6-11**).

1388 **Table 6-11 Discordant Results for the LLNA: DA When Multiple Decision Criteria**
 1389 **are Used¹**

Substance ²	Vehicle ³	LLNA: DA ⁴	Traditional LLNA ⁴	Skin Irritant?
Chlorobenzene	AOO	2.4, 25%	- (1.7, 25%) ⁵	No data. Low irritancy potential assumed based on clinical literature.
Hexane	AOO	2.3, 100%	- (2.2, 100%)	Irritant at 100% (humans)
Isopropanol	AOO	1.97, 50% ⁵	- (1.7, 50%) ⁵	Negative at 100% (rabbits)
Methyl salicylate	AOO	1.77, 25% ⁵	- (2.9, 20%)	Irritant at 10% AOO (mice)
Salicylic acid	AOO	2.0, 25%	- (2.4, 25%)	Irritant at 20% aq. (mice)
3-Aminophenol (3.2%) (2 LLNA: DA tests)	AOO	2.4, 10% and 1.8, 10% ⁶	+ (5.7, 10%)	Nonirritant at 5% (GP)
Cobalt chloride (0.6%)	DMSO	2.0, 5%	+ (7.2, 5%)	Negative at ≤ 0.5% (GP)
2-Mercaptobenzothiazole (1.7%)	DMF	2.0, 50% ⁵	+ (8.6, 10%)	Nonirritant at 10% (GP)
Methyl methacrylate (90%)	AOO	1.8, 100%	+ (3.6, 100%)	Nonirritant at 3 M (GP)
Nickel (II) sulfate hexahydrate (4.8%) (2 LLNA: DA tests)	DMSO	2.1, 10% and 2.2, 5% ⁷	+ (3.1, 5%)	Nonirritant at 0.15% (GP); Irritant at 10% (humans)

1390 Abbreviations: AOO = acetone: olive oil (4:1); aq. = aqueous; DMF = *N,N*-dimethylformamide; DMSO =
 1391 dimethyl sulfoxide; GP = guinea pig; LLNA = murine local lymph node assay; LLNA: DA = murine local
 1392 lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content.

1393 “+” = Sensitizer.

1394 “-” = Nonsensitizer.

1395 ¹Data source indicated in **Appendix C**.

1396 ²Numbers in parentheses are EC3 values (concentrations needed to produce a stimulation index [SI] of three)
 1397 for substances that are sensitizers in the traditional LLNA (see **Table 3-1**).

1398 ³Vehicle listed is that used in both the LLNA: DA and the traditional LLNA, unless otherwise noted.

1399 ⁴Numbers indicated are highest SI and maximum concentration tested; highest SI is at maximum concentration
 1400 tested, unless otherwise noted.

1401 ⁵Highest SI occurred at concentration 10%.

1402 ⁶Highest SI occurred at concentration 3%.

1403 ⁷Highest SI occurred at concentration 2.5%.

1404 **7.0 LLNA: DA Test Method Reliability**

1405 An assessment of test method reliability (intralaboratory repeatability and intra- and inter-
1406 laboratory reproducibility) is an essential element of any evaluation of the performance of an
1407 alternative test method (ICCVAM 2003). Repeatability refers to the closeness of agreement
1408 between test results obtained within a single laboratory when the procedure is performed on
1409 the same substance under identical conditions within a given time period (ICCVAM 1997,
1410 2003). Intralaboratory reproducibility refers to the extent to which qualified personnel within
1411 the same laboratory can replicate results using a specific test protocol at different times.
1412 Interlaboratory reproducibility refers to the extent to which different laboratories can
1413 replicate results using the same protocol and test substances, and indicates the extent to
1414 which a test method can be transferred successfully among laboratories. With regard to the
1415 LLNA: DA test method, there are no known intralaboratory repeatability studies, which was
1416 also the situation with the traditional LLNA.

1417 The reproducibility evaluation in this revised draft BRD has been updated from the January
1418 2008 draft BRD to include an interlaboratory reproducibility evaluation and a reproducibility
1419 analysis using separate SI criteria to identify sensitizers and nonsensitizers. The available
1420 LLNA: DA data were amenable to both intralaboratory and interlaboratory reproducibility
1421 analyses. The evaluation of a single decision criterion in **Section 6.6** showed that $SI \geq 2.0$
1422 was the SI value that produced the lowest false negative rate among the alternative decision
1423 criteria evaluated (i.e., 3% [1/32]) when the traditional LLNA was the reference test (**Table**
1424 **6-6**). **Appendix F** describes the evaluation of reproducibility for the decision criterion of $SI \geq$
1425 2.0 to identify sensitizers, which was evaluated in **Section 6.6**. The evaluation of multiple
1426 decision criteria in **Section 6.7** evaluated $SI \geq 2.5$ as the decision criterion for classifying
1427 substances as sensitizers when used with a decision criterion of $SI \leq 1.7$ to identify
1428 nonsensitizers. Thus, this section provides an assessment of reproducibility for the decision
1429 criterion of $SI \geq 2.5$ to identify sensitizers.

1430 **7.1 Intralaboratory Reproducibility**

1431 Idehara et al. (2008) evaluated intralaboratory reproducibility of EC3 values for the LLNA:
1432 DA using two substances (isoeugenol and eugenol) that were each tested in three different
1433 experiments (**Table 7-1**). The data indicate CVs of 21% and 11% for isoeugenol and

1434 eugenol, respectively. The authors state that for both compounds the EC3 values appeared to
 1435 be close and that for each test substance the SI values for the same concentration were fairly
 1436 reproducible (Idehara et al. 2008). NICEATM also determined the intralaboratory
 1437 reproducibility of EC2.5 values (estimated concentrations needed to produce a stimulation
 1438 index of 2.5) for the same set of data. The results for EC2.5 indicate slightly larger
 1439 intralaboratory variability compared to EC3 results with CVs of 33% and 13% for isoeugenol
 1440 and eugenol, respectively.

1441 **Table 7-1 Intralaboratory Reproducibility of EC3 and EC2.5 Values Using the**
 1442 **LLNA: DA¹**

Isoeugenol			
Concentration (%)	Experiment 1²	Experiment 2²	Experiment 3²
Vehicle (AOO)	1.00 ± 0.54	1.00 ± 0.54	1.00 ± 0.30
0.5	1.50 ± 0.54	-----	1.22 ± 0.13
1	2.28 ± 0.60	-----	2.77 ± 1.01
2.5	2.78 ± 0.17	3.11 ± 1.15	3.01 ± 0.98
5	3.39 ± 0.69	4.39 ± 1.25	-----
10	5.68 ± 1.19	6.77 ± 0.23	-----
EC3	3.40%	2.35%	2.46%
EC2.5	0.82%	1.37%	0.75%
<i>Mean EC3: 2.74% ± 0.58% and 21% CV</i>			
<i>Mean EC2.5: 1.46% ± 0.48% and 33% CV</i>			
Eugenol			
Concentration (%)	Experiment 1²	Experiment 2²	Experiment 3²
Vehicle (AOO)	1.00 ± 0.17	1.00 ± 0.17	1.00 ± 0.09
5	2.92 ± 1.00	2.80 ± 1.08	3.24 ± 0.70
10	7.35 ± 2.62	4.47 ± 0.98	4.79 ± 0.94
25	10.92 ± 3.63	5.62 ± 3.20	7.07 ± 0.44
EC3	5.09%	5.59%	4.50%
EC2.5	4.33%	3.59%	2.87%
<i>Mean EC3: 5.06% ± 0.55% and 11% CV</i>			
<i>Mean EC2.5: 4.23% ± 0.57% and 13% CV</i>			

1443 Abbreviations: AOO = acetone: olive oil (4:1); CV = coefficient of variation; EC2.5 = estimated concentration
 1444 needed to produce a stimulation index of 2.5; EC3 = estimated concentration needed to produce a stimulation
 1445 index of three; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd.
 1446 based on ATP content.

1447 ¹Based on results discussed in Idehara et al. 2008; the number per group was not specified.

1448 ²Mean stimulation index value ± standard deviation.

1449

1450 7.2 Interlaboratory Reproducibility

1451 Furthermore, data were submitted to NICEATM (**Appendix D**) from a two-phased
 1452 interlaboratory validation study on the LLNA: DA test method (Omori et al. 2008). In the

1453 first phase of the interlaboratory validation study, a blinded test of 12 substances was
1454 conducted in 10 laboratories. Three substances (i.e. 2,4-dinitrochlorobenzene, hexyl cinnamic
1455 aldehyde, and isopropanol) were tested in all 10 laboratories. The remaining nine substances
1456 were randomly assigned to subsets of three of the 10 laboratories (**Table 7-2**). In each
1457 laboratory, each substance was tested one time at three different concentrations. The dose
1458 levels for each substance were predetermined (i.e., the participating laboratories did not
1459 determine their own dose levels for testing). Nine substances are sensitizers and three
1460 substances are nonsensitizers according to the traditional LLNA. Six substances are
1461 ICCVAM-recommended LLNA performance standards reference substances: cobalt chloride,
1462 2,4-dinitrochlorobenzene, hexyl cinnamic aldehyde, isoeugenol, isopropanol, and methyl
1463 salicylate.

1464 The second phase of the interlaboratory validation study was designed to determine the
1465 reason for inconsistencies obtained from the two metals dissolved in DMSO (i.e., cobalt
1466 chloride and nickel (II) sulfate hexahydrate) and thus to further evaluate the reliability of the
1467 LLNA: DA for testing metallic salts using DMSO as a vehicle. Five coded substances (two
1468 of the five substances were unique to the second phase of the interlaboratory validation
1469 study) were tested in seven laboratories (**Table 7-3**). One substance (i.e. hexyl cinnamic
1470 aldehyde) was tested in all seven laboratories. The remaining four substances (i.e., cobalt
1471 chloride, nickel (II) sulfate hexahydrate, lactic acid, and potassium dichromate) were
1472 randomly assigned to subsets of four of the seven laboratories. Each laboratory tested the
1473 substance one time at three different dose levels. Again, the dose levels for each substance
1474 were predetermined. Of the two substances not previously tested in the first phase of the
1475 interlaboratory validation study (i.e., lactic acid and potassium dichromate), one is a
1476 nonsensitizer and the other is a sensitizer according to traditional LLNA results, respectively.
1477 In addition, lactic acid is an ICCVAM-recommended LLNA performance standards
1478 reference substance.

1479 The LLNA: DA test results from the two-phased interlaboratory validation studies are
1480 amenable to interlaboratory reproducibility analyses for three endpoints: sensitizer (positive)
1481 or nonsensitizer (negative) classification, and EC2.5 values. Analyses of interlaboratory
1482 reproducibility were performed using a concordance analysis for the qualitative results

1483 (sensitizer vs. nonsensitizer) (**Section 7.2.1**) and a CV analysis for the quantitative results
 1484 (EC2.5 values) (**Sections 7.2 and 7.3**).

1485 **Table 7-2 Substances and Allocation for the First Phase of the Interlaboratory**
 1486 **Validation Study for the LLNA: DA**

Substance ¹	Vehicle	Concentration Tested (%)			Laboratory									
					1	2	3	4	5	6	7	8	9	10
2,4-Dinitro-chlorobenzene (+)	AOO	0.03	0.10	0.30	X	X	X	X	X	X	X	X	X	X
Hexyl cinnamic aldehyde (+)	AOO	5	10	25	X	X	X	X	X	X	X	X	X	X
Isopropanol (-)	AOO	10	25	50	X	X	X	X	X	X	X	X	X	X
Abietic acid (+)	AOO	5	10	25		X				X	X			
3-Aminophenol (+)	AOO	1	3	10	X		X					X		
Dimethyl isophthalate (-)	AOO	5	10	25	X		X				X			
Isoeugenol (+)	AOO	1	3	10				X	X				X	
Methyl salicylate (-)	AOO	5	10	25			X				X			X
Formaldehyde (+)	ACE	0.5	1.5	5.0	X	X			X					
Glutaraldehyde (+)	ACE	0.05	0.15	0.50	X	X			X					
Cobalt chloride ² (+)	DMSO	0.3	1.0	3.0				X		X		X		
Nickel (II) sulfate hexahydrate (+)	DMSO	1	3	10				X		X		X		

1487 Abbreviations: ACE = acetone; AOO = acetone: olive oil (4:1); DMSO = dimethyl sulfoxide; LLNA: DA = murine local
 1488 lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content.

1489 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

1490 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 1491 of the interlaboratory validation study.
 1492

1492 **Table 7-3 Substances and Allocation for the Second Phase of the Interlaboratory**
 1493 **Validation Study for the LLNA: DA**

Substance ¹	Vehicle	Concentration Tested (%)			Laboratory						
					11	12	13	14	15	16	17
Hexyl cinnamic aldehyde (+)	AOO	5	10	25	X	X	X	X	X	X	X
Cobalt chloride ² (+)	DMSO	1	3	5	X		X	X			X
Lactic acid (-)	DMSO	5	10	25	X		X		X	X	
Nickel (II) sulfate hexahydrate (+)	DMSO	1	3	10	X	X		X		X	
Potassium dichromate (+)	DMSO	0.1	0.3	1.0	X	X			X		X

1494 Abbreviations: AOO = acetone: olive oil (4:1); DMSO = dimethyl sulfoxide; LLNA: DA = murine local lymph node assay
 1495 modified by Daicel Chemical Industries, Ltd. based on ATP content.

1496 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

1497 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 1498 of the interlaboratory validation study.
 1499

1500 7.2.1 Interlaboratory Reproducibility – Qualitative Results

1501 The qualitative (positive/negative) interlaboratory concordance analysis for the 12 substances
 1502 that were tested during the first phase of the LLNA: DA interlaboratory validation study is
 1503 shown in **Table 7-4** for $SI \geq 2.5$. In a qualitative comparison of LLNA: DA calls (i.e.,
 1504 sensitizer/nonsensitizer), ten substances tested in either three or 10 laboratories had
 1505 consistent results leading to 100% (3/3 or 10/10) interlaboratory concordance for those
 1506 substances. There were two discordant substances (i.e., 3-aminophenol and nickel (II) sulfate
 1507 hexahydrate) for which interlaboratory concordance was 67% (2/3). One of the three
 1508 laboratories that tested 3-aminophenol reported $SI \geq 2.5$, at the highest dose tested (i.e., $SI =$
 1509 2.83 at 10%) and two laboratories did not achieve $SI \geq 2.5$ at any dose tested (**Appendix D**).
 1510 One of the three laboratories that tested nickel (II) sulfate hexahydrate reported a maximum
 1511 $SI = 1.52$, while the other two laboratories produced an $SI \geq 2.5$ at all three doses tested
 1512 (**Appendix D**). Notably, when analyzing the dose response curves for the 3 tests performed
 1513 for nickel (II) sulfate in the first phase of the two-phased interlaboratory validation study,
 1514 only one study demonstrated a sufficient dose response (i.e., a parallel increase in SI relative
 1515 to increase in concentration). Since the evaluation of interlaboratory reproducibility for the
 1516 traditional LLNA did not include an evaluation of qualitative results (ICCVAM 1999), there

1517 were no traditional LLNA concordance data for comparison with the LLNA: DA
 1518 concordance data from the first phase of the interlaboratory validation study.

1519 **Table 7-4 Qualitative Results for the First Phase of the Interlaboratory Validation**
 1520 **Studies for the LLNA: DA (SI \geq 2.5)**

Substance ¹	Laboratory ²										Concordance
	1	2	3	4	5	6	7	8	9	10	
2,4-Dinitrochlorobenzene (+)	+	+	+	+	+	+	+	+	+	+	10/10
Hexyl cinnamic aldehyde (+)	+	+	+	+	+	+	+	+	+	+	10/10
Isopropanol (-)	-	-	-	-	-	-	-	-	-	-	10/10
Abietic acid (+)		+				+	+				3/3
3-Aminophenol (+)	+		-					-			2/3
Dimethyl isophthalate (-)	-		-				-				3/3
Isoeugenol (+)				+	+				+		3/3
Methyl salicylate (-)			-				-			-	3/3
Formaldehyde (+)	+	+			+						3/3
Glutaraldehyde (+)	+	+			+						3/3
Cobalt chloride ³ (+)				+ ⁴		+		+			3/3
Nickel (II) sulfate hexahydrate (+)				- ⁵		+		+ ⁵			2/3

1521 Bolded substances did not achieve 100% interlaboratory concordance.

1522 Abbreviations: LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP
 1523 content; SI = stimulation index

1524 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

1525 ²(+) indicates sensitizers and (-) indicates nonsensitizers according to LLNA: DA tests.

1526 ³Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 1527 of the interlaboratory validation study.

1528 ⁴Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

1529 ⁵Insufficient dose response.

1530

1531 The qualitative (positive/negative) interlaboratory concordance analysis for the five
 1532 substances that were tested during the second phase of the LLNA: DA interlaboratory
 1533 validation study is shown in **Table 7-5**. In a qualitative comparison of LLNA: DA calls (i.e.,
 1534 sensitizer/nonsensitizer), four substances (i.e., hexyl cinnamic aldehyde, lactic acid, nickel
 1535 [II] sulfate hexahydrate, and potassium dichromate) tested in either four or seven laboratories
 1536 had consistent results leading to 100% (4/4 or 7/7) interlaboratory concordance for those
 1537 substances. There was one discordant substance (i.e., cobalt chloride) for which
 1538 interlaboratory concordance was 75% (3/4). One of the four laboratories that tested cobalt

1539 chloride did not report a maximum $SI \geq 2.5$ at any dose, while the other three laboratories
 1540 produced an $SI \geq 2.5$ at the highest dose tested. Cobalt chloride was also tested in the first
 1541 phase of the interlaboratory validation study where interlaboratory concordance was 100%
 1542 (3/3). Furthermore, as mentioned previously, the evaluation of interlaboratory reproducibility
 1543 for the traditional LLNA did not include an evaluation of qualitative results (ICCVAM
 1544 1999), and therefore there were no traditional LLNA concordance data for comparison with
 1545 the LLNA: DA concordance data from the second phase of the interlaboratory validation
 1546 study.

1547 **Table 7-5 Qualitative Results for the Second Phase of the Interlaboratory**
 1548 **Validation Study for the LLNA: DA ($SI \geq 2.5$)**

Substance ¹	Laboratory ²							Concordance
	11	12	13	14	15	16	17	
Hexyl cinnamic aldehyde (+)	+	+	+	+	+	+	+	7/7
Cobalt chloride³ (+)	-		+	+			+	3/4
Lactic acid (-)	-		-		-	-		4/4
Nickel (II) sulfate hexahydrate (+)	-	-		-		-		4/4
Potassium dichromate (+)	+	+			+		+	4/4

1549 Bolded substance did not achieve 100% interlaboratory concordance.

1550 Abbreviations: LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP
 1551 content; SI = stimulation index.

1552 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

1553 ²(+) indicates sensitizers and (-) indicates nonsensitizers according to LLNA: DA tests.

1554 ³Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 1555 of the interlaboratory validation study.

1556

1557 7.2.2 Interlaboratory Reproducibility – EC2.5 Values

1558 The available quantitative (i.e., EC2.5 value) data for interlaboratory reproducibility analysis
 1559 were obtained from the LLNA: DA results for ten sensitizers that were tested during the first
 1560 and second phase of the LLNA: DA interlaboratory validation study. The equation used for
 1561 calculating EC2.5 values for the positive results was modified based on the method of linear
 1562 interpolation reported by Gerberick et al. (2004) for the EC3:

1563

$$EC2.5 = c + \left[\frac{(2.5 - d)}{(b - d)} \right] \times (a - c)$$

1564 where the data points lying immediately above and below the SI = 2.5 on the dose response
1565 curve have the coordinates of (a, b) and (c, d), respectively (Gerberick et al. 2004). For
1566 substances for which the lowest concentration tested resulted in an SI > 2.5, an EC2.5 value
1567 was extrapolated according to the equation:

$$1568 \quad EC2.5_{ex} = 2^{\left\{ \log_2(c) + \frac{(2.5-d)}{(b-d)} \times [\log_2(a) - \log_2(c)] \right\}}$$

1569 where the point with the higher SI is denoted with the coordinates of (a, b) and the point with
1570 the lower SI is denoted (c, d) (Gerberick et al. 2004).

1571 The EC2.5 values from each laboratory were used to calculate CV values for each substance.
1572 The resulting values for the first and second phase of the interlaboratory validation study are
1573 shown in **Tables 7-6** and **7-7**, respectively. In the first phase of the interlaboratory validation
1574 study, CV values ranged from 26% (i.e., hexyl cinnamic aldehyde) to 133% (i.e., cobalt
1575 chloride) and the mean CV was 79% (**Table 7-6**). In the second phase of the interlaboratory
1576 validation study, CV values ranged from 20% (i.e., hexyl cinnamic aldehyde) to 92% (i.e.,
1577 cobalt chloride) and the mean CV was 62% (**Table 7-7**).

1578 The ICCVAM-recommended LLNA performance standards indicate that interlaboratory
1579 reproducibility should be evaluated with at least two sensitizing chemicals with well-
1580 characterized activity in the traditional LLNA. Acceptable reproducibility is attained when
1581 each laboratory obtains EC_t values (estimated concentrations needed to produce a stimulation
1582 index of a specified threshold) within 0.025% to 0.1% for 2,4-dinitrochlorobenzene and
1583 within 5% to 20% for hexyl cinnamic aldehyde (ICCVAM 2009). In the first phase of the
1584 interlaboratory validation study, five laboratories reported EC2.5 values outside the
1585 acceptance range indicated for 2,4-dinitrochlorobenzene; two of the five laboratories
1586 obtained EC2.5 values that were lower than the specified acceptance range (i.e., 0.025%) and
1587 three of the five laboratories obtained EC2.5 values that were higher than the specified
1588 acceptance range (i.e., 0.1%) (**Table 7-6**). For hexyl cinnamic aldehyde, all the laboratories
1589 obtained an EC2.5 value within the acceptance range (5% to 20%). In the second phase of the
1590 interlaboratory validation study, only hexyl cinnamic aldehyde was tested and all seven
1591 laboratories obtained EC2.5 values that were within the acceptance range indicated (**Table**
1592 **7-7**).

Table 7-6 EC2.5 Values from the First Phase of the Interlaboratory Validation Study for the LLNA: DA

Substance ¹	Laboratory										Mean EC2.5 (%)	CV (%)
	1	2	3	4	5	6	7	8	9	10		
2,4-Dinitrochlorobenzene (+)	0.026 (11.97)	0.063 (9.23)	0.039 (9.96)	0.022 (8.53)	0.112 (7.86)	0.025 (15.14)	0.011 (13.18)	0.039 (12.60)	0.023 (10.89)	0.131 (4.71)	0.049	84
Hexyl cinnamic aldehyde (+)	8.473 (5.78)	9.414 (4.82)	11.402 (4.44)	7.900 (5.11)	14.594 (3.97)	10.759 (5.50)	6.778 (7.09)	7.032 (10.22)	12.530 (3.88)	9.135 (3.51)	9.802	26
Isopropanol (-)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Abietic acid (+)		6.418				6.469	11.525				8.137	36
3-Aminophenol (+)	5.471		NA					NA			5.471	NA
Dimethyl isophthalate (-)	NA		NA				NA				NA	NA
Isoeugenol (+)				0.657	5.191				0.874		2.240	114
Methyl salicylate (-)			NA				NA			NA	NA	NA
Formaldehyde (+)	0.393	1.105			4.179						1.892	106
Glutaraldehyde (+)	0.091	0.351			0.296						0.246	56
Cobalt chloride ² (+)				0.822 ³		0.047		0.104			0.325	133
Nickel (II) sulfate hexahydrate (+)				NA ⁴		0.352		IDR			0.352	NA

Bolded text indicates substances that are ICCVAM-recommended murine local lymph node assay (LLNA) performance standards reference substances (ICCVAM 2009). Values in parentheses are highest stimulation index (SI) values achieved. For both 2,4-dinitrochlorobenzene and hexyl cinnamic aldehyde, the highest SI values achieved were from the highest dose tested (i.e., 0.30% for 2,4-dinitrochlorobenzene and 25% for hexyl cinnamic aldehyde). Shading shows EC2.5 values (estimated concentration needed to produce a stimulation index of 2.5) that are outside of the acceptable range indicated in the ICCVAM-recommended LLNA performance standards: 5 - 20% for hexyl cinnamic aldehyde and 0.025 - 0.1% for 2,4-dinitrochlorobenzene.

Abbreviations: CV = coefficient of variation; IDR = insufficient dose response; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content. NA = not applicable.

¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%) of the interlaboratory validation study.

³Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

⁴Insufficient dose response.

1605 **Table 7-7 EC2.5 Values from the Second Phase of the Interlaboratory Validation**
 1606 **Study for the LLNA: DA**

Substance ¹	Laboratory							Mean	%CV
	11	12	13	14	15	16	17		
Hexyl cinnamic aldehyde (+)	7.737 (4.47)	7.374 (5.71)	6.772 (5.41)	6.361 (7.60)	9.902 (3.92)	5.366 (8.42)	6.783 (6.45)	7.185	20
Cobalt chloride ² (+)	NA		4.111	1.202			0.699	2.004	92
Lactic acid (-)	NA		NA		NA	NA		NA	NA
Nickel (II) sulfate hexahydrate (+)	NA	NA		NA		NA		NA	NA
Potassium dichromate (+)	0.372	0.269			0.087		0.063	0.198	75

1607 Bolded text indicates substances that are ICCVAM-recommended murine local lymph node assay (LLNA) performance
 1608 standards reference substances (ICCVAM 2009). Values in parentheses are highest stimulation index (SI) values achieved.
 1609 For hexyl cinnamic aldehyde, the highest SI values achieved were from the highest dose tested (i.e., 25%). None of the
 1610 EC2.5 values (estimated concentrations needed to produce a stimulation index of 2.5) are outside of the acceptable range
 1611 indicated in the ICCVAM-recommended LLNA performance standards (i.e., 5 - 20% for hexyl cinnamic aldehyde).

1612 Abbreviations: CV = coefficient of variation; NA = not applicable.

1613 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

1614 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 1615 of the interlaboratory validation study.

1616
 1617 The interlaboratory CV values for both the first and second phase of the interlaboratory
 1618 validation study for the LLNA: DA EC2.5 values were higher than that for the traditional
 1619 LLNA EC3 values. The analysis of interlaboratory variation of EC3 values for the traditional
 1620 LLNA reported CV values of 6.8 to 83.7% for five substances tested in five laboratories
 1621 (**Table 7-8**; ICCVAM 1999). Three of the same substances were evaluated in the traditional
 1622 LLNA and the LLNA: DA (i.e., hexyl cinnamic aldehyde, 2,4-dinitrochlorobenzene, and
 1623 isoeugenol). All interlaboratory CV values for the LLNA: DA were greater than that for the
 1624 traditional LLNA. The CV of 84% for 2,4-dinitrochlorobenzene was greater than the two CV
 1625 values of 37.4% and 27.2% (which were calculated from five values each), reported by
 1626 ICCVAM (1999). The CV of 26% and 20% for hexyl cinnamic aldehyde tested in the first
 1627 and second phase of the LLNA: DA interlaboratory validation study, respectively, were both
 1628 greater than the 6.8% reported by ICCVAM (1999). The CV of 114% for isoeugenol tested
 1629 in the LLNA: DA was greater than the 41.2% reported by ICCVAM (1999).

1630

1630 **Table 7-8 Interlaboratory Reproducibility of the EC3 for Substances Tested in the**
 1631 **Traditional LLNA¹**

Substance	Laboratory					CV (%)
	1	2	3	4	5	
2, 4-Dinitrochlorobenzene	0.3	0.5	0.6	0.9	0.6	37.4
	0.5	0.6	0.4	0.6	0.3	27.2
Hexyl cinnamic aldehyde	7.9	7.6	8.4	7.0	8.1	6.8
Isoeugenol	1.3	3.3	1.8	3.1	1.6	41.2
Eugenol	5.8	14.5	8.9	13.8	6.0	42.5
SLS	13.4	4.4	1.5	17.1	4.0	83.7

1632 Abbreviations: CV = coefficient of variation; EC3 = estimated concentration needed to produce a
 1633 stimulation index of three; LLNA = murine local lymph node assay; SLS = sodium lauryl sulfate.
 1634 ¹From ICCVAM 1999 report.

1635

1636 **7.3 Reproducibility for the LLNA: DA Accuracy Analysis Using Multiple**
 1637 **Alternative Decision Criteria**

1638 **Section 6.7** details the accuracy analysis for the LLNA: DA (using the most prevalent
 1639 outcome for substances with multiple tests) when using two decision criteria for LLNA: DA
 1640 results: one criterion to classify substances as sensitizers ($SI \geq 2.5$) and one criterion to
 1641 classify substances as nonsensitizers ($SI \leq 1.7$). $SI \geq 2.5$ was evaluated for classifying
 1642 sensitizers because it resulted in no false positives, and $SI \leq 1.7$ was evaluated for classifying
 1643 substances as nonsensitizers because it resulted in no false negatives, with respect to
 1644 traditional LLNA data. This section evaluates reproducibility of the concordance with the
 1645 traditional LLNA results by examining the frequency with which SI values in the validation
 1646 database of 44 substances occurred in one of three SI categories. The three SI categories
 1647 were:

- 1648 • $SI \leq 1.7$ for classifying nonsensitizers
- 1649 • $1.7 < SI < 2.5$, the range of uncertainty with respect to classification by the
 1650 traditional LLNA
- 1651 • $SI \geq 2.5$ to classify substances as sensitizers

1652 The validation database for the LLNA: DA consists of 123 tests of 44 substances. The
 1653 maximum SI achieved by each test and the traditional LLNA outcome (sensitizer vs.
 1654 nonsensitizer) were used to determine the frequency of the maximum SI. **Table 7-9** shows
 1655 the proportion of sensitizers and nonsensitizers, according to the traditional LLNA for each
 1656 SI category. Eighty-seven percent of the tests (27/31) that yielded $SI \leq 1.7$ were for
 1657 substances that were classified as nonsensitizers by the traditional LLNA; 13% of the tests
 1658 (4/31) that yielded $SI \leq 1.7$ were for substances that were classified as sensitizers by the
 1659 traditional LLNA. Fifty-eight percent (7/12) of the tests that yielded $1.7 < SI < 2.5$ were for
 1660 substances that were classified as sensitizers by the traditional LLNA. Four tests produced SI
 1661 values near either end of this range (i.e., $SI = 1.7$ or $SI = 2.5$). One of the 3-aminophenol
 1662 studies and one of the methyl salicylate studies produced $SI = 1.76$ and 1.77 , respectively,
 1663 and the chlorobenzene test produced $SI = 2.44$. The remainder of the tests in this category,
 1664 42% (5/12), were classified as nonsensitizers by the traditional LLNA. One hundred percent
 1665 (80/80) of the tests that yielded $SI \geq 2.5$ were for substances that were classified as
 1666 sensitizers by the traditional LLNA and 0% (0/80) were classified as nonsensitizers.

1667 **Table 7-9 Frequency of Maximum SI for LLNA: DA Tests by Category and**
 1668 **Traditional LLNA Outcome**

Classification Based on Traditional LLNA	Classification Concordance with Traditional LLNA ¹			Total
	Maximum $SI \leq 1.7$	$1.7 < \text{Maximum } SI < 2.5$	Maximum $SI \geq 2.5$	
Sensitizer	4 (13%)	7 (58%)	80 (100%)	91
Nonsensitizer	27 (87%)	5 (42%)	0 (0%)	32
Total	31	12	80	123

1669 Abbreviations: LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified
 1670 by Daicel Chemical Industries, Ltd. based on ATP content; SI = stimulation index.

1671 ¹Numbers shown reflect number of tests. Includes all tests of substances that were tested multiple times.

1672 Percentage in parentheses reflects percentage of the total number of tests for each SI category.

1673

1674 The 123 tests evaluated in **Table 7-9** include multiple tests for 14 substances. For the 14
 1675 substances, three to 18 tests were available. **Table 7-10** shows the proportion of the tests for
 1676 each substance that produced SI values in each category. For the four nonsensitizers with
 1677 multiple test results, there were 22 tests that produced $SI \leq 1.7$ and two tests that produced an
 1678 SI of between 1.7 and 2.5. For the 10 sensitizers with multiple test results, however, SI
 1679 values occurred in all three SI categories. The results for nickel (II) sulfate hexahydrate were
 1680 particularly variable: 50% (4/8) produced $SI \leq 1.7$ (i.e., four tests with $SI = 0.79, 1.24, 1.52,$

1681 and 1.56), 25% (2/8) produced $1.7 < SI < 2.5$ ($SI = 2.13$ and 2.17), and 25% (2/8) produced
 1682 $SI \geq 2.5$ ($SI = 3.49$ and 11.78). 3-Aminophenol produced SI values in two categories: 67%
 1683 (2/3) of the tests had $1.7 < SI < 2.5$ ($SI = 1.76$ and 2.38), and 33% (1/3) of the tests had $SI \geq$
 1684 2.5 ($SI = 2.83$). Cobalt chloride tests also produced SI values in two categories: 12.5% (1/8)
 1685 of the tests had $1.7 < SI < 2.5$ ($SI = 2.01$) and seven of eight tests (i.e., 87.5%) produced $SI \geq$
 1686 2.5 ($SI = 2.54, 2.66, 3.64, 4.25, 5.06, 8.07, \text{ and } 20.55$). The multiple test results for the
 1687 remaining seven traditional LLNA sensitizers were 100% concordant (**Table 7-10**).

1688 **Table 7-10 Concordance of LLNA: DA Tests for Substances with Multiple Tests by**
 1689 **Maximum SI Category**

Substance	Concordance Among Multiple Tests ¹			Total
	Maximum SI ≤ 1.7	$1.7 < \text{Maximum SI} < 2.5$	Maximum SI ≥ 2.5	
<i>Sensitizers²</i>				
Abietic acid	0 (0%)	0 (0%)	4 (100%)	4
3-Aminophenol	0 (0%)	2 (67%)	1 (33%)	3
Cobalt chloride	0 (0%)	1 (12.5%)	7 (87.5%)	8
2,4-Dinitrochlorobenzene	0 (0%)	0 (0%)	11 (100%)	11
Formaldehyde	0 (0%)	0 (0%)	4 (100%)	4
Glutaraldehyde	0 (0%)	0 (0%)	4 (100%)	4
Hexyl cinnamic aldehyde	0 (0%)	0 (0%)	18 (100%)	18
Isoeugenol	0 (0%)	0 (0%)	4 (100%)	4
Nickel (II) sulfate hexahydrate	4 (50%)	2 (25%)	2 (25%)	8
Potassium dichromate	0 (0%)	0 (0%)	5 (100%)	5
<i>Nonsensitizers²</i>				
Dimethyl isophthalate	4 (100%)	0 (0%)	0 (0%)	4
Isopropanol	10 (91%)	1 (9%)	0 (0%)	11
Lactic acid	5 (100%)	0 (0%)	0 (0%)	5
Methyl salicylate	3 (75%)	1 (25%)	0 (0%)	4

1690 Abbreviations: LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified
 1691 by Daicel Chemical Industries, Ltd. based on ATP content; SI = stimulation index.

1692 ¹Numbers shown reflect number of tests. Percentage in parentheses reflects percentage of the total number of
 1693 tests for each substance.

1694 ²According to traditional LLNA results.

1695

1696

1696 8.0 LLNA: DA Data Quality

1697 The data quality section in this revised draft BRD has been updated from the January 2008
1698 draft BRD to indicate that all of the studies included in this performance evaluation are based
1699 on individual animal data submitted to NICEATM in the form of original data and study
1700 records. Furthermore, since the January 2008 draft BRD was made available, manuscripts
1701 detailing the results for 31 substances evaluated in the intralaboratory study and 14
1702 substances evaluated in the two-phased interlaboratory validation have been published in the
1703 peer-reviewed literature (Idehara et al. 2008; Omori et al. 2008). Also, an independent audit
1704 has been conducted to confirm that the reported data from the intralaboratory validation
1705 study (i.e., assessment of 31 substances from Idehara et al. 2008) performed by Daicel
1706 Chemical Industries, Ltd. was the same as the data originally recorded (Idehara et al. 2008).
1707 The data from the two-phased interlaboratory validation study were not subjected to a formal
1708 audit, but the raw data were reportedly entered directly into formatted MS-Excel templates
1709 provided by the study management team prior to being used for analyses (Omori et al. 2007).
1710 In addition, data recently received for 14 substances evaluated in an intralaboratory
1711 validation study (Idehara, unpublished) were also not subjected to a formal audit. The
1712 intralaboratory assessment at Daicel Chemical Industries, Ltd. (Idehara et al. 2008; Idehara,
1713 unpublished), as well as the two-phased interlaboratory validation study (Omori et al. 2008),
1714 did not conduct their studies in compliance with Good Laboratory Practice guidelines,
1715 although all of the participating laboratories reportedly have this capability.

1716

1716 **9.0. Other Scientific Reports and Reviews**

1717 This section has been updated to include information on the intralaboratory validation study
1718 and the two-phased interlaboratory validation based on publication of the data since the
1719 January 2008 draft BRD. In addition, information is included on the regulatory acceptance of
1720 the LLNA: DA test method by the Japanese Center for the Validation of Alternative Methods
1721 (JaCVAM).

1722 Yamashita et al. (2005) describe the development of the LLNA: DA as an alternative non-
1723 radioisotope LLNA test method. The manuscript details the determination of an optimal
1724 dosing schedule and further compares SI values obtained from lymph node weights versus
1725 ATP content to determine an appropriate lymphocyte proliferation endpoint. The authors
1726 further assessed the intermediate precision and sensitivity/specificity of the LLNA: DA. In
1727 these experiments, four compounds (2,4-dinitrochlorobenzene, eugenol, α -hexyl cinnamic
1728 aldehyde, and methyl salicylate) were tested and no significant differences were noted in the
1729 SI levels generated from the LLNA: DA and the traditional LLNA. This study provided the
1730 basis for the expanded intralaboratory study of 31 substances analyzed by Daicel Chemical
1731 Industries, Ltd. (described in **Sections 6.0** and **7.0**) for which the data were published by
1732 Idehara et al. (2008).

1733 Idehara et al. (2008) summarize the LLNA: DA test method in terms of test substance dosing
1734 schedule, preparation of single cell suspensions of the auricular lymph nodes, measurement
1735 of ATP content, and explanation of statistical analyses employed. The authors further
1736 describe how the results correlate between ATP content and lymph node cell number, the test
1737 results (i.e., mean SI values and EC3) obtained for the 31 substances, the concordance of the
1738 LLNA: DA versus the traditional LLNA EC3, and the reproducibility of EC3 and SI values.
1739 Based on the details included in the manuscript, the authors conclude that the SI values
1740 obtained from measuring ATP content were similar to the traditional LLNA and therefore the
1741 LLNA: DA was a promising non-radioisotope modified test method for evaluating the skin
1742 sensitization potential of substances.

1743 Omori et al. (2008) describe the two-phased interlaboratory validation study used to evaluate
1744 the reliability and relevance of the LLNA: DA test method (see **Section 7.0**). They describe
1745 the organization and technology transfer of the test method between the laboratories, as well

1746 as test substance selection and allocation. They further describe the development of the
1747 LLNA: DA and the resulting standard protocol for the LLNA: DA interlaboratory study. The
1748 provide the interlaboratory data for analyzing both ATP content with regard to SI values and
1749 lymph node weight and discuss assay sensitivity and interlaboratory variability. Based on the
1750 data summarized in the manuscript, the authors conclude that in the first phase of the
1751 interlaboratory validation study, a large variation was observed for two substances (i.e.,
1752 cobalt chloride and nickel [II] sulfate hexahydrate) but in the second phase of the
1753 interlaboratory validation study this variation was small. The authors attributed the initial
1754 variation to application of DMSO as the solvent for the metallic salts and therefore, prior to
1755 the second phase of the interlaboratory validation study, included operation of LLNA: DA
1756 with DMSO in the technology transfer seminar. In conclusion, the authors view the LLNA:
1757 DA as a reliable test method for predicting skin sensitization potential of substances.

1758 Regarding the LLNA: DA test method, non-commission members of JaCVAM met on
1759 August 28, 2008 at the National Institute of Health Sciences, Tokyo, Japan, and endorsed the
1760 following statement: “Following the review of the results of the Ministry of Health, Labour
1761 and Welfare (MHLW)-funded validation study on the LLNA: DA coordinated by Japanese
1762 Society for Alternative to Animal Experiments, it is concluded that the LLNA: DA can be
1763 used for distinguishing between sensitizer and nonsensitizer chemicals within the context of
1764 the OECD testing guidelines No. 429 on skin sensitization: LLNA. The JaCVAM regulatory
1765 acceptance board has been regularly kept informed of the progress of the study, and this
1766 endorsement was based on an assessment of various documents, including, in particular, the
1767 report on the results from the study, and also on the evaluation supported by MHLW of the
1768 study prepared for the JaCVAM ad hoc peer review panel.” JaCVAM has informed
1769 NICEATM-ICCVAM that in January 2009 they will submit the SPSF for recommendation of
1770 the LLNA: DA from the Japanese National Coordinator to OECD secretary. They will make
1771 clear that the SPSF was produced in collaboration with NICEATM-ICCVAM.

1772

1772 **10.0 Animal Welfare Considerations**

1773 This section of the draft BRD has not changed from the January 2008 draft BRD. The
1774 LLNA: DA will require the use of the same number of animals when compared to the
1775 updated ICCVAM LLNA protocol (Appendix A of ICCVAM 2009). However, since the
1776 traditional LLNA uses radioactive materials and as such its use might be restricted due to the
1777 complications associated with storage, use, and disposal, broader use of a non-radioactive
1778 alternative to the traditional LLNA, such as the LLNA: DA, could further reduce the number
1779 of guinea pigs that are used to assess skin sensitization.

1780 **10.1 Rationale for the Need to Use Animals**

1781 The rationale for the use of animals in the LLNA: DA is the same as the rationale for the
1782 traditional LLNA. There currently are no valid and accepted non-animal test methods to
1783 determine the ACD potential of substances and products, except for situations where human
1784 studies could be conducted ethically and where such studies would meet regulatory safety
1785 assessment requirements. Additionally, the most detailed information about the induction and
1786 regulation of immunological responses are available for mice (ICCVAM 1999).

1787 **10.2 Basis for Determining the Number of Animals Used**

1788 The number of animals used for the experimental, vehicle, and positive control groups is
1789 based on the number of animals specified in the updated ICCVAM LLNA protocol
1790 (Appendix A of ICCVAM 2009).

1791 **10.3 Reduction considerations**

1792 A further reduction of 40% (15 vs. 25) could be achieved by using a reduced version of the
1793 LLNA: DA, in cases where dose response information is not needed for hazard identification
1794 purposes. In such an approach, only the highest soluble dose of the test article that does not
1795 elicit toxicity would be administered, and the two lower dose groups would not be used.
1796 Additional reductions could be achieved by testing more substances concurrently, so that the
1797 same vehicle and positive control group could be used for multiple substances.

1798

1798 **11.0 Practical Considerations**

1799 This section of the draft BRD has not changed from the January 2008 draft BRD. Several
1800 issues are taken into account when assessing the practicality of using an alternative to an
1801 existing test method. In addition to performance evaluations, assessments of the laboratory
1802 equipment and supplies needed to conduct the alternative test method, level of personnel
1803 training, labor costs, and the time required to complete the test method relative to the existing
1804 test method are necessary. The time, personnel cost, and effort required to conduct the
1805 proposed test method(s) must be considered to be reasonable when compared to the existing
1806 test method it is intended to replace.

1807 **11.1 Transferability of the LLNA: DA**

1808 Test method transferability addresses the ability of a method to be accurately and reliably
1809 performed by multiple laboratories (ICCVAM 2003), including those experienced in the
1810 particular type of procedure as well as laboratories with less or no experience in the
1811 particular procedure. It would be expected that the transferability of the LLNA: DA would be
1812 similar to the traditional LLNA, since their test method protocols are experimentally similar.
1813 Notably, the test method developer does indicate that when the LLNA: DA test method is
1814 conducted, all the procedural steps from lymph node excision to the determination of ATP
1815 content should be performed without delay since ATP content decreases over time (Idehara
1816 et al. 2008; Omori et al. 2008).

1817 **11.2 Laboratories and Major Fixed Equipment Required to Conduct the LLNA:** 1818 **DA**

1819 Compared to the traditional LLNA, the LLNA: DA will not require laboratories, equipment,
1820 and licensing permits for handling radioactive materials. However, the LLNA: DA does
1821 require access to a luminometer capable of detecting light emission by ATP for the
1822 assessment of lymphocyte proliferation. The remaining requirements (e.g., animal care
1823 laboratories) are the same between the two methods.

1824

1824 **11.3 LLNA: DA Training Considerations**

1825 The level of training and expertise needed to conduct the LLNA: DA should be similar to the
1826 traditional LLNA, although the LLNA: DA includes an additional requirement that users
1827 operate a luminometer instead of a scintillation counter and be able process this data.

1828

1828 **12.0 References**

- 1829 Basketter DA, Scholes EW. 1992. Comparison of the local lymph node assay with the
1830 guinea-pig maximization test for the detection of a range of contact allergens. *Food Chem*
1831 *Toxicol* 30:65-69.
- 1832 Basketter DA, Scholes EW, Wahlkyist H, Montelius J. 1995. An evaluation of the suitability
1833 of benzocaine as a positive control skin sensitizer. *Contact Dermatitis* 33:28-32.
- 1834 Basketter DA, Gerberick GF, Kimber I. 1998. Strategies for identifying false positive
1835 responses in predictive skin sensitization tests. *Food Chem Toxicol* 36:327-333.
- 1836 Basketter DA, Lea LJ, Cooper KJ, Ryan CA, Gerberick GF, Dearman RJ, et al. 1999.
1837 Identification of metal allergens in the local lymph node assay. *Am J Contact Dermat*
1838 10:207-212.
- 1839 Basketter DA, Lea LJ, Cooper K, Stocks J, Dickens A, Pate I, et al. 1999b. Threshold for
1840 classification as a skin sensitizer in the local lymph node assay: A statistical evaluation. *Food*
1841 *Chem Toxicol* 37:1167-1174.
- 1842 Basketter DA, Kimber I. 2001. Predictive testing in contact allergy: facts and future. *Allergy*
1843 56:937-943.
- 1844 Basketter DA, Wright ZM, Warbrick EV, Dearman RJ, Kimber I, Ryan CA, et al. 2001.
1845 Human potency predictions for aldehydes using the local lymph node assay. *Contact*
1846 *Dermatitis* 45:89-94.
- 1847 Basketter DA, Smith Pease CK, Patlewicz GY. 2003. Contact allergy: the local lymph node
1848 assay for the prediction of hazard and risk. *Clin Exp Dermatol* 28:218-221.
- 1849 Basketter DA, Clapp C, Jefferies D, Safford B, Ryan CA, Gerberick F, et al. 2005. Predictive
1850 identification of human skin sensitization thresholds. *Contact Dermatitis* 53:260-267.
- 1851 Basketter DA, Sanders D, Jowsey IR. 2007. The skin sensitization potential of resorcinol:
1852 experience with the local lymph node assay. *Contact Dermatitis* 56:196-200.
- 1853 Basketter DA, Kan-King-Yu D, Dierkes P, Jowsey IR. 2007b. Does irritation potency
1854 contribute to the skin sensitization potency of contact allergens? *Cutan Ocul Toxicol* 26:279-
1855 286.

- 1856 Betts CJ, Dearman RJ, Heylings JR, Kimber I, Basketter DA. 2006. Skin sensitization
1857 potency of methyl methacrylate in the local lymph node assay: comparisons with guinea-pig
1858 data and human experience. *Contact Dermatitis* 55:140-147.
- 1859 Cosmetic Ingredient Review Expert Panel. 1998. Final report on the safety assessment of
1860 glycolic acid, ammonium, calcium, potassium, and sodium glycolates, methyl, ethyl, propyl,
1861 and butyl glycolates, and lactic acid, ammonium, calcium, potassium, sodium, and tea-
1862 lactates, methyl, ethyl, isopropyl, and butyl lactates, and lauryl, myristyl, and cetyl lactates.
1863 *Int J Toxicol* 17(Suppl 1):1-203.
- 1864 De Jong WH, Tentij M, Spiekstra SW, Vandebriel RJ, Van Loveren H. 2002. Determination
1865 of the sensitising activity of the rubber contact sensitizers TMTD, ZDMC, MBT and DEA in
1866 a modified local lymph node assay and the effect of sodium dodecyl sulfate pretreatment on
1867 local lymph node responses. *Toxicology* 176:123-134.
- 1868 Dean J, Twerdok L, Tice R, Sailstad D, Hattan D, Stokes WS. 2001. Evaluation of the
1869 Murine Local Lymph Node Assay (LLNA) II: Conclusions and Recommendations of an
1870 Independent Scientific Peer Review Panel. *Regul Toxicol Pharmacol* 34:258-273,
- 1871 ECETOC. 1995. Skin Irritation and Corrosion: Reference Chemicals Data Bank. Technical
1872 Report Number 66. Brussels: European Centre for Ecotoxicology and Toxicology of
1873 Chemicals.
- 1874 EPA. 2003. Health Effects Test Guideline, OPPTS 870.2600. Skin Sensitization EPA 712-
1875 C-03-197. Washington, DC: U.S. Environmental Protection Agency.
- 1876 Gad SC, Dunn BJ, Dobbs DW, Reilly C, Walsh RD. 1986. Development and validation of an
1877 alternative dermal sensitization test: the mouse ear swelling test (MEST). *Toxicol Appl*
1878 *Pharmacol* 84:93-114.
- 1879 Gerberick GF, House RV, Fletcher ER, Ryan CA. 1992. Examination of the local lymph
1880 node assay for use in contact sensitization risk assessment. *Fundam Appl Toxicol* 19:438-
1881 445.
- 1882 Gerberick GF, Cruse LW, Ryan CA, Hulette BC, Chaney JG, Skinner RA, et al. 2002. Use of
1883 a B cell marker (B220) to discriminate between allergens and irritants in the local lymph
1884 node assay. *Toxicol Sci* 68:420-428.

- 1885 Gerberick GF, Ryan CA, Kern PS, Dearman RJ, Kimber I, Patlewicz GY, et al. 2004. A
1886 chemical dataset for evaluation of alternative approaches to skin-sensitization testing.
1887 Contact Dermatitis 50:274-288.
- 1888 Gerberick GF, Ryan CA, Kern PS, Schlatter H, Dearman RJ, Kimber I, et al. 2005.
1889 Compilation of historical local lymph node data for evaluation of skin sensitization
1890 alternative methods. Dermatitis 16:157-202.
- 1891 Gerberick GF, Vassallo JD, Foertsch LM, Price BB, Chaney JG, Lepoittevin JP. 2007.
1892 Quantification of chemical peptide reactivity for screening contact allergens: a classification
1893 tree model approach. Toxicol Sci 97:417-427.
- 1894 Hilton J, Dearman RJ, Harvey P, Evans P, Basketter DA, Kimber I. 1998. Estimation of
1895 relative skin sensitizing potency using the local lymph node assay: a comparison of
1896 formaldehyde with glutaraldehyde. Am J Contact Dermat 9:29-33.
- 1897 ICCVAM. 1997. Validation and Regulatory Acceptance of Toxicological Test Methods: A
1898 Report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative
1899 Methods. NIH Publication No.: 97-3981. Research Triangle Park: National Institute of
1900 Environmental Health Sciences.
- 1901 ICCVAM. 1999. The Murine Local Lymph Node Assay: A Test Method for Assessing the
1902 Allergic Contact Dermatitis Potential of Chemical/Compounds. NIH Publication No. 99-
1903 4494. Research Triangle Park: National Institute of Environmental Health Sciences.
- 1904 ICCVAM. 2001. Protocol: Murine Local Lymph Node Assay (LLNA); Recommended by
1905 ICCVAM Immunotoxicology Working Group - Based on an Independent Expert Peer
1906 Review Panel Evaluation of the LLNA. Research Triangle Park: National Institute of
1907 Environmental Health Sciences.
- 1908 ICCVAM. 2003. ICCVAM Guidelines for the Nomination and Submission of New, Revised,
1909 and Alternative Test Methods. NIH Publication No: 03-4508. Research Triangle Park:
1910 National Institute of Environmental Health Sciences.
- 1911 ICCVAM. 2009. Recommended Performance Standards: Murine Local Lymph Node Assay.
1912 NIH Publication Number 09-7357. Research Triangle Park, NC: National Institute of
1913 Environmental Health Sciences. Available at

- 1914 http://iccvam.niehs.nih.gov/methods/immunotox/llna_PerfStds.htm.
- 1915 Idehara K, Yamagishi G, Yamashita K, Ito M. 2008. Characterization and evaluation of a
1916 modified local lymph node assay using ATP content as a non-radio isotopic endpoint. J
1917 Pharmacol Toxicol Methods 58:1-10.
- 1918 ISO. 2002. Biological evaluation of medical devices -- Part 10: Tests for irritation and
1919 delayed-type hypersensitivity. Available for purchase at: <http://www.iso.org/iso/home.htm>.
- 1920 Jordan WP, King SE. 1977. Delayed hypersensitivity in females. The development of allergic
1921 contact dermatitis in females during the comparison of two predictive patch tests. Contact
1922 Dermatitis 3:119-26.
- 1923 Jowsey IR, Basketter DA, Westmoreland C, Kimber I. 2006. A future approach to measuring
1924 relative skin sensitising potency: A proposal. J Appl Toxicol 26:341-350.
- 1925 Kimber I, Dearman RJ. 1991. Investigation of lymph node cell proliferation as a possible
1926 immunological correlate of contact sensitizing potential. Food Chem Toxicol 29:125-129.
- 1927 Kimber I, Dearman RJ. 1996. Contact hypersensitivity: immunological mechanisms. In
1928 Toxicology of Contact Hypersensitivity. (Kimber I, Maurer T, eds). London:Taylor and
1929 Francis, 4-25.
- 1930 Klecak G, Geleicke H, Frey JR. 1977. Screening of fragrance materials for allergenicity in
1931 the guinea pig. I. Comparison of four testing methods. J Soc Cosmet Chem 28:53-64.
- 1932 Kligman AM. 1966. The identification of contact allergens by human assay. I. A critique of
1933 standard methods. J Invest Dermatol 47:369-409.
- 1934 Kligman AM. 1966b. The Identification of Contact Allergens by Human Assay. II. Factors
1935 influencing the induction and measurement of allergic contact dermatitis. J Invest Dermatol
1936 47:375-92.
- 1937 Kligman AM. 1966c. The Identification of Contact Allergens by Human Assay. III. The
1938 maximization test: a procedure for screening and rating contact sensitizers. J Invest Dermatol
1939 47:393-409.

- 1940 Kwon JA, Lee MS, Kim MI, Park YM, Kim HO, Kim CW. 2003. Allergic contact dermatitis
1941 from dodecyldiaminoethylglycine and isopropyl alcohol in a commercial disinfectant swab.
1942 *Contact Dermatitis* 48:339-340.
- 1943 Loveless SE, Ladics GS, Gerberick GF, Ryan CA, Basketter DA, Scholes EW, et al. 1996.
1944 Further evaluation of the local lymph node assay in the final phase of an international
1945 collaborative trial. *Toxicology* 108:141-152.
- 1946 Manetz TS, Meade BJ. 1999. Development of a flow cytometry assay for the identification
1947 and differentiation of chemicals with the potential to elicit irritation, IgE- mediated, or T cell-
1948 mediated hypersensitivity responses. *Toxicol Sci* 48:206-217.
- 1949 Marzulli FN, Maibach HI. 1974. The use of graded concentrations in studying skin
1950 sensitizers: experimental contact sensitization in man. *Food Cosmet Toxicol* 12:219-227.
- 1951 Marzulli FN, Maibach HI. 1980. Contact allergy: predictive testing of fragrance ingredients
1952 in humans by Draize and maximization methods. *J Environ Pathol Toxicol* 3:235-245.
- 1953 OECD. 2002. Test guideline 429. Skin Sensitisation: Local Lymph Node Assay, adopted
1954 April 24, 2002. In: *OECD Guidelines for Testing of Chemicals*. Paris:OECD.
- 1955 Omori T, Idehara K, Kojima H, Sozu T, Arima K, Goto H, et al. 2007. Validation studies on
1956 LLNA: DA: importance of study management [Abstract]. Sixth World Congress on
1957 Alternatives and Animal Use in the Life Sciences. Tokyo, Japan.
- 1958 Omori T, Idehara K, Kojima H, Sozu T, Arima K, Goto H, et al. 2008. Interlaboratory
1959 validation of the modified murine local lymph node assay based on adenosine triphosphate
1960 measurement. *J Pharmacol Toxicol Methods* 58:11-26.
- 1961 Poole RL, Griffith JF, MacMillan FSK. 1970. Experimental contact sensitization with
1962 benzoyl peroxide. *Arch Derm* 102:400-404.
- 1963 Robinson MK, Nusair TL, Fletcher ER, Ritz HL. 1990. A review of the Buehler guinea pig
1964 skin sensitization test and its use in a risk assessment process for human skin sensitization.
1965 *Toxicology* 61:91-107.

- 1966 Ryan CA, Cruse LW, Skinner RA, Dearman RJ, Kimber I, Gerberick GF. 2002. Examination
1967 of a vehicle for use with water soluble materials in the murine local lymph node assay. Food
1968 Chem Toxicol 40:1719-1725.
- 1969 Sailstad DM, Hattan D, Hill RN, Stokes WS. 2001. ICCVAM evaluation of the murine local
1970 lymph node assay (LLNA) I: the ICCVAM review process. Regul Toxicol Pharmacol
1971 34:249-257.
- 1972 Schneider K, Akkan Z. 2004. Quantitative relationship between the local lymph node assay
1973 and human skin sensitization assays. Regul Toxicol Pharmacol 39:245-255.
- 1974 Scholes EW, Basketter DA, Sarll AE, Kimber I, Evans CD, Miller K, et al. 1992. The local
1975 lymph node assay: results of a final inter-laboratory validation under field conditions. J Appl
1976 Toxicol 12:217-222.
- 1977 Van der Walle HB, Klecak G, Geleick H, Bensink T. 1982. Sensitizing potential of 14 mono
1978 (meth) acrylates in the guinea pig. Contact Dermatitis 8:223-235.
- 1979 Van Och FM, Slob W, de Jong WH, Vandebriel RJ, van Loveren H. 2000. A quantitative
1980 method for assessing the sensitizing potency of low molecular weight chemicals using a local
1981 lymph node assay: employment of a regression method that includes determination of the
1982 uncertainty margins. Toxicology 146:49-59.
- 1983 Van Och FMM, Vandebriel RJ, Prinsen MK, De Jong WH, Slob W, Van Loveren H. 2001.
1984 Comparison of dose-responses of contact allergens using the guinea pig maximization test
1985 and the local lymph node assay. Toxicology 167:207-215.
- 1986 Vandenberg JJ, Epstein WL. 1963. Experimental nickel contact sensitization in man. J Invest
1987 Dermatol 41:413-418.
- 1988 Wahlberg JE, Boman A. 1985. Guinea pig maximization test. Curr Probl Dermatol 14: 59-
1989 106.
- 1990 Yamashita K, Idehara K, Fukuda N, Yamagishi G, Kawada N. 2005. Development of a
1991 Modified Local Lymph Node Assay using ATP Measurement as an Endpoint. AATX
1992 11:136-144.
- 1993

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Appendix A

Standard Operating Procedures for the LLNA: DA Test Method

A1 Standard Operating Procedures/Protocol for the LLNA: DA Test MethodA-3
**A2 Results in the LLNA: DA Test Method for 1% Sodium Lauryl Sulfate (SLS)
Pretreatment versus without 1% SLS Pretreatment.....A-21**

17
18
19
20
21
22
23
24
25
26
27
28
29
30

[This Page Intentionally Left Blank]

31

32

33

34

35

36

37

38

39

40

41

Appendix A1

42

Standard Operating Procedures/Protocol for the LLNA: DA Test Method

43

44

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

[This Page Intentionally Left Blank]

59 These are the standard operating procedures performed during the two-phased interlaboratory
 60 test method validation study (Omori et al. 2008) for the murine local lymph node assay
 61 (LLNA) modified by Daicel Chemical Industries, Ltd., based on adenosine triphosphate
 62 content (ATP; referred to hereafter as the “LLNA: DA”) as confirmed by the LLNA: DA
 63 Validation Committee and provided by the study director.¹ These procedures are intended for
 64 tests conducted to evaluate a single test substance. Although the standard operating
 65 procedures detailed herein are specific for the interlaboratory test method validation study,
 66 the substances tested in the intralaboratory validation study followed a technically similar
 67 LLNA: DA test method protocol (Idehara et al. 2008; Idehara unpublished data).

68 1.0 Preparation of Equipment and Materials

69 Prepare the experimental equipment, materials, and reagents given in **Table A-1**.
 70 Luminometer tubes, 15 mL test tubes, 50 mL test tubes, petri dishes, and slide glass should
 71 be disposable. The underlined items will be provided by the LLNA: DA Validation
 72 Committee but in some cases, a luminometer will be furnished by the test facilities. All other
 73 materials will be provided by the test facilities.

74 **Table A-1 List of Required Equipment, Materials and Reagents**

Name of Equipment, Material, or Reagent	Manufacturer	Comment (Trade Name, Model Number, etc.)
<u>Luminometer</u>	Kikkoman Corporation, Japan	LUMITESTER C-100 Detection Range: 4×10^{-12} – 1×10^{-6} M Upper Limit: 1,000,000 RLU
<u>Luminometer tubes</u>	Kikkoman Corporation, Japan	Polypropylene, sterilized
<u>15 mL test tubes</u>	IWAKI brand	Polypropylene, sterilized
<u>50 mL test tubes</u>	IWAKI brand	Polypropylene, sterilized
<u>Petri dish</u>	Corning Incorporated	Cell culture dish, sterilized
<u>Cell scraper</u>	Costar brand	Disposable cell scraper, sterilized
<u>Slide glass</u>	Matsunami	Micro slide glass
<u>Vortex mixer</u>		
Analytical balance		For body weight measurements (readability of at least 0.1 g)

¹ 2/6/2006: Confirmed by LLNA: DA Validation Committee; 2/17/2006: Revised by Takashi Omori; 2/19/2006: Revised by Takashi Omori; 3/27/2006: Revised by Takashi Omori; 4/2/2006: Revised by Takashi Omori; 12/2/2006: Revised by Takashi Omori.

Name of Equipment, Material, or Reagent	Manufacturer	Comment (Trade Name, Model Number, etc.)
Analytical balance		For lymph node weight measurements (readability of at least 0.1 mg)
<u>Brush</u>	Ikkyuen	Osho
<u>Phosphate buffered saline</u>	Invitrogen Gibco™	pH 7.2, sterilized
<u>Luciferin-luciferase reagent</u>	Kikkoman Corporation, Japan	CheckLite™ 250 Plus ¹
Cages		Capable of housing four mice, with feed and water dispensers
Micropipette		For applying test solutions (25 µL), handling phosphate buffered saline (1000 µL), tissue suspension (20 µL), cell suspension (100 µL), and dissolved Luciferin-luciferase solution (100 µL)
Micropipette tips		Sterilized
Dissecting instruments		Large and small tweezers, scissors, surgical holder, injection needle and holder
Timer		With second display
General laboratory materials		Cotton, antiseptic solution, paper towel, clean sheet, test tube rack, microtube rack

75 Abbreviations: etc. = et cetera; g = grams; M = molar; mg = milligrams; µL = microliter; mL = milliliter; RLU
76 = relative luminescence units.

77 ¹For the substances tested in the intralaboratory validation study by Daicel Chemical Industries, Ltd. (Idehara et
78 al. 2008), the ATP content for potassium dichromate was measured by the CheckLite™ 250 Plus Kit
79 (Kikkoman Corporation, Japan) but that for all other substances was determined using the ViaLight® HS Kit
80 (Lonza Rockland, Inc., USA).

81 **2.0 Preparations Prior to Delivery of Animals**

82 The animals to be used in the tests are young adult female mice (nulliparous and non-
83 pregnant) of the CBA/JNCrlj strain, aged between eight to twelve weeks prior to application
84 of test and control substances. The animals will be provided by the LLNA: DA Validation
85 Committee. Preparations should be made according to the standards of the test facilities to
86 begin acclimatizing the animals once they have arrived on the previously agreed upon date of
87 delivery.

88 Six cages capable of holding four animals each should be prepared prior to the end of
 89 acclimatization.² The cages should be labeled as listed in **Table A-2**. The symbol “X”
 90 represents the code of the test substance to be provided. Mark the label using the letter
 91 indicated on the datasheets provided prior to the test. The animal test group numbers are also
 92 indicated on the datasheets. The numbers should be confirmed and the cages labeled with
 93 care. This test will be performed two or three times, so it is important to include the test
 94 number on the labels.

95 **Table A-2 Preparation of Test Group Cages**

Test Group Number	Label
Group 1	Acetone: Olive Oil (4:1)
Group 2	Positive Control
Group 3	Vehicle
Group 4	Test Substance “X” – Low Concentration
Group 5	Test Substance “X” – Medium Concentration
Group 6	Test Substance “X” – High Concentration

96 “X” represents the code of the test substance provided by the study management team.
 97

98 **3.0 Delivery, Acclimatization and Animal Assignment**

99 On the date of delivery, 25 animals will arrive and acclimatization should begin immediately.
 100 Acclimatization should be performed according to the standards of the test facilities. The
 101 animals should be acclimatized for at least five days, but no more than 16 days.

102 After acclimatization healthy animals with no observable skin lesions or other abnormalities
 103 should be randomly assigned to six groups of four animals each using randomly generated
 104 numbers. After assigning the animals to groups, four animals each should be placed in the six
 105 cages prepared as described in **Section 2.0**. Any animals remaining after the assignment of
 106 24 should be omitted from the test. Should there be fewer than 24 animals with no observed
 107 abnormalities, three animals should be assigned to each group beginning with the test group
 108 with the highest number until all of the animals are assigned.

² For the substances tested in the intralaboratory validation study by Daicel Chemical Industries, Ltd. (Idehara et al. 2008; Idehara unpublished data), at least three animals per dose group were used (i.e., in most cases, 4 animals per control group and three animals per test substance group).

109 From the delivery of the animals to the end of the test procedures the temperature of the
110 animal housing facility should be maintained at 22°C ($\pm 3^\circ\text{C}$) with a relative humidity of 30-
111 70%. The animals should be housed with a light: dark cycle of 12 hours light: 12 hours dark
112 and should be given food and water *ad libitum*. Any deviations from the standard housing
113 and feeding procedures should be recorded.

114 **4.0 Confirmation of Test Materials**

115 When the test materials sent by the LLNA: DA Validation Committee arrive, confirm that
116 the inventory document matches the contents.

117 The labels for each of the treatments (acetone: olive oil [4:1], positive control, vehicle, and
118 low, medium and high concentrations of test substances) include a test substance code and a
119 group number. After confirming that these codes match the datasheet, arrange the treatments
120 in a test tube rack according to group number. Sodium lauryl sulfate (SLS) solution will
121 arrive in one tube. Apportion 3 mL of SLS solution to each of the accompanying empty test
122 tubes, mark each tube with the group number, and arrange the tubes in order in the test tube
123 rack.

124 The treatments should be refrigerated immediately and only removed when beginning the
125 test. Refrigeration of the solutions used in these procedures should be between 0-10°C, and
126 preferably between 2-8°C, except when instructed differently. Should there be specific
127 instructions as to the handling of the solutions, the instructions will be included with the
128 materials shipment and they should be followed. For instance:

- 129 • SLS (CASRN: 151-21-3) is a 1% solution and should be kept at room
130 temperature
- 131 • Acetone: olive oil is 4:1 volume to volume ratio
- 132 • Positive control is a 25% acetone: olive oil (4:1) solution of hexyl cinnamic
133 aldehyde (CASRN: 101-86-0)

134 **5.0 Procedures on Test Days 1, 2, 3 and 7**

135 **5.1 Day 1**

136 Mark the animals on the tail with their test group number and a number from one to four.
137 Weigh the animals and record their weight to the nearest 0.1 g on the test forms.
138 Remove the test materials from the refrigerator. Should the materials arrive with instructions
139 to heat or sonicate the treatments prior to application, perform these procedures as instructed.

140 *5.1.1 Pre-treatment with 1% SLS Solution*

141 Beginning with Group 1 and proceeding in order to Group 6, the SLS solution should be
142 applied with a brush to the dorsum of both ears of the mice. The number of the SLS solution
143 used should match the test group number. The brush should be dipped in the SLS solution
144 and applied to the dorsum of one ear using a petting motion, covering the entire dorsum with
145 four to five strokes. Dip the brush again in the SLS solution and apply the solution to the
146 dorsum of the other ear in the same manner.

147 Record the time when beginning to apply SLS solution to Group 1 and when completing
148 application to Group 6. The application procedure should be performed continuously without
149 delay for Groups 1 through 6.

150 Six brushes should be prepared and numbered, using only one brush for each test group.
151 When performing the same application procedure on Days 2, 3, and 7 there is the possibility
152 of brush contamination due to residual solution on the mouse auricula. It is important to
153 switch brushes after finishing application for one group and check the number of the next
154 brush before proceeding to the next group. After use, the brushes should be washed
155 thoroughly and made available for the next day.

156 *5.1.2 Test Substance Application*

157 One hour after starting the SLS solution application, the numbered treatments should be
158 applied to the auriculae of the mice, beginning with Group 1 and ending with Group 6. Using
159 a micropipette or similar device, 25 µL of the test solution should be dripped slowly on the
160 dorsum of one of the mouse's ears, covering the dorsum entirely. Again take up 25µL of
161 treatment solution and apply it in the same manner to the dorsum of the mouse's other ear.

162 When applying the treatments, micropipette tips should be changed for each test group. After
163 completing application for one test group, remove the tip and spray the end of the
164 micropipette with an alcohol mist and wipe to avoid contamination.

165 Record the time when beginning to apply the test solution to Group 1 and when completing
166 application to Group 6. The application procedure should be performed continuously without
167 delay for Groups 1 through 6.

168 Immediately after completing application the test materials should be refrigerated.

169 5.1.3 *General Information on the 1% SLS Pre-treatment and Test Substance Application*

170 The objective of the application procedure is to first apply SLS solution to the entirety of the
171 dorsum of the ear and then to apply a prescribed amount of test solution to the same area.

172 Using ether anesthesia ensures ease and accuracy of the procedure. However, special care
173 should be taken to avoid taking the life of the animals in the course of anesthesia. If one
174 technician immobilizes the animal and extends the ear with tweezers while the other
175 technician applies the solution, the procedure can be performed with accuracy without using
176 anesthesia. If this approach is used six pairs of tweezers should be prepared, one for each
177 group, to avoid contamination. Alternatively, the tweezers should be wiped with an alcohol
178 swab after application is completed for each test group.

179 5.2 **Days 2 and 3**

180 Apply SLS solution and treatments using the same procedures as for Day 1.

181 When performing the application procedures the animals should be observed carefully for
182 necrosis, hardening, hyperplasia or erythema of the auricula, as well as piloerection, or a
183 decrease in locomotor activity. Any such abnormalities observed should be recorded on the
184 test forms.

185 5.3 **Day 7**

186 On Day 7 the same procedures should be performed as on Days 2 and 3.

187 Excision of the auricular lymph nodes will be performed from 24 to 30 hours after the start of
188 application on Day 7. It is therefore recommended that application procedures on Day 7
189 begin in the morning or early afternoon.

190 6.0 **Procedure on Test Day 8 (Excision of Auricular Lymph Nodes and 191 ATP Assay)**

192 6.1 **Laboratory Preparation**

193 Forty-eight 15 mL test tubes should each be filled with 1.98 mL of phosphate buffered saline
194 (PBS). The dispensing of PBS should be conducted under aseptic manipulation. Dispense a
195 minimum of 24 mL of PBS in a 50 mL test tube. Pipetting should be under aseptic
196 manipulation.

197 Dissolve the luciferin-luciferase reagent according to the ATP assay kit instructions (at least
198 4.8 mL are required). The ATP assay kit provided, CheckLite™ 250 Plus, includes five
199 bottles each of Luciferin-luciferase reagent, solvent water, and ATP releasing agent. Using
200 one bottle of each type, create a solution according to the instructions (approximately 5.5
201 mL). Shield the assay solutions from light using aluminum foil and refrigerate until the time
202 of use. Immediately before using, return to room temperature and remove the foil prior to
203 use. Dispense 0.1 mL of the ATP releasing agent included in the ATP assay kit to each of the
204 48 luminometer tubes. ATP assay kit reagents should be dispensed using sterilized pipette
205 tips under aseptic manipulation to avoid contamination with ATP and microorganisms.

206 **6.2 Body Weight Measurement**

207 Weigh the mice and record their body weights to the nearest 0.1 g on the test forms.

208 **6.3 Auricular Lymph Node Excision and Weight Measurement**

209 Perform procedures in **Sections 6.3, 6.4** and **6.5** within 24 to 30 hours after the start of
210 treatment application on Day 7. The necessary materials for procedures in **Sections 6.3, 6.4**
211 and **6.5** are given in **Annex I**.

212 Immediately after sacrificing the mice with ether anesthesia excise completely all auricular
213 lymph nodes for each ear (there can be one or two auricular lymph nodes) as illustrated in
214 **Figure A-1**. Place the excised lymph nodes for one animal in a disposable petri dish and
215 immediately measure the wet weight to the nearest 0.1 mg with an analytical balance.

216 **6.4 Preparation of Cell Suspension**

217 The lymph nodes from one animal should be sandwiched between two pieces of slide glass
218 and light pressure should be applied to crush the nodes (**Figure A-2**). After confirming that
219 the tissue has spread out thinly pull the two slides apart. Suspend the tissue on both pieces of
220 slide glass in 1 mL of PBS. As illustrated in **Figure A-3**, each piece of slide glass should be
221 held at an angle over the petri dish and rinsed with PBS while the tissue is scraped off of the


222 glass with repeated movements of a cell scraper. One mL of PBS should be used for rinsing
223 both slides.

224 The tissue suspension in the petri dish should be homogenized lightly with the cell scraper,
225 and 20 μ L of the suspension should be taken up with a micropipette, taking care not to take
226 up the membrane that is visible to the eye. The pipetted suspension should be added to 1.98
227 mL of PBS and homogenized well. This will be cell suspension No. 1. Again take up 20 μ L
228 of the suspension in the petri dish, add to 1.98 mL of PBS, and homogenize well. This will be
229 cell suspension No. 2.

230 These procedures should be performed while wearing gloves and a mask and micropipette
231 tips should be sterile. Detailed step-by-step procedures are given in **Annex II**.

232

232 **Figure A-1 Auricular lymph nodes³**




233

234

³ Taken from ICCVAM IWG LLNA Protocol (ICCVAM 2001)
A-13

234 **Figure A-2 Preparation of cell suspension**


235 Lymph nodes from each animal are sandwiched between two pieces of slide glass and light
236 pressure is applied to crush the nodes.



237

238 **Figure A-3 Preparation of cell suspension**

239 Rinse with PBS while scraping the tissue off of the glass with a cell scraper. Repeat the
240 scraping motion, scooping up liquid from the petri dish as need. Use 1 mL of PBS for the
241 nodes of each animal.



242

243

243 **6.5 ATP Assay**

244 Prepare 48 luminometer tubes in advance by dispensing 0.1 mL of the ATP releasing reagent
245 provided to each tube. Add 0.1 mL of each homogenized cell suspension to the luminometer
246 tubes and homogenize. After allowing the solution in the tube to stand for approximately 20
247 seconds, add 0.1 mL of the Luciferin-luciferase solution, promptly homogenize and place in
248 the luminometer. The amount of bioluminescence (RLU; relative luminescence units)
249 measured over 10 seconds will be displayed. Record this measurement on the test forms.

250 The amount of bioluminescence begins to decrease immediately after adding the Luciferin-
251 luciferase solution. It is therefore important that the series of procedures from the addition of
252 Luciferin-luciferase solution to switching on the luminometer are performed as quickly as
253 possible, ideally with the same rhythm.

254 These procedures should be performed while wearing gloves and a mask and micropipette
255 tips should be sterile. The detailed procedures are given in **Annex III**.

256 **7.0 Points of Caution on Procedures from Excision to ATP Assay**

257 The ATP content of the lymph node decreases over time after the sacrifice of the animal. It is
258 therefore desirable that the time elapsed between sacrifice of the animal and ATP assay is
259 uniform for each animal. The series of procedures from excision to ATP assay must be
260 performed rapidly and without delay.

261 If these procedures are performed by one technician, the animals should be sacrificed one at a
262 time. If there are multiple technicians, it is possible to divide tasks and sacrifice the animals
263 one group at a time. If two technicians perform the procedures, steps in **Section 6.3** should be
264 performed by one individual and steps in **Sections 6.4** and **6.5** should be performed by the
265 other. If three technicians perform the procedures, steps in **Sections 6.3, 6.4** and **6.5** can each
266 be handled by one individual. If multiple technicians are involved, it is important that the
267 timing of excision is carefully planned so that there are no delays in subsequent steps.

268 **8.0 Data Entry**

269 Input the body weights on Day 1 and Day 8, the lymph node weight, and the amount of ATP
270 bioluminescence into the designated Excel file.

271 **Annex I: Equipment and Reagents Used for the Experimental Procedures**
272 **in Sections 6.3, 6.4, and 6.5**

273 For the equipment and reagents underlined below, the items provided by the LLNA: DA
274 Validation Committee should be used. In the event the test facility provides a luminometer, it
275 can be used.

276 **6.3 Auricular Lymph Node Excision and Weight Measurement**

277 Dissecting instruments set (Tweezers, scissors, surgical holder, injection needle and holder)

278 Antiseptic solution

279 Cotton

280 Petri dish (24)

281 Analytical balance (readability of at least 0.1 mg)

282 **6.4 Preparation of Cell Suspension**

283 15 mL test tubes with 1.98 mL phosphate buffered saline (PBS) (48)

284 50 mL test tubes with at least 24 mL PBS (1)

285 Slide glass (48)

286 Tweezers (1)

287 Micropipette 1000 μ L (1) (Volume to be measured: 1 mL)

288 Micropipette 100 μ L (1) (Volume to be measured: 20 μ L)

289 Cell scraper (1)

290 Sterilized pipette tips for 1000 μ L micropipette (24) and for 100 μ L micropipette (24)

291 Vortex mixer (1)

292 Paper towels

293 Clean sheet

294 Test tube rack

295 **6.5 ATP Assay**

296 Luminometer tubes with 0.1 mL ATP releasing agent (48)

297 15 mL test tube with dissolved luciferin-luciferase solution (1)

298 Micropipette - 100 μ L or 200 μ L (2) (Volume to be measured: 0.1 mL)

299 Sterilized micropipette tips (96)

300 Timer (with second display) (1)

301 Luminometer (1)

302 Vortex mixer (can use same mixer listed under **Section 6.4** Preparation of Cell Suspension)

303 Test tube rack

304 Luminometer tube rack (microtube rack)

305 **Annex II: Preparation of Cell Suspension for the Experimental Procedures**
306 **in Section 6.4**

- 307 1. Cover the laboratory bench with a clean sheet and place one piece of slide glass on the
308 sheet.
- 309 2. After measuring the lymph node weights, use tweezers to move the lymph nodes from
310 one animal from the petri dish to the center of the slide glass.
- 311 3. Place another piece of slide glass on top.
- 312 4. Pick up the two sandwiched pieces of slide glass. Squeeze the two pieces in the center to
313 crush the lymph nodes. (Apply only light pressure. Too much pressure can break the
314 cells.)
- 315 5. Confirm that the tissue has spread out thinly between the two slides and place the
316 sandwiched slides on the clean sheet.
- 317 6. Fasten a tip on the 1000 μ L micropipette and draw 1 mL phosphate buffered saline (PBS)
318 from the 50 mL tube.
- 319 7. Remove the upper slide glass from the sandwiched slides and place it on the clean sheet
320 with the side that was in contact with the lymph node tissue facing up. The other slide
321 glass should be held at an angle in the petri dish, the side with lymph node tissue affixed
322 facing forward, and washed with 1 mL PBS.
- 323 8. Dispose of the 1000 μ L micropipette tip.
- 324 9. Scrape the tissue off of the glass with a cell scraper, scooping up PBS from the petri dish
325 and repeating the scraping motion. Confirm that there is no tissue, or only trace amounts
326 of tissue, left on the slide before disposing of the slide glass.
- 327 10. Pick up the slide glass laid aside at step 7; scrape the tissue off in the same manner and
328 dispose of the slide glass. Note that it becomes difficult to scrape the tissue off of the
329 slide glass once it has dried. Perform steps 4 through 10 without delay. The scraping
330 should be performed while keeping the area of the slide glass to which the lymph node
331 tissue is affixed sufficiently wet with PBS from the petri dish.

- 332 11. The tissue suspension in the petri dish should be homogenized lightly with the cell
333 scraper. If large pieces of tissue are observed, stir with the cell scraper to break up the
334 pieces and obtain a uniform solution.
- 335 12. Wipe the cell scraper with a paper towel. (The cell scraper will be used for the next
336 animal.)
- 337 13. Fasten a tip to the 100 μ L micropipette, tilt the petri dish at an angle and mix the
338 suspension by pipetting in and out several times. Take up 20 μ L of the suspension with
339 the pipette, taking care not to take up any membrane that is visible to the eye.
- 340 14. Add the 20 μ L of suspension to a 15 mL test tube containing 1.98 mL PBS. Pipette the
341 solution and proceed to homogenize with the vortex mixer. (cell suspension No. 1)
- 342 15. Repeat steps 13 and 14 to prepare cell suspension No. 2.
- 343 16. Dispose of the 100 μ L micropipette tip.
- 344

345 Annex III: ATP Assay for the Experimental Procedures in Section 6.5

- 346 1. Fasten a tip on the 100 μ L (or 200 μ L) micropipette and draw 0.1 mL of vortex-
347 homogenized cell suspension No. 1.
- 348 2. To the luminometer tube filled with 0.1 mL ATP releasing reagent, add 0.1 mL of cell
349 suspension No. 1, making sure to note the time with a timer. Dispose of the tip.
- 350 3. Homogenize with the vortex mixer and place in the luminometer tube rack.
- 351 4. Fasten a tip on a separate 100 μ L (or 200 μ L) micropipette and draw 0.1 mL of solution
352 from the 15 mL tube containing dissolved Luciferin-luciferase reagent.
- 353 5. Take the luminometer tube from the rack and add 0.1 mL of Luciferin-luciferase solution
354 to the luminometer tube 20 seconds after the time noted in step 2.
- 355 6. Promptly homogenize in the vortex mixer, place in the luminometer and turn on the
356 switch. The amount of bioluminescence begins to decrease immediately after adding the
357 Luciferin-luciferase solution. Step 6 should be performed as quickly as possible, ideally
358 with the same rhythm.
- 359 7. Dispose of the tip.
- 360 8. After 10 seconds the amount of bioluminescence (RLU; relative luminescence units) will
361 be displayed. Record this measurement on the test forms.
- 362 9. Repeat steps 1 through 8 for cell suspension No. 2, measure the bioluminescence and
363 record.

364

365

366

367

368

369

370

371

372

373

374

375

Appendix A2

376

Results in the LLNA: DA Test Method for 1% Sodium Lauryl Sulfate (SLS)

377

Pretreatment versus without 1% SLS Pretreatment

378

379

380

381

382

383

384

385

386

387

388

389

390

391

[This Page Intentionally Left Blank]

392

392 **Appendix A2 Summary of Results in the LLNA: DA Test Method with 1% SLS**
 393 **Pretreatment versus without 1% SLS Pretreatment**

Substance Name	Vehicle	Concentration (%)	SI ¹ (+ SLS)	SI ¹ (- SLS)	Calculated EC3 ² (%) (+ SLS)	Calculated EC3 ² (%) (- SLS)
2, 4-Dinitrochlorobenzene	AOO	0.03	2.10	1.88	0.05	0.06
		0.10	5.02	4.46		
		0.30	9.74	14.61		
Potassium dichromate	DMSO	0.1	2.61	2.54	0.15	0.22
		0.3	4.24	3.34		
		1.0	5.51	5.66		
Isoeugenol	AOO	1.0	2.05	1.32	2.46	4.24
		2.5	3.02	2.21		
		5.0	2.85	3.35		
Citral	AOO	5	1.93	1.88	7.4	10.4
		10	4.15	2.91		
		25	6.97	5.90		
Hexyl cinnamic aldehyde	AOO	5	1.51	0.99	7.5	8.8
		10	4.52	3.64		
		25	4.84	3.79		
Cinnamic alcohol	AOO	10	2.46	2.44	14.1	18.5
		25	4.40	3.43		
		50	6.36	4.01		
Hydroxycitronellal	AOO	10	1.98	1.49	15.8	19.8
		25	4.61	3.81		
		50	6.59	6.74		
Imidazolidinyl urea	DMF	10	2.36	2.54	20.3	33.0
		25	3.29	2.38		
		50	6.02	4.31		
Methyl methacrylate	AOO	25	0.73	1.11	NA	NA
		50	0.68	0.92		

Substance Name	Vehicle	Concentration (%)	SI ¹ (+ SLS)	SI ¹ (- SLS)	Calculated EC3 ² (%) (+ SLS)	Calculated EC3 ² (%) (- SLS)
		100	1.31	1.83		
Nickel (II) chloride	DMSO	2.5	1.53	0.98	NA	NA
		5.0	1.57	1.16		
		10.0	2.24	1.87		
Methyl salicylate	AOO	5	0.89	0.83	NA	NA
		10	1.59	1.32		
		25	1.69	2.34		
Salicylic acid	AOO	5	1.21	1.13	NA	NA
		10	2.05	1.29		
		25	2.48	2.44		
Sulfanilamide	DMF	10	1.08	0.92	NA	NA
		25	1.03	0.90		
		50	0.94	0.84		

394 Abbreviations: AOO = acetone: olive oil (4:1); DMF = *N,N*-dimethylformamide; DMSO = dimethyl sulfoxide;
395 EC3 = estimated concentration required to produce a stimulation index of three; NA = not applicable; RLU =
396 relative luminescence units; SI = stimulation index; SLS = sodium lauryl sulfate.

397 ¹SI determined from mean ATP content (RLU).

398 ²EC3 value was calculated based on interpolation or extrapolation formulas discussed in Gerberick et al. 2004.

399 + SLS = with pretreatment of 1% SLS prior to test substance application

400 - SLS = without pretreatment of 1% SLS prior to test substance application

401

402

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Appendix B








**Physico-Chemical Properties and Chemical Classes of Substances Tested in the
LLNA: DA**








15
16
17
18
19
20
21
22
23
24
25
26
27
28
29







[This Page Intentionally Left Blank]








30







Physico-Chemical Properties and Chemical Classes of Substances Tested in the LLNA: DA







Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
Abietic acid ^{a, c}	Sylvic acid	514-10-3	302.46	6.46	NA	Solid	Hydrocarbons, Cyclic; Polycyclic Compounds	
3-Aminophenol ^c	m-Aminophenol	591-27-5	109.13	0.24	Minimal	Solid	Amines; Phenols	
Benzalkonium chloride ^a	Alkylbenzyltrimethylammonium chloride; Germitol; Zephiral	8001-54-5	170.66	NA	NA	Solid/Liquid	Amines; Onium Compounds	
Benzocaine ^a	Ethyl 4-aminobenzoate	94-09-7	165.19	1.80	NA	Solid	Carboxylic Acids	
Benzoquinone ^b	p-Quinone 1,4-benzoquinone Cyclohexadienedione	106-51-4	108.10	1.17	High	Solid	Quinones	
1-Bromobutane ^a	Butyl bromide	109-65-9	137.02	2.65	Low	Liquid	Hydrocarbons, Halogenated	
Butyl glycidyl ether ^b	n- Butyl glycidyl ether	2426-08-6	130.19	1.42	NA	Liquid	Ethers	







Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
5-Chloro-2-methyl-4-isothiazolin-3-one ^b	Chloromethylisothiazolinone CMI	26172-55-4	132.30	0.92	High	Liquid	Sulfur Compounds Heterocyclic Compounds	
Chlorobenzene ^a	Phenyl chloride	108-90-7	112.56	2.64	Minimal	Liquid	Hydrocarbons, Cyclic; Hydrocarbons, Halogenated	
Cinnamic alcohol ^b	3-Phenyl-2-propen-1-ol Cinnamyl alcohol	104-54-1	134.18	2.29	NA	Solid	Alcohols	
Cinnamic aldehyde ^a	Cinnamaldehyde	104-55-2	132.16	1.82	High	Liquid	Aldehydes	
Citral ^a	2,6-Octadienal, 3,7-dimethyl-	5392-40-5	152.24	3.45	High	Liquid	Hydrocarbons, Other	
Cobalt chloride ^{a, c, d}	Cobaltous chloride	7646-79-9	129.84	0.85	NA	Solid	Inorganic Chemical, Elements; Inorganic Chemical, Metals	
Diethyl maleate ^b	Ethyl maleate	141-05-9	172.18	0.89	High	Liquid	Carboxylic Acids	


Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
Diethyl phthalate ^a	Ethyl phthalate	84-66-2	222.24	2.65	Minimal	Liquid	Carboxylic Acids	
Dimethyl isophthalate ^{b,c}	1,3-Benzenedicarboxylic acid, dimethyl ester	1459-93-4	194.19	1.66	NA	Solid	Carboxylic Acids	
2,4-Dinitrochlorobenzene ^{a,c}	Dinitrochlorobenzene; DNCB	97-00-7	202.55	2.27	High	Solid	Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Nitro Compounds	
Ethyl acrylate ^b	2-Propenoic acid, ethyl ester	140-88-5	100.10	NA	High	Liquid	Carboxylic Acids	
Ethylene glycol dimethacrylate ^b	EGDMA	97-90-5	198.22	1.38	High	Liquid	Carboxylic Acids	
Eugenol ^a	2-Methoxy-4-(2-propenyl)phenol; Allylguaiacol	97-53-0	164.20	2.73	NA	Liquid	Carboxylic Acids	

Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
Formaldehyde ^{a, c}	Formalin	50-00-0	30.03	0.35	Moderate	Liquid	Aldehydes	
Glutaraldehyde ^{a, c}	Glutaral; Pentanedial	111-30-8	100.12	-0.18	High	Liquid	Aldehydes	
Hexane ^a	Hexyl hydride; n-Hexane	110-54-3	86.18	3.29	Minimal	Liquid	Hydrocarbons, Acyclic	
Hexyl cinnamic aldehyde ^{a, c, d}	alpha-Hexylcinnamaldehyde; HCA	101-86-0	216.32	4.82	Minimal	Liquid	Aldehydes	
Hydroxycitronellal ^a	Citronellal hydrate	107-75-5	172.26	2.11	Low	Liquid	Hydrocarbons, Other	
Imidazolidinyl urea ^a	Germall 115; Imidurea	39236-46-9	388.30	-8.28	Moderate	Solid	Urea	
Isoeugenol ^{a, c}	2-Methoxy-4-propenylphenol; 4-Propenylguaiacol	97-54-1	164.20	2.65	NA	Liquid	Carboxylic Acids	

Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
Isopropanol ^{a, c}	Isopropyl alcohol, 2-Propanol	67-63-0	60.10	0.28	Minimal	Liquid	Alcohols	
Lactic acid ^{a, d}	2-Hydroxypropanoic acid	50-21-5	90.08	-0.65	Minimal	Solid	Carboxylic Acids	
2-Mercaptobenzothiazole ^a	Captax	149-30-4	167.26	2.86	High	Solid	Heterocyclic Compounds	
Methyl methacrylate ^b	MMA	80-62-6	100.12	NA	NA	Liquid	Carboxylic Acids	
Methyl salicylate ^{a, c}	Oil of wintergreen; Methyl 2-hydroxybenzoate	119-36-8	152.15	2.60	Minimal	Liquid	Carboxylic Acids; Phenols	
Nickel (II) chloride ^b	Nickel chloride	7718-54-9	129.60	NA	NA	Solid	Inorganic Chemical, Elements; Inorganic Chemical, Metals	

Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
Nickel (II) sulfate hexahydrate ^{a, c, d}	Nickel sulfate hexahydrate	10101-97-0	154.76	NA	NA	Solid	Inorganic Chemical, Elements; Inorganic Chemical, Metals	
Phenyl benzoate ^b	Diphenylcarboxylate	93-99-2	198.22	2.89	NA	Solid	Carboxylic Acids	
p-Phenylenediamine ^a	4-Phenylenediamine	106-50-3	108.14	-0.39	NA	Solid	Amines	
Phthalic anhydride ^a	1,2-Benzenedicarboxylic anhydride; 1,3-Dioxophthalan	85-44-9	148.12	2.07	Moderate	Solid	Anhydrides; Carboxylic Acids	
Potassium dichromate ^{a,d}	PDC; Dipotassium bichromate	7778-50-9	294.18	-3.59	NA	Solid	Inorganic Chemical, Chromium Compounds; Inorganic Chemical, Potassium Compounds	
Propyl gallate ^b	Benzoic acid, 3,4,5-trihydroxy-, propyl ester; Gallic acid, propyl ester;	121-79-9	212.20	NA	High	Solid	Carboxylic Acids	

Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
	Propyl 3,4,5-trihydroxybenzoate							
Propylparaben ^a	4-Hydroxybenzoic acid, propyl ester; Propyl p-hydroxybenzoate	94-13-3	180.20	2.98	Minimal	Solid	Carboxylic Acids; Phenols	
Resorcinol ^a	1,3-Dihydroxybenzene	108-46-3	110.11	1.03	Minimal	Solid	Phenols	
Salicylic acid ^b	2-Hydroxybenzoic acid	69-72-7	138.12	1.03	NA	Solid	Phenols; Carboxylic Acids	
Sodium lauryl sulfate ^a	Sodium dodecyl sulfate, SLS, SDS, Irium	151-21-3	288.38	1.69	NA	Solid	Alcohols; Sulfur Compounds; Lipids	
Sulfanilamide ^b	4-Aminobenzene-sulfonamide, p-Anilinesulfonamide, p-Sulfamidoaniline	63-74-1	172.21	0.40	Minimal	Solid	Hydrocarbons, Cyclic; Sulfur Compounds	
Toluene 2,4-diisocyanate ^a	2,4-TDI	584-54-9	174.16	3.74	NA	Liquid	Hydrocarbons, Cyclic; Isocyanates	

Substance Name ¹	Synonyms	CASRN	Mol. Weight (g/mol)	K _{ow} ²	Peptide Reactivity ³	Physical Form	Chemical Class ⁴	Structure
Trimellitic anhydride ^a	4-Carboxyphthalic anhydride	552-30-7	192.13	1.95	Low	Solid	Anhydride; Carboxylic Acids	

31 Abbreviations: CASRN = Chemical Abstracts Service Registry Number; K_{ow} = octanol-water partition coefficient; Mol. = molecular; LLNA: DA = murine local
 32 lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content; NA = not available.

33 ¹Total of 46 substances: intralaboratory validation study tested 45 substances (Idehara et al. 2008; Idehara unpublished data) and the two-phased interlaboratory
 34 validation study tested 13 of the 45 substances from the intralaboratory validation study and one substance not previously evaluated.

35 ²K_{ow} represents the estimated octanol-water partition coefficient (expressed on log scale) calculated by the Syracuse Research Corporation from the website:
 36 http://www.syrres.com/esc/est_kowdemo.htm.

37 ³Peptide reactivity based on Cys (1:10) and Lys (1:50) data as reported in Gerberick et al. 2004 and/or Gerberick et al. 2007.

38 ⁴Chemical classifications based on the Medical Subject Headings classification for chemicals and drugs, as developed by the National Library of Medicine:
 39 <http://www.nlm.nih.gov/mesh/meshhome.html>.

40 ^aSubstance tested in intralaboratory validation study (Idehara et al. 2008).

41 ^bSubstance tested in intralaboratory validation study (Idehara unpublished data).

42 ^cSubstance tested in phase one of two-phased interlaboratory validation study (Omori et al. 2008).

43 ^dSubstance tested in phase two of two-phased interlaboratory validation study (Omori et al. 2008).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Appendix C

**Comparative LLNA: DA, Traditional LLNA, Guinea Pig, and Human Skin
Sensitization Data**

**C1 Comparison of LLNA: DA, Traditional LLNA, Guinea Pig, and Human Results
(Alphanumeric Order).....C-3**

**C2 Comparison of Alternative LLNA: DA Decision Criteria and Traditional
LLNA Results (Alphanumeric Order).....C-15**

19
20
21
22
23
24
25
26
27
28
29
30
31
32

[This Page Intentionally Left Blank]

33

34

35

36

37

38

39

40

41

42

43

44

Appendix C1

45

Comparison of LLNA: DA, Traditional LLNA, Guinea Pig, and Human Results

46

(Alphanumeric Order)

47

48 **Appendix C-1 Comparative Performance of the LLNA: DA, Traditional LLNA, Guinea Pig, and Human Tests**
 49 **(Alphanumeric Order)**

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
Abietic acid	514-10-3	25	6.26	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	No at ≤ 2.5% (GP)	Basketter et al. 2007
Abietic acid	514-10-3	25	4.64	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	No at ≤ 2.5% (GP)	Basketter et al. 2007
Abietic acid	514-10-3	25	7.96	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	No at ≤ 2.5% (GP)	Basketter et al. 2007
Abietic acid	514-10-3	25	3.98 at 10%	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	No at ≤ 2.5% (GP)	Basketter et al. 2007
3-Aminophenol	591-27-5	10	2.83	Omori et al. 2008	+	NA	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al. 2007b
3-Aminophenol	591-27-5	10	1.76 at 3%	Omori et al. 2008	+	NA	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al. 2007b
3-Aminophenol	591-27-5	10	2.38	Omori et al. 2008	+	NA	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al. 2007b
Benzalkonium chloride	8001-54-5	2.5	6.68	Idehara et al. 2008	+	-	+	Gerberick 1992	ICCVAM 1999	ICCVAM 1999	Irritant at 2% ACE (mice)	Gerberick et al 2002 Manetz et al. 1999
Benzocaine	94-09-7	25	4.84	Idehara et al. 2008	+/- ⁴	+	+/-	ICCVAM 1999	ICCVAM 1999	Poole et al. 1970; ICCVAM 1999 (Equivocal data)	Negative at ≤ 10% (GP)	Basketter and Scholes
p-Benzoquinone	106-51-4	0.100	3.79	Idehara unpublished	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Nonirritant at 2.5% (GP)	Basketter et al. 2007b
1-Bromobutane	109-65-9	25	1.65	Idehara et al. 2008	-	NA	NA	ICCVAM 1999	NA	NA	NA	NA
Butyl glycidyl ether	2426-08-6	50	4.59	Idehara unpublished	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.1% (GP)	Wahlberg and Boman 1985
Chlorobenzene	108-90-7	25	2.44	Idehara et al. 2008	-	-	NA	ICCVAM 1999	ICCVAM 1999	NA	No data. Low irritancy	Basketter et al. 1998

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
											potential assumed based on clinical literature.	
5-Chloro-2-methyl-4-isothiazolin-3-one	26172-55-4	0.100	7.50	Idehara unpublished	+	+	+	ICCVAM 1999; Gerberick et al. 2005	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
Cinnamic alcohol	104-54-1	90	5.66 at 50%	Idehara unpublished	+	+	+	Gerberick et al. 2005	Robinson et al. 1990	Jordan and King 1977	Nonirritant at 1% (GP)	Robinson et al. 1990
Cinnamic aldehyde	104-55-2	15	4.73	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.75% (GP); Mild Irritant at 100% (rabbits)	Basketter et al. 2007b; ECETOC #66, 1995
Citral	5392-40-5	25	4.40	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.5% (GP)	Basketter et al. 2007b
Cobalt chloride	7646-79-9	5	3.64	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	1 ⁵	2.66	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	3	20.55	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	3	8.07	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	5	2.01	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	5	2.54	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	5	4.25	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes
Cobalt chloride	7646-79-9	5	5.06	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 0.5% (GP)	Basketter and Scholes

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
Diethyl maleate	141-05-9	10.0	3.78	Idehara unpublished				Gerberick et al. 2005	NA	Marzulli and Maibach 1980	Nonirritant at 100% (GP)	Basketter et al. 2007b
Diethyl phthalate	84-66-2	100	1.09	Idehara et al. 2008	-	-	-	Gerberick et al. 2005	Klecak et al. 1977	Schneider and Akkan 2004	Negative at 100% (rabbits)	ECETOC #66, 1995
Dimethyl isophthalate	1459-93-4	25	0.89 at 5%	Idehara unpublished	-	-	-	ICCVAM 1999; Basketter et al. 1999b	ICCVAM 1999; Basketter et al. 1999b	Basketter et al. 1999b	Negative at ≤ 10% (GP)	Basketter and Scholes
Dimethyl isophthalate	1459-93-4	25	1.34 at 5%	Omori et al. 2008	-	-	-	ICCVAM 1999; Basketter et al. 1999b	ICCVAM 1999; Basketter et al. 1999b	Basketter et al. 1999b	Negative at ≤ 10% (GP)	Basketter and Scholes
Dimethyl isophthalate	1459-93-4	25	1.00 at 5%	Omori et al. 2008	-	-	-	ICCVAM 1999; Basketter et al. 1999b	ICCVAM 1999; Basketter et al. 1999b	Basketter et al. 1999b	Negative at ≤ 10% (GP)	Basketter and Scholes
Dimethyl isophthalate	1459-93-4	25	1.26 at 5%	Omori et al. 2008	-	-	-	ICCVAM 1999; Basketter et al. 1999b	ICCVAM 1999; Basketter et al. 1999b	Basketter et al. 1999b	Negative at ≤ 10% (GP)	Basketter and Scholes
2,4-Dinitrochlorobenzene	97-00-7	1	7.10	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	11.97	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	9.23	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	9.96	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	8.53	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
2,4-Dinitrochlorobenzene	97-00-7	0.30	7.86	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	15.14	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	13.18	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	12.60	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	10.89	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	0.30	4.71	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
2,4-Dinitrochlorobenzene	97-00-7	1	7.10	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Schneider and Akkan 2004	Nonirritant at 0.1% (GP)	Basketter et al. 2007b
Ethyl acrylate	140-88-5	50	4.29 at 25%	Idehara unpublished	+	-	+	Gerberick et al. 2005	Van der Walle et al. 1982	Marzulli and Maibach 1974	Nonirritant at 0.3 M (GP)	Van der Walle et al. 1982
Ethylene glycol dimethacrylate	97-90-5	50	4.45	Idehara unpublished	+	-	+	ICCVAM 1999	ICCVAM 1999; Gerberick 1992	ICCVAM 1999; Basketter et al. 1999b	Nonirritant at 1% (GP)	Wahlberg and Boman 1985
Eugenol	97-53-0	25	7.07	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 25% (GP); Mild irritant at 100% (rabbits)	Basketter et al. 2007b; ECETOC #66, 1995
Formaldehyde	50-00-0	2.50	5.10	Idehara et al. 2008	+	+	+	Gerberick et al. 2005;	ICCVAM 1999	ICCVAM 1999; Kwon et	Nonirritant at 2% (GP)	Basketter et al.

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
								Hilton et al. 1998		al. 2003		2007b
Formaldehyde	50-00-0	5.0	4.84	Omori et al. 2008	+	+	+	Gerberick et al. 2005; Hilton et al. 1998	ICCVAM 1999	ICCVAM 1999; Kwon et al. 2003	Nonirritant at 2% (GP)	Basketter et al. 2007b
Formaldehyde	50-00-0	5.0	3.18	Omori et al. 2008	+	+	+	Gerberick et al. 2005; Hilton et al. 1998	ICCVAM 1999	ICCVAM 1999; Kwon et al. 2003	Nonirritant at 2% (GP)	Basketter et al. 2007b
Formaldehyde	50-00-0	5.0	2.69	Omori et al. 2008	+	+	+	Gerberick et al. 2005; Hilton et al. 1998	ICCVAM 1999	ICCVAM 1999; Kwon et al. 2003	Nonirritant at 2% (GP)	Basketter et al. 2007b
Glutaraldehyde	111-30-8	0.25	6.45	Idehara et al. 2008	+	+	+	Basketter et al. 2005; Hilton et al. 1998	Gad et al. 1986	Marzulli et al. 1974; Schneider and Akkan 2004	NA	NA
Glutaraldehyde	111-30-8	0.50	5.00	Omori et al. 2008	+	+	+	Basketter et al. 2005; Hilton et al. 1998	Gad et al. 1986	Marzulli et al. 1974; Schneider and Akkan 2004	NA	NA
Glutaraldehyde	111-30-8	0.50	3.39	Omori et al. 2008	+	+	+	Basketter et al. 2005; Hilton et al. 1998	Gad et al. 1986	Marzulli et al. 1974; Schneider and Akkan 2004	NA	NA
Glutaraldehyde	111-30-8	0.50	2.57	Omori et al. 2008	+	+	+	Basketter et al. 2005; Hilton et al. 1998	Gad et al. 1986	Marzulli et al. 1974; Schneider and Akkan 2004	NA	NA
Hexane	110-54-3	100	2.31	Idehara et al. 2008	-	NA	-	ICCVAM 1999	NA	ICCVAM 1999	Irritant at 100% (humans)	Kligman 1966c
Hexyl cinnamic aldehyde	101-86-0	25	6.47	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	5.78	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	4.82	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	4.44	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
Hexyl cinnamic aldehyde	101-86-0	25	5.11	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	3.97	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	5.50	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	7.09	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	10.22	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	3.88	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	3.51	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	4.47	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	5.71	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	5.41	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	7.60	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	3.92	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	8.42	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hexyl cinnamic aldehyde	101-86-0	25	6.45	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Mild irritant at 100% (rabbits)	ECETOC #66, 1995
Hydroxycitronellal	107-75-5	50	5.69	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 50% (GP); Negative at 100% (rabbits)	Basketter et al. 2007b; ECETOC #66, 1995
Imidazolidinyl urea	39236-46-9	50	4.67	Idehara et al. 2008	+	+	+	Gerberick et al. 2005	ICCVAM 1999	ICCVAM 1999	Negative at ≤ 75% (GP)	Basketter and Scholes
Isoeugenol	97-54-1	50	12.36 at 25%	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al. 2007b
Isoeugenol	97-54-1	10	6.11	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al.

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
												2007b
Isoeugenol	97-54-1	10	5.54	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al. 2007b
Isoeugenol	97-54-1	10	7.09	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter et al. 2007b
Isopropanol	67-63-0	50	1.08 at 25%	Idehara et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.54 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	0.91 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.01 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.57 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	0.76 at 25%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.97 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.45 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.21 at 10%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	0.70 at 25%	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Isopropanol	67-63-0	50	1.25	Omori et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	Kwon et al. 2003	Negative at 100% (rabbits)	ECETOC #66, 1995
Lactic acid	50-21-5	50	1.06 at 10%	Idehara et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Slightly irritating at 10% aq. (rabbits)	Cosmetic Ingredient Review Expert Panel 1998
Lactic acid	50-21-5	25	0.93 at 5%	Omori et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Slightly irritating at 10% aq. (rabbits)	Cosmetic Ingredient Review Expert Panel

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
												1998
Lactic acid	50-21-5	25	0.99 at 5%	Omori et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Slightly irritating at 10% aq. (rabbits)	Cosmetic Ingredient Review Expert Panel 1998
Lactic acid	50-21-5	25	0.97 at 10%	Omori et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Slightly irritating at 10% aq. (rabbits)	Cosmetic Ingredient Review Expert Panel 1998
Lactic acid	50-21-5	25	0.91	Omori et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	Basketter et al. 1999b	Slightly irritating at 10% aq. (rabbits)	Cosmetic Ingredient Review Expert Panel 1998
2-Mercaptobenzo-thiazole	149-30-4	50	2.00	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 10% (GP)	Basketter et al. 2007b
Methyl methacrylate	80-62-6	100	1.81	Idehara unpublished	+	+	+ (case studies, no exposure concentration)	Betts et al. 2006	Van der Walle et al. 1982	Betts et al. 2006	Nonirritant at 3 M (GP)	Van der Walle et al. 1982
Methyl salicylate	119-36-8	25	1.20	Idehara et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Irritant at 10% AOO (mice)	Gerberick et al 2002
Methyl salicylate	119-36-8	25	1.55	Omori et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Irritant at 10% AOO (mice)	Gerberick et al 2002
Methyl salicylate	119-36-8	25	1.77 at 10%	Omori et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Irritant at 10% AOO (mice)	Gerberick et al 2002
Methyl salicylate	119-36-8	25	0.83	Idehara et al. 2008	-	-	-	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Irritant at 10% AOO (mice)	Gerberick et al 2002
Nickel (II) chloride	7718-54-9	10	1.30	Idehara unpublished	-	+	+	ICCVAM 1999	ICCVAM 1999	Vandenbergh and Epstein 1963	Negative at ≤ 0.15% (GP)	Basketter and Scholes
Nickel (II) sulfate hexahydrate	10101-97-0	5.0	2.17 at 2.5%	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans);	Kligman 1966c;

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
											Nonirritant at 0.15% (GP)	Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	1.52 at 3%	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	11.78	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	3.49 at 1%	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	0.79 at 3%	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	1.24 at 3%	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	2.13	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Nickel (II) sulfate hexahydrate	10101-97-0	10	1.56 at 3%	Omori et al. 2008	+	+	+	Ryan et al. 2002	ICCVAM 1999	ICCVAM 1999	Irritant at 10% (humans); Nonirritant at 0.15% (GP)	Kligman 1966c; Scholes et al. 1992
Phenyl benzoate	93-99-2	10	4.24 at 5%	Idehara unpublished	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al 2005a	NA	NA
p-Phenylenediamine	106-50-3	1	5.14 at 0.25%	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.5% (GP)	Basketter et al. 2007b
Phthalic anhydride	85-44-9	1.0	5.49	Idehara et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	Basketter et al. 2001	Negative at ≤ 10% (GP)	Basketter and Scholes
Potassium dichromate	7778-50-9	1.0	4.78	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.15% (GP)	Basketter et al. 2007b

Substance Name	CASRN	LLNA: DA Highest Conc. Tested (%)	LLNA: DA Highest SI ¹	LLNA: DA Reference	Trad. LLNA Result	GP Result ²	Human Result ³	Trad. LLNA Reference	GP Reference	Human Reference	Skin Irritant?	Skin Irritation Data Reference
Potassium dichromate	7778-50-9	1.0	4.08	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.15% (GP)	Basketter et al. 2007b
Potassium dichromate	7778-50-9	1.0	6.01	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.15% (GP)	Basketter et al. 2007b
Potassium dichromate	7778-50-9	1.0	6.37	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.15% (GP)	Basketter et al. 2007b
Potassium dichromate	7778-50-9	1.0	5.49	Omori et al. 2008	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 0.15% (GP)	Basketter et al. 2007b
Propyl gallate	121-79-9	2.5	4.95	Idehara unpublished	+	+	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 5% (GP)	Basketter and Scholes
Propylparaben	94-13-3	25	1.28	Idehara et al. 2008	-	-	+	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Nonirritant at 10% (GP)	Basketter and Scholes
Resorcinol	108-46-3	25	4.33	Idehara et al. 2008	+	-	+	Basketter et al. 2007	ICCVAM 1999	ICCVAM 1999; Basketter et al. 2007	Nonirritant at 15% (humans)	Kligman 1966c
Salicylic acid	69-72-7	25	2.00	Idehara unpublished	-	-	+(6/23 at 1%)	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999 (Kligman 1966b for nickel sulfate)	Irritant at 20% aq. (mice)	Gerberick et al. 2002
Sodium lauryl sulfate	151-21-3	10	3.39	Idehara et al. 2008	+	-	-	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999	Irritant at 20% (rabbits)	ECETOC #66, 1995
Sulfanilamide	63-74-1	50	0.86 at 25%	Idehara unpublished	-	-	-	ICCVAM 1999	ICCVAM 1999	ICCVAM 1999; Kligman 1966c	Nonirritant at 25% (humans)	Kligman 1966c
Toluene 2,4-diisocyanate	584-84-9	0.25	9.43	Idehara et al. 2008	+	+	+	van Och et al. 2001	NA	Basketter et al. 2001	NA	NA
Trimellitic anhydride	552-30-7	0.50	4.96	Idehara et al. 2008	+	+	NA	ICCVAM 1999; Basketter and Scholes 1992	ICCVAM 1999; Gad et al. 1986	ICCVAM 1999; Basketter et al. 2001	Negative at ≤ 10% (GP)	Basketter and Scholes

Abbreviations: ACE = acetone; AOO = acetone: olive oil (4:1); aq. = aqueous; CASRN = Chemical Abstracts Service Registry Number; Conc. = concentration; ECETOC = European Centre for Ecotoxicology and Toxicology of Chemicals; GP = guinea pig; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content; NA = not available; SI = stimulation index; Trad. = traditional;

“+” = Sensitizer.

“-” = Nonsensitizer.

- 55 ¹Highest SI achieved at highest concentration tested, unless otherwise noted.
56 ²GP refers to outcomes obtained by studies conducted using either the guinea pig maximization test or the Buehler test.
57 ³Human refers to outcomes obtained by studies conducted using the human maximization test, inclusion of the test substance in a human patch test allergen kit, and/or published clinical case
58 studies/reports.
59 ⁴Equivocal traditional LLNA data (ICCVAM 1999); substance not included in accuracy analyses.
60 ⁵Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.
61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Appendix C2

76 **Comparison of Alternative LLNA: DA Decision Criteria and Traditional LLNA Results**

77

(Alphanumeric Order)

78
79
80
81
82
83
84
85
86
87
88
89
90
91

[This Page Intentionally Left Blank]

92 **Appendix C-2 Comparative Performance of Various LLNA: DA SI Values and Traditional LLNA Tests (Alphanumeric**
 93 **Order)**

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95% CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Abietic acid	514-10-3	25	6.26	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Abietic acid	514-10-3	25	4.64	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Abietic acid	514-10-3	25	7.96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Abietic acid	514-10-3	25	3.98 at 10%	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
3-Aminophenol	591-27-5	10	2.83	+	+	+	+	-	-	-	-	-	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
3-Aminophenol	591-27-5	10	1.76 at 3%	+	+	+	+	-	-	-	-	-	-	-	+	+	+	Omori et al. 2008	+	ICCVAM 1999
3-Aminophenol	591-27-5	10	2.38	+	+	+	+	-	-	-	-	-	-	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Benzalkonium chloride	8001-54-5	2.5	6.68	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	Gerberick 1992
Benzocaine	94-09-7	25	4.84	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+/- ³	ICCVAM 1999
p-Benzoquinone	106-51-4	0.100	3.79	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Idehara unpublished	+	ICCVAM 1999
1-Bromobutane	109-65-9	25	1.65	+	+	+	+	-	-	-	-	-	-	-	+	+	+	Idehara et al. 2008	-	ICCVAM 1999
Butyl glycidyl ether	2426-08-6	50	4.59	+	-	+	+	-	+	+	+	+	+	+	+	+	+	Idehara unpublished	+	ICCVAM 1999
Chlorobenzene	108-90-7	25	2.44	+	+	+	+	-	-	-	-	-	-	+	+	+	+	Idehara et al. 2008	-	ICCVAM 1999

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
5-Chloro-2-methyl-4-isothiazolin-3-one	26172-55-4	0.100	7.50	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara unpublished	+	ICCVAM 1999; Gerberick et al. 2005
Cinnamic alcohol	104-54-1	90	5.66 at 50%	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara unpublished	+	Gerberick et al. 2005
Cinnamic aldehyde	104-55-2	15	4.73	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Citral	5392-40-5	25	4.40	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	5	3.64	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	1 ⁴	2.66	+	+	+	+	-	-	-	-	-	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	3	20.55	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	3	8.07	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	5	2.01	+	+	+	+	-	-	-	-	-	-	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	5	2.54	+	+	+	+	-	-	-	-	-	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	5	4.25	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Cobalt chloride	7646-79-9	5	5.06	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Diethyl maleate	141-05-9	10.0	3.78	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Idehara unpublished	+	Gerberick et al. 2005

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Diethyl phthalate	84-66-2	100	1.09	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Idehara et al. 2008	-	Gerberick et al. 2005
Dimethyl isophthalate	1459-93-4	25	0.89 at 5%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Idehara unpublished	-	ICCVAM 1999; Basketter et al. 1999b
Dimethyl isophthalate	1459-93-4	25	1.34 at 5%	+	-	-	-	-	-	-	-	-	-	-	-	+	+	Omori et al. 2008	-	ICCVAM 1999; Basketter et al. 1999b
Dimethyl isophthalate	1459-93-4	25	1.00 at 5%	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	-	ICCVAM 1999; Basketter et al. 1999b
Dimethyl isophthalate	1459-93-4	25	1.26 at 5%	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	-	ICCVAM 1999; Basketter et al. 1999b
2,4-Dinitrochlorobenzene	97-00-7	1	7.10	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	11.97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	9.23	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	9.96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	8.53	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
2,4-Dinitrochlorobenzene	97-00-7	0.30	7.86	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	15.14	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	13.18	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	12.60	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	10.89	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	0.30	4.71	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
2,4-Dinitrochlorobenzene	97-00-7	1	7.10	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Ethyl acrylate	140-88-5	50	4.29 at 25%	+	-	-	+	-	-	+	+	+	+	+	+	+	+	Idehara unpublished	+	Gerberick et al. 2005
Ethylene glycol dimethacrylate	97-90-5	50	4.45	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Idehara unpublished	+	ICCVAM 1999
Eugenol	97-53-0	25	7.07	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Formaldehyde	50-00-0	2.50	5.10	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	Gerberick et al. 2005; Hilton et al. 1998
Formaldehyde	50-00-0	5.0	4.84	+	+	+	+	-	-	-	-	+	+	+	+	+	+	Omori et al. 2008	+	Gerberick et al. 2005; Hilton et al. 1998
Formaldehyde	50-00-0	5.0	3.18	+	+	+	+	-	-	-	-	-	+	+	+	+	+	Omori et al. 2008	+	Gerberick et al. 2005; Hilton et al. 1998

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Formaldehyde	50-00-0	5.0	2.69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	Gerberick et al. 2005; Hilton et al. 1998
Glutaraldehyde	111-30-8	0.25	6.45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	Basketter et al. 2005; Hilton et al. 1998
Glutaraldehyde	111-30-8	0.50	5.00	+	+	+	+	-	-	-	-	+	+	+	+	+	+	Omori et al. 2008	+	Basketter et al. 2005; Hilton et al. 1998
Glutaraldehyde	111-30-8	0.50	3.39	+	+	+	+	-	-	-	-	-	+	+	+	+	+	Omori et al. 2008	+	Basketter et al. 2005; Hilton et al. 1998
Glutaraldehyde	111-30-8	0.50	2.57	+	+	+	+	-	-	-	-	-	-	+	+	+	+	Omori et al. 2008	+	Basketter et al. 2005; Hilton et al. 1998
Hexane	110-54-3	100	2.31	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	-	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	6.47	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	5.78	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	4.82	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	4.44	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	5.11	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Hexyl cinnamic aldehyde	101-86-0	25	3.97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	5.50	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	7.09	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	10.22	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	3.88	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	3.51	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	4.47	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	5.71	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	5.41	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	7.60	+	+	+	+	-	-	-	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	3.92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	8.42	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hexyl cinnamic aldehyde	101-86-0	25	6.45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Hydroxycitronella l	107-75-5	50	5.69	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Imidazolidinyl urea	39236-46-9	50	4.67	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	Gerberick et al. 2005

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Isoeugenol	97-54-1	50	12.36 at 25%	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Isoeugenol	97-54-1	10	6.11	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Isoeugenol	97-54-1	10	5.54	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Isoeugenol	97-54-1	10	7.09	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	+	ICCVAM 1999
Isopropanol	67-63-0	50	1.08 at 25%	+	-	+	-	-	-	-	-	-	-	-	+	+	+	Idehara et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	1.54 at 10%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	0.91 at 10%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	1.01 at 10%	+	-	+	+	-	-	-	-	-	-	-	+	+	+	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	1.57 at 10%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	0.76 at 25%	+	+	+	-	-	-	-	-	-	-	-	+	+	+	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	1.97 at 10%	+	-	+	-	-	-	-	-	-	-	-	-	+	+	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	1.45 at 10%	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	1.21 at 10%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Isopropanol	67-63-0	50	0.70 at 25%	+	-	+	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	-	ICCVAM 1999

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Isopropanol	67-63-0	50	1.25	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	-	ICCVAM 1999
Lactic acid	50-21-5	50	1.06 at 10%	+	-	-	-	-	-	-	-	-	-	-	-	-	+	Idehara et al. 2008	-	ICCVAM 1999
Lactic acid	50-21-5	25	0.93 at 5%	+	-	-	+	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	-	ICCVAM 1999
Lactic acid	50-21-5	25	0.99 at 5%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Lactic acid	50-21-5	25	0.97 at 10%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Lactic acid	50-21-5	25	0.91	+	+	+	-	-	-	-	-	-	-	+	+	+	+	Omori et al. 2008	-	ICCVAM 1999
2-Mercaptobenzo-thiazole	149-30-4	50	2.00	+	-	+	-	-	-	-	-	-	-	-	-	-	+	Idehara et al. 2008	+	ICCVAM 1999
Methyl methacrylate	80-62-6	100	1.81	+	-	-	+	-	-	-	-	-	-	-	+	+	+	Idehara unpublished	+	Betts et al. 2006
Methyl salicylate	119-36-8	25	1.20	+	+	+	-	-	-	-	-	-	-	-	+	+	+	Idehara et al. 2008	-	ICCVAM 1999
Methyl salicylate	119-36-8	25	1.55	+	-	-	-	-	-	-	-	-	-	-	+	+	+	Omori et al. 2008	-	ICCVAM 1999
Methyl salicylate	119-36-8	25	1.77 at 10%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	-	ICCVAM 1999
Methyl salicylate	119-36-8	25	0.83	+	+	+	+	-	-	-	-	-	-	+	+	+	+	Idehara et al. 2008	-	ICCVAM 1999
Nickel (II) chloride	7718-54-9	10	1.30	+	+	+	-	-	-	-	-	-	-	-	-	+	+	Idehara unpublished	-	ICCVAM 1999
Nickel (II) sulfate hexahydrate	10101-97-0	5.0	2.17 at 2.5%	+	-	-	-	-	-	-	-	-	-	-	+	+	+	Omori et al. 2008	+	Ryan et al. 2002
Nickel (II) sulfate hexahydrate	10101-97-0	10	1.52 at 3%	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	Ryan et al. 2002

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Nickel (II) sulfate hexahydrate	10101-97-0	10	11.78	+	+	+	+	-	-	-	-	+	+	+	+	+	+	Omori et al. 2008	+	Ryan et al. 2002
Nickel (II) sulfate hexahydrate	10101-97-0	10	3.49 at 1%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Omori et al. 2008	+	Ryan et al. 2002
Nickel (II) sulfate hexahydrate	10101-97-0	10	0.79 at 3%	+	+	+	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	+	Ryan et al. 2002
Nickel (II) sulfate hexahydrate	10101-97-0	10	1.24 at 3%	+	+	+	+	-	-	-	-	-	-	+	+	+	+	Omori et al. 2008	+	Ryan et al. 2002
Nickel (II) sulfate hexahydrate	10101-97-0	10	2.13	+	-	-	-	-	-	-	-	-	-	-	+	+	+	Omori et al. 2008	+	Ryan et al. 2002
Nickel (II) sulfate hexahydrate	10101-97-0	10	1.56 at 3%	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	Ryan et al. 2002
Phenyl benzoate	93-99-2	10.0	4.24 at 5%	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Idehara unpublished	+	ICCVAM 1999
p-Phenylenediamine	106-50-3	1	5.14 at 0.25%	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Phthalic anhydride	85-44-9	1.0	5.49	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Potassium dichromate	7778-50-9	1.0	4.78	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Potassium dichromate	7778-50-9	1.0	4.08	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Potassium dichromate	7778-50-9	1.0	6.01	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Potassium dichromate	7778-50-9	1.0	6.37	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Omori et al. 2008	+	ICCVAM 1999
Potassium dichromate	7778-50-9	1.0	5.49	+	+	+	-	-	-	-	-	-	-	-	-	-	+	Omori et al. 2008	+	ICCVAM 1999

Substance Name	CASRN	Highest Conc. Tested (%)	Highest SI ¹	≥95 % CI	≥3 SD	≥2 SD	Stats. ²	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3	SI ≥ 1.0	LLNA: DA Ref.	Trad. LLNA Result	Trad. LLNA Ref.
Propyl gallate	121-79-9	2.5	4.95	+	-	-	+	-	+	+	+	+	+	+	+	+	+	Idehara unpublished	+	ICCVAM 1999
Propylparaben	94-13-3	25	1.28	+	+	+	+	-	-	+	+	+	+	+	+	+	+	Idehara et al. 2008	-	ICCVAM 1999
Resorcinol	108-46-3	25	4.33	+	+	+	+	-	-	-	-	+	+	+	+	+	+	Idehara et al. 2008	+	Basketter et al. 2007
Salicylic acid	69-72-7	25	2.00	+	-	+	+	-	-	-	-	-	-	+	+	+	+	Idehara unpublished	-	ICCVAM 1999
Sodium lauryl sulfate	151-21-3	10	3.39	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999
Sulfanilamide	63-74-1	50	0.86 at 25%	-	-	-	+	-	-	-	-	-	-	-	-	-	-	Idehara unpublished	-	ICCVAM 1999
Toluene 2,4-diisocyanate	584-84-9	0.25	9.43	+	+	+	+	-	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	Van Och et al. 2001
Trimellitic anhydride	552-30-7	0.50	4.96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Idehara et al. 2008	+	ICCVAM 1999; Basketter and Scholes 1992

Abbreviations: CASRN = Chemical Abstracts Service Registry Number; CI = confidence interval (mean ATP measurement of any treatment group is greater than 95% CI of mean ATP measurement for vehicle control group); Conc. = concentration; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content; Ref. = reference; SD = standard deviation (mean ATP measurement of any treatment group is greater than two or three SD for vehicle control group); SI = stimulation index; stats. = statistics (analysis of variance for multiple dose groups or *t*-test to compare one treatment group to the vehicle control group); Trad. = traditional.

“+” = Sensitizer.

“-” = Nonsensitizer.

¹Highest SI achieved at highest concentration tested, unless otherwise noted.

²The ATP data were log-transformed prior to statistical analyses. For analysis of variance, significance at *p* < 0.05 was further tested by Dunnett’s test.

³Equivocal traditional LLNA data (ICCVAM 1999). Substance not included in accuracy analyses.

⁴Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Appendix D

Data for the LLNA: DA Intralaboratory and Interlaboratory Validation Studies

D1 Individual Animal Data for the LLNA: DA (Intralaboratory).....D-3
D2 Summary Data for 14 Additional Substances Tested in the LLNA: DA
(Intralaboratory)D-21
D3 Individual Animal Data for the LLNA: DA (Interlaboratory)D-27

17
18
19
20
21
22
23
24
25
26
27
28
29
30

[This Page Intentionally Left Blank]

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Appendix D1

Individual Animal Data for the LLNA: DA (Intralaboratory)

45

46

47

48

49

50

51

52

53

54

55

56

57

58

[This Page Intentionally Left Blank]

Appendix D1 Individual Animal Data for the LLNA: DA Intralaboratory Validation Study¹

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵	
Vehicle Control	AOO	1-1	0	4927	1.12																							
Vehicle Control	AOO	1-2	0	3547	0.80																							
Vehicle Control	AOO	1-3	0	4758	1.08																							
Vehicle Control	AOO	Mean	0	4411	1.0																							
Positive Control - Eugenol	AOO	2-1	10	17020	3.86																							
Positive Control - Eugenol	AOO	2-2	10	14029	3.18																							
Positive Control - Eugenol	AOO	2-3	10	12117	2.75																							
Positive Control - Eugenol	AOO	Mean	10	14388	3.26																							
Citral	AOO	3-1	5	9191	2.08	4-1	10	9937	2.25	5-1	15	12297	2.79	6-1	25	18200	4.13											
Citral	AOO	3-2	5	12120	2.75	4-2	10	7447	1.69	5-2	15	11863	2.69	6-2	25	22609	5.13											
Citral	AOO	3-3	5	4808	1.09	4-3	10	10528	2.39	5-3	15	14283	3.24	6-3	25	17469	3.96											
Citral	AOO	Mean	5	8706	1.97	Mean	10	9304	2.11	Mean	15	12814	2.91	Mean	25	19426	4.40									15.63	5.96	
Cinnamic aldehyde	AOO	7-1	1.0	6780	1.54	8-1	2.5	13624	3.09	9-1	5.0	21945	4.98	10-1	15	20037	4.54											
Cinnamic aldehyde	AOO	7-2	1.0	13271	3.01	8-2	2.5	8924	2.02	9-2	5.0	17313	3.93	10-2	15	18085	4.10											
Cinnamic aldehyde	AOO	7-3	1.0	7545	1.71	8-3	2.5	12681	2.88	9-3	5.0	19218	4.36	10-3	15	24421	5.54											
Cinnamic aldehyde	AOO	Mean	1.0	9199	2.09	Mean	2.5	11743	2.66	Mean	5.0	19492	4.42	Mean	15	20848	4.73									2.98	0.92	
Vehicle Control	AOO	1-1	0	3759	0.97																							
Vehicle Control	AOO	1-2	0	3995	1.03																							
Vehicle Control	AOO	1-3	0	3461	0.89																							
Vehicle Control	AOO	1-4	0	4269	1.10																							
Vehicle Control	AOO	Mean	0	3871	1.00																							

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵		
Positive Control - Eugenol	AOO	3-1	10	16624	4.30																								
Positive Control - Eugenol	AOO	3-2	10	23785	6.15																								
Positive Control - Eugenol	AOO	3-3	10	15667	4.05																								
Positive Control - Eugenol	AOO	3-4	10	18066	4.67																								
Positive Control - Eugenol	AOO	Mean	10	18535	4.79																								
Eugenol	AOO	2-1	5	12594	3.25	3-1	10	16624	4.30	4-1	25	26107	6.75																
Eugenol	AOO	2-2	5	15216	3.93	3-2	10	23785	6.15	4-2	25	26713	6.90																
Eugenol	AOO	2-3	5	9790	2.53	3-3	10	15667	4.05	4-3	25	29297	7.57																
Eugenol	NT	NT	NT	NT	NT	3-4	10	18066	4.67	NT	NT	NT	NT																
Eugenol	AOO	Mean	5	12533	3.24	Mean	10	18535	4.79	Mean	25	27372	7.07													4.50	2.88		
Propylparaben	AOO	5-1	5	5058	1.31	6-1	10	5539	1.43	7-1	25	6385	1.65																
Propylparaben	AOO	5-2	5	4773	1.233	6-2	10	3919	1.012	7-2	25	5813	1.50																
Propylparaben	AOO	5-3	5	3034	0.784	6-3	10	3713	0.959	7-3	25	2679	0.69																
Propylparaben	AOO	Mean	5	4288	1.11	Mean	10	4390	1.13	Mean	25	4959	1.28													NA	NA		
HCA	AOO	8-1	5	7375	1.91	9-1	10	9217	2.38	10-1	25	30420	7.86																
HCA	AOO	8-2	5	3858	1.00	9-2	10	12654	3.27	10-2	25	27682	7.15																
HCA	AOO	8-3	5	3782	1.00	9-3	10	8072	2.09	10-3	25	17014	4.40																
HCA	AOO	Mean	5	5005	1.29	Mean	10	9981	2.58	Mean	25	25038	6.47													11.62	7.75		
Methyl salicylate	AOO	11-1	5	3250	0.84	12-1	10	4499	1.16	13-1	25	4542	1.17																
Methyl salicylate	AOO	11-2	5	3310	0.86	12-2	10	4637	1.20	13-2	25	5445	1.41																
Methyl salicylate	AOO	11-3	5	1760	0.46	12-3	10	2035	0.53	13-3	25	3996	1.03																
Methyl salicylate	AOO	Mean	5	2773	0.72	Mean	10	3723	0.96	Mean	25	4661	1.20													NA	NA		

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵
Vehicle Control 1	AOO	1-1	0	3529	1.17																						
Vehicle Control 1	AOO	1-2	0	3106	1.03																						
Vehicle Control 1	AOO	1-3	0	2949	0.98																						
Vehicle Control 1	AOO	1-4	0	2473	0.82																						
Vehicle Control 1	AOO	Mean	0	3014	1.00																						
Positive Control 1 - Eugenol	AOO	2-1	10	20105	6.67																						
Positive Control 1 - Eugenol	AOO	2-2	10	14663	4.87																						
Positive Control 1 - Eugenol	AOO	2-3	10	14233	4.72																						
Positive Control 1 - Eugenol	AOO	2-4	10	13137	4.36																						
Positive Control 1 - Eugenol	AOO	Mean	10	15535	5.15																						
Vehicle Control 2	DMSO	3-1	0	4770	0.72																						
Vehicle Control 2	DMSO	3-2	0	6914	1.04																						
Vehicle Control 2	DMSO	3-3	0	8487	1.27																						
Vehicle Control 2	DMSO	3-4	0	6527	0.98																						
Vehicle Control 2	DMSO	Mean	0	6674	1.00																						
Positive Control 2 - Eugenol	DMSO	4-1	10	10887	1.63																						
Positive Control 2 - Eugenol	DMSO	4-2	10	16454	2.47																						
Positive Control 2 - Eugenol	DMSO	4-3	10	9982	1.50																						
Positive Control 2 - Eugenol	DMSO	4-4	10	12245	1.84																						
Positive Control 2 - Eugenol	DMSO	Mean	10	12392	1.86	Failed PC																					
Abietic acid	AOO	5-1	5	4143	1.38	6-1	10	13190	4.3	7-1	25	20693	6.87														
Abietic acid	AOO	5-2	5	9059	3.01	6-2	10	8354	2.772	7-2	25	17109	5.68														
Abietic acid	AOO	5-3	5	7056	2.34	6-3	10	10561	3.50	7-3	25	18770	6.23														

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵		
Abietic acid	AOO	Mean	5	6752	2.24	Mean	10	10701	3.55	Mean	25	18857	6.26														7.90	4.40	
Cobalt II chloride	DMSO	8-1	1.0	17709	2.65	9-1	2.5	17680	2.65	10-1	5.0	28248	4.23																
Cobalt II chloride	DMSO	8-2	1.0	12673	1.90	9-2	2.5	17863	2.68	10-2	5.0	27268	4.09																
Cobalt II chloride	DMSO	8-3	1.0	12428	1.86	9-3	2.5	18809	2.82	10-3	5.0	17378	2.60																
Cobalt II chloride	DMSO	Mean	1.0	14270	2.14	Mean	2.5	18117	2.71	Mean	5.0	24298	3.64														3.27	0.88	
Nickel (II) sulfate hexahydrate	DMSO	11-1	1.0	7672	1.15	12-1	2.5	10829	1.62	13-1	5.0	15969	2.39																
Nickel (II) sulfate hexahydrate	DMSO	11-2	1.0	11041	1.65	12-2	2.5	10925	1.64	13-2	5.0	9433	1.41																
Nickel (II) sulfate hexahydrate	DMSO	11-3	1.0	8581	1.29	12-3	2.5	21735	3.26	13-3	5.0	11636	1.74																
Nickel (II) sulfate hexahydrate	DMSO	Mean	1.0	9098	1.36	Mean	2.5	14496	2.17	Mean	5.0	12346	1.85														NA	2.18	
Vehicle Control 1	AOO	1-1	0	2660	1.03																								
Vehicle Control 1	AOO	1-2	0	2856	1.11																								
Vehicle Control 1	AOO	1-3	0	1828	0.71																								
Vehicle Control 1	AOO	1-4	0	2975	1.15																								
Vehicle Control 1	AOO	Mean	0	2580	1.00																								
Positive Control 1 - Eugenol	AOO	2-1	10	19298	7.48																								
Positive Control 1 - Eugenol	AOO	2-2	10	17360	6.73																								
Positive Control 1 - Eugenol	AOO	2-3	10	14953	5.80																								
Positive Control 1 - Eugenol	AOO	2-4	10	11827	4.59																								
Positive Control 1 - Eugenol	AOO	Mean	10	15859	6.15																								
Vehicle Control 2	DMF	3-1	0	4424	1.29																								
Vehicle Control 2	DMF	3-2	0	3087	0.90																								
Vehicle Control 2	DMF	3-3	0	2348	0.69																								
Vehicle Control 2	DMF	3-4	0	3854	1.12																								

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵		
Vehicle Control 2	DMF	Mean	0	3428	1.00																								
Positive Control 2 - Eugenol	DMF	4-1	10	5738	1.67																								
Positive Control 2 - Eugenol	DMF	4-2	10	5644	1.65																								
Positive Control 2 - Eugenol	DMF	4-3	10	3688	1.08																								
Positive Control 2 - Eugenol	DMF	4-4	10	8185	2.39																								
Positive Control 2 - Eugenol	DMF	Mean	10	5813	1.70	Failed PC																							
Benzocaine	AOO	5-1	5	10495	4.07	6-1	10	10314	4.00	7-1	25	10512	4.08																
Benzocaine	AOO	5-2	5	3052	1.18	6-2	10	10880	4.22	7-2	25	14366	5.57																
Benzocaine	AOO	5-3	5	6751	2.62	6-3	10	8378	3.25	7-3	25	12564	4.87																
Benzocaine	AOO	Mean	5	6766	2.62	Mean	10	9857	3.82	Mean	25	12480	4.84													6.57	3.49		
Imidazolidinyl urea	DMF	8-1	10	7333	2.14	9-1	25	9854	2.88	10-1	50	14760	4.31																
Imidazolidinyl urea	DMF	8-2	10	6777	1.98	9-2	25	13907	4.06	10-2	50	15299	4.46																
Imidazolidinyl urea	DMF	8-3	10	10143	2.96	9-3	25	11783	3.44	10-3	50	17971	5.24																
Imidazolidinyl urea	DMF	Mean	10	8084	2.36	Mean	25	11848	3.46	Mean	50	16010	4.67													18.77	7.42		
2-Mercaptbenzothiazole	DMF	11-1	10	7829	2.28	12-1	25	6978	2.04	13-1	50	3976	1.16																
2-Mercaptbenzothiazole	DMF	11-2	10	7102	2.07	12-2	25	2425	0.71	13-2	50	4375	1.28																
2-Mercaptbenzothiazole	DMF	11-3	10	5647	1.65	12-3	25	4401	1.28	13-3	50	2675	0.78																
2-Mercaptbenzothiazole	DMF	Mean	10	6859	2.00	Mean	25	4601	1.34	Mean	50	3675	1.07													NA	9.99		
Vehicle Control	AOO	1-1	0	1453	0.28																								
Vehicle Control	AOO	1-2	0	11748	2.27																								
Vehicle Control	AOO	1-3	0	4663	0.90																								
Vehicle Control	AOO	1-4	0	2810	0.54																								
Vehicle Control	AOO	Mean	0	5168	1.00																								

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵
Positive Control - Eugenol	AOO	2-1	10	13351	2.58																						
Positive Control - Eugenol	AOO	2-2	10	27023	5.229																						
Positive Control - Eugenol	AOO	2-3	10	12875	2.49																						
Positive Control - Eugenol	AOO	2-4	10	15921	3.08																						
Positive Control - Eugenol	AOO	Mean	10	17292	3.35																						
2-4-Dinitrochlorobenzene	AOO	10-1	0.025	11884	2.30	11-1	0.05	10848	2.10	12-1	0.10	13205	2.56	13-1	0.25	34300	6.64	14-1	0.5	33092	6.40	15-1	1.0	40795	7.89		
2-4-Dinitrochlorobenzene	AOO	10-2	0.025	11146	2.16	11-2	0.05	7394	1.43	12-2	0.10	8679	1.68	13-2	0.25	26924	5.21	14-2	0.5	46685	9.03	15-2	1.0	36807	7.12		
2-4-Dinitrochlorobenzene	AOO	10-3	0.025	5799	1.12	11-3	0.05	8468	1.64	12-3	0.10	6740	1.30	13-3	0.25	15631	3.03	14-3	0.5	30241	5.85	15-3	1.0	32445	6.29		
2-4-Dinitrochlorobenzene	AOO	Mean	0.025	9610	1.86	Mean	0.05	8903	1.72	Mean	0.10	9541	1.85	Mean	0.25	25618	4.96	Mean	0.5	36673	7.10	Mean	1.0	36682	7.10	0.16	0.11
Vehicle Control	AOO	1-1	0	1460	0.41																						
Vehicle Control	AOO	1-2	0	5137	1.46																						
Vehicle Control	AOO	1-3	0	3988	1.13																						
Vehicle Control	AOO	Mean	0	3528	1.00																						
Positive Control - Eugenol	AOO	2-1	10	22813	6.47																						
Positive Control - Eugenol	AOO	2-2	10	21142	5.99																						
Positive Control - Eugenol	AOO	2-3	10	30985	8.78																						
Positive Control - Eugenol	AOO	Mean	10	24980	7.08																						
Isoeugenol	AOO	3-1	2.5	15638	4.43	4-1	5.0	15773	4.47	5-1	10	24776	7.02	6-1	25	40328	11.43	7-1	50	43389	12.30						
Isoeugenol	AOO	3-2	2.5	9113	2.58	4-2	5.0	19726	5.59	5-2	10	23236	6.59	6-2	25	50432	14.30	7-2	50	28424	8.06						
Isoeugenol	AOO	3-3	2.5	8197	2.32	4-3	5.0	10920	3.10	5-3	10	23595	6.69	6-3	25	40035	11.35	7-3	50	40263	11.41						
Isoeugenol	AOO	Mean	2.5	10982	3.11	Mean	5.0	15473	4.39	Mean	10	23869	6.77	Mean	25	43598	12.36	Mean	50	37359	10.59				2.35	1.36	
Vehicle Control	AOO	1-1	0	836	0.55																						
Vehicle Control	AOO	1-2	0	1815	1.20																						

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵	
Vehicle Control	AOO	1-3	0	1752	1.16																							
Vehicle Control	AOO	1-4	0	1631	1.08																							
Vehicle Control	AOO	Mean	0	1508	1.00																							
Positive Control - Eugenol	AOO	2-1	10	13707	9.09																							
Positive Control - Eugenol	AOO	2-2	10	6746	4.47																							
Positive Control - Eugenol	AOO	2-3	10	10475	6.95																							
Positive Control - Eugenol	AOO	2-4	10	6855	4.54																							
Positive Control - Eugenol	AOO	Mean	10	9446	6.26																							
Benzalkonium chloride	AOO	12-1	0.5	3027	2.01	13-1	1.0	9672	6.41	14-1	2.5	10292	6.82															
Benzalkonium chloride	AOO	12-2	0.5	5780	3.83	13-2	1.0	7809	5.18	14-2	2.5	11879	7.88															
Benzalkonium chloride	AOO	12-3	0.5	4183	2.77	13-3	1.0	10868	7.21	14-3	2.5	8070	5.35															
Benzalkonium chloride	AOO	Mean	0.5	4330	2.87	Mean	1.0	9449	6.26	Mean	2.5	10080	6.68													0.52	0.42	
Vehicle Control	DMF	1-1	0	2926	1.10																							
Vehicle Control	DMF	1-2	0	1674	0.63																							
Vehicle Control	DMF	1-3	0	3984	1.49																							
Vehicle Control	DMF	1-4	0	2091	0.78																							
Vehicle Control	DMF	Mean	0	2668	1.00																							
Positive Control - Cinnamic aldehyde	DMF	2-1	5	17595	6.59																							
Positive Control - Cinnamic aldehyde	DMF	2-2	5	12322	4.62																							
Positive Control - Cinnamic aldehyde	DMF	2-3	5	10331	3.87																							
Positive Control - Cinnamic aldehyde	DMF	2-4	5	12297	4.61																							

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵
Positive Control - Cinnamic aldehyde	DMF	Mean	5	13136	4.92																						
Sodium lauryl sulfate	DMF	3-1	1.0	3870	1.45	4-1	2.5	7965	2.99	5-1	5.0	2945	1.10	6-1	10	10337	3.87										
Sodium lauryl sulfate	DMF	3-2	1.0	2899	1.09	4-2	2.5	4802	1.80	5-2	5.0	7161	2.68	6-2	10	6881	2.58										
Sodium lauryl sulfate	DMF	3-3	1.0	3777	1.42	4-3	2.5	6838	2.56	5-3	5.0	7913	2.97	6-3	10	9932	3.72										
Sodium lauryl sulfate	DMF	Mean	1.0	3515	1.32	Mean	2.5	6535	2.45	Mean	5.0	6006	2.25	Mean	10	9050	3.39									6.88	1.91
Vehicle Control	AOO	1-1	0	2045	0.97																						
Vehicle Control	AOO	1-2	0	1990	0.94																						
Vehicle Control	AOO	1-3	0	2212	1.05																						
Vehicle Control	AOO	1-4	0	2212	1.05																						
Vehicle Control	AOO	Mean	0	2115	1.00																						
Positive Control - HCA	AOO	2-1	15	14020	6.63																						
Positive Control - HCA	AOO	2-2	15	9078	4.29																						
Positive Control - HCA	AOO	2-3	15	8912	4.21																						
Positive Control - HCA	AOO	Mean	15	10670	5.05																						
Isopropanol	AOO	6-1	10	1364	0.65	7-1	25	3820	1.81	8-1	50	2249	1.06														
Isopropanol	AOO	6-2	10	2872	1.36	7-2	25	1746	0.83	8-2	50	700	0.33														
Isopropanol	AOO	6-3	10	2417	1.14	7-3	25	1298	0.61	8-3	50	2454	1.16														
Isopropanol	AOO	Mean	10	2218	1.05	Mean	25	2288	1.08	Mean	50	1801	0.85													NA	NA
Vehicle Control	AOO	1-1	0	2386	0.76																						
Vehicle Control	AOO	1-2	0	2967	0.95																						
Vehicle Control	AOO	1-3	0	4347	1.39																						
Vehicle Control	AOO	1-4	0	2816	0.90																						
Vehicle Control	AOO	Mean	0	3129	1.00																						
Positive Control - HCA	AOO	2-1	15	9352	2.99																						

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵
Positive Control - HCA	AOO	2-2	15	16201	5.18																						
Positive Control - HCA	AOO	2-3	15	10538	3.37																						
Positive Control - HCA	AOO	2-4	15	9135	2.92																						
Positive Control - HCA	AOO	Mean	15	11306	3.61																						
Hexane	AOO	12-1	25	3755	1.20	13-1	50	3070	0.98	14-1	100	9027	2.89														
Hexane	AOO	12-2	25	3240	1.04	13-2	50	2491	0.80	14-2	100	6802	2.17														
Hexane	AOO	12-3	25	3136	1.00	13-3	50	2658	0.85	14-3	100	5850	1.87														
Hexane	AOO	Mean	25	3377	1.08	Mean	50	2740	0.88	Mean	100	7226	2.31													NA	89.19
Vehicle Control	AOO	1-1	0	2370	0.84																						
Vehicle Control	AOO	1-2	0	3124	1.11																						
Vehicle Control	AOO	1-3	0	2314	0.82																						
Vehicle Control	AOO	1-4	0	3464	1.23																						
Vehicle Control	AOO	Mean	0	2818	1.00																						
Positive Control - HCA	AOO	2-1	15	7739	2.75																						
Positive Control - HCA	AOO	2-2	15	10867	3.86																						
Positive Control - HCA	AOO	2-3	15	5290	1.88																						
Positive Control - HCA	AOO	2-4	15	8570	3.04																						
Positive Control - HCA	AOO	Mean	15	8116	2.88	Failed PC when SI ≥ 3.0																					
Toluene-2,4-diisocyanate	AOO	12-1	0.05	9445	3.35	13-1	0.10	12732	4.52	14-1	0.25	25104	8.91														
Toluene-2,4-diisocyanate	AOO	12-2	0.05	11471	4.07	13-2	0.10	17962	6.38	14-2	0.25	27791	9.86														
Toluene-2,4-diisocyanate	AOO	12-3	0.05	5999	2.13	13-3	0.10	16204	5.75	14-3	0.25	26785	9.51														
Toluene-2,4-diisocyanate	AOO	Mean	0.05	8972	3.18	Mean	0.10	15632	5.55	Mean	0.25	26560	9.43													0.05	0.04

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵	
Vehicle Control	AOO	1-1	0	1727	0.80																							
Vehicle Control	AOO	1-2	0	2122	0.99																							
Vehicle Control	AOO	1-3	0	2111	0.98																							
Vehicle Control	AOO	1-4	0	2645	1.23																							
Vehicle Control	AOO	Mean	0	2151	1.00																							
Positive Control - HCA	AOO	2-1	15	14931	6.94																							
Positive Control - HCA	AOO	2-2	15	15575	7.24																							
Positive Control - HCA	AOO	2-3	15	13043	6.06																							
Positive Control - HCA	AOO	2-4	15	11199	5.21																							
Positive Control - HCA	AOO	Mean	15	13687	6.36																							
1-Bromobutane	AOO	3-1	5	2701	1.26	4-1	10	1810	0.84	5-1	25	3483	1.62															
1-Bromobutane	AOO	3-2	5	2491	1.16	4-2	10	2130	0.99	5-2	25	2916	1.36															
1-Bromobutane	AOO	3-3	5	4272	1.99	4-3	10	878	0.41	5-3	25	4220	1.96															
1-Bromobutane	AOO	Mean	5	3154	1.47	Mean	10	1606	0.75	Mean	25	3539	1.65														NA	NA
Chlorobenzene	AOO	6-1	5	1875	0.87	7-1	10	2505	1.16	8-1	25	2848	1.32															
Chlorobenzene	AOO	6-2	5	2180	1.01	7-2	10	1840	0.86	8-2	25	5302	2.47															
Chlorobenzene	AOO	6-3	5	1088	0.51	7-3	10	2682	1.25	8-3	25	7615	3.54															
Chlorobenzene	AOO	Mean	5	1714	0.80	Mean	10	2342	1.09	Mean	25	5255	2.44														NA	20.09
Diethyl-phthalate	AOO	9-1	25	1543	0.72	10-1	50	1781	0.83	11-1	100	1808	0.84															
Diethyl-phthalate	AOO	9-2	25	2561	1.19	10-2	50	1371	0.64	11-2	100	1288	0.60															
Diethyl-phthalate	AOO	9-3	25	2906	1.35	10-3	50	2477	1.15	11-3	100	2139	0.99															
Diethyl-phthalate	AOO	Mean	25	2336	1.09	Mean	50	1876	0.87	Mean	100	1745	0.81														NA	NA
Hydroxycitronellal	AOO	12-1	10	5201	2.42	13-1	25	9519	4.43	14-1	50	14400	6.70															
Hydroxycitronellal	AOO	12-2	10	4094	1.90	13-2	25	13562	6.31	14-2	50	8741	4.06															
Hydroxycitronellal	AOO	12-3	10	5293	2.46	13-3	25	10656	4.95	14-3	50	13563	6.31															

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵		
Hydroxycitronellal	AOO	Mean	10	4862	2.26	Mean	25	11246	5.23	Mean	50	12234	5.69														13.74	9.23	
Vehicle Control	ACE	9-1	0	2232	1.39																								
Vehicle Control	ACE	9-2	0	1509	0.94																								
Vehicle Control	ACE	9-3	0	1287	0.80																								
Vehicle Control	ACE	9-4	0	1419	0.88																								
Vehicle Control	ACE	Mean	0	1611	1.00																								
Positive Control - HCA	ACE	10-1	15	13901	8.63																								
Positive Control - HCA	ACE	10-2	15	16265	10.09																								
Positive Control - HCA	ACE	10-3	15	15531	9.64																								
Positive Control - HCA	ACE	10-4	15	15749	9.77																								
Positive Control - HCA	ACE	Mean	15	15361	9.53																								
Glutaraldehyde	ACE	11-1	0.05	1821	1.13	12-1	0.10	5389	3.34	13-1	0.25	16484	10.23																
Glutaraldehyde	ACE	11-2	0.05	2181	1.35	12-2	0.10	2496	1.55	13-2	0.25	6814	4.23																
Glutaraldehyde	ACE	11-3	0.05	1931	1.12	12-3	0.10	6344	3.94	13-3	0.25	7889	4.90																
Glutaraldehyde	ACE	Mean	0.05	1978	1.23	Mean	0.10	4743	2.94	Mean	0.25	10396	6.45														0.10	0.07	
Vehicle Control	AOO	1-1	0	3101	0.92																								
Vehicle Control	AOO	1-2	0	3253	0.97																								
Vehicle Control	AOO	1-3	0	2687	0.80																								
Vehicle Control	AOO	1-4	0	4407	1.31																								
Vehicle Control	AOO	Mean	0	3362	1.00																								
Positive Control - HCA	AOO	2-1	15	22800	6.78																								
Positive Control - HCA	AOO	2-2	15	16696	4.97																								
Positive Control - HCA	AOO	2-3	15	17973	5.35																								
Positive Control -	AOO	2-4	15	18757	5.58																								

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵	
HCA																												
Positive Control - HCA	AOO	Mean	15	19056	5.67																							
Trimellitic anhydride	AOO	7-1	0.10	5681	1.69	8-1	0.25	13902	4.14	9-1	0.50	14361	4.27															
Trimellitic anhydride	AOO	7-2	0.10	7841	2.33	8-2	0.25	11270	3.35	9-2	0.50	18976	5.64															
Trimellitic anhydride	AOO	7-3	0.10	11293	3.36	8-3	0.25	10963	3.26	9-3	0.50	16673	4.96															
Trimellitic anhydride	AOO	Mean	0.10	8272	2.46	Mean	0.25	12045	3.58	Mean	0.50	16670	4.96														0.17	0.07
Phthalic anhydride	AOO	10-1	0.10	11304	3.36	11-1	0.25	8332	2.48	12-1	0.50	22051	6.56	13-1	1.0	19987	5.95											
Phthalic anhydride	AOO	10-2	0.10	13066	3.89	11-2	0.25	15717	4.68	12-2	0.50	12828	3.82	13-2	1.0	32118	9.55											
Phthalic anhydride	AOO	10-3	0.10	12448	3.70	11-3	0.25	9833	2.93	12-3	0.50	24315	7.23	13-3	1.0	17006	5.09											
Phthalic anhydride	AOO	Mean	0.10	12272	3.65	Mean	0.25	11294	3.36	Mean	0.50	19731	5.87	Mean	1.0	23037	6.85										0.08	0.04
Vehicle Control 1	DMSO	1-1	0	13832	1.36																							
Vehicle Control 1	DMSO	1-2	0	9930	0.97																							
Vehicle Control 1	DMSO	1-3	0	9958	0.98																							
Vehicle Control 1	DMSO	1-4	0	7097	0.70																							
Vehicle Control 1	DMSO	Mean	0	10204	1.00																							
Positive Control 1 - HCA	DMSO	2-1	15	17741	1.74																							
Positive Control 1 - HCA	DMSO	2-2	15	18810	1.84																							
Positive Control 1 - HCA	DMSO	2-3	15	18045	1.77																							
Positive Control 1 - HCA	DMSO	2-4	15	12293	1.21																							
Positive Control 1 - HCA	DMSO	Mean	15	16722	1.64	Failed PC																						
Lactic acid	DMSO	3-1	5	6741	0.66	4-1	10	11054	1.08	5-1	25	7025	0.69	6-1	50	8623	0.85											
Lactic acid	DMSO	3-2	5	12789	1.25	4-2	10	11929	1.17	5-2	25	13796	1.35	6-2	50	10101	0.99											
Lactic acid	DMSO	3-3	5	12217	1.12	4-3	10	9542	0.94	5-3	25	8677	0.85	6-3	50	11594	1.14											
Lactic acid	DMSO	Mean	5	10582	1.04	Mean	10	10841	1.06	Mean	25	9832	0.96	Mean	50	10106	0.99										NA	NA

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵	
Vehicle Control 2	AOO	7-1	0	5263	1.07																							
Vehicle Control 2	AOO	7-2	0	4970	1.01																							
Vehicle Control 2	AOO	7-3	0	5431	1.11																							
Vehicle Control 2	AOO	7-4	0	3965	0.81																							
Vehicle Control 2	AOO	Mean	0	4907	1.00																							
Positive Control 2 - HCA	AOO	8-1	15	25796	5.26																							
Positive Control 2 - HCA	AOO	8-2	15	24279	4.95																							
Positive Control 2 - HCA	AOO	8-3	15	13979	2.85																							
Positive Control 2 - HCA	AOO	8-4	15	23991	4.89																							
Positive Control 2 - HCA	AOO	Mean	15	22011	4.49																							
Resorcinol	AOO	9-1	5	12461	2.54	10-1	10	25798	5.26	11-1	25	20760	4.23															
Resorcinol	AOO	9-2	5	11743	2.39	10-2	10	16771	3.42	11-2	25	21215	4.32															
Resorcinol	AOO	9-3	5	12095	2.47	10-3	10	21121	4.30	11-3	25	9659	1.97															
Resorcinol	AOO	Mean	5	12099	2.47	Mean	10	21230	4.33	Mean	25	17211	3.51													6.44	4.20	
Vehicle Control	ACE	1-1	0	3937	1.45																							
Vehicle Control	ACE	1-2	0	2374	0.88																							
Vehicle Control	ACE	1-3	0	2360	0.87																							
Vehicle Control	ACE	1-4	0	2173	0.80																							
Vehicle Control	ACE	Mean	0	2711	1.00																							
Positive Control - HCA	ACE	2-1	15	21117	7.79																							
Positive Control - HCA	ACE	2-2	15	19843	7.32																							
Positive Control - HCA	ACE	2-3	15	12203	4.50																							
Positive Control - HCA	ACE	2-4	15	13734	5.07																							

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵
Positive Control - HCA	ACE	Mean	15	16724	6.17																						
Formaldehyde	ACE	3-1	0.10	5222	1.93	4-1	0.25	6167	2.28	5-1	0.50	2317	0.86	6-1	1.0	7846	2.90	7-1	2.5	17242	6.36						
Formaldehyde	ACE	3-2	0.10	3045	1.12	4-2	0.25	2933	1.08	5-2	0.50	4479	1.65	6-2	1.0	10628	3.92	7-2	2.5	14355	5.30						
Formaldehyde	ACE	3-3	0.10	2923	1.08	4-3	0.25	5093	1.88	5-3	0.50	5263	1.94	6-3	1.0	3894	1.44	7-3	2.5	9904	3.65						
Formaldehyde	ACE	Mean	0.10	3730	1.38	Mean	0.25	4731	1.75	Mean	0.50	4019	1.48	Mean	1.0	7456	2.75	Mean	2.5	13833	5.10					1.16	0.44
Vehicle Control	DMSO	1-1	0	82453	1.27																						
Vehicle Control	DMSO	1-2	0	78192	1.21																						
Vehicle Control	DMSO	1-3	0	42838	0.66																						
Vehicle Control	DMSO	1-4	0	56114	0.87																						
Vehicle Control	DMSO	Mean	0	64899	1.00																						
Positive Control	NT	NT	NT	NT	NT																						
Positive Control	NT	NT	NT	NT	NT																						
Positive Control	NT	NT	NT	NT	NT																						
Positive Control	NT	NT	NT	NT	NT																						
Positive Control	NT	Mean	NT	NT	NT	No PC																					
Potassium dichromate	DMSO	4-1	0.1	193231	2.98	5-1	0.3	209189	3.22	6-1	1.0	286418	4.41														
Potassium dichromate	DMSO	4-2	0.1	140171	2.16	5-2	0.3	274466	4.23	6-2	1.0	304081	4.69														
Potassium dichromate	DMSO	4-3	0.1	186039	2.87	5-3	0.3	421230	6.49	6-3	1.0	440493	6.79														
Potassium dichromate	DMSO	4-4	0.1	152378	2.35	5-4	0.3	253302	3.90	6-4	1.0	394755	6.08														
Potassium dichromate	DMSO	Mean	0.1	167954	2.59	Mean	0.3	289546	4.46	Mean	1.0	356437	5.49													0.14	0.07
Vehicle Control	AOO	1-1	0	4172	1.44																						
Vehicle Control	AOO	1-2	0	3078	1.06																						
Vehicle Control	AOO	1-3	0	2136	0.74																						
Vehicle Control	AOO	1-4	0	2192	0.76																						
Vehicle Control	AOO	Mean	0	2894	1.00																						
Positive Control - HCA	AOO	2-1	15	10569	3.65																						

Substance ²	Veh.	An. #	1 Conc. (%)	1 Mean ATP ³	1 SI	An. #	2 Conc. (%)	2 Mean ATP ³	2 SI	An. #	3 Conc. (%)	3 Mean ATP ³	3 SI	An. #	4 Conc. (%)	4 Mean ATP ³	4 SI	An. #	5 Conc. (%)	5 Mean ATP ³	5 SI	An. #	6 Conc. (%)	6 Mean ATP ³	6 SI	Calc. EC3 ⁴	Calc. EC2 ⁵
Positive Control - HCA	AOO	2-2	15	11027	3.81																						
Positive Control - HCA	AOO	2-3	15	12928	4.47																						
Positive Control - HCA	AOO	2-4	15	12520	4.33																						
Positive Control - HCA	AOO	Mean	15	11761	4.06																						
p-Phenylene-diamine	AOO	3-1	0.10	8259	2.85	4-1	0.25	12197	4.21	5-1	0.50	16392	5.66	6-1	1.0	10644	3.68										
p-Phenylene-diamine	AOO	3-2	0.10	11194	3.87	4-2	0.25	15785	5.45	5-2	0.50	9781	3.38	6-2	1.0	10669	3.69										
p-Phenylene-diamine	AOO	3-3	0.10	11454	3.96	4-3	0.25	16610	5.74	5-3	0.50	10173	3.52	6-3	1.0	5942	2.05										
p-Phenylene-diamine	AOO	Mean	0.10	10302	3.56	Mean	0.25	14864	5.14	Mean	0.50	12115	4.19	Mean	1.0	9085	3.14									0.07	0.04

Abbreviations: ACE = acetone; An. # = animal number; AOO = acetone: olive oil (4:1); ATP = adenosine triphosphate; Calc. = calculated; conc. = Concentration; DMF = N,N-dimethylformamide; DMSO = dimethyl sulfoxide; HCA = hexyl cinnamic aldehyde; NA = not applicable; No. = number; NT = not tested; PC = positive control; SI = stimulation Index; Veh = vehicle.

¹Original laboratory records with individual animal data for the 31 substances tested in the LLNA: DA intralaboratory validation study (Idehara et al. 2008) provided by Kenji Idehara, Ph.D., Daicel Chemical Industries, Ltd.

²The 31 substances in the intralaboratory validation study were evaluated during one of 18 LLNA: DA tests that were conducted between July 2003 through September 2007 and are listed in order based on the date that they were tested.

³Two ATP measurements were taken for each animal and the mean ATP is indicated.

⁴EC3 value was calculated based on interpolation or extrapolation formulas discussed in Gerberick et al. 2004.

⁵EC2 value was calculated based on modified interpolation or extrapolation formulas for EC3 discussed in Gerberick et al. 2004.

73
74
75
76
77
78
79
80
81
82
83
84
85
86

[This Page Intentionally Left Blank]

87

88

89

90

91

92

93

94

95

96

97

Appendix D2

98

Summary Data for 14 Additional Substances Tested in the

99

LLNA: DA (Intralaboratory)

100

101

101
102
103
104
105
106
107
108
109
110
111
112
113
114
115

[This Page Intentionally Left Blank]

116 **Appendix D2** **Summary of the Results for 14 Additional Substances Tested in the LLNA: DA (Intralaboratory)**

Substance Name	Vehicle	Concentration (%)	SI ¹	Calculated EC3 ² (%)	Calculated EC2 ³ (%)
5-Chloro-2-methyl-4-isothiazolin-3-one (CMI)	DMF	0.005	1.2	0.03	0.01
		0.010	1.9		
		0.025	2.7		
		0.050	4.0		
		0.100	7.5		
p-Benzoquinone	AOO	0.005	2.6	0.06	0.003
		0.010	2.6		
		0.025	2.5		
		0.050	2.7		
		0.100	3.8		
Propyl gallate	AOO	0.5	2.8	1.09	0.28
		1.0	2.9		
		2.5	4.9		
Phenyl benzoate	AOO	1.0	2.2	2.26	0.80
		2.5	3.2		
		5.0	4.2		
		10.0	3.7		
Diethyl maleate	AOO	0.5	1.9	3.71	1.18

Substance Name	Vehicle	Concentration (%)	SI ¹	Calculated EC3 ² (%)	Calculated EC2 ³ (%)
		1.0	1.9		
		2.5	2.7		
		5.0	3.3		
		10.0	3.8		
Ethyl acrylate	AOO	10	2.5	13.94	7.54
		25	4.3		
		50	3.4		
Cinnamic alcohol	AOO	10	2.4	21.34	6.54
		25	3.2		
		50	5.7		
		90	4.4		
Ethylene glycol dimethacrylate	MEK	10	1.2	34.03	22.27
		25	2.2		
		50	4.4		
Butyl glycidyl ether	AOO	10	1.2	31.68	19.92
		25	2.4		
		50	4.6		
Nickel (II) chloride	DMSO	2.5	0.9	NA	NA

Substance Name	Vehicle	Concentration (%)	SI ¹	Calculated EC3 ² (%)	Calculated EC2 ³ (%)
		5.0	1.1		
		10.0	1.3		
Salicylic acid	AOO	5	1.5	NA	25.00
		10	1.6		
		25	2.0		
Sulfanilamide	DMF	10	0.8	NA	NA
		25	0.9		
		50	0.6		
Methyl methacrylate	AOO	25	1.0	NA	NA
		50	1.2		
		75	1.3		
		100	1.8		
Dimethyl isophthalate ⁴	AOO	5	0.9	NA	NA
		10	0.9		
		25	0.8		

117 Abbreviations: AOO = acetone: olive oil (4:1); DMF = *N,N*-dimethylformamide; DMSO = dimethyl sulfoxide; EC3 = estimated concentration needed to produce
 118 a stimulation index of three; MEK = methyl ethyl ketone; NA = not applicable; RLU = relative luminescence units; SI = stimulation index.

119 ¹SI determined from mean ATP content (RLU).

120 ²EC3 value was calculated based on interpolation or extrapolation formulas discussed in Gerberick et al. 2004.

121 ³EC2 value was calculated based on modified interpolation or extrapolation formulas for EC3 discussed in Gerberick et al. 2004

122 ⁴This substance was also tested in the first phase of the interlaboratory validation study (Omori et al. 2008).

123
124
125
126
127
128
129
130
131
132
133
134
135
136

[This Page Intentionally Left Blank]

137

138

139

140

141

142

143

144

145

146

147

148

149

Appendix D3

150

Individual Animal Data for the LLNA: DA (Interlaboratory)

151

152

152
153
154
155
156
157
158
159
160
161
162
163
164
165
166

[This Page Intentionally Left Blank]

Appendix D3 Individual Animal Data for the LLNA: DA Two-Phase Interlaboratory Validation Study

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Vehicle - Positive Control	1		1	0	27373	1.09									
Vehicle - Positive Control	1		2	0	23473	0.93									
Vehicle - Positive Control	1		3	0	30778	1.22									
Vehicle - Positive Control	1		4	0	19231	0.76									
Vehicle - Positive Control	1		MEAN	0	25214	1.00									
Positive Control	1		1	NA	163662	6.49									
Positive Control	1		2	NA	118724	4.71									
Positive Control	1		3	NA	120098	4.76									
Positive Control	1		4	NA	172911	6.86									
Positive Control	1		MEAN	NA	143849	5.71									
Vehicle - Substance	1	AOO	1	0	30365	1.24									
Vehicle - Substance	1	AOO	2	0	26124	1.06									
Vehicle - Substance	1	AOO	3	0	25218	1.03									
Vehicle - Substance	1	AOO	4	0	16624	0.68									
Vehicle - Substance	1	AOO	MEAN	0	24583	1.00									
Hexyl cinnamic aldehyde	1	AOO	1	5	39462	1.61	10	94155	3.83	25	174255	7.09			
Hexyl cinnamic aldehyde	1	AOO	2	5	29952	1.22	10	60720	2.47	25	140034	5.70			
Hexyl cinnamic aldehyde	1	AOO	3	5	37759	1.54	10	70595	2.87	25	103168	4.20			
Hexyl cinnamic aldehyde	1	AOO	4	5	25613	1.04	10	70068	2.85	25	151064	6.15			
Hexyl cinnamic aldehyde	1	AOO	MEAN	5	33196	1.35	10	73884	3.01	25	142130	5.78	9.98	8.47	6.96
Isopropanol	1	AOO	1	10	49049	2.00	25	28917	1.18	50	32979	1.34			
Isopropanol	1	AOO	2	10	46692	1.90	25	28183	1.15	50	28219	1.15			
Isopropanol	1	AOO	3	10	22501	0.92	25	28099	1.14	50	28788	1.17			
Isopropanol	1	AOO	4	10	32783	1.33	25	23206	0.94	50	24907	1.01			
Isopropanol	1	AOO	MEAN	10	37756	1.54	25	27101	1.10	50	28723	1.17	NA	NA	NA
Vehicle - Positive Control	1		1	0	27603	1.19									
Vehicle - Positive Control	1		2	0	29165	1.26									
Vehicle - Positive Control	1		3	0	13867	0.60									
Vehicle - Positive Control	1		4	0	21857	0.95									
Vehicle - Positive Control	1		MEAN	0	23123	1.00									
Positive Control	1		1	NA	187061	8.09									
Positive Control	1		2	NA	192723	8.33									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵	
Positive Control	1		3	NA	152209	6.58										
Positive Control	1		4	NA	120141	5.20										
Positive Control	1		MEAN	NA	163033	7.05										
Vehicle - Substance	1	ACE	1	0	23522	1.31										
Vehicle - Substance	1	ACE	2	0	17328	0.97										
Vehicle - Substance	1	ACE	3	0	19286	1.07										
Vehicle - Substance	1	ACE	4	0	11653	0.65										
Vehicle - Substance	1	ACE	MEAN	0	17947	1.00										
Glutaraldehyde	1	ACE	1	0.05	39029	2.17	0.15	86407	4.81	0.50	117767	6.56				
Glutaraldehyde	1	ACE	2	0.05	21473	1.20	0.15	69645	3.88	0.50	91139	5.08				
Glutaraldehyde	1	ACE	3	0.05	17442	0.97	0.15	44897	2.50	0.50	85284	4.75				
Glutaraldehyde	1	ACE	4	0.05	24434	1.36	0.15	90044	5.02	0.50	64878	3.62				
Glutaraldehyde	1	ACE	MEAN	0.05	25594	1.43	0.15	72748	4.05	0.50	89767	5.00	0.11	0.09	0.07	
Formaldehyde	1	ACE	1	0.5	54229	3.02	1.5	65799	3.67	5.0	92516	5.16				
Formaldehyde	1	ACE	2	0.5	65863	3.67	1.5	35118	1.96	5.0	131184	7.31				
Formaldehyde	1	ACE	3	0.5	49268	2.75	1.5	48274	2.69	5.0	52728	2.94				
Formaldehyde	1	ACE	4	0.5	39499	2.20	1.5	56430	3.14	5.0	71309	3.97				
Formaldehyde	1	ACE	MEAN	0.5	52214	2.91	1.5	51405	2.86	5.0	86934	4.84	1.75	0.39	0.26	
Vehicle - Positive Control	1		1	0	25568	1.13										
Vehicle - Positive Control	1		2	0	30989	1.37										
Vehicle - Positive Control	1		3	0	15244	0.68										
Vehicle - Positive Control	1		4	0	18525	0.82										
Vehicle - Positive Control	1		MEAN	0	22582	1.00										
Positive Control	1		1	NA	160326	7.10										
Positive Control	1		2	NA	97979	4.34										
Positive Control	1		3	NA	126572	5.61										
Positive Control	1		4	NA	151977	6.73										
Positive Control	1		MEAN	NA	134213	5.94										
Vehicle - Substance	1	AOO	1	0	36866	1.36										
Vehicle - Substance	1	AOO	2	0	33905	1.25										
Vehicle - Substance	1	AOO	3	0	15218	0.56										
Vehicle - Substance	1	AOO	4	0	22764	0.84										
Vehicle - Substance	1	AOO	MEAN	0	27188	1.00										

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
2,4-Dinitrochlorobenzene	1	AOO	1	0.03	108431	3.99	0.10	185139	6.81	0.30	334363	12.30			
2,4-Dinitrochlorobenzene	1	AOO	2	0.03	83821	3.08	0.10	159188	5.86	0.30	258002	9.49			
2,4-Dinitrochlorobenzene	1	AOO	3	0.03	68037	2.50	0.10	133437	4.91	0.30	366438	13.48			
2,4-Dinitrochlorobenzene	1	AOO	4	0.03	48931	1.80	0.10	110880	4.08	0.30	343140	12.62			
2,4-Dinitrochlorobenzene	1	AOO	MEAN	0.03	77305	2.84	0.10	147161	5.41	0.30	325485	11.97	0.03	0.03	0.02
Dimethyl isophthalate	1	AOO	1	5	41322	1.52	10	46499	1.71	25	39741	1.46			
Dimethyl isophthalate	1	AOO	2	5	32753	1.20	10	27887	1.03	25	21245	0.78			
Dimethyl isophthalate	1	AOO	3	5	24319	0.89	10	29565	1.09	25	38401	1.41			
Dimethyl isophthalate	1	AOO	4	5	47742	1.76	10	20851	0.77	25	20734	0.76			
Dimethyl isophthalate	1	AOO	MEAN	5	36534	1.34	10	31200	1.15	25	30030	1.10	NA	NA	NA
3-Aminophenol	1	AOO	1	1	48998	1.80	3	65491	2.41	10	93723	3.45			
3-Aminophenol	1	AOO	2	1	50122	1.84	3	55831	2.05	10	57142	2.10			
3-Aminophenol	1	AOO	3	1	47237	1.74	3	55478	2.04	10	82054	3.02			
3-Aminophenol	1	AOO	4	1	44007	1.62	3	75285	2.77	10	74792	2.75			
3-Aminophenol	1	AOO	MEAN	1	47591	1.75	3	63021	2.32	10	76927	2.83	NA	5.49	1.88
Vehicle - Positive Control	2		1	0	29854	0.94									
Vehicle - Positive Control	2		2	0	36425	1.15									
Vehicle - Positive Control	2		3	0	42387	1.34									
Vehicle - Positive Control	2		4	0	18060	0.57									
Vehicle - Positive Control	2		MEAN	0	31681	1.00									
Positive Control	2		1	NA	194745	6.15									
Positive Control	2		2	NA	196510	6.20									
Positive Control	2		3	NA	202311	6.39									
Positive Control	2		4	NA	171703	5.42									
Positive Control	2		MEAN	P	191317	6.04									
Vehicle - Substance	2	AOO	1	0	26727	0.65									
Vehicle - Substance	2	AOO	2	0	62370	1.51									
Vehicle - Substance	2	AOO	3	0	48632	1.18									
Vehicle - Substance	2	AOO	4	0	27029	0.66									
Vehicle - Substance	2	AOO	MEAN	0	41189	1.00									
Hexyl cinnamic aldehyde	2	AOO	1	5	49355	1.20	10	129128	3.13	25	259210	6.29			
Hexyl cinnamic aldehyde	2	AOO	2	5	57775	1.40	10	98419	2.39	25	185538	4.50			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Hexyl cinnamic aldehyde	2	AOO	3	5	62556	1.52	10	96062	2.33	25	176096	4.28			
Hexyl cinnamic aldehyde	2	AOO	4	5	55479	1.35	10	113209	2.75	25	173235	4.21			
Hexyl cinnamic aldehyde	2	AOO	MEAN	5	56291	1.37	10	109204	2.65	25	198520	4.82	12.41	9.41	7.46
Isopropanol	2	AOO	1	10	48933	1.19	25	40741	0.99	50	31132	0.76			
Isopropanol	2	AOO	2	10	26716	0.65	25	33529	0.81	50	44432	1.08			
Isopropanol	2	AOO	3	10	38147	0.93	25	36625	0.89	50	30372	0.74			
Isopropanol	2	AOO	4	10	35351	0.86	25	29201	0.71	50	27101	0.66			
Isopropanol	2	AOO	MEAN	10	37286	0.91	25	35024	0.85	50	33259	0.81	NA	NA	NA
Vehicle - Positive Control	2		1	0	16450	0.51									
Vehicle - Positive Control	2		2	0	56211	1.74									
Vehicle - Positive Control	2		3	0	29690	0.92									
Vehicle - Positive Control	2		4	0	26911	0.83									
Vehicle - Positive Control	2		MEAN	0	32315	1.00									
Positive Control	2		1	NA	100365	3.11									
Positive Control	2		2	NA	144864	4.48									
Positive Control	2		3	NA	121515	3.76									
Positive Control	2		4	NA	131149	4.06									
Positive Control	2		MEAN	NA	124473	3.85									
Vehicle - Substance	2	AOO	1	0	26982	1.03									
Vehicle - Substance	2	AOO	2	0	26503	1.01									
Vehicle - Substance	2	AOO	3	0	23078	0.88									
Vehicle - Substance	2	AOO	4	0	28074	1.07									
Vehicle - Substance	2	AOO	MEAN	0	26159	1.00									
2,4-Dinitrochlorobenzene	2	AOO	1	0.03	46482	1.78	0.10	54947	2.10	0.30	154655	5.91			
2,4-Dinitrochlorobenzene	2	AOO	2	0.03	45109	1.72	0.10	79087	3.02	0.30	244903	9.36			
2,4-Dinitrochlorobenzene	2	AOO	3	0.03	64419	2.46	0.10	103400	3.95	0.30	231793	8.86			
2,4-Dinitrochlorobenzene	2	AOO	4	0.03	87361	3.34	0.10	44369	1.70	0.30	334511	12.79			
2,4-Dinitrochlorobenzene	2	AOO	MEAN	0.03	60843	2.33	0.10	70451	2.69	0.30	241465	9.23	0.11	0.06	0.02
Abietic acid	2	AOO	1	5	53429	2.04	10	76437	2.92	25	109226	4.18			
Abietic acid	2	AOO	2	5	44953	1.72	10	106616	4.08	25	165358	6.32			
Abietic acid	2	AOO	3	5	55417	2.12	10	106351	4.07	25	78960	3.02			
Abietic acid	2	AOO	4	5	66359	2.54	10	77421	2.96	25	131863	5.04			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Abietic acid	2	AOO	MEAN	5	55039	2.10	10	91706	3.51	25	121351	4.64	8.20	6.41	4.76
Vehicle - Positive Control	2		1	0	15977	0.59									
Vehicle - Positive Control	2		2	0	29941	1.11									
Vehicle - Positive Control	2		3	0	25288	0.94									
Vehicle - Positive Control	2		4	0	36217	1.35									
Vehicle - Positive Control	2		MEAN	0	26856	1.00									
Positive Control	2		1	NA	105933	3.94									
Positive Control	2		2	NA	170707	6.36									
Positive Control	2		3	NA	134656	5.01									
Positive Control	2		4	NA	173488	6.46									
Positive Control	2		MEAN	NA	146196	5.44									
Vehicle - Substance	2	ACE	1	0	56525	1.49									
Vehicle - Substance	2	ACE	2	0	38645	1.02									
Vehicle - Substance	2	ACE	3	0	28667	0.75									
Vehicle - Substance	2	ACE	4	0	28339	0.74									
Vehicle - Substance	2	ACE	MEAN	0	38044	1.00									
Glutaraldehyde	2	ACE	1	0.05	34115	0.90	0.15	50405	1.32	0.50	172747	4.54			
Glutaraldehyde	2	ACE	2	0.05	37388	0.98	0.15	36212	0.95	0.50	104608	2.75			
Glutaraldehyde	2	ACE	3	0.05	17955	0.47	0.15	54707	1.44	0.50	105731	2.78			
Glutaraldehyde	2	ACE	4	0.05	22926	0.60	0.15	54598	1.44	0.50	133355	3.51			
Glutaraldehyde	2	ACE	MEAN	0.05	28096	0.74	0.15	48980	1.29	0.50	129110	3.39	0.44	0.35	0.27
Formaldehyde	2	ACE	1	0.5	71257	1.87	1.5	120557	3.17	5.0	148089	3.89			
Formaldehyde	2	ACE	2	0.5	61368	1.61	1.5	110027	2.89	5.0	111959	2.94			
Formaldehyde	2	ACE	3	0.5	74954	1.97	1.5	139716	3.67	5.0	97241	2.56			
Formaldehyde	2	ACE	4	0.5	50290	1.32	1.5	90274	2.37	5.0	126577	3.33			
Formaldehyde	2	ACE	MEAN	0.5	64467	1.69	1.5	115143	3.03	5.0	120966	3.18	1.48	1.11	0.73
Vehicle - Positive Control	3		1	0	14012	0.68									
Vehicle - Positive Control	3		2	0	25742	1.25									
Vehicle - Positive Control	3		3	0	18482	0.90									
Vehicle - Positive Control	3		4	0	24206	1.17									
Vehicle - Positive Control	3		MEAN	0	20610	1.00									
Positive Control	3		1	NA	147051	7.13									
Positive Control	3		2	NA	129657	6.29									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Positive Control	3		3	NA	119376	5.79									
Positive Control	3		4	NA	132756	6.44									
Positive Control	3		MEAN	NA	132210	6.41									
Vehicle - Substance	3	AOO	1	0	22801	0.95									
Vehicle - Substance	3	AOO	2	0	28208	1.17									
Vehicle - Substance	3	AOO	3	0	19180	0.80									
Vehicle - Substance	3	AOO	4	0	26000	1.08									
Vehicle - Substance	3	AOO	MEAN	0	24047	1.00									
Methyl salicylate	3	AOO	1	5	22109	0.92	10	35176	1.46	25	53142	2.21			
Methyl salicylate	3	AOO	2	5	22812	0.95	10	22115	0.92	25	31027	1.29			
Methyl salicylate	3	AOO	3	5	21410	0.89	10	21251	0.88	25	31120	1.29			
Methyl salicylate	3	AOO	4	5	36725	1.53	10	26904	1.12	25	34146	1.42			
Methyl salicylate	3	AOO	MEAN	5	25764	1.07	10	26361	1.10	25	37359	1.55	NA	NA	NA
3-Aminophenol	3	AOO	1	1	40069	1.67	3	51109	2.13	10	39746	1.65			
3-Aminophenol	3	AOO	2	1	31036	1.29	3	34706	1.44	10	38143	1.59			
3-Aminophenol	3	AOO	3	1	28933	1.20	3	53201	2.21	10	35330	1.47			
3-Aminophenol	3	AOO	4	1	35464	1.47	3	30394	1.26	10	53816	2.24			
3-Aminophenol	3	AOO	MEAN	1	33875	1.41	3	42352	1.76	10	41759	1.74	NA	NA	NA
Vehicle - Positive Control	3		1	0	32037	1.14									
Vehicle - Positive Control	3		2	0	27673	0.98									
Vehicle - Positive Control	3		3	0	25512	0.91									
Vehicle - Positive Control	3		4	0	27174	0.97									
Vehicle - Positive Control	3		MEAN	0	28099	1.00									
Positive Control	3		1	NA	133836	4.76									
Positive Control	3		2	NA	122152	4.35									
Positive Control	3		3	NA	164019	5.84									
Positive Control	3		4	NA	133810	4.76									
Positive Control	3		MEAN	NA	138454	4.93									
Vehicle - Substance	3	AOO	1	0	52047	1.46									
Vehicle - Substance	3	AOO	2	0	31377	0.88									
Vehicle - Substance	3	AOO	3	0	36296	1.02									
Vehicle - Substance	3	AOO	4	0	22887	0.64									
Vehicle - Substance	3	AOO	MEAN	0	35652	1.00									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Hexyl cinnamic aldehyde	3	AOO	1	5	38213	1.07	10	69749	1.96	25	124915	3.50			
Hexyl cinnamic aldehyde	3	AOO	2	5	35942	1.01	10	85956	2.41	25	168780	4.73			
Hexyl cinnamic aldehyde	3	AOO	3	5	68561	1.92	10	97018	2.72	25	188378	5.28			
Hexyl cinnamic aldehyde	3	AOO	4	5	50818	1.43	10	75438	2.12	25	151145	4.24			
Hexyl cinnamic aldehyde	3	AOO	MEAN	5	48383	1.36	10	82040	2.30	25	158304	4.44	14.90	11.39	8.40
Isopropanol	3	AOO	1	10	32440	0.91	25	30325	0.85	50	29038	0.81			
Isopropanol	3	AOO	2	10	45395	1.27	25	27645	0.78	50	28736	0.81			
Isopropanol	3	AOO	3	10	38482	1.08	25	23613	0.66	50	37489	1.05			
Isopropanol	3	AOO	4	10	28304	0.79	25	12277	0.34	50	28026	0.79			
Isopropanol	3	AOO	MEAN	10	36155	1.01	25	23465	0.66	50	30822	0.86	NA	NA	NA
Vehicle - Positive Control	3		1	0	19428	0.70									
Vehicle - Positive Control	3		2	0	34843	1.26									
Vehicle - Positive Control	3		3	0	30475	1.11									
Vehicle - Positive Control	3		4	0	25568	0.93									
Vehicle - Positive Control	3		MEAN	0	27578	1.00									
Positive Control	3		1	NA	152890	5.54									
Positive Control	3		2	NA	150397	5.45									
Positive Control	3		3	NA	179030	6.49									
Positive Control	3		4	NA	164124	5.95									
Positive Control	3		MEAN	NA	161610	5.86									
Vehicle - Substance	3	AOO	1	0	27832	0.78									
Vehicle - Substance	3	AOO	2	0	43858	1.23									
Vehicle - Substance	3	AOO	3	0	39077	1.10									
Vehicle - Substance	3	AOO	4	0	31673	0.89									
Vehicle - Substance	3	AOO	MEAN	0	35610	1.00									
2,4-Dinitrochlorobenzene	3	AOO	1	0.03	78157	2.19	0.10	121518	3.41	0.30	333041	9.35			
2,4-Dinitrochlorobenzene	3	AOO	2	0.03	124013	3.48	0.10	178885	5.02	0.30	332166	9.33			
2,4-Dinitrochlorobenzene	3	AOO	3	0.03	79811	2.24	0.10	152199	4.27	0.30	364546	10.24			
2,4-Dinitrochlorobenzene	3	AOO	4	0.03	40213	1.13	0.10	149717	4.20	0.30	388959	10.92			
2,4-Dinitrochlorobenzene	3	AOO	MEAN	0.03	80548	2.26	0.10	150579	4.23	0.30	354678	9.96	0.06	0.04	0.03
Dimethyl isophthalate	3	AOO	1	5	31045	0.87	10	42990	1.21	25	21801	0.61			
Dimethyl isophthalate	3	AOO	2	5	35735	1.00	10	26663	0.75	25	20892	0.59			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Dimethyl isophthalate	3	AOO	3	5	28933	0.81	10	27736	0.78	25	29220	0.82			
Dimethyl isophthalate	3	AOO	4	5	47129	1.32	10	40039	1.12	25	23687	0.67			
Dimethyl isophthalate	3	AOO	MEAN	5	35710	1.00	10	34357	0.96	25	23900	0.67	NA	NA	NA
Vehicle - Positive Control	4		1	0	48083	1.06									
Vehicle - Positive Control	4		2	0	39428	0.87									
Vehicle - Positive Control	4		3	0	55411	1.22									
Vehicle - Positive Control	4		4	0	38284	0.85									
Vehicle - Positive Control	4		MEAN	0	45301	1.00									
Positive Control	4		1	NA	211896	4.68									
Positive Control	4		2	NA	262733	5.80									
Positive Control	4		3	NA	242739	5.36									
Positive Control	4		4	NA	275773	6.09									
Positive Control	4		MEAN	NA	248285	5.48									
Vehicle - Substance	4	DMSO	1	0	132462	1.32									
Vehicle - Substance	4	DMSO	2	0	79967	0.80									
Vehicle - Substance	4	DMSO	3	0	82192	0.82									
Vehicle - Substance	4	DMSO	4	0	106964	1.07									
Vehicle - Substance	4	DMSO	MEAN	0	100396	1.00									
Cobalt chloride	4	DMSO	1	0.3	175468	1.75	1.0	272071	2.71	NA	NA	NA			
Cobalt chloride	4	DMSO	2	0.3	192922	1.92	1.0	206730	2.06	NA	NA	NA			
Cobalt chloride	4	DMSO	3	0.3	230415	2.30	1.0	333152	3.32	NA	NA	NA			
Cobalt chloride	4	DMSO	4	0.3	216774	2.16	1.0	256734	2.56	NA	NA	NA			
Cobalt chloride	4	DMSO	MEAN	0.3	203895	2.03	1.0	267172	2.66	NA	NA	NA	NA	0.82	0.28
Nickel (II) sulfate hexahydrate	4	DMSO	1	1	136287	1.36	3	152054	1.51	10	129555	1.29			
Nickel (II) sulfate hexahydrate	4	DMSO	2	1	84335	0.84	3	166405	1.66	10	89825	0.89			
Nickel (II) sulfate hexahydrate	4	DMSO	3	1	125617	1.25	3	188337	1.88	10	85180	0.85			
Nickel (II) sulfate hexahydrate	4	DMSO	4	1	118828	1.18	3	105499	1.05	10	109822	1.09			
Nickel (II) sulfate hexahydrate	4	DMSO	MEAN	1	116266	1.16	3	153074	1.52	10	103595	1.03	NA	NA	NA

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Vehicle - Positive Control	4		1	0	42028	0.90									
Vehicle - Positive Control	4		2	0	49964	1.07									
Vehicle - Positive Control	4		3	0	44351	0.95									
Vehicle - Positive Control	4		4	0	50162	1.08									
Vehicle - Positive Control	4		MEAN	0	46626	1.00									
Positive Control	4		1	NA	266538	5.72									
Positive Control	4		2	NA	297022	6.37									
Positive Control	4		3	NA	208438	4.47									
Positive Control	4		4	NA	238300	5.11									
Positive Control	4		MEAN	NA	252574	5.42									
Vehicle - Substance	4	AOO	1	0	38814	0.90									
Vehicle - Substance	4	AOO	2	0	40081	0.93									
Vehicle - Substance	4	AOO	3	0	36876	0.86									
Vehicle - Substance	4	AOO	4	0	56256	1.31									
Vehicle - Substance	4	AOO	MEAN	0	43007	1.00									
Hexyl cinnamic aldehyde	4	AOO	1	5	66346	1.54	10	92375	2.15	25	183245	4.26			
Hexyl cinnamic aldehyde	4	AOO	2	5	63590	1.48	10	128592	2.99	25	237260	5.52			
Hexyl cinnamic aldehyde	4	AOO	3	5	71486	1.66	10	121376	2.82	25	208440	4.85			
Hexyl cinnamic aldehyde	4	AOO	4	5	55427	1.29	10	213148	4.96	25	249803	5.81			
Hexyl cinnamic aldehyde	4	AOO	MEAN	5	64212	1.49	10	138873	3.23	25	219687	5.11	9.34	7.90	6.46
Isopropanol	4	AOO	1	10	62566	1.45	25	29136	0.68	50	33511	0.78			
Isopropanol	4	AOO	2	10	86226	2.00	25	45518	1.06	50	41282	0.96			
Isopropanol	4	AOO	3	10	63529	1.48	25	42708	0.99	50	36712	0.85			
Isopropanol	4	AOO	4	10	56908	1.32	25	38074	0.89	50	26023	0.61			
Isopropanol	4	AOO	MEAN	10	67307	1.57	25	38859	0.90	50	34382	0.80	NA	NA	NA
Vehicle - Positive Control	4		1	0	61301	1.49									
Vehicle - Positive Control	4		2	0	42018	1.02									
Vehicle - Positive Control	4		3	0	31933	0.78									
Vehicle - Positive Control	4		4	0	29486	0.72									
Vehicle - Positive Control	4		MEAN	0	41184	1.00									
Positive Control	4		1	NA	188993	4.59									
Positive Control	4		2	NA	168896	4.10									
Positive Control	4		3	NA	258012	6.26									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵	
Positive Control	4		4	NA	307187	7.46										
Positive Control	4		MEAN	NA	230772	5.60										
Vehicle - Substance	4	AOO	1	0	55245	1.29										
Vehicle - Substance	4	AOO	2	0	32859	0.77										
Vehicle - Substance	4	AOO	3	0	37143	0.87										
Vehicle - Substance	4	AOO	4	0	46219	1.08										
Vehicle - Substance	4	AOO	MEAN	0	42866	1.00										
Isoeugenol	4	AOO	1	1	117220	2.73	3	167018	3.90	10	278270	6.49				
Isoeugenol	4	AOO	2	1	159050	3.71	3	172577	4.03	10	266047	6.21				
Isoeugenol	4	AOO	3	1	114887	2.68	3	190296	4.44	10	212878	4.97				
Isoeugenol	4	AOO	4	1	112197	2.62	3	171216	3.99	10	291279	6.80				
Isoeugenol	4	AOO	MEAN	1	125838	2.94	3	175277	4.09	10	262118	6.11	1.11	0.66	0.41	
2,4-Dinitrochlorobenzene	4	AOO	1	0.03	99433	2.32	0.10	239929	5.60	0.30	351048	8.19				
2,4-Dinitrochlorobenzene	4	AOO	2	0.03	124385	2.90	0.10	248752	5.80	0.30	304028	7.09				
2,4-Dinitrochlorobenzene	4	AOO	3	0.03	156964	3.66	0.10	226511	5.28	0.30	426667	9.95				
2,4-Dinitrochlorobenzene	4	AOO	4	0.03	131177	3.06	0.10	125633	2.93	0.30	381330	8.90				
2,4-Dinitrochlorobenzene	4	AOO	MEAN	0.03	127990	2.99	0.10	210206	4.90	0.30	365768	8.53	0.03	0.02	0.02	
Vehicle - Positive Control	5		1	0	7783	0.65										
Vehicle - Positive Control	5		2	0	7273	0.61										
Vehicle - Positive Control	5		3	0	22835	1.92										
Vehicle - Positive Control	5		4	0	9704	0.82										
Vehicle - Positive Control	5		MEAN	0	11899	1.00										
Positive Control	5		1	NA	60519	5.09										
Positive Control	5		2	NA	57983	4.87										
Positive Control	5		3	NA	48159	4.05										
Positive Control	5		4	NA	72951	6.13										
Positive Control	5		MEAN	NA	59903	5.03										
Vehicle - Substance	5	AOO	1	0	31442	1.49										
Vehicle - Substance	5	AOO	2	0	12103	0.57										
Vehicle - Substance	5	AOO	3	0	20941	0.99										
Vehicle - Substance	5	AOO	4	0	20115	0.95										
Vehicle - Substance	5	AOO	MEAN	0	21150	1.00										

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
2,4-Dinitrochlorobenzene	5	AOO	1	0.03	19491	0.92	0.10	40351	1.91	0.30	199476	9.43			
2,4-Dinitrochlorobenzene	5	AOO	2	0.03	14102	0.67	0.10	76157	3.60	0.30	109134	5.16			
2,4-Dinitrochlorobenzene	5	AOO	3	0.03	17254	0.82	0.10	39813	1.88	0.30	155961	7.37			
2,4-Dinitrochlorobenzene	5	AOO	4	0.03	21584	1.02	0.10	26445	1.25	0.30	200326	9.47			
2,4-Dinitrochlorobenzene	5	AOO	MEAN	0.03	18107	0.86	0.10	45691	2.16	0.30	166224	7.86	0.13	0.11	0.09
Isoeugenol	5	AOO	1	1	20321	0.96	3	12620	0.60	10	123238	5.83			
Isoeugenol	5	AOO	2	1	19512	0.92	3	28001	1.32	10	110582	5.23			
Isoeugenol	5	AOO	3	1	33957	1.61	3	20937	0.99	10	118049	5.58			
Isoeugenol	5	AOO	4	1	17792	0.84	3	32921	1.56	10	116524	5.51			
Isoeugenol	5	AOO	MEAN	1	22896	1.08	3	23619	1.12	10	117098	5.54	5.98	5.19	4.40
Vehicle - Positive Control	5		1	0	22681	1.23									
Vehicle - Positive Control	5		2	0	15429	0.84									
Vehicle - Positive Control	5		3	0	20405	1.11									
Vehicle - Positive Control	5		4	0	15143	0.82									
Vehicle - Positive Control	5		MEAN	0	18414	1.00									
Positive Control	5		1	NA	97304	5.28									
Positive Control	5		2	NA	83132	4.51									
Positive Control	5		3	NA	67441	3.66									
Positive Control	5		4	NA	117794	6.40									
Positive Control	5		MEAN	NA	91418	4.96									
Vehicle - Substance	5	AOO	1	0	16435	0.86									
Vehicle - Substance	5	AOO	2	0	22909	1.20									
Vehicle - Substance	5	AOO	3	0	25965	1.36									
Vehicle - Substance	5	AOO	4	0	11275	0.59									
Vehicle - Substance	5	AOO	MEAN	0	19146	1.00									
Hexyl cinnamic aldehyde	5	AOO	1	5	17037	0.89	10	32966	1.72	25	73109	3.82			
Hexyl cinnamic aldehyde	5	AOO	2	5	30640	1.60	10	38027	1.99	25	83266	4.35			
Hexyl cinnamic aldehyde	5	AOO	3	5	26481	1.38	10	17968	0.94	25	77637	4.05			
Hexyl cinnamic aldehyde	5	AOO	4	5	19509	1.02	10	52769	2.76	25	70103	3.66			
Hexyl cinnamic aldehyde	5	AOO	MEAN	5	23417	1.22	10	35432	1.85	25	76029	3.97	18.13	14.59	11.06
Isopropanol	5	AOO	1	10	9967	0.52	25	15066	0.79	50	18749	0.98			
Isopropanol	5	AOO	2	10	5679	0.30	25	15418	0.81	50	13502	0.71			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Isopropanol	5	AOO	3	10	12157	0.63	25	12221	0.64	50	10223	0.53			
Isopropanol	5	AOO	4	10	12621	0.66	25	15418	0.81	50	11851	0.62			
Isopropanol	5	AOO	MEAN	10	10106	0.53	25	14531	0.76	50	13581	0.71	NA	NA	NA
Vehicle - Positive Control	5		1	0	15918	1.04									
Vehicle - Positive Control	5		2	0	13724	0.90									
Vehicle - Positive Control	5		3	0	10819	0.71									
Vehicle - Positive Control	5		4	0	20489	1.34									
Vehicle - Positive Control	5		MEAN	0	15237	1.00									
Positive Control	5		1	NA	67799	4.45									
Positive Control	5		2	NA	56834	3.73									
Positive Control	5		3	NA	60000	3.94									
Positive Control	5		4	NA	84607	5.55									
Positive Control	5		MEAN	NA	67310	4.42									
Vehicle - Substance	5	ACE	1	0	8265	0.50									
Vehicle - Substance	5	ACE	2	0	23012	1.40									
Vehicle - Substance	5	ACE	3	0	14503	0.88									
Vehicle - Substance	5	ACE	4	0	19975	1.22									
Vehicle - Substance	5	ACE	MEAN	0	16439	1.00									
Glutaraldehyde	5	ACE	1	0.05	23621	1.44	0.15	38622	2.35	0.50	34431	2.09			
Glutaraldehyde	5	ACE	2	0.05	11837	0.72	0.15	64431	3.92	0.50	42955	2.61			
Glutaraldehyde	5	ACE	3	0.05	14251	0.87	0.15	24666	1.50	0.50	42380	2.58			
Glutaraldehyde	5	ACE	4	0.05	18389	1.12	0.15	33558	2.04	0.50	49184	2.99			
Glutaraldehyde	5	ACE	MEAN	0.05	17024	1.04	0.15	40319	2.45	0.50	42237	2.57	NA	0.29	0.12
Formaldehyde	5	ACE	1	0.5	24898	1.51	1.5	36696	2.23	5.0	44219	2.69			
Formaldehyde	5	ACE	2	0.5	18454	1.12	1.5	29172	1.77	5.0	47739	2.90			
Formaldehyde	5	ACE	3	0.5	21972	1.34	1.5	43949	2.67	5.0	33377	2.03			
Formaldehyde	5	ACE	4	0.5	12719	0.77	1.5	14018	0.85	5.0	51542	3.14			
Formaldehyde	5	ACE	MEAN	0.5	19510	1.19	1.5	30959	1.88	5.0	44219	2.69	NA	4.18	2.02
Vehicle - Positive Control	6		1	0	16022	1.79									
Vehicle - Positive Control	6		2	0	9436	1.05									
Vehicle - Positive Control	6		3	0	3788	0.42									
Vehicle - Positive Control	6		4	0	6561	0.73									
Vehicle - Positive Control	6		MEAN	0	8952	1.00									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Positive Control	6		1	NA	80444	8.99									
Positive Control	6		2	NA	92491	10.33									
Positive Control	6		3	NA	73767	8.24									
Positive Control	6		4	NA	101082	11.29									
Positive Control	6		MEAN	NA	86946	9.71									
Vehicle - Substance	6	DMSO	1	0	7575	1.81									
Vehicle - Substance	6	DMSO	2	0	4135	0.99									
Vehicle - Substance	6	DMSO	3	0	2759	0.66									
Vehicle - Substance	6	DMSO	4	0	2267	0.54									
Vehicle - Substance	6	DMSO	MEAN	0	4184	1.00									
Nickel (II) sulfate hexahydrate	6	DMSO	1	1	30363	7.26	3	32830	7.85	10	46902	11.21			
Nickel (II) sulfate hexahydrate	6	DMSO	2	1	12902	3.08	3	28614	6.84	10	64448	15.40			
Nickel (II) sulfate hexahydrate	6	DMSO	3	1	22353	5.34	3	31319	7.49	10	56156	13.42			
Nickel (II) sulfate hexahydrate	6	DMSO	4	1	22343	5.34	3	19101	4.57	10	29707	7.10			
Nickel (II) sulfate hexahydrate	6	DMSO	MEAN	1	21990	5.26	3	27966	6.68	10	49303	11.78	0.47	0.35	0.24
Cobalt chloride	6	DMSO	1	0.3	88782	21.22	1.0	59079	14.12	3.0	108860	26.02			
Cobalt chloride	6	DMSO	2	0.3	40452	9.67	1.0	24246	5.80	3.0	62637	14.97			
Cobalt chloride	6	DMSO	3	0.3	22788	5.45	1.0	69511	16.61	3.0	106164	25.38			
Cobalt chloride	6	DMSO	4	0.3	23988	5.73	1.0	25023	5.98	3.0	66252	15.84			
Cobalt chloride	6	DMSO	MEAN	0.3	44002	10.52	1.0	44465	10.63	3.0	85978	20.55	0.06	0.05	0.03
Vehicle - Positive Control	6		1	0	7997	0.75									
Vehicle - Positive Control	6		2	0	10763	1.01									
Vehicle - Positive Control	6		3	0	13602	1.27									
Vehicle - Positive Control	6		4	0	10360	0.97									
Vehicle - Positive Control	6		MEAN	0	10680	1.00									
Positive Control	6		1	NA	52468	4.91									
Positive Control	6		2	NA	66048	6.18									
Positive Control	6		3	NA	81979	7.68									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Positive Control	6		4	NA	76135	7.13									
Positive Control	6		MEAN	NA	69157	6.48									
Vehicle - Substance	6	AOO	1	0	8621	0.62									
Vehicle - Substance	6	AOO	2	0	14670	1.05									
Vehicle - Substance	6	AOO	3	0	18086	1.30									
Vehicle - Substance	6	AOO	4	0	14263	1.03									
Vehicle - Substance	6	AOO	MEAN	0	13910	1.00									
Abietic acid	6	AOO	1	5	38117	2.74	10	57039	4.10	25	98752	7.10			
Abietic acid	6	AOO	2	5	18850	1.36	10	73842	5.31	25	129426	9.30			
Abietic acid	6	AOO	3	5	25525	1.83	10	56561	4.07	25	139343	10.02			
Abietic acid	6	AOO	4	5	18617	1.34	10	43018	3.09	25	75268	5.41			
Abietic acid	6	AOO	MEAN	5	25277	1.82	10	57615	4.14	25	110697	7.96	7.54	6.47	5.39
2,4-Dinitrochlorobenzene	6	AOO	1	0.03	29344	2.11	0.10	32064	2.31	0.30	170451	12.25			
2,4-Dinitrochlorobenzene	6	AOO	2	0.03	53129	3.82	0.10	78273	5.63	0.30	258700	18.60			
2,4-Dinitrochlorobenzene	6	AOO	3	0.03	39348	2.83	0.10	66285	4.77	0.30	241703	17.38			
2,4-Dinitrochlorobenzene	6	AOO	4	0.03	31167	2.24	0.10	60587	4.36	0.30	171691	12.34			
2,4-Dinitrochlorobenzene	6	AOO	MEAN	0.03	38247	2.75	0.10	59302	4.26	0.30	210636	15.14	0.04	0.03	0.02
Vehicle - Positive Control	6		1	0	18240	1.56									
Vehicle - Positive Control	6		2	0	4174	0.36									
Vehicle - Positive Control	6		3	0	11817	1.01									
Vehicle - Positive Control	6		4	0	12605	1.08									
Vehicle - Positive Control	6		MEAN	0	11709	1.00									
Positive Control	6		1	NA	105716	9.03									
Positive Control	6		2	NA	92508	7.90									
Positive Control	6		3	NA	86410	7.38									
Positive Control	6		4	NA	107936	9.22									
Positive Control	6		MEAN	NA	98142	8.38									
Vehicle - Substance	6	AOO	1	0	13188	0.81									
Vehicle - Substance	6	AOO	2	0	16677	1.02									
Vehicle - Substance	6	AOO	3	0	13789	0.84									
Vehicle - Substance	6	AOO	4	0	21847	1.33									
Vehicle - Substance	6	AOO	MEAN	0	16375	1.00									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Hexyl cinnamic aldehyde	6	AOO	1	5	34939	2.13	10	50225	3.07	25	61340	3.75			
Hexyl cinnamic aldehyde	6	AOO	2	5	34548	2.11	10	38763	2.37	25	71280	4.35			
Hexyl cinnamic aldehyde	6	AOO	3	5	18582	1.13	10	26933	1.64	25	110980	6.78			
Hexyl cinnamic aldehyde	6	AOO	4	5	21408	1.31	10	37387	2.28	25	116668	7.12			
Hexyl cinnamic aldehyde	6	AOO	MEAN	5	27369	1.67	10	38327	2.34	25	90067	5.50	13.13	10.76	7.46
Isopropanol	6	AOO	1	10	71570	4.37	25	14610	0.89	50	16623	1.02			
Isopropanol	6	AOO	2	10	20763	1.27	25	19836	1.21	50	19168	1.17			
Isopropanol	6	AOO	3	10	19846	1.21	25	17188	1.05	50	28176	1.72			
Isopropanol	6	AOO	4	10	16753	1.02	25	7416	0.45	50	21474	1.31			
Isopropanol	6	AOO	MEAN	10	32233	1.97	25	14762	0.90	50	21360	1.30	NA	NA	NA
Vehicle - Positive Control	7		1	0	10954	0.47									
Vehicle - Positive Control	7		2	0	14547	0.62									
Vehicle - Positive Control	7		3	0	33870	1.44									
Vehicle - Positive Control	7		4	0	34460	1.47									
Vehicle - Positive Control	7		MEAN	0	23458	1.00									
Positive Control	7		1	NA	93512	3.99									
Positive Control	7		2	NA	104433	4.45									
Positive Control	7		3	NA	114003	4.86									
Positive Control	7		4	NA	180482	7.69									
Positive Control	7		MEAN	NA	123107	5.25									
Vehicle - Substance	7	AOO	1	0	15339	0.71									
Vehicle - Substance	7	AOO	2	0	11627	0.54									
Vehicle - Substance	7	AOO	3	0	17793	0.83									
Vehicle - Substance	7	AOO	4	0	41425	1.92									
Vehicle - Substance	7	AOO	MEAN	0	21546	1.00									
Methyl salicylate	7	AOO	1	5	26796	1.24	10	30066	1.40	25	14218	0.66			
Methyl salicylate	7	AOO	2	5	23023	1.07	10	45494	2.11	25	31612	1.47			
Methyl salicylate	7	AOO	3	5	12934	0.60	10	41639	1.93	25	31551	1.46			
Methyl salicylate	7	AOO	4	5	31083	1.44	10	35433	1.64	25	42145	1.96			
Methyl salicylate	7	AOO	MEAN	5	23459	1.09	10	38158	1.77	25	29881	1.39	NA	NA	NA
Abietic acid	7	AOO	1	5	28706	1.33	10	50807	2.36	25	45895	2.13			
Abietic acid	7	AOO	2	5	46411	2.15	10	92597	4.30	25	102739	4.77			
Abietic acid	7	AOO	3	5	46541	2.16	10	105497	4.90	25	87409	4.06			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Abietic acid	7	AOO	4	5	39654	1.84	10	94381	4.38	25	91230	4.23			
Abietic acid	7	AOO	MEAN	5	40328	1.87	10	85821	3.98	25	81818	3.80	7.68	11.53	6.33
Vehicle - Positive Control	7		1	0	17271	0.75									
Vehicle - Positive Control	7		2	0	23663	1.03									
Vehicle - Positive Control	7		3	0	24070	1.04									
Vehicle - Positive Control	7		4	0	27154	1.18									
Vehicle - Positive Control	7		MEAN	0	23039	1.00									
Positive Control	7		1	NA	127080	5.52									
Positive Control	7		2	NA	150247	6.52									
Positive Control	7		3	NA	122132	5.30									
Positive Control	7		4	NA	128311	5.57									
Positive Control	7		MEAN	NA	131942	5.73									
Vehicle - Substance	7	AOO	1	0	36823	1.23									
Vehicle - Substance	7	AOO	2	0	31245	1.04									
Vehicle - Substance	7	AOO	3	0	21937	0.73									
Vehicle - Substance	7	AOO	4	0	29694	0.99									
Vehicle - Substance	7	AOO	MEAN	0	29925	1.00									
Hexyl cinnamic aldehyde	7	AOO	1	5	42392	1.42	10	106569	3.56	25	170985	5.71			
Hexyl cinnamic aldehyde	7	AOO	2	5	33988	1.14	10	151880	5.08	25	193134	6.45			
Hexyl cinnamic aldehyde	7	AOO	3	5	66350	2.22	10	161431	5.39	25	198620	6.64			
Hexyl cinnamic aldehyde	7	AOO	4	5	41865	1.40	10	87141	2.91	25	286402	9.57			
Hexyl cinnamic aldehyde	7	AOO	MEAN	5	46148	1.54	10	126755	4.24	25	212285	7.09	7.71	6.78	5.85
Isopropanol	7	AOO	1	10	30442	1.02	25	15392	0.51	50	26039	0.87			
Isopropanol	7	AOO	2	10	32600	1.09	25	39028	1.30	50	25885	0.87			
Isopropanol	7	AOO	3	10	41239	1.38	25	22387	0.75	50	27685	0.93			
Isopropanol	7	AOO	4	10	69502	2.32	25	32333	1.08	50	19497	0.65			
Isopropanol	7	AOO	MEAN	10	43446	1.45	25	27285	0.91	50	24776	0.83	NA	NA	NA
Vehicle - Positive Control	7		1	0	20353	0.71									
Vehicle - Positive Control	7		2	0	31709	1.10									
Vehicle - Positive Control	7		3	0	34254	1.19									
Vehicle - Positive Control	7		4	0	29038	1.01									
Vehicle - Positive Control	7		MEAN	0	28838	1.00									
Positive Control	7		1	NA	170163	5.90									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Positive Control	7		2	NA	142824	4.95									
Positive Control	7		3	NA	167113	5.79									
Positive Control	7		4	NA	135621	4.70									
Positive Control	7		MEAN	NA	153930	5.34									
Vehicle - Substance	7	AOO	1	0	25299	1.13									
Vehicle - Substance	7	AOO	2	0	25685	1.14									
Vehicle - Substance	7	AOO	3	0	19870	0.88									
Vehicle - Substance	7	AOO	4	0	19010	0.85									
Vehicle - Substance	7	AOO	MEAN	0	22466	1.00									
Dimethyl isophthalate	7	AOO	1	5	30872	1.37	10	28765	1.28	25	24457	1.09			
Dimethyl isophthalate	7	AOO	2	5	23829	1.06	10	27567	1.23	25	25583	1.14			
Dimethyl isophthalate	7	AOO	3	5	26046	1.16	10	22517	1.00	25	18065	0.80			
Dimethyl isophthalate	7	AOO	4	5	32477	1.45	10	23373	1.04	25	26228	1.17			
Dimethyl isophthalate	7	AOO	MEAN	5	28306	1.26	10	25555	1.14	25	23583	1.05	NA	NA	NA
2,4-Dinitrochlorobenzene	7	AOO	1	0.03	54379	2.42	0.10	142045	6.32	0.30	282805	12.59			
2,4-Dinitrochlorobenzene	7	AOO	2	0.03	95575	4.25	0.10	139187	6.20	0.30	336813	14.99			
2,4-Dinitrochlorobenzene	7	AOO	3	0.03	95094	4.23	0.10	108882	4.85	0.30	258764	11.52			
2,4-Dinitrochlorobenzene	7	AOO	4	0.03	99284	4.42	0.10	93969	4.18	0.30	305713	13.61			
2,4-Dinitrochlorobenzene	7	AOO	MEAN	0.03	86083	3.83	0.10	121021	5.39	0.30	296024	13.18	0.02	0.01	0.01
Vehicle - Positive Control	8		1	0	18303	0.95									
Vehicle - Positive Control	8		2	0	25980	1.34									
Vehicle - Positive Control	8		3	0	17493	0.90									
Vehicle - Positive Control	8		4	0	15606	0.81									
Vehicle - Positive Control	8		MEAN	0	19345	1.00									
Positive Control	8		1	NA	98761	5.11									
Positive Control	8		2	NA	72937	3.77									
Positive Control	8		3	NA	86236	4.46									
Positive Control	8		4	NA	76278	3.94									
Positive Control	8		MEAN	NA	83553	4.32									
Vehicle - Substance	8	AOO	1	0	9463	0.78									
Vehicle - Substance	8	AOO	2	0	13874	1.14									
Vehicle - Substance	8	AOO	3	0	17229	1.41									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Vehicle - Substance	8	AOO	4	0	8262	0.68									
Vehicle - Substance	8	AOO	MEAN	0	12207	1.00									
Isopropanol	8	AOO	1	10	12562	1.03	25	17249	1.41	50	14510	1.19			
Isopropanol	8	AOO	2	10	17330	1.42	25	9264	0.76	50	14113	1.16			
Isopropanol	8	AOO	3	10	11886	0.97	25	11845	0.97	50	12238	1.00			
Isopropanol	8	AOO	4	10	17410	1.43	25	11193	0.92	50	13342	1.09			
Isopropanol	8	AOO	MEAN	10	14797	1.21	25	12387	1.01	50	13551	1.11	NA	NA	NA
Hexyl cinnamic aldehyde	8	AOO	1	5	16997	1.39	10	40975	3.36	25	155208	12.71			
Hexyl cinnamic aldehyde	8	AOO	2	5	15777	1.29	10	56754	4.65	25	133055	10.90			
Hexyl cinnamic aldehyde	8	AOO	3	5	22473	1.84	10	58346	4.78	25	75582	6.19			
Hexyl cinnamic aldehyde	8	AOO	4	5	11217	0.92	10	47242	3.87	25	135369	11.09			
Hexyl cinnamic aldehyde	8	AOO	MEAN	5	16616	1.36	10	50829	4.16	25	124803	10.22	7.92	7.03	6.14
Vehicle - Positive Control	8		1	0	11818	0.62									
Vehicle - Positive Control	8		2	0	22893	1.19									
Vehicle - Positive Control	8		3	0	21441	1.12									
Vehicle - Positive Control	8		4	0	20608	1.07									
Vehicle - Positive Control	8		MEAN	0	19190	1.00									
Positive Control	8		1	NA	117067	6.10									
Positive Control	8		2	NA	100222	5.22									
Positive Control	8		3	NA	91462	4.77									
Positive Control	8		4	NA	80907	4.22									
Positive Control	8		MEAN	NA	97414	5.08									
Vehicle - Substance	8	DMSO	1	0	15322	0.77									
Vehicle - Substance	8	DMSO	2	0	24630	1.24									
Vehicle - Substance	8	DMSO	3	0	16802	0.85									
Vehicle - Substance	8	DMSO	4	0	22460	1.13									
Vehicle - Substance	8	DMSO	MEAN	0	19803	1.00									
Nickel (II) sulfate hexahydrate	8	DMSO	1	1	64139	3.24	3	64301	3.25	10	40447	2.04			
Nickel (II) sulfate hexahydrate	8	DMSO	2	1	59705	3.01	3	70343	3.55	10	45033	2.27			
Nickel (II) sulfate hexahydrate	8	DMSO	3	1	61654	3.11	3	55459	2.80	10	62589	3.16			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Nickel (II) sulfate hexahydrate	8	DMSO	4	1	90810	4.59	3	53420	2.70	10	54206	2.74			
Nickel (II) sulfate hexahydrate	8	DMSO	MEAN	1	69077	3.49	3	60881	3.07	10	50568	2.55	IDR	IDR	IDR
Cobalt chloride	8	DMSO	1	0.3	68800	3.47	1.0	123857	6.25	3.0	175242	8.85			
Cobalt chloride	8	DMSO	2	0.3	98124	4.95	1.0	178916	9.03	3.0	143477	7.25			
Cobalt chloride	8	DMSO	3	0.3	95925	4.84	1.0	96477	4.87	3.0	155827	7.87			
Cobalt chloride	8	DMSO	4	0.3	87399	4.41	1.0	124765	6.30	3.0	164687	8.32			
Cobalt chloride	8	DMSO	MEAN	0.3	87562	4.42	1.0	131004	6.62	3.0	159808	8.07	0.14	0.10	0.08
Vehicle - Positive Control	8		1	0	17139	1.02									
Vehicle - Positive Control	8		2	0	23311	1.39									
Vehicle - Positive Control	8		3	0	14001	0.84									
Vehicle - Positive Control	8		4	0	12548	0.75									
Vehicle - Positive Control	8		MEAN	0	16749	1.00									
Positive Control	8		1	NA	133873	7.99									
Positive Control	8		2	NA	147108	8.78									
Positive Control	8		3	NA	114171	6.82									
Positive Control	8		4	NA	97568	5.83									
Positive Control	8		MEAN	NA	123180	7.35									
Vehicle - Substance	8	AOO	1	0	18744	0.91									
Vehicle - Substance	8	AOO	2	0	20074	0.98									
Vehicle - Substance	8	AOO	3	0	15187	0.74									
Vehicle - Substance	8	AOO	4	0	28298	1.38									
Vehicle - Substance	8	AOO	MEAN	0	20576	1.00									
2,4-Dinitrochlorobenzene	8	AOO	1	0.03	40777	1.98	0.10	41930	2.04	0.30	228871	11.12			
2,4-Dinitrochlorobenzene	8	AOO	2	0.03	45024	2.19	0.10	50135	2.44	0.30	393845	19.14			
2,4-Dinitrochlorobenzene	8	AOO	3	0.03	30526	1.48	0.10	107465	5.22	0.30	273309	13.28			
2,4-Dinitrochlorobenzene	8	AOO	4	0.03	82593	4.01	0.10	50754	2.47	0.30	140789	6.84			
2,4-Dinitrochlorobenzene	8	AOO	MEAN	0.03	49730	2.42	0.10	62571	3.04	0.30	259203	12.60	0.10	0.04	0.01
3-Aminophenol	8	AOO	1	1	25653	1.25	3	51618	2.51	10	57296	2.78			
3-Aminophenol	8	AOO	2	1	27127	1.32	3	47941	2.33	10	52938	2.57			
3-Aminophenol	8	AOO	3	1	28861	1.40	3	36281	1.76	10	38134	1.85			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
3-Aminophenol	8	AOO	4	1	19026	0.92	3	27846	1.35	10	47782	2.32			
3-Aminophenol	8	AOO	MEAN	1	25167	1.22	3	40921	1.99	10	49037	2.38	NA	NA	3.18
Vehicle - Positive Control	9		1	0	25729	0.98									
Vehicle - Positive Control	9		2	0	31786	1.22									
Vehicle - Positive Control	9		3	0	24343	0.93									
Vehicle - Positive Control	9		4	0	22785	0.87									
Vehicle - Positive Control	9		MEAN	0	26161	1.00									
Positive Control	9		1	NA	155962	5.96									
Positive Control	9		2	NA	112682	4.31									
Positive Control	9		3	NA	124334	4.75									
Positive Control	9		4	NA	122066	4.67									
Positive Control	9		MEAN	NA	128761	4.92									
Vehicle - Substance	9	AOO	1	0	21600	0.73									
Vehicle - Substance	9	AOO	2	0	38136	1.29									
Vehicle - Substance	9	AOO	3	0	34690	1.17									
Vehicle - Substance	9	AOO	4	0	23981	0.81									
Vehicle - Substance	9	AOO	MEAN	0	29602	1.00									
Hexyl cinnamic aldehyde	9	AOO	1	5	35263	1.19	10	32104	1.08	25	109826	3.71			
Hexyl cinnamic aldehyde	9	AOO	2	5	34558	1.17	10	68901	2.33	25	114755	3.88			
Hexyl cinnamic aldehyde	9	AOO	3	5	20309	0.69	10	61583	2.08	25	101116	3.42			
Hexyl cinnamic aldehyde	9	AOO	4	5	12277	0.41	10	99972	3.38	25	133469	4.51			
Hexyl cinnamic aldehyde	9	AOO	MEAN	5	25602	0.86	10	65640	2.22	25	114791	3.88	17.07	12.55	9.19
Isopropanol	9	AOO	1	10	16071	0.54	25	18605	0.63	50	11350	0.38			
Isopropanol	9	AOO	2	10	29909	1.01	25	12916	0.44	50	14836	0.50			
Isopropanol	9	AOO	3	10	16721	0.56	25	26806	0.91	50	13840	0.47			
Isopropanol	9	AOO	4	10	12462	0.42	25	24183	0.82	50	20129	0.68			
Isopropanol	9	AOO	MEAN	10	18791	0.63	25	20627	0.70	50	15039	0.51	NA	NA	NA
Vehicle - Positive Control	9		1	0	21626	0.82									
Vehicle - Positive Control	9		2	0	28191	1.06									
Vehicle - Positive Control	9		3	0	36208	1.37									
Vehicle - Positive Control	9		4	0	19953	0.75									
Vehicle - Positive Control	9		MEAN	0	26494	1.00									
Positive Control	9		1	NA	152153	5.74									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Positive Control	9		2	NA	173639	6.55									
Positive Control	9		3	NA	117177	4.42									
Positive Control	9		4	NA	165097	6.23									
Positive Control	9		MEAN	NA	152016	5.74									
Vehicle - Substance	9	AOO	1	0	37188	1.39									
Vehicle - Substance	9	AOO	2	0	20177	0.75									
Vehicle - Substance	9	AOO	3	0	17473	0.65									
Vehicle - Substance	9	AOO	4	0	32530	1.21									
Vehicle - Substance	9	AOO	MEAN	0	26842	1.00									
Isoeugenol	9	AOO	1	1	43063	1.60	3	82412	3.07	10	241256	8.99			
Isoeugenol	9	AOO	2	1	92318	3.44	3	114677	4.27	10	169293	6.31			
Isoeugenol	9	AOO	3	1	73315	2.73	3	83819	3.12	10	153506	5.72			
Isoeugenol	9	AOO	4	1	68329	2.55	3	65486	2.44	10	197513	7.36			
Isoeugenol	9	AOO	MEAN	1	69256	2.58	3	86598	3.23	10	190392	7.09	2.30	0.87	0.38
2,4-Dinitrochlorobenzene	9	AOO	1	0.03	80731	3.01	0.10	81426	3.03	0.30	294486	10.97			
2,4-Dinitrochlorobenzene	9	AOO	2	0.03	46072	1.72	0.10	105837	3.94	0.30	287848	10.72			
2,4-Dinitrochlorobenzene	9	AOO	3	0.03	82472	3.07	0.10	164718	6.14	0.30	287739	10.72			
2,4-Dinitrochlorobenzene	9	AOO	4	0.03	91886	3.42	0.10	97148	3.62	0.30	298846	11.13			
2,4-Dinitrochlorobenzene	9	AOO	MEAN	0.03	75290	2.80	0.10	112282	4.18	0.30	292230	10.89	0.04	0.02	0.02
Vehicle - Positive Control	10		1	0	20162	0.95									
Vehicle - Positive Control	10		2	0	15285	0.72									
Vehicle - Positive Control	10		3	0	30517	1.43									
Vehicle - Positive Control	10		4	0	19166	0.90									
Vehicle - Positive Control	10		MEAN	0	21282	1.00									
Positive Control	10		1	NA	116157	5.46									
Positive Control	10		2	NA	142905	6.71									
Positive Control	10		3	NA	135316	6.36									
Positive Control	10		4	NA	117862	5.54									
Positive Control	10		MEAN	NA	128060	6.02									
Vehicle - Substance	10	AOO	1	0	45394	0.85									
Vehicle - Substance	10	AOO	2	0	67917	1.27									
Vehicle - Substance	10	AOO	3	0	36479	0.68									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Vehicle - Substance	10	AOO	4	0	63610	1.19									
Vehicle - Substance	10	AOO	MEAN	0	53350	1.00									
2,4-Dinitrochlorobenzene	10	AOO	1	0.03	52123	0.98	0.10	113324	2.12	0.30	202245	3.79			
2,4-Dinitrochlorobenzene	10	AOO	2	0.03	66363	1.24	0.10	80089	1.50	0.30	264292	4.95			
2,4-Dinitrochlorobenzene	10	AOO	3	0.03	36583	0.69	0.10	127648	2.39	0.30	298490	5.59			
2,4-Dinitrochlorobenzene	10	AOO	4	0.03	92933	1.74	0.10	127592	2.39	0.30	239662	4.49			
2,4-Dinitrochlorobenzene	10	AOO	MEAN	0.03	62000	1.16	0.10	112163	2.10	0.30	251172	4.71	0.17	0.13	0.09
Methyl salicylate	10	AOO	1	5	36446	0.68	10	47420	0.89	25	53941	1.01			
Methyl salicylate	10	AOO	2	5	34905	0.65	10	47616	0.89	25	54989	1.03			
Methyl salicylate	10	AOO	3	5	37286	0.70	10	40117	0.75	25	43082	0.81			
Methyl salicylate	10	AOO	4	5	26017	0.49	10	31641	0.59	25	25692	0.48			
Methyl salicylate	10	AOO	MEAN	5	33663	0.63	10	41698	0.78	25	44426	0.83	NA	NA	NA
Vehicle - Positive Control	10		1	0	20445	0.88									
Vehicle - Positive Control	10		2	0	15079	0.65									
Vehicle - Positive Control	10		3	0	26464	1.13									
Vehicle - Positive Control	10		4	0	31358	1.34									
Vehicle - Positive Control	10		MEAN	0	23336	1.00									
Positive Control	10		1	NA	89914	3.85									
Positive Control	10		2	NA	107768	4.62									
Positive Control	10		3	NA	93418	4.00									
Positive Control	10		4	NA	102331	4.39									
Positive Control	10		MEAN	NA	98357	4.21									
Vehicle - Substance	10	AOO	1	0	28181	0.97									
Vehicle - Substance	10	AOO	2	0	33325	1.15									
Vehicle - Substance	10	AOO	3	0	27821	0.96									
Vehicle - Substance	10	AOO	4	0	26981	0.93									
Vehicle - Substance	10	AOO	MEAN	0	29077	1.00									
Hexyl cinnamic aldehyde	10	AOO	1	5	35684	1.23	10	86735	2.98	25	78538	2.70			
Hexyl cinnamic aldehyde	10	AOO	2	5	30080	1.03	10	88833	3.06	25	107305	3.69			
Hexyl cinnamic aldehyde	10	AOO	3	5	62393	2.15	10	75607	2.60	25	129081	4.44			
Hexyl cinnamic aldehyde	10	AOO	4	5	34584	1.19	10	66109	2.27	25	93013	3.20			
Hexyl cinnamic aldehyde	10	AOO	MEAN	5	40685	1.40	10	79321	2.73	25	101984	3.51	15.24	9.14	7.26

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Isopropanol	10	AOO	1	10	19691	0.68	25	30241	1.04	50	42188	1.45			
Isopropanol	10	AOO	2	10	28293	0.97	25	24774	0.85	50	37228	1.28			
Isopropanol	10	AOO	3	10	29845	1.03	25	29230	1.01	50	35247	1.21			
Isopropanol	10	AOO	4	10	28091	0.97	25	38461	1.32	50	30201	1.04			
Isopropanol	10	AOO	MEAN	10	26480	0.91	25	30676	1.06	50	36216	1.25	NA	NA	NA
Vehicle - Positive Control	11		1	0	13452	0.45									
Vehicle - Positive Control	11		2	0	32469	1.09									
Vehicle - Positive Control	11		3	0	37235	1.25									
Vehicle - Positive Control	11		4	0	35940	1.21									
Vehicle - Positive Control	11		MEAN	0	29774	1.00									
Positive Control	11		1	NA	113708	3.82									
Positive Control	11		2	NA	108755	3.65									
Positive Control	11		3	NA	57560	1.93									
Positive Control	11		4	NA	97736	3.28									
Positive Control	11		MEAN	NA	94440	3.17									
Vehicle - Substance	11	AOO	1	0	16175	0.76									
Vehicle - Substance	11	AOO	2	0	31955	1.50									
Vehicle - Substance	11	AOO	3	0	24257	1.14									
Vehicle - Substance	11	AOO	4	0	12926	0.61									
Vehicle - Substance	11	AOO	MEAN	0	21328	1.00									
Hexyl cinnamic aldehyde	11	AOO	1	5	24541	1.15	10	73959	3.47	25	56324	2.64			
Hexyl cinnamic aldehyde	11	AOO	2	5	31920	1.50	10	73920	3.47	25	81323	3.81			
Hexyl cinnamic aldehyde	11	AOO	3	5	42454	1.99	10	74762	3.51	25	117271	5.50			
Hexyl cinnamic aldehyde	11	AOO	4	5	30308	1.42	10	60117	2.82	25	126476	5.93			
Hexyl cinnamic aldehyde	11	AOO	MEAN	5	32306	1.51	10	70689	3.31	25	95348	4.47	9.13	7.74	6.35
Vehicle - Positive Control	11		1	0	6855	0.32									
Vehicle - Positive Control	11		2	0	23315	1.10									
Vehicle - Positive Control	11		3	0	27767	1.30									
Vehicle - Positive Control	11		4	0	27187	1.28									
Vehicle - Positive Control	11		MEAN	0	21281	1.00									
Positive Control	11		1	NA	118741	5.58									
Positive Control	11		2	NA	114600	5.39									
Positive Control	11		3	NA	86525	4.07									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵	
Positive Control	11		4	NA	115969	5.45										
Positive Control	11		MEAN	NA	108959	5.12										
Vehicle - Substance	11	DMSO	1	0	67859	1.04										
Vehicle - Substance	11	DMSO	2	0	76567	1.18										
Vehicle - Substance	11	DMSO	3	0	60349	0.93										
Vehicle - Substance	11	DMSO	4	0	55465	0.85										
Vehicle - Substance	11	DMSO	MEAN	0	65060	1.00										
Potassium dichromate	11	DMSO	1	0.1	134992	2.07	0.3	194686	2.99	1.0	283541	4.36				
Potassium dichromate	11	DMSO	2	0.1	133187	2.05	0.3	104933	1.61	1.0	340279	5.23				
Potassium dichromate	11	DMSO	3	0.1	130433	2.00	0.3	166086	2.55	1.0	318543	4.90				
Potassium dichromate	11	DMSO	4	0.1	97134	1.49	0.3	117627	1.81	1.0	301673	4.64				
Potassium dichromate	11	DMSO	MEAN	0.1	123936	1.90	0.3	145833	2.24	1.0	311009	4.78	0.51	0.37	0.16	
Lactic acid	11	DMSO	1	5	34889	0.54	10	57810	0.89	25	73850	1.14				
Lactic acid	11	DMSO	2	5	70275	1.08	10	60103	0.92	25	38479	0.59				
Lactic acid	11	DMSO	3	5	81876	1.26	10	42148	0.65	25	54647	0.84				
Lactic acid	11	DMSO	4	5	55263	0.85	10	36073	0.55	25	41547	0.64				
Lactic acid	11	DMSO	MEAN	5	60576	0.93	10	49033	0.75	25	52131	0.80	NA	NA	NA	
Vehicle - Positive Control	11		1	0	25338	0.96										
Vehicle - Positive Control	11		2	0	29261	1.11										
Vehicle - Positive Control	11		3	0	21131	0.80										
Vehicle - Positive Control	11		4	0	29732	1.13										
Vehicle - Positive Control	11		MEAN	0	26365	1.00										
Positive Control	11		1	NA	136936	5.19										
Positive Control	11		2	NA	81100	3.08										
Positive Control	11		3	NA	114598	4.35										
Positive Control	11		4	NA	79191	3.00										
Positive Control	11		MEAN	NA	102956	3.90										
Vehicle - Substance	11	DMSO	1	0	86043	1.05										
Vehicle - Substance	11	DMSO	2	0	65589	0.80										
Vehicle - Substance	11	DMSO	3	0	117592	1.43										
Vehicle - Substance	11	DMSO	4	0	59151	0.72										
Vehicle - Substance	11	DMSO	MEAN	0	82093	1.00										
Cobalt chloride	11	DMSO	1	1	113621	1.38	3	123437	1.50	5	167985	2.05				

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Cobalt chloride	11	DMSO	2	1	130468	1.59	3	115859	1.41	5	167593	2.04			
Cobalt chloride	11	DMSO	3	1	97082	1.18	3	189281	2.31	5	174922	2.13			
Cobalt chloride	11	DMSO	4	1	147603	1.80	3	139101	1.69	5	150902	1.84			
Cobalt chloride	11	DMSO	MEAN	1	122193	1.49	3	141919	1.73	5	165350	2.01	NA	NA	4.93
Nickel (II) sulfate hexahydrate	11	DMSO	1	1	65339	0.80	3	89247	1.09	10	80662	0.98			
Nickel (II) sulfate hexahydrate	11	DMSO	2	1	51981	0.63	3	49391	0.60	10	49864	0.61			
Nickel (II) sulfate hexahydrate	11	DMSO	3	1	46829	0.57	3	83879	1.02	10	41820	0.51			
Nickel (II) sulfate hexahydrate	11	DMSO	4	1	50461	0.61	3	37620	0.46	10	69460	0.85			
Nickel (II) sulfate hexahydrate	11	DMSO	MEAN	1	53652	0.65	3	65034	0.79	10	60451	0.74	NA	NA	NA
Vehicle - Positive Control	12		1	0	31062	1.15									
Vehicle - Positive Control	12		2	0	34769	1.28									
Vehicle - Positive Control	12		3	0	19233	0.71									
Vehicle - Positive Control	12		4	0	23272	0.86									
Vehicle - Positive Control	12		MEAN	0	27084	1.00									
Positive Control	12		1	NA	32499	1.20									
Positive Control	12		2	NA	149284	5.51									
Positive Control	12		3	NA	138062	5.10									
Positive Control	12		4	NA	155617	5.75									
Positive Control	12		MEAN	NA	118865	4.39									
Vehicle - Substance	12	AOO	1	0	34707	1.27									
Vehicle - Substance	12	AOO	2	0	19823	0.72									
Vehicle - Substance	12	AOO	3	0	21963	0.80									
Vehicle - Substance	12	AOO	4	0	33252	1.21									
Vehicle - Substance	12	AOO	MEAN	0	27436	1.00									
Hexyl cinnamic aldehyde	12	AOO	1	5	45866	1.67	10	96208	3.51	25	146684	5.35			
Hexyl cinnamic aldehyde	12	AOO	2	5	32444	1.18	10	70432	2.57	25	176112	6.42			
Hexyl cinnamic aldehyde	12	AOO	3	5	52964	1.93	10	121167	4.42	25	135063	4.92			
Hexyl cinnamic aldehyde	12	AOO	4	5	49440	1.80	10	90169	3.29	25	168604	6.15			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Hexyl cinnamic aldehyde	12	AOO	MEAN	5	45178	1.65	10	94494	3.44	25	156615	5.71	8.76	7.37	5.98
Vehicle - Positive Control	12		1	0	26207	0.79									
Vehicle - Positive Control	12		2	0	39177	1.18									
Vehicle - Positive Control	12		3	0	37398	1.13									
Vehicle - Positive Control	12		4	0	30062	0.91									
Vehicle - Positive Control	12		MEAN	0	33211	1.00									
Positive Control	12		1	NA	151987	4.58									
Positive Control	12		2	NA	169589	5.11									
Positive Control	12		3	NA	209928	6.32									
Positive Control	12		4	NA	134469	4.05									
Positive Control	12		MEAN	NA	166493	5.01									
Vehicle - Substance	12	DMSO	1	0	78629	0.95									
Vehicle - Substance	12	DMSO	2	0	88765	1.07									
Vehicle - Substance	12	DMSO	3	0	76637	0.92									
Vehicle - Substance	12	DMSO	4	0	88155	1.06									
Vehicle - Substance	12	DMSO	MEAN	0	83046	1.00									
Nickel (II) sulfate hexahydrate	12	DMSO	1	1	98797	1.19	3	84327	1.02	10	105221	1.27			
Nickel (II) sulfate hexahydrate	12	DMSO	2	1	80665	0.97	3	86877	1.05	10	71971	0.87			
Nickel (II) sulfate hexahydrate	12	DMSO	3	1	86949	1.05	3	137747	1.66	10	55567	0.67			
Nickel (II) sulfate hexahydrate	12	DMSO	4	1	65175	0.78	3	104430	1.26	10	89624	1.08			
Nickel (II) sulfate hexahydrate	12	DMSO	MEAN	1	82896	1.00	3	103345	1.24	10	80596	0.97	NA	NA	NA
Potassium dichromate	12	DMSO	1	0.1	170554	2.05	0.3	198199	2.39	1.0	301077	3.63			
Potassium dichromate	12	DMSO	2	0.1	113710	1.37	0.3	205018	2.47	1.0	323900	3.90			
Potassium dichromate	12	DMSO	3	0.1	166200	2.00	0.3	273194	3.29	1.0	378405	4.56			
Potassium dichromate	12	DMSO	4	0.1	179394	2.16	0.3	191835	2.31	1.0	351057	4.23			
Potassium dichromate	12	DMSO	MEAN	0.1	157464	1.90	0.3	217061	2.61	1.0	338610	4.08	0.49	0.27	0.13
Vehicle - Positive Control	13		1	0	21808	0.80									
Vehicle - Positive Control	13		2	0	23919	0.87									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Vehicle - Positive Control	13		3	0	24606	0.90									
Vehicle - Positive Control	13		4	0	39312	1.43									
Vehicle - Positive Control	13		MEAN	0	27411	1.00									
Positive Control	13		1	NA	138513	5.05									
Positive Control	13		2	NA	94225	3.44									
Positive Control	13		3	NA	118316	4.32									
Positive Control	13		4	NA	161413	5.89									
Positive Control	13		MEAN	NA	128117	4.67									
Vehicle - Substance	13	AOO	1	0	33895	1.37									
Vehicle - Substance	13	AOO	2	0	20013	0.81									
Vehicle - Substance	13	AOO	3	0	20945	0.85									
Vehicle - Substance	13	AOO	4	0	24103	0.97									
Vehicle - Substance	13	AOO	MEAN	0	24739	1.00									
Hexyl cinnamic aldehyde	13	AOO	1	5	28705	1.16	10	106862	4.32	25	164960	6.67			
Hexyl cinnamic aldehyde	13	AOO	2	5	19630	0.79	10	92835	3.75	25	116945	4.73			
Hexyl cinnamic aldehyde	13	AOO	3	5	45958	1.86	10	83026	3.36	25	118296	4.78			
Hexyl cinnamic aldehyde	13	AOO	4	5	45943	1.86	10	159832	6.46	25	135132	5.46			
Hexyl cinnamic aldehyde	13	AOO	MEAN	5	35059	1.42	10	110638	4.47	25	133833	5.41	7.59	6.77	5.95
Vehicle - Positive Control	13		1	0	16810	0.75									
Vehicle - Positive Control	13		2	0	25921	1.15									
Vehicle - Positive Control	13		3	0	21544	0.96									
Vehicle - Positive Control	13		4	0	25627	1.14									
Vehicle - Positive Control	13		MEAN	0	22475	1.00									
Positive Control	13		1	NA	156378	6.96									
Positive Control	13		2	NA	133906	5.96									
Positive Control	13		3	NA	140685	6.26									
Positive Control	13		4	NA	152161	6.77									
Positive Control	13		MEAN	NA	145782	6.49									
Vehicle - Substance	13	DMSO	1	0	93878	1.15									
Vehicle - Substance	13	DMSO	2	0	70631	0.87									
Vehicle - Substance	13	DMSO	3	0	91822	1.13									
Vehicle - Substance	13	DMSO	4	0	68974	0.85									
Vehicle - Substance	13	DMSO	MEAN	0	81326	1.00									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Cobalt chloride	13	DMSO	1	1	120105	1.48	3	199869	2.46	5	192357	2.37			
Cobalt chloride	13	DMSO	2	1	148835	1.83	3	195046	2.40	5	215391	2.65			
Cobalt chloride	13	DMSO	3	1	93820	1.15	3	207281	2.55	5	224902	2.77			
Cobalt chloride	13	DMSO	4	1	172802	2.12	3	195145	2.40	5	192928	2.37			
Cobalt chloride	13	DMSO	MEAN	1	133890	1.65	3	199335	2.45	5	206394	2.54	NA	4.13	1.88
Lactic acid	13	DMSO	1	5	71011	0.87	10	58052	0.71	25	61451	0.76			
Lactic acid	13	DMSO	2	5	58742	0.72	10	44480	0.55	25	47962	0.59			
Lactic acid	13	DMSO	3	5	95883	1.18	10	56725	0.70	25	79235	0.97			
Lactic acid	13	DMSO	4	5	96922	1.19	10	62219	0.77	25	51848	0.64			
Lactic acid	13	DMSO	MEAN	5	80639	0.99	10	55369	0.68	25	60124	0.74	NA	NA	NA
Vehicle - Positive Control	14		1	0	25953	0.86									
Vehicle - Positive Control	14		2	0	42071	1.39									
Vehicle - Positive Control	14		3	0	22870	0.76									
Vehicle - Positive Control	14		4	0	30199	1.00									
Vehicle - Positive Control	14		MEAN	0	30273	1.00									
Positive Control	14		1	NA	198381	6.55									
Positive Control	14		2	NA	164826	5.44									
Positive Control	14		3	NA	205542	6.79									
Positive Control	14		4	NA	198361	6.55									
Positive Control	14		MEAN	NA	191777	6.33									
Vehicle - Substance	14	AOO	1	0	21623	0.89									
Vehicle - Substance	14	AOO	2	0	27737	1.14									
Vehicle - Substance	14	AOO	3	0	33618	1.38									
Vehicle - Substance	14	AOO	4	0	14415	0.59									
Vehicle - Substance	14	AOO	MEAN	0	24348	1.00									
Hexyl cinnamic aldehyde	14	AOO	1	5	45466	1.87	10	100580	4.13	25	164791	6.77			
Hexyl cinnamic aldehyde	14	AOO	2	5	40112	1.65	10	134453	5.52	25	155059	6.37			
Hexyl cinnamic aldehyde	14	AOO	3	5	72779	2.99	10	18994	0.78	25	249145	10.23			
Hexyl cinnamic aldehyde	14	AOO	4	5	43275	1.78	10	101713	4.18	25	171572	7.05			
Hexyl cinnamic aldehyde	14	AOO	MEAN	5	50408	2.07	10	88935	3.65	25	185142	7.60	7.94	6.36	4.85
Vehicle - Positive Control	14		1	0	18024	0.74									
Vehicle - Positive Control	14		2	0	24615	1.02									
Vehicle - Positive Control	14		3	0	28493	1.18									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Vehicle - Positive Control	14		4	0	25735	1.06									
Vehicle - Positive Control	14		MEAN	0	24216	1.00									
Positive Control	14		1	NA	116341	4.80									
Positive Control	14		2	NA	213773	8.83									
Positive Control	14		3	NA	182037	7.52									
Positive Control	14		4	NA	192821	7.96									
Positive Control	14		MEAN	NA	176243	7.28									
Vehicle - Substance	14	DMSO	1	0	33858	0.81									
Vehicle - Substance	14	DMSO	2	0	31373	0.75									
Vehicle - Substance	14	DMSO	3	0	60046	1.44									
Vehicle - Substance	14	DMSO	4	0	41804	1.00									
Vehicle - Substance	14	DMSO	MEAN	0	41770	1.00									
Cobalt chloride	14	DMSO	1	1	104955	2.51	3	193202	4.63	5	239096	5.72			
Cobalt chloride	14	DMSO	2	1	83477	2.00	3	147696	3.54	5	128719	3.08			
Cobalt chloride	14	DMSO	3	1	85107	2.04	3	165128	3.95	5	160037	3.83			
Cobalt chloride	14	DMSO	4	1	114867	2.75	3	179062	4.29	5	182970	4.38			
Cobalt chloride	14	DMSO	MEAN	1	97101	2.32	3	171272	4.10	5	177705	4.25	1.76	1.20	0.82
Nickel (II) sulfate hexahydrate	14	DMSO	1	1	104492	2.50	3	72152	1.73	10	71690	1.72			
Nickel (II) sulfate hexahydrate	14	DMSO	2	1	58854	1.41	3	48034	1.15	10	NA	NA			
Nickel (II) sulfate hexahydrate	14	DMSO	3	1	94853	2.27	3	68084	1.63	10	97605	2.34			
Nickel (II) sulfate hexahydrate	14	DMSO	4	1	53019	1.27	3	72530	1.74	10	97675	2.34			
Nickel (II) sulfate hexahydrate	14	DMSO	MEAN	1	77804	1.86	3	65200	1.56	10	88990	2.13	NA	NA	8.40
Vehicle - Positive Control	15		1	0	39487	1.12									
Vehicle - Positive Control	15		2	0	45663	1.30									
Vehicle - Positive Control	15		3	0	28492	0.81									
Vehicle - Positive Control	15		4	0	26819	0.76									
Vehicle - Positive Control	15		MEAN	0	35115	1.00									
Positive Control	15		1	NA	157090	4.47									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Positive Control	15		2	NA	164583	4.69									
Positive Control	15		3	NA	77120	2.20									
Positive Control	15		4	NA	157960	4.50									
Positive Control	15		MEAN	NA	139188	3.96									
Vehicle - Substance	15	AOO	1	0	26758	0.86									
Vehicle - Substance	15	AOO	2	0	46603	1.49									
Vehicle - Substance	15	AOO	3	0	23061	0.74									
Vehicle - Substance	15	AOO	4	0	28334	0.91									
Vehicle - Substance	15	AOO	MEAN	0	31189	1.00									
Hexyl cinnamic aldehyde	15	AOO	1	5	38890	1.25	10	71984	2.31	25	124344	3.99			
Hexyl cinnamic aldehyde	15	AOO	2	5	55784	1.79	10	66130	2.12	25	85306	2.74			
Hexyl cinnamic aldehyde	15	AOO	3	5	43619	1.40	10	84295	2.70	25	142287	4.56			
Hexyl cinnamic aldehyde	15	AOO	4	5	49120	1.57	10	91478	2.93	25	136649	4.38			
Hexyl cinnamic aldehyde	15	AOO	MEAN	5	46853	1.50	10	78471	2.52	25	122146	3.92	15.18	9.92	7.45
Vehicle - Positive Control	15		1	0	43807	1.36									
Vehicle - Positive Control	15		2	0	26515	0.82									
Vehicle - Positive Control	15		3	0	29210	0.90									
Vehicle - Positive Control	15		4	0	29709	0.92									
Vehicle - Positive Control	15		MEAN	0	32310	1.00									
Positive Control	15		1	NA	118146	3.66									
Positive Control	15		2	NA	172004	5.32									
Positive Control	15		3	NA	135989	4.21									
Positive Control	15		4	NA	163682	5.07									
Positive Control	15		MEAN	NA	147455	4.56									
Vehicle - Substance	15	DMSO	1	0	35762	0.72									
Vehicle - Substance	15	DMSO	2	0	32858	0.67									
Vehicle - Substance	15	DMSO	3	0	49385	1.00									
Vehicle - Substance	15	DMSO	4	0	79406	1.61									
Vehicle - Substance	15	DMSO	MEAN	0	49353	1.00									
Lactic acid	15	DMSO	1	5	35838	0.73	10	40908	0.83	25	31906	0.65			
Lactic acid	15	DMSO	2	5	46572	0.94	10	44335	0.90	25	37990	0.77			
Lactic acid	15	DMSO	3	5	43793	0.89	10	70146	1.42	25	33696	0.68			
Lactic acid	15	DMSO	4	5	56717	1.15	10	36323	0.74	25	37444	0.76			

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Lactic acid	15	DMSO	MEAN	5	45730	0.93	10	47928	0.97	25	35259	0.71	NA	NA	NA
Potassium dichromate	15	DMSO	1	0.1	121714	2.47	0.3	215997	4.38	1.0	360162	7.30			
Potassium dichromate	15	DMSO	2	0.1	177882	3.60	0.3	210129	4.26	1.0	191584	3.88			
Potassium dichromate	15	DMSO	3	0.1	132281	2.68	0.3	226134	4.58	1.0	340917	6.91			
Potassium dichromate	15	DMSO	4	0.1	93102	1.89	0.3	115017	2.33	1.0	293061	5.94			
Potassium dichromate	15	DMSO	MEAN	0.1	131244	2.66	0.3	191819	3.89	1.0	296431	6.01	0.16	0.09	0.06
Vehicle - Positive Control	16		1	0	40980	1.14									
Vehicle - Positive Control	16		2	0	29750	0.83									
Vehicle - Positive Control	16		3	0	37809	1.05									
Vehicle - Positive Control	16		4	0	35687	0.99									
Vehicle - Positive Control	16		MEAN	0	36056	1.00									
Positive Control	16		1	NA	166596	4.62									
Positive Control	16		2	NA	324494	9.00									
Positive Control	16		3	NA	309550	8.59									
Positive Control	16		4	NA	255550	7.09									
Positive Control	17		MEAN	NA	264047	7.32									
Vehicle - Substance	16	AOO	1	0	28428	1.00									
Vehicle - Substance	16	AOO	2	0	25378	0.89									
Vehicle - Substance	16	AOO	3	0	40570	1.43									
Vehicle - Substance	16	AOO	4	0	19307	0.68									
Vehicle - Substance	16	AOO	MEAN	0	28421	1.00									
Hexyl cinnamic aldehyde	16	AOO	1	5	68037	2.39	10	134273	4.72	25	255545	8.99			
Hexyl cinnamic aldehyde	16	AOO	2	5	75307	2.65	10	132074	4.65	25	274377	9.65			
Hexyl cinnamic aldehyde	16	AOO	3	5	70208	2.47	10	192936	6.79	25	235997	8.30			
Hexyl cinnamic aldehyde	16	AOO	4	5	47285	1.66	10	127598	4.49	25	190963	6.72			
Hexyl cinnamic aldehyde	16	AOO	MEAN	5	65209	2.29	10	146720	5.16	25	239220	8.42	6.23	5.36	4.66
Vehicle - Positive Control	16		1	0	45989	1.19									
Vehicle - Positive Control	16		2	0	31080	0.80									
Vehicle - Positive Control	16		3	0	40234	1.04									
Vehicle - Positive Control	16		4	0	37535	0.97									
Vehicle - Positive Control	16		MEAN	0	38709	1.00									
Positive Control	16		1	NA	266865	6.89									
Positive Control	16		2	NA	266443	6.88									

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵	
Positive Control	16		3	NA	291111	7.52										
Positive Control	16		4	NA	264989	6.85										
Positive Control	16		MEAN	NA	272352	7.04										
Vehicle - Substance	16	DMSO	1	0	78052	1.02										
Vehicle - Substance	16	DMSO	2	0	111835	1.47										
Vehicle - Substance	16	DMSO	3	0	43088	0.57										
Vehicle - Substance	16	DMSO	4	0	71636	0.94										
Vehicle - Substance	16	DMSO	MEAN	0	76153	1.00										
Nickel (II) sulfate hexahydrate	16	DMSO	1	1	104880	1.38	3	109460	1.44	10	78555	1.03				
Nickel (II) sulfate hexahydrate	16	DMSO	2	1	80888	1.06	3	116987	1.54	10	115405	1.52				
Nickel (II) sulfate hexahydrate	16	DMSO	3	1	92663	1.22	3	110261	1.45	10	88420	1.16				
Nickel (II) sulfate hexahydrate	16	DMSO	4	1	81686	1.07	3	139021	1.83	10	71548	0.94				
Nickel (II) sulfate hexahydrate	16	DMSO	MEAN	1	90029	1.18	3	118932	1.56	10	88482	1.16	NA	NA	NA	
Lactic acid	16	DMSO	1	5	56025	0.74	10	44029	0.58	25	72313	0.95				
Lactic acid	16	DMSO	2	5	72079	0.95	10	67039	0.88	25	47618	0.63				
Lactic acid	16	DMSO	3	5	58768	0.77	10	63161	0.83	25	75699	0.99				
Lactic acid	16	DMSO	4	5	90115	1.18	10	68256	0.90	25	80804	1.06				
Lactic acid	16	DMSO	MEAN	5	69247	0.91	10	60621	0.80	25	69108	0.91	NA	NA	NA	
Vehicle - Positive Control	17		1	0	16598	1.00										
Vehicle - Positive Control	17		2	0	21167	1.28										
Vehicle - Positive Control	17		3	0	20244	1.22										
Vehicle - Positive Control	17		4	0	8376	0.50										
Vehicle - Positive Control	17		MEAN	0	16596	1.00										
Positive Control	17		1	NA	130759	7.88										
Positive Control	17		2	NA	159307	9.60										
Positive Control	17		3	NA	101692	6.13										
Positive Control	17		4	NA	105306	6.35										
Positive Control	17		MEAN	NA	124266	7.49										

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵	
Vehicle - Substance	17	AOO	1	0	22001	0.92										
Vehicle - Substance	17	AOO	2	0	17205	0.72										
Vehicle - Substance	17	AOO	3	0	38937	1.63										
Vehicle - Substance	17	AOO	4	0	17407	0.73										
Vehicle - Substance	17	AOO	MEAN	0	23888	1.00										
Hexyl cinnamic aldehyde	17	AOO	1	5	37307	1.56	10	96209	4.03	25	123470	5.17				
Hexyl cinnamic aldehyde	17	AOO	2	5	23097	0.97	10	106660	4.47	25	144993	6.07				
Hexyl cinnamic aldehyde	17	AOO	3	5	33287	1.39	10	109225	4.57	25	191859	8.03				
Hexyl cinnamic aldehyde	17	AOO	4	5	32984	1.38	10	129230	5.41	25	156101	6.53				
Hexyl cinnamic aldehyde	17	AOO	MEAN	5	31668	1.33	10	110331	4.62	25	154106	6.45	7.54	6.78	6.02	
Vehicle - Positive Control	17		1	0	11526	0.63										
Vehicle - Positive Control	17		2	0	12942	0.71										
Vehicle - Positive Control	17		3	0	16830	0.92										
Vehicle - Positive Control	17		4	0	31658	1.74										
Vehicle - Positive Control	17		MEAN	0	18239	1.00										
Positive Control	17		1	NA	152686	8.37										
Positive Control	17		2	NA	167020	9.16										
Positive Control	17		3	NA	133016	7.29										
Positive Control	17		4	NA	160607	8.81										
Positive Control	17		MEAN	NA	153332	8.41										
Vehicle - Substance	17	DMSO	1	0	47192	0.93										
Vehicle - Substance	17	DMSO	2	0	45146	0.89										
Vehicle - Substance	17	DMSO	3	0	57466	1.13										
Vehicle - Substance	17	DMSO	4	0	53459	1.05										
Vehicle - Substance	17	DMSO	MEAN	0	50815	1.00										
Cobalt chloride	17	DMSO	1	1	134969	2.66	3	206718	4.07	5	297901	5.86				
Cobalt chloride	17	DMSO	2	1	249468	4.91	3	243849	4.80	5	231316	4.55				
Cobalt chloride	17	DMSO	3	1	104002	2.05	3	212124	4.17	5	192465	3.79				
Cobalt chloride	17	DMSO	4	1	106668	2.10	3	201772	3.97	5	306231	6.03				
Cobalt chloride	17	DMSO	MEAN	1	148776	2.93	3	216116	4.25	5	256978	5.06	1.11	0.70	0.46	
Potassium dichromate	17	DMSO	1	0.1	212537	4.18	0.3	281536	5.54	1.0	349431	6.88				
Potassium dichromate	17	DMSO	2	0.1	192220	3.78	0.3	284296	5.59	1.0	269795	5.31				
Potassium dichromate	17	DMSO	3	0.1	110195	2.17	0.3	229749	4.52	1.0	278313	5.48				

Substance	Lab No. ¹	Vehicle	Animal No.	1 Conc. (%)	1 Mean ATP ²	1 SI	2 Conc. (%)	2 Mean ATP ²	2 SI	3 Conc. (%)	3 Mean ATP ²	3 SI	Calc. EC3 ³	Calc. EC2.5 ⁴	Calc. EC2 ⁵
Potassium dichromate	17	DMSO	4	0.1	146041	2.87	0.3	232971	4.58	1.0	397799	7.83			
Potassium dichromate	17	DMSO	MEAN	0.1	165248	3.25	0.3	257138	5.06	1.0	323834	6.37	0.09	0.06	0.05

Abbreviations: ACE = acetone; AOO = acetone: olive oil (4:1); ATP = adenosine triphosphate; Calc. = calculated; Conc. = concentration; DMSO = dimethyl sulfoxide; IDR = insufficient dose response; NA = not applicable; No. = number; NT = not tested; SI = stimulation Index.

¹Laboratories 1 – 10 participated in the first phase, and laboratories 11 – 17 participated in the second phase of the two-phased interlaboratory validation study.

²Two ATP measurements were taken for each animal and the mean ATP is indicated.

³EC3 value was calculated based on interpolation or extrapolation formulas discussed in Gerberick et al. 2004.

⁴EC2.5 value was calculated based on modified interpolation or extrapolation formulas for EC3 discussed in Gerberick et al. 2004.

⁵EC2 value was calculated based on modified interpolation or extrapolation formulas for EC3 discussed in Gerberick et al. 2004.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Appendix E

LLNA: DA Accuracy Analysis Using Additional Approaches for Combining Multiple Test Results

19

20

21

22

23

24

25

26

27

28

29

[This Page Intentionally Left Blank]

30

30 **1.0 Accuracy Analysis Using Alternative Decision Criteria and**
31 **Alternate Methods for Combining Data for Substances Tested**
32 **Multiple Times**

33 This appendix shows performance analyses for the murine local lymph node assay (LLNA)
34 modified by Daicel Chemical Industries, Ltd., based on adenosine triphosphate content
35 (ATP; referred to hereafter as the “LLNA: DA”) for alternative decision criteria when using
36 two different approaches for combining test results for the 14 substances with multiple
37 LLNA: DA tests.

- 38 1. The positive/negative outcome for each substance for each criterion was
39 determined by the outcome of the test with the highest maximum stimulation
40 index (SI) of the multiple tests.
- 41 2. The positive/negative outcome for each substance for each criterion was
42 determined by the outcome of the test with the lowest maximum SI of the
43 multiple tests.

44 **Section 6.0** of this background review document provides the results for the analysis when
45 the most prevalent outcome was used to represent the result for each substance tested
46 multiple times (for each criterion).


47 **1.1 Results of LLNA: DA Accuracy Analysis Using Alternative Decision Criteria**
48 **and Highest Maximum SI for the Outcome of Multiple Tests**

49 When combining multiple test results for a single substance by using the outcome of the test
50 with the highest maximum SI, the decision criterion of $SI \geq 3.0$ (used by the LLNA: DA
51 validation study team) to identify sensitizers yielded an accuracy of 93% (41/44), a
52 sensitivity of 91% (29/32), a specificity of 100% (12/12), a false positive rate of 0% (0/12),
53 and a false negative rate of 9% (3/32) (**Table E-1**). The decision criteria using higher SI
54 values, $SI \geq 3.5$ to $SI \geq 5.0$, decreased performance except for the specificity and the false
55 positive rate, which remained at 100% (12/12) and 0% (0/12), respectively (**Figure E-1** and
56 **Table E-1**). The lower SI criterion, $SI \geq 2.5$, increased accuracy to 96% (42/44) and
57 sensitivity to 94% (30/32), while the specificity and the false positive rate remained the same
58 at 100% (12/12) and 0% (0/12), respectively. Further, the false negative rate decreased to 6%

59 (2/32) at $SI \geq 2.5$. At an even lower SI criterion, $SI \geq 1.3$, accuracy was 82% (36/44) and
60 sensitivity was 100% (32/32), while the specificity was low (33% [4/12]) and the false
61 positive rate was high (67% [8/12]). Further, the false negative rate decreased to 0% (0/32) at
62 $SI \geq 1.3$. The use of analysis of variance (ANOVA) and summary statistics (i.e., mean ATP
63 measurement of treated groups $\geq 95\%$ confidence interval (CI) of the control group, or ≥ 2 or
64 ≥ 3 standard deviation [SD] from the control group mean), yielded accuracy values of 75% to
65 84%, with sensitivity values of 88% to 100%, and false negative rates of 0 to 13%. The
66 specificity for these criteria ranged from 8% to 58% and the false positive rates were 42% to
67 92%. Of these alternative decision criteria, the best overall performance for the approach
68 using the highest maximum SI for the substances with more than one test was achieved using
69 an $SI \geq 2.5$, as summarized above. Using an $SI \geq 2.5$, however, incorrectly classified 2-
70 mercaptobenzothiazole, a commonly know skin sensitizer.

71

71 **Figure E-1 Performance of the LLNA: DA with SI Compared to the Traditional**
72 **LLNA Using the Highest Maximum SI for Substances with Multiple**
73 **Tests**



74

75 As compared to traditional LLNA results, the lines show the change in performance characteristics
76 for the LLNA: DA with the SI cutoff used to identify sensitizers. This analysis used LLNA: DA and
77 traditional LLNA results for 44 substances (32 traditional LLNA sensitizers and 12 traditional LLNA
78 nonsensitizers). For the 14 substances with multiple test results, the results for each substance were
79 combined by using the outcome for the test with the highest maximum SI value. The solid line shows
80 accuracy, the dashed line shows the false positive rate, and the dotted line shows the false negative
81 rate.

82 **Table E-1 Performance of the LLNA: DA Compared with the Traditional LLNA Using Alternative Decision Criteria to**
 83 **Identify Sensitizers Based on the Highest Maximum SI for Substances with Multiple Tests**

Alternate Criterion	N ¹	Accuracy		Sensitivity		Specificity		False Positive Rate		False Negative Rate		Positive Predictivity		Negative Predictivity	
		%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²
Statistics ³	44	84	37/44	94	30/32	58	7/12	42	5/12	6	2/32	86	30/35	78	7/9
≥ 95% CI ⁴	44	75	33/44	100	32/32	8	1/12	92	11/12	0	0/32	74	32/43	100	1/1
≥ 2 SD ⁵	44	77	34/44	91	29/32	42	5/12	58	7/12	9	3/32	81	29/36	63	5/8
≥ 3 SD ⁶	44	77	34/44	88	28/32	50	6/12	50	6/12	13	4/32	82	28/34	60	6/10
SI ≥ 5.0	44	64	28/44	50	16/32	100	12/12	0	0/12	50	16/32	100	16/16	43	12/28
SI ≥ 4.5	44	75	33/44	66	21/32	100	12/12	0	0/12	34	11/32	100	21/21	52	12/23
SI ≥ 4.0	44	86	38/44	81	26/32	100	12/12	0	0/12	19	6/32	100	26/26	67	12/18
SI ≥ 3.5	44	91	40/44	88	28/32	100	12/12	0	0/12	13	4/32	100	28/28	75	12/16
SI ≥ 3.0	44	93	41/44	91	29/32	100	12/12	0	0/12	9	3/32	100	29/29	80	12/15
SI ≥ 2.5	44	96	42/44	94	30/32	100	12/12	0	0/12	6	2/32	100	30/30	86	12/14
SI ≥ 2.0	44	91	40/44	97	31/32	75	9/12	25	3/12	3	1/32	91	31/34	90	9/10
SI ≥ 1.5	44	86	38/44	100	32/32	50	6/12	50	6/12	0	0/32	84	32/38	100	6/6
SI ≥ 1.3	44	82	36/44	100	32/32	33	4/12	67	8/12	0	0/32	80	32/40	100	4/4

84 Bolded text indicates the decision criterion chosen by the LLNA: DA validation study team; Italicized text indicates the single decision criterion that had an overall increased performance in predicting
 85 skin sensitization potential when compared to the traditional LLNA.

86 Abbreviations: CI = confidence interval; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP Content;
 87 No. = number; SD = standard deviation; SI = stimulation index

88 ¹N = Number of substances included in this analysis.

89 ²The proportion on which the percentage calculation is based.

90 ³Analysis of variance for difference of group means when substances were tested at multiple doses or *t*-test when substances were tested at one dose. The ATP data were log-transformed prior to
 91 statistical analyses. For analysis of variance, significance at *p* < 0.05 was further tested by Dunnett's test.

92 ⁴The mean ATP of at least one treatment group was outside the 95% CI for the mean ATP of the vehicle control group.

93
94

⁵ The mean ATP of at least one treatment group was greater than 2 SD from the mean ATP of the vehicle control group.


⁶ The mean ATP of at least one treatment group was greater than 3 SD from the mean ATP of the vehicle control group.

95 **1.2 Results of LLNA: DA Accuracy Analysis Using Alternative Decision Criteria**
96 **and Lowest Maximum SI for the Outcome of Multiple Tests**

97 When combining multiple test results for a single substance using the outcome of the test
98 with the lowest maximum SI to identify sensitizers, the decision criterion of $SI \geq 3.0$ (used by
99 the LLNA: DA validation study team) yielded an accuracy of 84% (37/44), a sensitivity of
100 78% (25/32), a specificity of 100% (12/12), a false positive rate of 0% (0/12), and a false
101 negative rate of 22% (7/32) (**Table E-2**). The decision criteria using higher SI values,
102 $SI \geq 3.5$ to $SI \geq 5.0$, decreased performance except for the specificity and the false positive
103 rate, which remained at 100% (12/12) and 0% (0/12), respectively (**Figure E-2** and **Table E-**
104 **2**). At $SI \geq 5.0$, accuracy decreased to 46% (20/44) and the false negative rate increased to
105 75% (24/32). Use of a lower SI at $SI \geq 2.5$ increased accuracy to 89% (39/44) and sensitivity
106 to 84% (27/32), while the specificity and false positive rate remained the same at 100%
107 (12/12) and 0% (0/12), respectively. Further, the false negative rate decreased to 16% (5/32)
108 at $SI \geq 2.5$. At an even lower SI criterion, $SI \geq 1.3$, accuracy was decreased to 86% (38/44)
109 but the sensitivity increased to 97% (31/32), while the specificity was 58% (7/12) and the
110 false positive rate was 42% (5/12). Further, the false negative rate decreased to 3% (1/32) at
111 $SI \geq 1.3$. Use of a statistical test (i.e., ANOVA or *t*-test) and summary statistics (i.e., mean
112 ATP measurements of treated groups $\geq 95\%$ CI of the control group, or ≥ 2 or ≥ 3 SD from the
113 control group mean), yielded accuracy values of 77 to 82%, with sensitivity values of 84 to
114 97%, and false negative rates of 3 to 16%. Both the specificity and false positive rate for
115 these criteria ranged from 42 to 58%. Of these alternative decision criteria, the best overall
116 performance for the approach using the lowest maximum SI for the substances with more
117 than one test was achieved using $SI \geq 2.5$, as summarized above.

118

118 **Figure E-2 Performance of the LLNA: DA with SI Compared to the Traditional**
 119 **LLNA Using the Lowest Maximum SI for Substances with Multiple Tests**



120

121 As compared to traditional LLNA results, the lines show the change in performance characteristics
 122 for the LLNA: DA with the SI cutoff used to identify sensitizers. This analysis used LLNA: DA and
 123 traditional LLNA results for 44 substances (32 traditional LLNA sensitizers and 12 traditional LLNA
 124 nonsensitizers). For the 14 substances with multiple test results, the results for each substance were
 125 combined by using the outcome for the test with the lowest maximum SI value. The solid line shows
 126 accuracy, the dashed line shows the false positive rate, and the dotted line shows the false negative
 127 rate.

128 **Table E-2 Performance of the LLNA: DA Compared with the Traditional LLNA Using Alternative Decision Criteria to**
 129 **Identify Sensitizers Based on the Lowest Maximum SI for Substances with Multiple Tests**

Alternate Criterion	N ¹	Accuracy		Sensitivity		Specificity		False Positive Rate		False Negative Rate		Positive Predictivity		Negative Predictivity	
		%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²	%	No. ²
Statistics ³	44	82	36/44	91	29/32	58	7/12	42	5/12	9	3/32	85	29/34	70	7/10
≥ 95% CI ⁴	44	82	36/44	97	31/32	42	5/12	58	7/12	3	1/32	82	31/38	83	5/6
≥ 2 SD ⁵	44	77	34/44	88	28/32	50	6/12	50	6/12	13	4/32	82	28/34	60	6/10
≥ 3 SD ⁶	44	77	34/44	84	27/32	58	7/12	42	5/12	16	5/32	84	27/32	58	7/12
SI ≥ 5.0	44	46	20/44	25	8/32	100	12/12	0	0/12	75	24/32	100	8/8	33	12/36
SI ≥ 4.5	44	59	26/44	44	14/32	100	12/12	0	0/12	56	18/32	100	14/14	40	12/30
SI ≥ 4.0	44	73	32/44	63	20/32	100	12/12	0	0/12	38	12/32	100	20/20	50	12/24
SI ≥ 3.5	44	82	36/44	75	24/32	100	12/12	0	0/12	25	8/32	100	24/24	60	12/20
SI ≥ 3.0	44	84	37/44	78	25/32	100	12/12	0	0/12	22	7/32	100	25/25	63	12/19
<i>SI ≥ 2.5</i>	<i>44</i>	<i>89</i>	<i>39/44</i>	<i>84</i>	<i>27/32</i>	<i>100</i>	<i>12/12</i>	<i>0</i>	<i>0/12</i>	<i>16</i>	<i>5/32</i>	<i>100</i>	<i>27/27</i>	<i>71</i>	<i>12/17</i>
SI ≥ 2.0	44	86	38/44	91	29/32	75	9/12	25	3/12	9	3/32	91	29/32	75	9/12
SI ≥ 1.5	44	89	39/44	97	31/32	67	8/12	33	4/12	3	1/32	89	31/35	89	8/9
SI ≥ 1.3	44	86	38/44	97	31/32	58	7/12	42	5/12	3	1/32	86	31/36	88	7/8

130 Bolded text indicates the decision criterion chosen by the LLNA: DA validation study team; Italicized text indicates the single decision criterion that had an overall increased performance in predicting
 131 skin sensitization potential when compared to the traditional LLNA.

132 Abbreviations: CI = confidence interval; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP Content; No. = number; SD = standard deviation; SI =
 133 stimulation index

134 ¹N = Number of substances included in this analysis.

135 ²The proportion on which the percentage calculation is based.

136 ³Analysis of variance for difference of group means when substances were tested at multiple doses or *t*-test when substances were tested at one dose. The ATP data were log-transformed prior to
 137 statistical analyses. For analysis of variance, significance at *p* < 0.05 was further tested by Dunnett's test.

138 ⁴The mean ATP of at least one treatment group was outside the 95% confidence interval for the mean ATP of the vehicle control group.

139
140
141

⁵ The mean ATP of at least one treatment group was greater than 2 SD from the mean ATP of the vehicle control group.

⁶ The mean ATP of at least one treatment group was greater than 3 SD from the mean ATP of the vehicle control group.

.

142 **2.0 Discordant Results for Accuracy Analysis of Alternative Decision** 143 **Criteria**

144 As mentioned above, for the 14 substances with multiple test results using the decision
145 criteria of $SI \geq 2.5$ to identify sensitizers (based on the test with the highest maximum SI)
146 yielded the best overall performance among the alternative decision criteria evaluated. When
147 compared to the traditional LLNA, 2-mercaptobenzothiazole, a well-known skin sensitizer
148 was misclassified as a nonsensitizer (**Table E-3**).

149 **2.1 Discordant Results Using Alternative Decision Criteria and Highest** 150 **Maximum SI Outcome for Multiple Tests**

151 Using the decision criterion of $SI \geq 3.0$ to identify sensitizers and the test with the highest
152 maximum SI as the representative result for substances with multiple tests yielded three
153 discordant substances (i.e., 3-aminophenol, 2-mercaptobenzothiazole, and methyl
154 methacrylate), all misclassified as nonsensitizers by the LLNA: DA.

155 **Table E-3** shows how the number and identity of discordant substances changes with the
156 alternate decision criteria when using the test with the highest maximum SI to represent the
157 outcome for substances with multiple tests. Using an SI cutoff lower than three to identify
158 sensitizers, such as $SI \geq 2.0$, yielded four discordant substances: chlorobenzene, hexane, and
159 salicylic acid were misclassified as sensitizers and methyl methacrylate was misclassified as
160 a nonsensitizer. Using an even lower SI cutoff of $SI \geq 1.3$ to identify sensitizers, yielded five
161 additional discordant substances that were all misclassified as sensitizers (i.e., 1-
162 bromobutane, dimethyl isophthalate, isopropanol, methyl salicylate, and nickel [II] chloride).
163 Increasing the SI cutoff to values greater than three, increased the number of sensitizers that
164 were misclassified as nonsensitizers. At $SI \geq 4.0$, six traditional LLNA sensitizers were
165 misclassified as nonsensitizers by the LLNA: DA while at $SI \geq 5.0$, 17 sensitizers were
166 classified as nonsensitizers (**Table E-3**).

167 Use of a statistical test (i.e., ANOVA or *t*-test) or summary statistics (i.e., $\geq 95\%$ CI, ≥ 2 SD,
168 or ≥ 3 SD) tended to misclassify nonsensitizers in the traditional LLNA as sensitizers in the
169 LLNA: DA. Using ANOVA or *t*-test to identify sensitizers misclassified five nonsensitizers
170 (i.e., 1-bromobutane, chlorobenzene, hexane, salicylic acid, and sulfanilamide) as sensitizers

171 and two sensitizers (i.e., 2-mercaptobenzothiazole and methyl methacrylate) as
172 nonsensitizers. Using treatment group ATP measurement with ≥ 2 SD or ≥ 3 SD of the vehicle
173 control mean or a $\geq 95\%$ CI of the vehicle control mean, all misclassified the following six
174 traditional LLNA nonsensitizers as sensitizers: 1-bromobutane, chlorobenzene, hexane,
175 isopropanol, nickel (II) chloride, and propylparaben. The $\geq 95\%$ CI of the vehicle control
176 mean misclassified four additional nonsensitizers (i.e., diethyl phthalate, dimethyl
177 isophthalate, lactic acid, and methyl salicylate) as sensitizers. In addition, ≥ 2 SD or ≥ 3 SD of
178 the vehicle control mean commonly misclassified three sensitizers as nonsensitizers (i.e.,
179 ethyl acrylate, methyl methacrylate, and propyl gallate).

180 Thirteen of the 22 ICCVAM-recommended LLNA performance standards reference
181 substances (ICCVAM 2009) tested in the LLNA: DA were discordant for the analysis of
182 alternate decision criteria using the test with the highest maximum SI to represent substances
183 with multiple tests (**Table E-3**) when compared to the traditional LLNA. Six nonsensitizers
184 in the traditional LLNA (i.e., chlorobenzene, isopropanol, lactic acid, methyl salicylate,
185 nickel [II] chloride, and salicylic acid) were misclassified by some criteria in the LLNA: DA
186 as a sensitizers, and seven sensitizers in the traditional LLNA (i.e., citral, ethylene glycol
187 dimethacrylate, imidazolidinyl urea, 2-mercaptobenzothiazole, methyl methacrylate, phenyl
188 benzoate, and sodium lauryl sulfate) were misclassified as nonsensitizers by some criteria
189 when tested in the LLNA: DA.

190 **Table E-3 Discordant Results for the LLNA: DA Using Alternative Decision Criteria Compared to the Traditional LLNA**
 191 **Based on the Highest Maximum SI for Substances with Multiple Tests**

Discordant Substance ¹	Alternate Decision Criterion ²												
	Statistics ³	≥95% CI ⁴	≥2 SD ⁵	≥3 SD ⁶	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3
3-Aminophenol (3.2%)					-	-	-	-	-				
p-Benzoquinone (0.01%)					-	-	-						
1-Bromobutane (-)	+	+	+	+								+	+
Butyl glycidyl ether (30.9%)				-	-								
Chlorobenzene (-)	+	+	+	+							+	+	+
Cinnamic aldehyde (1.9%)					-								
Citral (9.2%)					-	-							
Diethyl maleate (3.6%)					-	-	-						
Diethyl phthalate (-)		+											
Dimethyl isophthalate (-)													+
Ethyl acrylate (32.8%)			-	-	-	-							
Ethylene glycol dimethacrylate (28.0%)					-	-							
Hexane (-)	+	+	+	+							+	+	+
Imidazolidinyl urea (24.0%)					-								
Isopropanol (-)		+	+	+								+	+
Lactic acid (-)		+											
2-Mercaptobenzothiazole	-				-	-	-	-	-	-			

Discordant Substance ¹	Alternate Decision Criterion ²												
	Statistics ³	≥95% CI ⁴	≥2 SD ⁵	≥3 SD ⁶	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3
(1.7%)													
Methyl methacrylate (90.0%)	-		-	-	-	-	-	-	-	-	-		
Methyl salicylate (-)		+										+	+
Nickel (II) chloride (-)		+	+	+									+
Phenyl benzoate (13.6%)					-	-							
Propyl gallate (0.32%)			-	-	-								
Propylparaben (-)		+	+	+									
Resorcinol (6.3%)					-	-							
Salicylic acid (-)	+	+	+								+	+	+
Sodium lauryl sulfate (8.1%)					-	-	-	-					
Sulfanilamide (-)	+												
Trimellitic anhydride (4.7%)					-								

192 Abbreviations: CI = confidence interval; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by
 193 Daicel Chemical Industries, Ltd. based on ATP Content; SD = standard deviation; SI = stimulation index.

194 ¹Compared to the traditional LLNA; traditional LLNA result in parentheses are “-” for nonsensitizers and EC3 (%) for sensitizers.

195 ²LLNA: DA outcomes are indicated by “+” for sensitizer results and “-” for nonsensitizer results.

196 ³Analysis of variance assessed difference of group means when substances were tested at multiple doses or *t*-test when substances were tested at
 197 one dose. The ATP data were log-transformed prior to statistical analyses. Significance by analysis of variance at *p* < 0.05 was further tested by
 198 Dunnett’s test.

199 ⁴The mean ATP of at least one treatment group was outside the 95% CI for the mean ATP of the vehicle control group.

200 ⁵The mean ATP of at least one treatment group was greater than 2 SD from the mean ATP of the vehicle control group.

201 ⁶The mean ATP of at least one treatment group was greater than 3 SD from the mean ATP of the vehicle control group.

202 2.2 Discordant Results Using Alternative Decision Criteria and Lowest Maximum 203 SI Outcome for Multiple Tests

204 As mentioned above, for the substances with multiple tests, using the decision criterion of
205 $SI \geq 2.5$ to identify sensitizers (based on the test with the lowest maximum SI) yielded the
206 best overall performance for the LLNA: DA when compared to the traditional LLNA. This
207 decision criterion yielded five discordant substances; all five were sensitizers in the
208 traditional LLNA but were misclassified as nonsensitizers in the LLNA: DA (i.e., 3-
209 aminophenol, cobalt chloride, 2-mercaptobenzothiazole, methyl methacrylate, and nickel [II]
210 sulfate hexahydrate) (**Table E-4**).

211 **Table E-4** shows how the number and identity of discordant substances changes with the
212 alternate decision criteria when using the test with the lowest maximum SI as the
213 representative result for substances with multiple tests. Using an SI cutoff less than three,
214 $SI \geq 2.0$, to identify sensitizers yielded six discordant substances. Three of the six discordant
215 substances (i.e., 3-aminophenol, methyl methacrylate, and nickel [II] sulfate hexahydrate)
216 were misclassified as nonsensitizers by the LLNA: DA compared to the traditional LLNA
217 and the remaining three (i.e., chlorobenzene, hexane, and salicylic acid) were misclassified as
218 sensitizers. Using an even lower SI to identify sensitizers, $SI \geq 1.3$, also yielded six discordant
219 substances. Chlorobenzene, hexane, and salicylic acid were still misclassified as sensitizers
220 and nickel (II) sulfate hexahydrate was still misclassified as a nonsensitizer by the LLNA:
221 DA compared to the traditional LLNA. In addition, 1-bromobutane and nickel (II) chloride
222 were also misclassified as sensitizers. Increasing the SI cutoff to values greater than three,
223 increased the number of sensitizers that were misclassified as nonsensitizers. At $SI \geq 4.0$, 12
224 sensitizers were misclassified as nonsensitizers while at $SI \geq 5.0$, 24 sensitizers were
225 misclassified as nonsensitizers (**Table E-4**). Using the test with the lowest maximum SI as
226 the result for substances with multiple tests caused even potent sensitizers to be misclassified
227 as nonsensitizers at the higher SI cutoffs. For instance, at $SI \geq 5.0$, 2,4-dinitrochlorobenzene
228 and glutaraldehyde were classified as nonsensitizers.

229 **Table E-4 Discordant Results for the LLNA: DA Using Alternative Decision Criteria Compared to the Traditional LLNA**
 230 **Based on the Lowest Maximum SI for Substances with Multiple Tests**

Discordant Substance ¹	Alternate Decision Criterion ²												
	Statistics ³	≥95% CI ⁴	≥2 SD ⁵	≥3 SD ⁶	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3
Abietic Acid (11.9%)					-	-	-						
3-Aminophenol (3.2%)					-	-	-	-	-	-	-		
p-Benzoquinone (0.01%)					-	-	-						
1-Bromobutane (-)	+	+	+	+	-							+	+
Butyl glycidyl ether (30.9%)				-	-								
Chlorobenzene (-)	+	+	+	+							+	+	+
Cinnamic aldehyde (1.9%)					-								
Citral (9.2%)					-	-							
Cobalt chloride (0.60%)					-	-	-	-	-	-			
Diethyl phthalate (-)		+											
Dimethyl isophthalate (-)													
Diethyl maleate (3.6%)					-	-	-						
2,4-Dinitrochlorobenzene (0.05%)					-								
Ethyl acrylate (32.8%)			-	-	-	-							
Ethylene glycol dimethacrylate (28.0)					-	-							
Formaldehyde (0.50%)					-	-	-	-	-				
Glutaraldehyde (0.08%)					-	-	-	-	-				

Discordant Substance ¹	Alternate Decision Criterion ²												
	Statistics ³	≥95% CI ⁴	≥2 SD ⁵	≥3 SD ⁶	SI ≥ 5.0	SI ≥ 4.5	SI ≥ 4.0	SI ≥ 3.5	SI ≥ 3.0	SI ≥ 2.5	SI ≥ 2.0	SI ≥ 1.5	SI ≥ 1.3
Hexane (-)	+	+	+	+							+	+	+
Hexyl cinnamic aldehyde (9.7%)					-	-	-						
Imidazolidinyl urea (24.0%)					-								
2-Mercaptobenzothiazole (1.7%)	-				-	-	-	-	-	-			
Methyl methacrylate (90.0%)	-		-	-		-	-	-	-	-	-		
Nickel (II) chloride (-)		+	+	+									+
Nickel (II) sulfate hexahydrate (4.8%)	-	-	-	-	-	-	-	-	-	-	-	-	-
Phenyl benzoate (13.6%)					-	-							
Potassium dichromate (0.17%)					-	-							
Propyl gallate (0.32%)			-	-	-								
Propylparaben (-)		+	+	+									
Resorcinol (6.3%)					-	-							
Salicylic acid (-)	+	+	+								+	+	+
Sulfanilamide (-)	+												
Sodium lauryl sulfate (8.1%)					-	-	-	-					
Trimellitic anhydride (4.7%)					-								

231 Abbreviations: CI = confidence interval; LLNA = murine local lymph node assay; LLNA: DA = murine local lymph node assay modified by
232 Daicel Chemical Industries, Ltd. based on ATP Content; SD = Standard deviation; SI = Stimulation index.

233 ¹Compared to the traditional LLNA; traditional LLNA result in parentheses are “-” for nonsensitizers and EC3 (%) for sensitizers.

234 ²LLNA: DA outcomes are indicated by “+” for sensitizer results and “-” for nonsensitizer results.

235 ³Analysis of variance for difference of group means when substances were tested at multiple doses or *t*-test when substances were tested at one
236 dose. The ATP data were log-transformed prior to statistical analyses. Significance by analysis of variance at $p < 0.05$ was further tested by
237 Dunnett’s test.

238 ⁴The mean ATP of at least one treatment group was outside the 95% CI for the mean ATP of the vehicle control group.

239 ⁵The mean ATP of at least one treatment group was greater than 2 SD from the mean ATP of the vehicle control group.

240 ⁶The mean ATP of at least one treatment group was greater than 3 SD from the mean ATP of the vehicle control group.

241 Use of a statistical test (i.e., ANOVA or *t*-test) or summary statistics (i.e., $\geq 95\%$ CI, ≥ 2 SD,
242 or ≥ 3 SD) more often misclassified traditional LLNA nonsensitizers than sensitizers (**Table**
243 **E-4**). Using ANOVA or *t*-test to identify sensitizers misclassified three sensitizers in the
244 traditional LLNA (i.e., 2-mercaptobenzothiazole, methyl methacrylate, and nickel [II] sulfate
245 hexahydrate) as nonsensitizers in the LLNA: DA. Further, five nonsensitizers in the
246 traditional LLNA (i.e., 1-bromobutane, chlorobenzene, hexane, salicylic acid, and
247 sulfanilamide) were misclassified as sensitizers in the LLNA: DA. Using treatment group
248 ATP measurement $\geq 95\%$ CI, ≥ 2 SD or ≥ 3 SD of vehicle control mean commonly
249 misclassified 1-bromobutane, chlorobenzene, hexane, nickel (II) chloride, and propylparaben
250 as sensitizers and nickel (II) sulfate hexahydrate as a nonsensitizer compared to traditional
251 LLNA results. In addition each summary statistic misclassified from two to four additional
252 substances when compared to traditional LLNA results (see Table E-4).

253 Thirteen of the 22 ICCVAM-recommended LLNA performance standards reference
254 substances (ICCVAM 2009) were discordant for the analysis of alternate decision criteria
255 using the test with the lowest maximum SI as the representative result for substances with
256 multiple tests (**Table E-4**). One strong sensitizer in the traditional LLNA, 2,4-
257 dinitrochlorobenzene, was misclassified by $SI \geq 5.0$ as a nonsensitizer in the LLNA: DA.
258 Nine additional sensitizers (i.e., citral, cobalt chloride, ethylene glycol dimethacrylate, hexyl
259 cinnamic aldehyde, imidazolidinyl urea, 2-mercaptobenzothiazole, methyl methacrylate,
260 phenyl benzoate, and sodium lauryl sulfate) were also misclassified as nonsensitizers by
261 some criteria in the LLNA: DA. Three nonsensitizers in the traditional LLNA (i.e.,
262 chlorobenzene, nickel [II] chloride, and salicylic acid) were misclassified as sensitizers by
263 some criteria in the LLNA: DA.

264

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Appendix F
Reproducibility Analyses for the LLNA: DA Using a Decision Criterion
of $SI \geq 3.0$ or $SI \geq 2.0$

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

[This Page Intentionally Left Blank]

30 **1.0 LLNA: DA Test Method Reliability**

31 An assessment of test method reliability (intralaboratory repeatability and intra- and inter-
32 laboratory reproducibility) is an essential element of any evaluation of the performance of an
33 alternative test method (ICCVAM 2003). Repeatability refers to the closeness of agreement
34 between test results obtained within a single laboratory when the procedure is performed on
35 the same substance under identical conditions within a given time period (ICCVAM 1997,
36 2003). Intralaboratory reproducibility refers to the extent to which qualified personnel within
37 the same laboratory can replicate results using a specific test protocol at different times.
38 Interlaboratory reproducibility refers to the extent to which different laboratories can
39 replicate results using the same protocol and test substances, and indicates the extent to
40 which a test method can be transferred successfully among laboratories. With regard to the
41 murine local lymph node assay modified by Daicel Chemical Industries, Ltd., based on ATP
42 content (referred to hereafter as the “LLNA: DA”) test method, there are no known
43 intralaboratory repeatability studies, which was also the situation with the traditional murine
44 local lymph node assay (LLNA).

45 The reproducibility evaluation in this revised draft background review document (BRD) has
46 been updated from the January 2008 draft BRD to include an interlaboratory reproducibility
47 evaluation and a reproducibility analysis using separate stimulation index (SI) criteria to
48 identify sensitizers and nonsensitizers (see **Section 7.0**). The available LLNA: DA data were
49 amenable to both intralaboratory and interlaboratory reproducibility analyses. The evaluation
50 of a single decision criterion in **Section 6.6** showed that $SI \geq 2.0$ was the SI value that
51 produced the lowest false negative rate among the alternative decision criteria evaluated (i.e.,
52 3% [1/32]) when the traditional LLNA was the reference test (**Table 6-6**). Thus, this
53 appendix describes the evaluation of reproducibility for the decision criterion of $SI \geq 2.0$ to
54 identify sensitizers, which was evaluated in **Section 6.6**. In addition the reproducibility for
55 $SI \geq 3.0$, the SI cut-off used in the LLNA: DA validation studies, is also evaluated in this
56 appendix.

57 **1.1 Intralaboratory Reproducibility ($SI \geq 3.0$ and $SI \geq 2.0$)**

58 Idehara et al. (2008) evaluated the intralaboratory reproducibility of EC3 (i.e., estimated
59 concentration needed to produce a stimulation index of three) values for the LLNA: DA

60 using two substances (i.e., isoeugenol and eugenol) that were each tested in three different
 61 experiments (**Table F-1**). The data indicate coefficient of variations (CVs) of 21% and 11%
 62 for isoeugenol and eugenol, respectively. The authors state that for both compounds the EC3
 63 values appeared to be close and that for each test substance the SI values for the same
 64 concentration were fairly reproducible (Idehara et al. 2008). The National Toxicology
 65 Program Interagency Center for the Evaluation of Alternative Toxicological Methods
 66 (NICEATM) also determined the intralaboratory reproducibility of EC2 (i.e., estimated
 67 concentration needed to produce a stimulation index of two) values for the same set of data.
 68 The EC2 results indicate slightly larger intralaboratory variability compared to EC3 results
 69 with CVs of 35% and 20% for isoeugenol and eugenol, respectively.

70 **Table F-1 Intralaboratory Reproducibility of EC3 and EC2 Values Using the**
 71 **LLNA: DA¹**

Isoeugenol			
Concentration (%)	Experiment 1²	Experiment 2²	Experiment 3²
Vehicle (AOO)	1.00 ± 0.54	1.00 ± 0.54	1.00 ± 0.30
0.5	1.50 ± 0.54	-----	1.22 ± 0.13
1	2.28 ± 0.60	-----	2.77 ± 1.01
2.5	2.78 ± 0.17	3.11 ± 1.15	3.01 ± 0.98
5	3.39 ± 0.69	4.39 ± 1.25	-----
10	5.68 ± 1.19	6.77 ± 0.23	-----
EC3	3.40%	2.35%	2.46%
EC2	0.82%	1.37%	0.75%
<i>Mean EC3: 2.74% ± 0.58% and 21% CV</i>			
<i>Mean EC2: 0.98% ± 0.34% and 35% CV</i>			
Eugenol			
Concentration (%)	Experiment 1²	Experiment 2²	Experiment 3²
Vehicle (AOO)	1.00 ± 0.17	1.00 ± 0.17	1.00 ± 0.09
5	2.92 ± 1.00	2.80 ± 1.08	3.24 ± 0.70
10	7.35 ± 2.62	4.47 ± 0.98	4.79 ± 0.94
25	10.92 ± 3.63	5.62 ± 3.20	7.07 ± 0.44
EC3	5.09%	5.59%	4.50%
EC2	4.33%	3.59%	2.87%
<i>Mean EC3: 5.06% ± 0.55% and 11% CV</i>			
<i>Mean EC2: 3.60% ± 0.73% and 20% CV</i>			

72 Abbreviations: AOO = acetone: olive oil (4:1); CV = coefficient of variation; EC2 = estimated concentration
 73 needed to produce a stimulation index of two; EC3 = estimated concentration needed to produce a stimulation
 74 index of three; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd.
 75 based on ATP content.

76 ¹Based on results discussed in Idehara et al. 2008; the number per group was not specified.

77 ²Mean stimulation index value ± standard deviation.

78

78 1.2 Interlaboratory Reproducibility

79 Furthermore, data were submitted to NICEATM (**Appendix D**) from a two-phased
80 interlaboratory validation study on the LLNA: DA test method (Omori et al. 2008). In the
81 first phase of the interlaboratory validation study, a blinded test of 12 substances was
82 conducted in 10 laboratories. Three substances (i.e. 2,4-dinitrochlorobenzene, hexyl cinnamic
83 aldehyde, and isopropanol) were tested in all 10 laboratories. The remaining nine substances
84 were randomly assigned to subsets of three of the 10 laboratories (**Table F-2**). In each
85 laboratory, each substance was tested one time at three different concentrations. The dose
86 levels for each substance were pre-determined (i.e., the participating laboratories did not
87 determine their own dose levels for testing). Nine substances are sensitizers and three
88 substances are nonsensitizers according to the traditional LLNA. Six substances are
89 recommended LLNA performance standards reference substances: cobalt chloride, 2,4-
90 dinitrochlorobenzene, hexyl cinnamic aldehyde, isoeugenol, isopropanol, and methyl
91 salicylate (ICCVAM 2009).

92 The second phase of the interlaboratory validation study was designed to determine the
93 reason for inconsistencies obtained from the two metals dissolved in dimethyl sulfoxide
94 (DMSO) (i.e., cobalt chloride and nickel [II] sulfate hexahydrate) and thus to further evaluate
95 the reliability of the LLNA: DA for testing metallic salts using DMSO as a vehicle. A
96 blinded test of five substances (two of the five substances were unique to the second phase of
97 the interlaboratory validation study) was conducted in seven laboratories (different from the
98 10 laboratories that performed the first interlaboratory validation study) (**Table F-3**). One
99 substance (i.e. hexyl cinnamic aldehyde) was tested in all seven laboratories. The remaining
100 four substances (i.e., cobalt chloride, nickel [II] sulfate hexahydrate, lactic acid, and
101 potassium dichromate) were randomly assigned to subsets of four of the seven laboratories.
102 Each laboratory tested the substance one time at three different dose levels. Again, the dose
103 levels for each substance were pre-determined. Of the two substances not previously tested in
104 the first phase of the interlaboratory validation study (i.e., lactic acid and potassium
105 dichromate), one is a nonsensitizer and the other is a sensitizer according to traditional
106 LLNA results, respectively. In addition, lactic acid is a recommended LLNA performance
107 standards reference substance (ICCVAM 2009).

108 The LLNA: DA test results from the two-phased interlaboratory validation study are
 109 amenable to interlaboratory reproducibility analyses for three endpoints: sensitizer (positive)
 110 or nonsensitizer (negative) classification (based on $SI \geq 3.0$ and $SI \geq 2.0$), and EC3 and EC2
 111 values. Analyses of interlaboratory reproducibility were performed using a concordance
 112 analysis for the qualitative results (sensitizer vs. nonsensitizer based on $SI \geq 3.0$ and $SI \geq 2.0$)
 113 (Sections 1.2.1 and 1.2.3, respectively) and a CV analysis for the quantitative results (EC3
 114 and EC2 values) (Sections 1.2.2 and 1.2.4, respectively).

115 **Table F-2 Substances and Allocation for the First Phase of the Interlaboratory**
 116 **Validation Study for the LLNA: DA**

Substance ¹	Vehicle	Concentration Tested (%)			Laboratory									
					1	2	3	4	5	6	7	8	9	10
2,4-Dinitrochlorobenzene (+)	AOO	0.03	0.10	0.30	X	X	X	X	X	X	X	X	X	X
Hexyl cinnamic aldehyde (+)	AOO	5	10	25	X	X	X	X	X	X	X	X	X	X
Isopropanol (-)	AOO	10	25	50	X	X	X	X	X	X	X	X	X	X
Abietic acid (+)	AOO	5	10	25		X				X	X			
3-Aminophenol (+)	AOO	1	3	10	X		X					X		
Dimethyl isophthalate (-)	AOO	5	10	25	X		X				X			
Isoeugenol (+)	AOO	1	3	10				X	X				X	
Methyl salicylate (-)	AOO	5	10	25			X				X			X
Formaldehyde (+)	ACE	0.5	1.5	5.0	X	X			X					
Glutaraldehyde (+)	ACE	0.05	0.15	0.50	X	X			X					
Cobalt chloride ² (+)	DMSO	0.3	1.0	3.0				X		X		X		
Nickel (II) sulfate hexahydrate (+)	DMSO	1	3	10				X		X		X		

117 Abbreviations: ACE = acetone; AOO = acetone: olive oil (4:1); DMSO = dimethyl sulfoxide; LLNA: DA = murine local
 118 lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP content.

119 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

120 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 121 of the interlaboratory validation study.
 122

122 **Table F-3 Substances and Allocation for the Second Phase of the Interlaboratory**
 123 **Validation Study for the LLNA: DA**

Substance ¹	Vehicle	Concentration Tested (%)			Laboratory						
					11	12	13	14	15	16	17
Hexyl cinnamic aldehyde (+)	AOO	5	10	25	X	X	X	X	X	X	X
Cobalt chloride ² (+)	DMSO	1	3	5	X		X	X			X
Lactic acid (-)	DMSO	5	10	25	X		X		X	X	
Nickel (II) sulfate hexahydrate (+)	DMSO	1	3	10	X	X		X		X	
Potassium dichromate (+)	DMSO	0.1	0.3	1.0	X	X			X		X

124 Abbreviations: AOO = acetone: olive oil (4:1); DMSO = dimethyl sulfoxide; LLNA: DA = murine local lymph node assay
 125 modified by Daicel Chemical Industries, Ltd. based on ATP content.

126 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

127 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 128 of the interlaboratory validation study.
 129

130 1.2.1 Interlaboratory Reproducibility – Qualitative Results ($SI \geq 3.0$)

131 The qualitative (i.e., positive/negative) interlaboratory concordance analysis for the 12
 132 substances that were tested during the first phase of the LLNA: DA interlaboratory validation
 133 study is shown in **Table F-4** using $SI \geq 3.0$ as the decision criterion to distinguish sensitizers
 134 from nonsensitizers. In a qualitative comparison of LLNA: DA calls (i.e., positive/negative),
 135 eight substances tested in either three or 10 laboratories had consistent results leading to
 136 100% (3/3 or 10/10) interlaboratory concordance for those substances. There were four
 137 discordant substances (i.e., formaldehyde, glutaraldehyde, cobalt chloride, and nickel [II]
 138 sulfate hexahydrate) for which interlaboratory concordance was 67% (2/3). One of the three
 139 laboratories that tested formaldehyde reported a maximum $SI = 2.69$ while the other two
 140 laboratories produced at least one $SI \geq 3.0$. Similarly, one of the three laboratories that tested
 141 glutaraldehyde reported a maximum $SI = 2.57$ while the other two laboratories had at least
 142 one $SI \geq 3.0$. Two of the three laboratories that tested cobalt chloride yielded an $SI \geq 3.0$ at
 143 all three doses tested (0.3%, 1.0%, and 3.0%) and therefore classified the substance as a
 144 sensitizer similar to the traditional LLNA test method. Notably, the laboratory that did not
 145 generate an $SI \geq 3.0$ did not test cobalt chloride at the highest dose and the middle dose
 146 yielded an $SI = 2.66$. One of the three laboratories that tested nickel (II) sulfate hexahydrate
 147 reported a maximum $SI = 1.52$, while the other two laboratories had at least two doses that

148 yielded an $SI \geq 3.0$. Since the evaluation of interlaboratory reproducibility for the traditional
 149 LLNA did not include an evaluation of qualitative results (ICCVAM 1999), there were no
 150 traditional LLNA concordance data for comparison with the LLNA: DA concordance data
 151 from the first phase of the interlaboratory validation study.

152 **Table F-4 Qualitative Results for the First Phase of the Interlaboratory Validation**
 153 **Study for the LLNA: DA ($SI \geq 3.0$)**

Substance ¹	Laboratory ²										Concordance
	1	2	3	4	5	6	7	8	9	10	
2,4-Dinitrochlorobenzene (+)	+	+	+	+	+	+	+	+	+	+	10/10
Hexyl cinnamic aldehyde (+)	+	+	+	+	+	+	+	+	+	+	10/10
Isopropanol (-)	-	-	-	-	-	-	-	-	-	-	10/10
Abietic acid (+)		+				+	+				3/3
3-Aminophenol (+)	-		-					-			3/3
Dimethyl isophthalate (-)	-		-					-			3/3
Isoeugenol (+)				+	+				+		3/3
Methyl salicylate (-)			-					-		-	3/3
Formaldehyde (+)	+	+			-						2/3
Glutaraldehyde (+)	+	+			-						2/3
Cobalt chloride³ (+)				- ⁴		+		+			2/3
Nickel (II) sulfate hexahydrate (+)				- ⁵		+		+ ⁵			2/3

154 Bolded substances did not achieve 100% interlaboratory concordance.

155 Abbreviations: LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP
 156 content; SI = stimulation index.

157 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

158 ²(+) indicates sensitizers and (-) indicates nonsensitizers according to LLNA: DA tests.

159 ³Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 160 of the interlaboratory validation study.

161 ⁴Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

162 ⁵Insufficient dose response.

163

164 The qualitative (positive/negative) interlaboratory concordance analysis for the five
 165 substances that were tested during the second phase of the LLNA: DA interlaboratory
 166 validation study is shown in **Table F-5** using $SI \geq 3.0$ as the decision criterion to distinguish
 167 sensitizers from nonsensitizers. In a qualitative comparison of LLNA: DA calls (i.e.,
 168 positive/negative), four substances (i.e., hexyl cinnamic aldehyde, lactic acid, nickel [II]
 169 sulfate hexahydrate, and potassium dichromate) tested in either four or seven laboratories had

170 consistent results leading to 100% (4/4 or 7/7) interlaboratory concordance for those
 171 substances. There was one discordant substance (i.e., cobalt chloride) for which
 172 interlaboratory concordance was 50% (2/4). Two of the four laboratories that tested cobalt
 173 chloride reported a maximum SI = 2.01 and 2.54, respectively, while the other two
 174 laboratories had at least two doses that yielded an SI \geq 3.0. As was discussed previously,
 175 cobalt chloride was also discordant among the laboratories that tested the substance in the
 176 first phase of the interlaboratory validation study and interlaboratory concordance was 67%
 177 (2/3). Notably, different doses of cobalt chloride were tested in the first phase (0.3%, 1%, and
 178 3%) and in the second phase (1%, 3%, and 10%) of the interlaboratory validation study.
 179 Furthermore, as mentioned previously, the evaluation of interlaboratory reproducibility for
 180 the traditional LLNA did not include an evaluation of qualitative results (ICCVAM 1999),
 181 and therefore there were no traditional LLNA concordance data for comparison with the
 182 LLNA: DA concordance data from the second phase of the interlaboratory validation study.

183 **Table F-5 Qualitative Results for the Second Phase of the Interlaboratory**
 184 **Validation Study for the LLNA: DA (SI \geq 3.0)**

Substance ¹	Laboratory ²							Concordance
	11	12	13	14	15	16	17	
Hexyl cinnamic aldehyde (+)	+	+	+	+	+	+	+	7/7
Cobalt chloride³ (+)	-		-	+			+	2/4
Lactic acid (-)	-		-		-	-		4/4
Nickel (II) sulfate hexahydrate (+)	-	-		-		-		4/4
Potassium dichromate (+)	+	+			+		+	4/4

185 Bolded substances did not achieve 100% interlaboratory concordance.

186 Abbreviations: LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd. based on ATP
 187 Content; SI = stimulation index.

188 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

189 ²(+) indicates sensitizers and (-) indicates nonsensitizers according to LLNA: DA tests.

190 ³Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 191 of the interlaboratory validation study.

192

193 1.2.2 Interlaboratory Reproducibility – EC3 Values

194 The available quantitative (i.e., EC3 value) data for interlaboratory reproducibility analysis
 195 were obtained from the LLNA: DA results for the nine sensitizers that were tested during the
 196 first and second phase of the LLNA: DA interlaboratory validation study. The method for

197 calculating EC3 values for the positive results was based on the method of linear
198 interpolation reported by Gerberick et al. (2004) according to the equation:

199
$$EC3 = c + \left[\frac{(3-d)}{(b-d)} \right] \times (a-c)$$

200 where the data points lying immediately above and below the SI = 3.0 on the dose response
201 curve have the coordinates of (a, b) and (c, d), respectively (Gerberick et al. 2004). For
202 substances for which the lowest concentration tested resulted in an SI \geq 3.0, an EC3 value
203 was extrapolated according to the equation:

204
$$EC3_{ex} = 2^{\left\{ \log_2(c) + \frac{(3-d)}{(b-d)} \times [\log_2(a) - \log_2(c)] \right\}}$$

205 where the point with the higher SI is denoted with the coordinates of (a, b) and the point with
206 the lower SI is denoted (c, d) (Gerberick et al. 2004).

207 The EC3 values from each laboratory were used to calculate CV values for each substance.
208 The resulting values for the first and second phase of the interlaboratory validation study are
209 shown in **Tables F-6** and **F-7**, respectively. In the first phase of the interlaboratory validation
210 study, CV values ranged from 4% (i.e., abietic acid) to 84% (i.e., glutaraldehyde) and the
211 mean CV was 48% (**Table F-6**). Notably, although nickel (II) sulfate hexahydrate was a
212 sensitizer in two of three laboratories, a CV could not be determined because one of the two
213 laboratories that yielded a positive test demonstrated an insufficient dose response from
214 which to calculate an EC3 (i.e., an inverse dose response curve). In the second phase of the
215 interlaboratory validation study, CV values ranged from 32% (i.e., cobalt chloride) to 71%
216 (i.e., potassium dichromate) and the mean CV was 45% (**Table F-7**).

217 *Recommended Performance Standards: Murine Local Lymph Node Assay* (ICCVAM 2009)
218 indicates that interlaboratory reproducibility should be evaluated with at least two sensitizing
219 chemicals with well-characterized activity in the traditional LLNA. Acceptable
220 reproducibility is attained when each laboratory obtains ECt values (i.e., estimated
221 concentration needed to produce a stimulation index of a specified threshold) within 0.025%
222 to 0.1% for 2,4-dinitrochlorobenzene and within 5% to 20% for hexyl cinnamic aldehyde
223 (ICCVAM 2009). In the first phase of the interlaboratory validation study, four laboratories
224 reported EC3 values outside the range indicated for 2,4-dinitrochlorobenzene; one laboratory

225 obtained an EC3 value that was lower than the specified acceptance range (i.e., 0.025%) and
226 three laboratories obtained EC3 values that were higher than the specified acceptance range
227 (i.e., 0.1%) (**Table F-6**). For hexyl cinnamic aldehyde, all the laboratories obtained an EC3
228 value within the acceptance range (5% to 20%). In the second phase of the interlaboratory
229 validation study, only hexyl cinnamic aldehyde was tested and all seven laboratories obtained
230 EC3 values that were within the acceptance range indicated (**Table F-7**).

231 **Table F-6 EC3 Values from the First Phase of the Interlaboratory Validation Study for the LLNA: DA**

Substance ¹	Laboratory										Mean EC3 (%)	CV (%)
	1	2	3	4	5	6	7	8	9	10		
2,4-Dinitrochlorobenzene (+)	0.034 (11.97)	0.109 (9.23)	0.056 (9.96)	0.031 (8.53)	0.129 (7.86)	0.042 (15.14)	0.016 (13.18)	0.095 (12.60)	0.040 (10.89)	0.169 (4.71)	0.072	70
Hexyl cinnamic aldehyde (+)	9.983 (5.78)	12.412 (4.82)	14.90 (4.44)	9.340 (5.11)	18.131 (3.97)	13.130 (5.50)	7.706 (7.09)	7.924 (10.22)	17.070 (3.88)	15.235 (3.51)	12.583	30
Isopropanol (-)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Abietic acid (+)		8.196				7.544	7.676				7.805	4
3-Aminophenol (+)	NA		NA					NA			NA	NA
Dimethyl isophthalate (-)	NA		NA				NA				NA	NA
Isoeugenol (+)				1.112	5.983				2.300		3.131	81
Methyl salicylate (-)			NA				NA			NA	NA	NA
Formaldehyde (+)	1.747	1.480			NA						1.614	12
Glutaraldehyde (+)	0.110	0.435			NA						0.272	84
Cobalt chloride ² (+)				NA ³		0.063		0.137			0.100	53
Nickel (II) sulfate hexahydrate (+)				NA ⁴		0.469		IDR			0.469	NA

232 Note: Bolded text indicates recommended LLNA performance standards reference substances (ICCVAM 2009). Values in parentheses are highest SI values achieved. For both 2,4-
233 dinitrochlorobenzene and hexyl cinnamic aldehyde, the highest SI values achieved are from the highest dose tested (i.e., 0.30% for 2,4-dinitrochlorobenzene and 25% for hexyl
234 cinnamic aldehyde). Shading shows EC3 values that are outside of the acceptable range indicated by the recommended LLNA performance standards: 5 - 20% for hexyl cinnamic
235 aldehyde and 0.025 - 0.1% for 2,4-dinitrochlorobenzene.

236 Abbreviations: CV = coefficient of variation; EC3 = estimated concentration needed to produce a stimulation index of three; LLNA: DA = murine local lymph node assay
237 modified by Daicel Chemical Industries, Ltd., based on ATP content; IDR = insufficient dose response; NA = not available.

238 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

239 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%) of the interlaboratory validation study.

240 ³Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

241 ⁴Insufficient dose response.

242 **Table F-7 EC3 Values from the Second Phase of the Interlaboratory Validation**
 243 **Study for the LLNA: DA**

Substance ¹	Laboratory							Mean EC3 (%)	CV (%)
	11	12	13	14	15	16	17		
Hexyl cinnamic aldehyde (+)	9.127 (4.47)	8.764 (5.71)	7.590 (5.41)	7.938 (7.60)	15.184 (3.92)	6.230 (8.42)	7.542 (6.45)	8.911	33
Cobalt chloride ² (+)	NA		NA	1.761			1.109	1.435	32
Lactic acid (-)	NA		NA		NA	NA		NA	NA
Nickel (II) sulfate hexahydrate (+)	NA	NA		NA		NA		NA	NA
Potassium dichromate (+)	0.509	0.485			0.156		0.086	0.309	71

244 Bolded text indicates a recommended LLNA performance standards reference substance (ICCVAM 2009). Values in
 245 parentheses are highest SI values achieved. For hexyl cinnamic aldehyde, the highest SI values achieved are from the
 246 highest dose tested (i.e., 25%). None of the EC3 values are outside of the acceptable range indicated by the recommended
 247 LLNA performance standards (i.e., 5 - 20% for hexyl cinnamic aldehyde).

248 Abbreviations: CV = coefficient of variation; EC3 = estimated concentration needed to produce a stimulation index of three;
 249 LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd., based on ATP content; NA =
 250 not available.

251 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

252 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 253 of the interlaboratory validation study.

254
 255 The interlaboratory CV values for both the first and second phases of the interlaboratory
 256 validation study for the LLNA: DA EC3 values were higher than that for the traditional
 257 LLNA EC3 values. The analysis of interlaboratory variation of EC3 values for the traditional
 258 LLNA reported CV values of 6.8 to 83.7% for five substances tested in five laboratories
 259 (**Table F-8**; ICCVAM 1999). Three of the same substances were evaluated in the traditional
 260 LLNA and the LLNA: DA (i.e., hexyl cinnamic aldehyde, 2,4-dinitrochlorobenzene, and
 261 isoeugenol). All interlaboratory CV values for the LLNA: DA were greater than that for the
 262 traditional LLNA. The CV of 70% for 2,4-dinitrochlorobenzene was greater than the two CV
 263 values of 37.4% and 27.2%, calculated from five values each, reported by ICCVAM (1999).
 264 The CV values of 30% and 33% for hexyl cinnamic aldehyde tested in the first and second
 265 phase of the LLNA: DA interlaboratory validation study, respectively, were both greater than
 266 the 6.8% reported by ICCVAM (1999). The CV of 81% for isoeugenol tested in the LLNA:
 267 DA was greater than the 41.2% reported by ICCVAM (1999).

268
 269

269 **Table F-8 Interlaboratory Reproducibility of the EC3 for Substances Tested in the**
 270 **Traditional LLNA¹**

Substance	Laboratory					CV (%)
	1	2	3	4	5	
2,4-Dinitrochlorobenzene	0.3	0.5	0.6	0.9	0.6	37.4
	0.5	0.6	0.4	0.6	0.3	27.2
Hexyl cinnamic aldehyde	7.9	7.6	8.4	7.0	8.1	6.8
Isoeugenol	1.3	3.3	1.8	3.1	1.6	41.2
Eugenol	5.8	14.5	8.9	13.8	6.0	42.5
Sodium lauryl sulfate	13.4	4.4	1.5	17.1	4.0	83.7

271 Abbreviations: CV = coefficient of variation; EC3 = estimated concentration needed to produce a
 272 stimulation index of three; LLNA = murine local lymph node assay.

273 ¹From ICCVAM 1999 report.

274

275 1.2.3 Interlaboratory Reproducibility – Qualitative Results ($SI \geq 2.0$)

276 The qualitative (positive/negative) interlaboratory concordance analysis for the 12 substances
 277 that were tested during the first phase of the LLNA: DA interlaboratory validation study is
 278 shown in **Table F-9** for $SI \geq 2.0$. In a qualitative comparison of LLNA: DA calls (i.e.,
 279 sensitizer/nonsensitizer), ten substances tested in either three or 10 laboratories had
 280 consistent results leading to 100% (3/3 or 10/10) interlaboratory concordance for those
 281 substances. There were two discordant substances (i.e., 3-aminophenol and nickel [II] sulfate
 282 hexahydrate) for which interlaboratory concordance was 67% (2/3). Two of the three
 283 laboratories that tested 3-aminophenol reported $SI \geq 2.0$, at least at the highest dose tested
 284 (i.e., $SI = 2.83$ and 2.38 , respectively) but one lab did not achieve $SI \geq 2.0$ at any dose tested
 285 (**Appendix D**). One of the three laboratories that tested nickel (II) sulfate hexahydrate
 286 reported a maximum $SI = 1.52$, while the other two laboratories produced $SI \geq 2.0$ at all three
 287 doses tested (**Appendix D**). Since the evaluation of interlaboratory reproducibility for the
 288 traditional LLNA did not include an evaluation of qualitative results (ICCVAM 1999), there
 289 were no traditional LLNA concordance data for comparison with the LLNA: DA
 290 concordance data from the first phase of the interlaboratory validation study.

291

291 **Table F-9 Qualitative Results for the First Phase of the Interlaboratory Validation**
 292 **Studies for the LLNA: DA (SI ≥ 2.0)**

Substance ¹	Laboratory ²										Concordance
	1	2	3	4	5	6	7	8	9	10	
2,4-Dinitrochlorobenzene (+)	+	+	+	+	+	+	+	+	+	+	10/10
Hexyl cinnamic aldehyde (+)	+	+	+	+	+	+	+	+	+	+	10/10
Isopropanol (-)	-	-	-	-	-	-	-	-	-	-	10/10
Abietic acid (+)		+				+	+				3/3
3-Aminophenol (+)	+		-					+			2/3
Dimethyl isophthalate (-)	-		-				-				3/3
Isoeugenol (+)				+	+				+		3/3
Methyl salicylate (-)			-				-			-	3/3
Formaldehyde (+)	+	+			+						3/3
Glutaraldehyde (+)	+	+			+						3/3
Cobalt chloride ³ (+)				+ ⁴		+		+			3/3
Nickel (II) sulfate hexahydrate (+)				- ⁵		+		+ ⁵			2/3

293 Bolded substances did not achieve 100% interlaboratory concordance.

294 Abbreviations: LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd., based on ATP
 295 content; SI = stimulation index.

296 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

297 ²(+) indicates sensitizer result and (-) indicates nonsensitizer result in the LLNA: DA test.

298 ³Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 299 of the interlaboratory validation study.

300 ⁴Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

301 ⁵Insufficient dose response.

303 The qualitative (positive/negative) interlaboratory concordance analysis for the five
 304 substances that were tested during the second phase of the LLNA: DA interlaboratory
 305 validation study is shown in **Table F-10**. In a qualitative comparison of LLNA: DA calls
 306 (i.e., sensitizer/nonsensitizer), four substances (i.e., hexyl cinnamic aldehyde, cobalt chloride,
 307 lactic acid, and potassium dichromate) tested in either four or seven laboratories had
 308 consistent results leading to 100% (4/4 or 7/7) interlaboratory concordance for those
 309 substances. There was one discordant substance (i.e., nickel [II] sulfate hexahydrate) for
 310 which interlaboratory concordance was 75% (3/4). Three of the four laboratories that tested
 311 nickel (II) sulfate hexahydrate did not report a maximum SI ≥ 2.0, while the other laboratory
 312 produced an SI ≥ 2.0 at the highest dose tested. As was discussed previously, nickel (II)

313 sulfate hexahydrate was also discordant among the laboratories that tested the substance in
 314 the first phase of the interlaboratory validation study and interlaboratory concordance was
 315 67% (2/3). Notably, when analyzing the dose response curves for the seven tests performed
 316 for nickel (II) sulfate hexahydrate in the two-phased interlaboratory validation study, only
 317 one study demonstrated a sufficient dose response (i.e., a parallel increase in SI relative to
 318 increase in concentration). Furthermore, as mentioned previously, the evaluation of
 319 interlaboratory reproducibility for the traditional LLNA did not include an evaluation of
 320 qualitative results (ICCVAM 1999), and therefore there were no traditional LLNA
 321 concordance data for comparison with the LLNA: DA concordance data from the second
 322 phase of the interlaboratory validation study.

323 **Table F-10 Qualitative Results for the Second Phase of the Interlaboratory**
 324 **Validation Study for the LLNA: DA (SI ≥ 2.0)**

Substance ¹	Laboratory ²							Concordance
	11	12	13	14	15	16	17	
Hexyl cinnamic aldehyde (+)	+	+	+	+	+	+	+	7/7
Cobalt chloride ³ (+)	+		+	+			+	4/4
Lactic acid (-)	-		-		-	-		4/4
Nickel (II) sulfate hexahydrate (+)	-	-		+		-		3/4
Potassium dichromate (+)	+	+			+		+	4/4

325 Bolded substance did not achieve 100% interlaboratory concordance.

326 Abbreviations: LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd., based on ATP
 327 content; SI = stimulation index.

328 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

329 ²(+) indicates sensitizer result and (-) indicates nonsensitizer result in the LLNA: DA test.

330 ³Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 331 interlaboratory validation studies.

332

333 1.2.4 Interlaboratory Reproducibility – EC2 Values

334 The available quantitative (i.e., EC2 value) data for interlaboratory reproducibility analysis
 335 were obtained from the LLNA: DA results for the ten sensitizers that were tested during the
 336 first and second phase of the LLNA: DA interlaboratory validation study. The equation used
 337 for calculating EC2 values for the positive results was modified based on the method of
 338 linear interpolation reported by Gerberick et al. (2004) for the EC3:

339
$$EC2 = c + \left[\frac{(2-d)}{(b-d)} \right] \times (a-c)$$

340 where the data points lying immediately above and below the SI = 2.0 on the dose response
341 curve have the coordinates of (a, b) and (c, d), respectively (Gerberick et al. 2004). For
342 substances for which the lowest concentration tested resulted in an SI \geq 2.0, an EC2 value
343 was extrapolated according to the equation:

344
$$EC2_{ex} = 2^{\left\{ \log_2(c) + \frac{(2-d)}{(b-d)} \times [\log_2(a) - \log_2(c)] \right\}}$$

345 where the point with the higher SI is denoted with the coordinates of (a, b) and the point with
346 the lower SI is denoted (c, d) (Gerberick et al. 2004).

347 The EC2 values from each laboratory were used to calculate CV values for each substance.
348 The resulting values for the first and second phase of the interlaboratory validation study are
349 shown in **Tables F-11** and **F-12**, respectively. In the first phase of the interlaboratory
350 validation study, CV values ranged from 14% (i.e., abietic acid) to 134% (isoeugenol) and
351 the mean CV was 70% (**Table F-11**). In the second phase of the interlaboratory validation
352 study, CV values ranged from 16% (i.e., hexyl cinnamic aldehyde) to 100% (i.e., cobalt
353 chloride) and the mean CV was 57% (**Table F-12**).

354 The recommended LLNA performance standards indicate that interlaboratory reproducibility
355 should be evaluated with at least two sensitizing chemicals with well-characterized activity in
356 the traditional LLNA (ICCVAM 2009). Acceptable reproducibility is attained when each
357 laboratory obtains ECt (i.e., estimated concentration needed to produce a stimulation index
358 threshold) values within 0.025% to 0.1% for 2,4-dinitrochlorobenzene and within 5% to 20%
359 for hexyl cinnamic aldehyde (ICCVAM 2009). In the first phase of the interlaboratory
360 validation study, seven laboratories reported EC2 values outside the range indicated for 2,4-
361 dinitrochlorobenzene; all seven laboratories obtained EC2 values that were lower than the
362 specified acceptance range (i.e., 0.025%) (**Table F-11**). For hexyl cinnamic aldehyde, all the
363 laboratories obtained an EC2 value within the acceptance range (5% to 20%). In the second
364 phase of the interlaboratory validation study, only hexyl cinnamic aldehyde was tested and
365 two of the seven laboratories obtained EC2 values that were below the acceptance range
366 indicated (**Table F-12**).

Table F-11 EC2 Values from the First Phase Interlaboratory Validation Study for the LLNA: DA

Substance ¹	Laboratory										Mean EC2 (%)	CV (%)
	1	2	3	4	5	6	7	8	9	10		
2,4-Dinitrochlorobenzene (+)	0.020 (11.97)	0.023 (9.23)	0.026 (9.96)	0.016 (8.53)	0.091 (7.86)	0.016 (15.14)	0.007 (13.18)	0.013 (12.60)	0.019 (10.89)	0.093 (4.71)	0.032	98
Hexyl cinnamic aldehyde (+)	6.962 (5.78)	7.461 (4.82)	8.404 (4.44)	6.460 (5.11)	11.057 (3.97)	7.463 (5.50)	5.850 (7.09)	6.140 (10.22)	9.191 (3.88)	7.256 (3.51)	7.624	21
Isopropanol (-)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Abietic acid (+)		4.760				5.393	6.333				5.495	14
3-Aminophenol (+)	1.877		NA					3.179			2.528	36
Dimethyl isophthalate (-)	NA		NA				NA				NA	NA
Isoeugenol (+)				0.407	4.399				0.375		1.727	134
Methyl salicylate (-)			NA				NA			NA	NA	NA
Formaldehyde (+)	0.262	0.729			2.019						1.003	91
Glutaraldehyde (+)	0.072	0.268			0.118						0.153	67
Cobalt chloride ² (+)				0.283 ³		0.032		0.079			0.131	102
Nickel (II) sulfate hexahydrate (+)				NA ⁴		0.235		IDR			0.235	NA

Bolded text indicates substances that are recommended LLNA performance standards reference substances (ICCVAM 2009). Values in parentheses are highest SI values achieved. For both 2,4-dinitrochlorobenzene and hexyl cinnamic aldehyde, the highest SI values achieved were from the highest dose tested (i.e., 0.30% for 2,4-dinitrochlorobenzene and 25% for hexyl cinnamic aldehyde). Shading shows EC2 values that are outside of the acceptable range indicated by the recommended LLNA performance standards: 5 - 20% for hexyl cinnamic aldehyde and 0.025 - 0.1% for 2,4-dinitrochlorobenzene.

Abbreviations: CV = coefficient of variation; EC2 = estimated concentration needed to produce a stimulation index of two; LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd., based on ATP content; IDR = insufficient dose response; NA = not available.

¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%) interlaboratory validation studies.

³Data not reported for the highest dose (i.e., 3%), only for 0.3% and 1%.

⁴Insufficient dose response.

378 **Table F-12 EC2 Values from the Second Phase of the Interlaboratory Validation**
 379 **Study for the LLNA: DA**

Substance ¹	Laboratory							Mean EC2 (%)	CV (%)
	11	12	13	14	15	16	17		
Hexyl cinnamic aldehyde (+)	6.348 (4.47)	5.983 (5.71)	5.954 (5.41)	4.849 (7.60)	7.451 (3.92)	4.662 (8.42)	6.024 (6.45)	5.896	16
Cobalt chloride ² (+)	4.929		1.875	0.821			0.461	2.021	100
Lactic acid (-)	NA		NA		NA	NA		NA	NA
Nickel (II) sulfate hexahydrate (+)	NA	NA		NA		8.404		8.404	
Potassium dichromate (+)	0.159	0.128			0.055		0.047	0.097	56

380 Bolded text indicates substances that are recommended LLNA performance standards reference substances. Values in
 381 parentheses are highest SI values achieved. For hexyl cinnamic aldehyde, the highest SI values achieved were from the
 382 highest dose tested (i.e., 25%). Two of the EC2 values are outside of the acceptable range indicated by the recommended
 383 LLNA performance standards (i.e., 5 - 20% for hexyl cinnamic aldehyde), indicated by shading.
 384 Abbreviations: CV = coefficient of variation; EC2 = estimated concentration needed to produce a stimulation index of two;
 385 LLNA: DA = murine local lymph node assay modified by Daicel Chemical Industries, Ltd., based on ATP content; NA =
 386 not available.

387 ¹(+) indicates sensitizers and (-) indicates nonsensitizers according to traditional LLNA tests.

388 ²Different doses tested for cobalt chloride in the first phase (0.3%, 1%, and 3%) and in the second phase (1%, 3%, and 10%)
 389 of the interlaboratory validation study.
 390

391 The interlaboratory CV values for both the first and second phases of the interlaboratory
 392 validation study for the LLNA: DA EC2 values were higher than that for the traditional
 393 LLNA EC3 values. The analysis of interlaboratory variation of EC3 values for the traditional
 394 LLNA reported CV values of 6.8 to 83.7% for five substances tested in five laboratories
 395 (**Table F-8**; ICCVAM 1999). Three of the same substances were evaluated in the traditional
 396 LLNA and the LLNA: DA (i.e., hexyl cinnamic aldehyde, 2,4-dinitrochlorobenzene, and
 397 isoeugenol). All interlaboratory CV values for LLNA: DA EC2 were greater than that for the
 398 traditional LLNA. The CV of 98% for 2,4-dinitrochlorobenzene was greater than the two CV
 399 values of 37.4% and 27.2% (which were calculated from five values each), reported by
 400 ICCVAM (1999). The CV of 21% and 16% for hexyl cinnamic aldehyde tested in the first
 401 and second phase of the LLNA: DA interlaboratory validation study, respectively, were both
 402 greater than the 6.8% reported by ICCVAM (1999). The CV of 134% for isoeugenol tested
 403 in the LLNA: DA was greater than the 41.2% reported by ICCVAM (1999).